<SEC-DOCUMENT>0001410578-24-000865.txt : 20240515
<SEC-HEADER>0001410578-24-000865.hdr.sgml : 20240515
<ACCEPTANCE-DATETIME>20240515160321
ACCESSION NUMBER:		0001410578-24-000865
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240515
DATE AS OF CHANGE:		20240515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Marker Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001094038
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				880277072
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37939
		FILM NUMBER:		24950225

	BUSINESS ADDRESS:	
		STREET 1:		4551 KENNEDY COMMERCE DR.
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77032
		BUSINESS PHONE:		(713) 400-6400

	MAIL ADDRESS:	
		STREET 1:		4551 KENNEDY COMMERCE DR.
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77032

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAPIMMUNE INC.
		DATE OF NAME CHANGE:	20170629

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAPIMMUNE INC
		DATE OF NAME CHANGE:	20070628

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENEMAX CORP
		DATE OF NAME CHANGE:	20020718
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mrkr-20240331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.6.2.5 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 5/15/2024 4:51:40 PM -->
<!-- iXBRL Library version: 1.0.8826.24652 -->
<!-- iXBRL Service Job ID: badd2467-6142-4728-9ac8-cc60f21c5543 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:mrkr="http://www.tapimmune.com/20240331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:EntityCentralIndexKey" id="Tc_dUdvazYi1EeJDQ7ujmlepg_2_1">0001094038</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:CurrentFiscalYearEndDate" id="Tc_AtudQRHr2UmZePQA6BAdOQ_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:DocumentFiscalYearFocus" id="Tc_TollByoMb0KO85NWy8EKZA_4_1">2024</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:DocumentFiscalPeriodFocus" id="Tc_nT7YhQc4O0CbEtz-Lbg0jw_5_1">Q1</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="-6" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_d8A94XILEUSIZkCJWtA08w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="-6" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_ypl3Op3GZUeoYe7U6x8r3A">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="-5" name="us-gaap:CommonStockSharesIssued" id="Hidden_xZcP8zevh0SMmFY9mdQCNw">8900000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="-5" name="us-gaap:CommonStockSharesIssued" id="Hidden_DI79ktFaDU2FiQQuTTR4Cg">8900000</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:EntityIncorporationStateCountryCode" id="Hidden_eP8QxLPiWkuT0RbekEoLwA">DE</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" name="us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_o_clvdFkYE-lZq-yDAIsKQ">http://fasb.org/us-gaap/2023#RelatedPartyMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" xs:nil="true" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" name="us-gaap:PreferredStockValue" id="Hidden_04FEx9nTU06ez0X5F_GGKg"/><ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" xs:nil="true" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" name="us-gaap:PreferredStockValue" id="Hidden_zytu6CC3zEW7oCs1koSO5g"/><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:AmendmentFlag" id="Narr_J3sgSDifsEuvuzv0PXFjMA">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="mrkr-20240331.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_3_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_7HG6TYGhSkuj85Yk7cyx0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J_5wr1xoCUiUQha0LU7yxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4CuqoUChNU6LCLMJQNy2vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_h4ZLvIQokUOG-qQCkBlAeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_N9zarOSsVEuBpoYtfzkupQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_26_2023_To_1_26_2023_awyJo1ParUe6ER8qP8Er1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-26</xbrli:startDate><xbrli:endDate>2023-01-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PKZChDUbxEO2qD8-67k5Hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hteoEo475kS8tfpScfdJoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_O2ehFFy9IkO1iNk3wb4ojA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dPQr3dLFZE-DSSf241ybww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PUYOhITdW02F2X4CUsXlkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TabWhcOewUWWAHC4rI6AMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dAcdkzltg0mbv8cPmlI6WA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bkjZN5Y5rEWwwaBWPP47cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L3GqS7LIaEaMZLbGeyWEVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p2J4oIHCPEuZlK3Ssu23sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ARak6biMC0C2vE3aHgU_OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj8-kTaoPUeqeGIfHnTabg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_JNor-YkRMES_vEoMGuLiUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_uiVzVsnzbEO2OvPv-3o_Jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_X9phuL_RxUqyj7QCXMC4zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_M8QVuqpUVkWUQBZalnnUIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_wZXVoXh7Q0KniAnmTI3IqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_aF3HC3hiPEGwEVjTVodC_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:CpritGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_tSwV_5BIrEK_el6Vtlcjzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_dFfPvaLfIEikU4XiNmZE_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_SJSbS_G9j0aQNGKHeaocXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:CpritGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_j4d_NUsf-U6y0TlpBZ0hiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:CpritGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_31_2021_To_8_31_2021_wLINgxwAtEqXJr9cCHPb-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-31</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_4_30_2024_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_sE3cONnYgEmmcMHZ2wUk0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_4_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_dqKTucMUbUGZUuzFK_dOyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_n7CziHvjvE--LojpNufD4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_OIylfIWvwk61OIbrkzAtLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_v0PCHlsRw0uzmua5_m8DQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_hcxj8tGJMUufaz5d7_ww7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_30_2022_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_wPOXGWAUdk2rreQDgrYe6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:RelatedPartyServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BindingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_07W_qsYgcEudbi5GDRWobg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CellReadyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8ps6npQK00elvbaMdGpAAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CellReadyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_CellReadyMember_IthHVQzVkEC_BWostaNF4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:CellReadyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_awaPZGwxYkOh-Kh6ZKEEGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_H1facwiFj0qZIcr4nQ49VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wroXSHfJ30-xSPaXlw7fRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HbuT4I4LOEWfD8qUtjixAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_aZw1rDA380KfM4Tw_qsCzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:CpritGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2023_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_nozZmEEAxEWXLrXsS0VZYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_o77qs3ys40OOa0GfLhRa-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_HuG04-O0U0-9tr34MqB3RA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:RelatedPartyServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_caUp8WmODEqDoW7woCj3OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_csS-ol7uukaNejaEqG1D1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_26_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_XIIQwpm8KkCnK2MdeGDs6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:CellReadyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_26_2023_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember__S3prYqHtE6Us-UKNLgTqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:CellReadyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_0E4EMJOdr0W3g33PvIH_sQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_090YrRTZKEOoBAZPdsIihw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2023_srt_RangeAxis_srt_MinimumMember_PkV5_ayFjkm8F2rhSnUmqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2023_srt_RangeAxis_srt_MaximumMember_e2_Hkwej-0-x0rfYttNybA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2023_lWBBv-azxUmgoxtZqB0QnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2023_UtL_c0KyKEWg0Dz7B0kqYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_u5io9Qini0SROgijz_sG3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_N3CIHFtK7keuOQ6DeBbsBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dDnDDGPKLkOOtV5YB9PuYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_W07D8lnky0aimmBd-R3YIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BuQkUd2NSUCXfasuFdBgPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_65JWbw2x0UWpZJA7_fd3rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_qmoIEv97Rk2jUyIAWQnjTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_MCdjUbOPBEuJBGWUJszvmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_vBXDcg9tlkOH2-yBzo50cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_YwRyxwQa5U2Ym0Gma3rUFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_XBUskIaJ10C-ReGlI38TAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_GrantMember_dzr8lBZFQUCRXXMJiuJ70Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_up4ngz1fg02kE_1r6itooQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:CpritGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_xgSQFi7SKUC3P-uEqMdsgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember__N7KeTtie0WOfM9lUAInzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_26_2023_To_6_26_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_I4S7uiZnTE-bi56dzKi0tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:CellReadyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-26</xbrli:startDate><xbrli:endDate>2023-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kLbzwvujTEy1z59aTzl4IQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yie4PE_5UKKtvhQWc8ymQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_wgAA0Ldo_UOtaTkJBKsynw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:CellReadyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_t3VLl29vOk-QUwtoTypBUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_QKfSVv0dhkacuUG8PSdyzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_4_30_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_YTxnqMIXBE2WBHHgARjHqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_4_30_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_0K6azYZMnkS3HVng864fgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_4_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_b7OtDgPp-kyyI1YWR77jEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_K-XuDOatfU2spHjQPAU4OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_9_n_o50vykCM5Ly004kRVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_fMwy5Q-88kG0ISyjxlel4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_RKze1ypjXU6RtzdpbC9cRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_K0gVoKOl8EymtFxIsG-9UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:RelatedPartyServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BindingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_FeJJ4O0CM0OwiGmy1OureA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:RelatedPartyServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BindingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_6_2024_IcLYBeGAjE-ofQtI4ltuRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_Qbvl_Q3p3U-i5knuHKFQlQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_employee_YXZ7VHgYFkK0MKSPoxHTNQ"><xbrli:measure>mrkr:employee</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:60.04pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_6b57f1b9_dee7_4836_b4e2_ed780dbf1466"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:DocumentType" id="Narr_KrSpVflDyk-l4qpz4_kQgQ"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:DocumentQuarterlyReport" id="Narr_UaV9EWefqE2lk9tUi8H1pQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;</span><span style="font-size:9pt;">Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended </span><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:DocumentPeriodEndDate" id="Narr_110cRvk9ZkyOXaQTe57TmQ"><span style="font-size:9pt;">March 31, 2024</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:DocumentTransitionReport" id="Narr_sZa5NEdPC0-EpLvGQmqEtQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Commission File Number: </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:EntityFileNumber" id="Narr_eK0L9_m9aki7_TvaJc22nQ"><b style="font-size:9pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">001-37939</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrkr-20240331x10q001.jpg" alt="Graphic" style="display:inline-block;height:59.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:209.97pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:EntityRegistrantName" id="Narr_mCe9rrFcIkiXPmIodB_2-A"><b style="font-weight:bold;">MARKER THERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Name of registrant in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9af6c5aa_2964_4dcd_963c_1242e1a24825"></a><a id="Tc_1lVL4h-Ia06ZlP8zllSabw_2_0"></a><a id="Tc_MGPyVCYlRUu3pwgYD2B-Lg_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_eP8QxLPiWkuT0RbekEoLwA;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">DELAWARE</b></span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:EntityTaxIdentificationNumber" id="Tc_iierfnrsWkOrGx-hPXeU0g_1_2"><b style="font-size:9pt;font-weight:bold;">45-4497941</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or organization)</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><a id="_b494b851_bca4_40ad_954f_bf49924fdd67"></a><a id="Tc_d_ulMaPGE0K-P1HAO9ssvQ_2_0"></a><a id="Tc_07au1hdVVk66LCmsms1ZzQ_3_0"></a><a id="Tc_uTWNUJdYjUufZUOPwinhnA_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0pt 1pt 0pt;"/><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0pt 1pt 0pt;"/><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt 0pt 1pt 0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0pt 1pt 0pt;"/><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0pt 1pt 0pt;"/><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt 0pt 1pt 0pt;"/></tr><tr><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:EntityAddressAddressLine1" id="Narr_MgpVjA9I_k2eiNA11i-EHw"><b style="font-size:9pt;font-weight:bold;">9350 Kirby Drive, Suite 300</b></ix:nonNumeric><span style="font-size:9pt;"><br/></span><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:EntityAddressCityOrTown" id="Narr_zJ_HE9xE_UWbETRxy9YRTw"><b style="font-size:9pt;font-weight:bold;">Houston</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:EntityAddressStateOrProvince" id="Narr_hb01H1Sa7EWomETqv_2dFg"><b style="font-size:9pt;font-weight:bold;">Texas</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:EntityAddressPostalZipCode" id="Tc_56fJIVYxh0iGGeq5wiKTWw_2_2"><b style="font-size:9pt;font-weight:bold;">77054</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:CityAreaCode" id="Narr_-8ic7h8r50eA9HTOJBCeBw"><b style="font-size:9pt;font-weight:bold;">713</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:LocalPhoneNumber" id="Narr_VQonva1sUEO1W8ryv1kfOA"><b style="font-size:9pt;font-weight:bold;">400-6400</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0pt 1pt 0pt;"/></tr><tr><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Issuer&#8217;s telephone number)</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><a id="_00ef329c_6308_41d1_b8be_3ecc9fb2756b"></a><a id="Tc_0sDuu_aT9EmUeqFePTahWg_1_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:18pt;margin:0pt;">(Former name, former address and former fiscal year, if changed since last report)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_48eb8589_7c2b_4e5e_aafa_5d79a6048cfb"></a><a id="Tc_hx3yXYMbB0KxyXhzMUD1Dg_1_0"></a><a id="Tc_SaxELEyL7k6_FTZuUBpNJQ_1_2"></a><a id="Tc_n53kLZAvYk2syD_Rb5_a6Q_1_4"></a><a id="Tc_YaF-2rTmYE2q8HhXbG2XXw_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.10185242%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"/><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:34.35%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:38.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title&#160;of&#160;each&#160;class</b></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:23.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:1.66%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:34.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</b></p></td></tr><tr><td style="vertical-align:top;width:38.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:Security12bTitle" id="Tc_3vTbAfAMrUONxSVwrcU25g_2_0">Common Stock, par value $0.001 per share</ix:nonNumeric></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:23.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:TradingSymbol" id="Tc_57gZF9HuLk-1vWolHO1U1w_2_2"><span style="font-size:9pt;">MRKR</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:34.35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The <ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:SecurityExchangeName" id="Narr_qKtP-7DHEkS5g-RxC2Gnxw">Nasdaq</ix:nonNumeric> Stock Market LLC</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:EntityCurrentReportingStatus" id="Narr_LwaaLLlVNU29FQQ9HqDNgg"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted&#160;pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:EntityInteractiveDataCurrent" id="Narr_fU4LbDjUFECtmORUTphTUw"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; accelerated filer&#8221;, &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3975667d_23b5_4fb5_9a7d_66c55553b849"></a><a id="Tc_-EcG7niPRka4QokU0oI5Og_1_1"></a><a id="Tc_J1sgzCqWz02bokUZgirpAw_1_2"></a><a id="Tc_Ohr6sDwzaEyYS_ARDqR57g_1_3"></a><a id="Tc_bl6vvkSRWkaD25utMJLf4Q_1_4"></a><a id="Tc_FIDXt0mo2U24kU_TWn4f2Q_2_1"></a><a id="Tc_iMPsEdYKAU2DWYe4w35YFA_2_2"></a><a id="Tc_a41JVsvh0UaP3hSBpE1i1w_2_3"></a><a id="Tc_UTVKpiQCFECtkVQT9RMC7Q_3_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:31.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:26.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:36.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:1.12%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:26.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:36.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:1.12%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:EntityFilerCategory" id="Narr_a7PXN8oB1U2i0Hrgnabfdg"><span style="font-size:9pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:9pt;"> </span></p></td><td style="vertical-align:top;width:26.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:36.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:EntitySmallBusiness" id="Tc_yrhwra0REECzd9bQ9vbGcA_2_4"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:32.6%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:26.65%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:36.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:EntityEmergingGrowthCompany" id="Tc_4R0p1abLAUquL6ImQADsBg_3_4"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160; </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="dei:EntityShellCompany" id="Narr_eEmRwPIS-kev-hgMnW-TDg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;No </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">The registrant had <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_5_6_2024_IcLYBeGAjE-ofQtI4ltuRg" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_RVUP07ZGck2oQPdHP1B8bg">8,919,095</ix:nonFraction> shares of common stock outstanding as of May 6, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="TOC"></a><a id="_d3deab6e_1ee5_432e_9c51_9ba8752c255d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:90.41%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:90.41%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_341259"><b style="font-style:normal;font-weight:bold;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:middle;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item1FinancialStatements_6919"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:82.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item1FinancialStatements_6919"><span style="font-style:normal;font-weight:normal;">Financial Statements (Unaudited)</span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:middle;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_74901"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets As of March 31, 2024 and December 31, 2023</span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:middle;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023 </span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHO"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three months ended March 31, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:middle;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:middle;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#NOTESTOCONDENSEDCONSOLIDATEDFINANCIALSTA"><span style="font-style:normal;font-weight:normal;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:middle;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:82.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16</p></td></tr><tr><td style="vertical-align:middle;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:82.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk.</span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24</p></td></tr><tr><td style="vertical-align:middle;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item4ControlsandProcedures_453239"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:82.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item4ControlsandProcedures_453239"><span style="font-style:normal;font-weight:normal;">Controls and Procedures.</span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:90.41%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:90.41%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_786639"><b style="font-style:normal;font-weight:bold;">PART II &#8211; OTHER INFORMATION </b></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:middle;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item1LegalProceedings_798737"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:82.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item1LegalProceedings_798737"><span style="font-style:normal;font-weight:normal;">Legal Proceedings.</span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:middle;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item1ARiskFactors_449487"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:82.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item1ARiskFactors_449487"><span style="font-style:normal;font-weight:normal;">Risk Factors.</span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:middle;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:82.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds.</span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:middle;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_390946"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:82.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_390946"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities.</span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:middle;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item4MineSafetyDisclosure_210061"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:82.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item4MineSafetyDisclosure_210061"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosure.</span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:middle;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item5OtherInformation_200318"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:82.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item5OtherInformation_200318"><span style="font-style:normal;font-weight:normal;">Other Information.</span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:middle;width:7.5%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:82.91%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item6Exhibits_556633"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:82.91%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#Item6Exhibits_556633"><span style="font-style:normal;font-weight:normal;">Exhibits.</span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:90.41%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:90.41%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#SIGNATURES_772915"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;width:9.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9150ba58_e59f_46f6_8c17_527b34b25b29"></a><a id="PARTIFINANCIALINFORMATION_341259"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:48.95pt;text-align:justify;text-indent:-48.95pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART I.&#160;&#160;&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</b></p><a id="Item1FinancialStatements_6919"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:48.95pt;text-align:justify;text-indent:-48.95pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statement</b><b style="font-weight:bold;">s</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_74901"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26afe0e9_21d1_4a66_8191_7bdba9228693"></a><a id="Tc_OcNXZHCEDE-j5qmWAkwudA_1_2"></a><a id="Tc_65_-Ef4_qkuUxP9UEvOYQg_1_5"></a><a id="Tc__lEYMxu8bkWn1MGVOtbOYA_2_2"></a><a id="Tc_SIfSaLOBREyq545jUjLhvg_2_5"></a><a id="Tc_7tDu0_yvhkaLP4vykLyEDw_3_0"></a><a id="Tc_TeZgGLwBZkCGBXX6RK1Ggw_4_0"></a><a id="Tc_1cNmMfYpA0yivOCXGcxZNg_5_0"></a><a id="Tc_oxmMJuSDBEOS6-h-J27qYw_5_2"></a><a id="Tc_YOP2wIzQJEuXaN_0BONypQ_5_5"></a><a id="Tc_n-DnDQYwJEKc_kpik7Xgew_6_0"></a><a id="Tc_bKqEc_SFpkCaqZDotCJQeQ_7_0"></a><a id="Tc_S3wCrAxdQE25y_P5jRsKXg_8_0"></a><a id="Tc_bDkOl_fql0SSy0NXLbnIPQ_9_0"></a><a id="Tc_HDYG-tGUS0eGErgwdyKgJg_9_2"></a><a id="Tc_thatXhBbz0KiM-4rcoR0Qw_9_5"></a><a id="Tc_7fMlHx7srUK5jbgtBPGjoQ_11_0"></a><a id="Tc_T_aOalJQQU-N1PtucKqFmg_12_0"></a><a id="Tc_T3K-XIvtDEqq76LMVLqm9Q_13_0"></a><a id="Tc_5_xjDyEtBEu-GU5p_LB2GA_13_2"></a><a id="Tc_JS8JH8u1vEmD-cXEg3vWHg_13_5"></a><a id="Tc_FGHZhvsicEGpbzmP9ExfOA_15_0"></a><a id="Tc_a0MJGansV0Cq_0Ee0Ei1Qg_16_0"></a><a id="Tc_ujglIfS7CUOeQQS8xQo27Q_18_0"></a><a id="Tc_OCkT3RuSzkqKrXqYCeX4bg_19_0"></a><a id="_580b4c59_65c1_4369_bc67_2c2f717423bb"></a><a id="_580b4c59_65c1_4369_bc67_2c2f717423bb_2"></a><a id="_580b4c59_65c1_4369_bc67_2c2f717423bb_3"></a><a id="Tc_q7UUI3eAYUGKHvTlgGRryA_20_0"></a><a id="_631ed40b_7952_48cd_847d_8a7fc40fa661"></a><a id="_631ed40b_7952_48cd_847d_8a7fc40fa661_2"></a><a id="_631ed40b_7952_48cd_847d_8a7fc40fa661_3"></a><a id="Tc_mjoGvFNYtU-9f5ye3qKZbQ_21_0"></a><a id="Tc_0S3ZoTkZvEaV_wpY2eGuCA_22_0"></a><a id="Tc_LO41O8rMRECSVLOe-NYYHA_23_0"></a><a id="Tc_miFPCqhJKkuyzTGah72TzQ_24_0"></a><a id="Tc_u34tr_gP3kCPpCh2Ymy5LA_24_2"></a><a id="Tc_FcLCQARPG06Z2P9PWhKfVQ_24_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_P1zv6mzg9EaK6kPA-EOU7A_5_3">11,323,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_4cEicDrV-UGDFJF7s3-DJQ_5_6">15,111,450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_St0qa1kJF0-M7P-KVbFIrw_6_3">917,009</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_wexfpNN7B0SyURzU5_Tyeg_6_6">988,126</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Tc_oYl95mw630m4e2XqqSyvCA_7_3">1,851,462</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Tc_rNMDnu7NnUmNSQ2OEaFJqQ_7_6">1,027,815</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_J5xAC6sVWEKdkFL3fy8Qug_8_3">14,091,899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_7fMV_QK0lkmzyBK7rKE2-Q_8_6">17,127,391</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_k8lAYzqfmkyxJY4CkQ7rQw_9_3">14,091,899</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_M_ql5Em5V02qVHglPpUa8w_9_6">17,127,391</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_cxDz8ibUL0mrKUcqhJteoQ_13_3">1,949,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_aGM35sKWOkCaEzIp-3uuxg_13_6">1,745,193</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_o_clvdFkYE-lZq-yDAIsKQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Related party payable</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_wXym1NTlx02pHOTkZZFS_w_14_3">353,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_fF2wKpOOn0y98oMEnOnigA_14_6">1,329,655</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_ef0PYiJxE0uXiMaTmYH5ZQ_15_3">2,303,665</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_ytRWMYxpGkGGXDLdaYx8ug_15_6">3,074,848</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_QHg0ufR_ykSYPvYq9EPShA_16_3">2,303,665</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_NEeb-PDpOUucRrjRRLnOBg_16_6">3,074,848</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_x-cDcaXalEeIx8iD95c1iQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_IN5tjbHWck-n4U9xrol5mQ">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_WMtyHTcfNU6Vcwelv3Wguw"><ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_GoOscfj_f02uhWs4HMkucQ">5</ix:nonFraction></ix:nonFraction> million shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="6" id="Narr_UrZDqDzoXkW5BpEeotfuDw"><ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="6" id="Narr_CG2wJsRmUUSYvmJwyGMGMA">0</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_04FEx9nTU06ez0X5F_GGKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_zytu6CC3zEW7oCs1koSO5g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_BN6r02niD0mPDtlwMhDqYQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ILtN8ZaiZkGsj0blfMs9JQ">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="Narr_baBnM0bomkyap3-KQIztsw"><ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="Narr_ZTeGozHP4kS52hurpBhkEQ">30</ix:nonFraction></ix:nonFraction> million shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="Narr_SteYzzfL-UKZnPV7IDbFLQ"><ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="Narr_onZ_dAPsskadu8TIe7nfCw">8.9</ix:nonFraction></ix:nonFraction> million shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively (see Note 9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_15FBHIvIq0S_S51MKuYg4Q_20_3">8,910</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_govGlk1O30-_26Go0UFF4w_20_6">8,891</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_B_l-wXGfc0ayI5XubwDNFA_21_3">450,458,009</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_BlCGDjq_akGaUpnK6DyWDA_21_6">450,329,515</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_vRnGyLbQo0emdWWBDfrN0Q_22_3">438,678,685</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_sciHL38CU0ubSgUGpuT3Xw_22_6">436,285,863</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_hCN5YdMvVUmdh7EUEW6xJA_23_3">11,788,234</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc__B6ctlztfEKupGVA8EmScw_23_6">14,052,543</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities and stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_QDOFhk1uI0mQhAJEgvYHuQ_24_3">14,091,899</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_umVTwJuCsU6dnAbAX0v60Q_24_6">17,127,391</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to these unaudited condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_58709877_ba56_4d31_9216_fb273f707299"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">(UNAUDITED)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2588ab24_cc7a_4032_b34b_4756242da2f0"></a><a id="_27f4abe9_6cf8_486a_b066_c8b756ce667b"></a><a id="Tc_cw_oHb_0REicDO_5TgVDjg_1_2"></a><a id="Tc_rjDjYOgkEUK-3DkYqvc-Fw_2_2"></a><a id="Tc_-HPRSXdaT0yX1Qr1DL0T-g_3_2"></a><a id="Tc_mfdtTQGB20ej2rxzfEeHKw_3_5"></a><a id="Tc_v5CeFC4ymU2gZJ0_4tC4DQ_4_0"></a><a id="Tc_jcrhtWUzCkmB8ekVNC4UpA_5_0"></a><a id="Tc_2xlrrDnamkahfNnF-Tt0OA_5_2"></a><a id="Tc_w4tNLr56CEyCfB-TbKoBgQ_5_5"></a><a id="Tc_QPMuzyzjWE-OB7iDfzpAAQ_6_0"></a><a id="Tc_Ra94sMwuZkSkGgtoZEf2Cw_7_0"></a><a id="Tc_jcjo9njX3Ei8NEafXCGKaQ_8_0"></a><a id="Tc_ipBwU_Q2kUi8MX05_kTYyw_9_0"></a><a id="Tc_M69VmZVrc0KyqPK8qrIJDA_10_0"></a><a id="Tc_ML3GDaGwDUq-Ddy2kDAcsA_11_0"></a><a id="Tc_d9IgH0mYSkGDKmUaMPmW9w_12_0"></a><a id="Tc_oKxj-iqkrk27052NVi4FyA_13_0"></a><a id="Tc_M-OAVDJTI0msCC3SkXraMg_14_0"></a><a id="Tc_updMD5Ip9E-plkvkRCDVUw_15_0"></a><a id="Tc_KJ7JzfXkgkqpjA4xI32O8w_16_0"></a><a id="Tc_2FY1PFK-l0SLB6FLzC9Rmg_16_3"></a><a id="Tc_wO6GMVlupkKMxDwh5I-H3A_17_0"></a><a id="Tc_7mqlY1n3tUigKAF-Yla3ZQ_17_3"></a><a id="Tc__rnYXkbr5Ee8cLN6enpONw_18_0"></a><a id="Tc_nAfBlVgRsUeHA7oAc-2A5g_18_2"></a><a id="Tc_Ws2JfrSt20qTLXQDd5voFg_18_5"></a><a id="Tc_x5Qjv_TBxUe2rqUTdJ6ETw_20_0"></a><a id="Tc_3CBgyjZ7rUqjyf0Dawu3Rw_21_0"></a><a id="Tc_oYaY7czQwkCp0HRAUB0r3g_21_2"></a><a id="Tc_tuKAE_rz7EWTzzOXmhOtUg_21_5"></a><a id="Tc_E6fEhw83V0eQL6lh09rLug_22_0"></a><a id="Tc_nfM57sd7Ik2u7OQUFEdohg_22_2"></a><a id="Tc_ixD-xWYpNUKDExNduj2obg_22_3"></a><a id="Tc_bLifb-p8uk-6pZdBLQSE0w_22_5"></a><a id="Tc_eA19vEGO90-LzonQjGo4nA_23_0"></a><a id="Tc_HqeC-gLBxEK_nKOazpX8HA_23_2"></a><a id="Tc_72sla3exVEq9RRYl6s7MUg_23_5"></a><a id="Tc_DKEAC5awLE-FSeGRVGUZVg_25_0"></a><a id="Tc_oLqsy8rCSkmtSEyGchggDQ_26_0"></a><a id="Tc_MyDij-ywYk66bQvpAzausg_27_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenues:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_GrantMember_dzr8lBZFQUCRXXMJiuJ70Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_Xisdisujdk-__7tbu4Zx7w_5_3">1,244,061</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_tSwV_5BIrEK_el6Vtlcjzg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_Y8AYJPRmKUyk8ahxzDF05A_5_6">1,234,336</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_6S_jykJjM06fT5aIh-H1oA_6_3">1,244,061</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_3vY0wbljX0qfFcEZqDtQ5w_6_6">1,234,336</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_s6-nV-10xkmyPoEyo868Qg_8_3">2,575,015</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_nGkY97V0EEGImWp1S-YkKA_8_6">3,376,497</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_TUF-mBM8NEyy-4GQ76IYTg_9_3">1,218,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_EEd1VEez9UmGXcR95iaEXw_9_6">2,167,318</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_o79xY0s2uUyarltB_yaURg_10_3">3,793,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_6bpyHcGIqk-0SD9HSL7U9w_10_6">5,543,815</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_onTSb_ktzEegEahN7_V9GQ_11_3">2,549,017</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_DkzEErHKWUuI1XCTWq3I7w_11_6">4,309,479</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other income (expenses):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_HZLn4eN-TUmWk7nRSk2Yqg_13_3">156,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_U0jB4T_grU6q3LegpxPxGA_13_6">84,654</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="0" id="Tc_vSOOdxm07km6nUmSV2V23Q_14_3">2,392,822</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="0" id="Tc_gBt_GdJEkUa_hXBvWroI0Q_14_6">4,224,825</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Discontinued operations:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Loss from discontinued operations, net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" sign="-" scale="0" id="Tc_JwuPhQavfkOvW-KUpOnzdg_16_6">742,751</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="0" id="Tc_yl5ucuPpckaJaXHED4kwrg_17_6">742,751</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_LKwcPV7SiUyNM_wFD7y4VA_18_3">2,392,822</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_6dnORrlExUaYXXjkT7BT8A_18_6">4,967,576</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Loss from continuing operations, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_ppRtnx6mokC3Cu0VMpBWVg_21_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" sign="-" scale="0" id="Tc_ppRtnx6mokC3Cu0VMpBWVg_21_3_2">0.27</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_srN3w7LZBkOfI_Hhnb2eFQ_21_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" sign="-" scale="0" id="Tc_srN3w7LZBkOfI_Hhnb2eFQ_21_6_2">0.48</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Loss from discontinued operations, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_JpOB3GcQTkyA1V5b1aT6VA_22_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" sign="-" scale="0" id="Tc_JpOB3GcQTkyA1V5b1aT6VA_22_6_2">0.09</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_tiwtYm9Grka06hTwZeihFA_23_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_tiwtYm9Grka06hTwZeihFA_23_3_2">0.27</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_xUl_jG-65kWruJOEbt-S_w_23_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_xUl_jG-65kWruJOEbt-S_w_23_6_2">0.57</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of common shares outstanding:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_BtW_X9ji10moSYyPNXYLBg_26_3">8,901,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_ikSLvETCjU-meWuYan_b8w_26_6">8,721,031</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_ongVgJC-I0mNjk0ZdwgIVg_27_3">8,901,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_6FOEusaym06wJ7AmBYsm1Q_27_6">8,721,031</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to these unaudited condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_195d7d0f_c303_4668_b0be_84bbf4d1f717"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">(UNAUDITED)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_54c1946e_d944_416e_89a0_b6e5afed3a82"></a><a id="Tc_HlLcKAC_JkatnnfY44Pjgw_1_2"></a><a id="Tc_iwo8Kr094kuC5V39-Zm2EQ_2_13"></a><a id="Tc_x0O9vJPSXkmnsv6ZOZKHnA_3_2"></a><a id="Tc_Ry6FMIrbxkSL0NrO9GUUnA_3_7"></a><a id="Tc_K7pswmQ5rUS-lHgOhFPdNg_3_10"></a><a id="Tc_IGtzF7i1KU-LzwSlU5ES0A_3_13"></a><a id="Tc_a9JFKdByq0eAPFDLjQUwDw_4_2"></a><a id="Tc_LHjsFlfeBk-9dhk5Qm0JAw_4_4"></a><a id="Tc_-SHRG_XEgk6Nb2PWHTWFjw_4_7"></a><a id="Tc_b8WVOlcQ_kGLYeAPZXJdMw_4_10"></a><a id="Tc_fhoVxCUbmUi8FOagwGEARw_4_13"></a><a id="Tc_7PUCG-FloUu2nejYqecj5A_5_0"></a><a id="Tc_uk4GSKNY60O7c3A6ml8aXA_5_4"></a><a id="Tc_uT6NtuJ2nkeC2ivJ20TOpQ_5_7"></a><a id="Tc_IyVGaXadc0aOd-Tgv3aPng_5_10"></a><a id="Tc_9xmD4h6D6UifS_VQE7DTJg_5_13"></a><a id="Tc_Yz7syLClwUKWFatTfhYH1g_6_0"></a><a id="Tc_y64C--cnnU27iBG6-0A4dA_6_11"></a><a id="Tc_-ox8NOrCVkyAOzR3kKVphQ_7_0"></a><a id="Tc_iphNdesEtEmm9cXzgWVLbw_7_2"></a><a id="Tc_j-ohgr0T4US3LNlhM_AZoA_7_5"></a><a id="Tc_5TdhOvWJAU-T4SPwQF4IPw_7_11"></a><a id="Tc_nXW2mo-hXkG0ccVoUQ4rMA_8_0"></a><a id="Tc_DgrOfTd9QkqU5uKXAKffTw_8_2"></a><a id="Tc_1nlD41kKHEqH2o2IX81IDg_8_5"></a><a id="Tc_qYYXAlerIU6LtrwYw9B9sQ_8_8"></a><a id="Tc_h3xxfYbYvEyqf1qb38Mt2w_9_0"></a><a id="Tc_naKcqEKP90m_x25mJQvyKg_9_4"></a><a id="Tc_4Rxb0JOc9EWr182Qr-BjLA_9_7"></a><a id="Tc_DY8TVQVJIkOOGW2RVzNE5Q_9_10"></a><a id="Tc_1ujF7sJzWkK7329HnRqajg_9_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months Ended March&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional&#160;Paid-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Par&#160;value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balance at December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p2J4oIHCPEuZlK3Ssu23sA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_gMbFn58QHkuxiYMfP8p0BA_5_2">8,891,420</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p2J4oIHCPEuZlK3Ssu23sA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_OWsp8W0ulk6JcMXR75r1kw_5_5">8,891</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dPQr3dLFZE-DSSf241ybww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_AgN4EIrkCkyfgDCQtkdyXA_5_8">450,329,515</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_O2ehFFy9IkO1iNk3wb4ojA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_yRZJZljvoEKxzWY5maQg8A_5_11">436,285,863</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_16IYXOUHp0yaYUyPUNGsdA_5_14">14,052,543</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"> Issuance of common stock from exercise of stock options </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4CuqoUChNU6LCLMJQNy2vg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_bsLOFFgWx0i5G0zRpUiM7Q_6_2">19,497</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4CuqoUChNU6LCLMJQNy2vg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_gb5AcMJmXUyqSCVcR3_c2w_6_5">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J_5wr1xoCUiUQha0LU7yxQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_qS5fjvnEsEiEsLuvZjtgDg_6_8">49,077</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_8yLdFWlao0mf6xMxo0oK8w_6_14">49,096</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J_5wr1xoCUiUQha0LU7yxQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_zZF3f_1IGEqNlv-5bWPfpg_7_8">79,417</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_OnlVWiBESkebU-JsI9OebQ_7_14">79,417</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"> Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wroXSHfJ30-xSPaXlw7fRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_93H0gkAFkkudnMzPihZWYQ_8_11">2,392,822</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_pzeVdXROT0i195WTxQe8zQ_8_14">2,392,822</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balance at March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L3GqS7LIaEaMZLbGeyWEVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_ijIAy9WkjkSVd1t9i-m_eA_9_2">8,910,917</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L3GqS7LIaEaMZLbGeyWEVw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_c8lKYvyPRkKDYEx4ponA9w_9_5">8,910</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hteoEo475kS8tfpScfdJoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_YhLpHTKhEka8aZet6l_EPA_9_8">450,458,009</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PKZChDUbxEO2qD8-67k5Hw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_0QiMklXgcUqeWp9vT-sScA_9_11">438,678,685</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_4B55WbgL3ke9MRLJxhcJaQ_9_14">11,788,234</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_1b3ec23e_d425_4652_ba59_9304c2a44292"></a><a id="Tc_iUmD9uqs5k-mG0OHbevQ0g_1_2"></a><a id="Tc_5gYOTeQTdk-3yu_CWZYuUA_2_13"></a><a id="Tc_vkwFfJseOkWr6plAXH3Xrw_3_2"></a><a id="Tc_Tb2dmUNk7kyz6v0BeosPBg_3_7"></a><a id="Tc__cqPcbkeiUuNhhYiOxf61w_3_10"></a><a id="Tc_tKMqP0xKVE-R-xrBexSKGA_3_13"></a><a id="Tc_bwFsqz-1AEyXHUug_HepRg_4_2"></a><a id="Tc_uD6PLlz5GEiMKSEIgnALqw_4_4"></a><a id="Tc_i1lbeXL7UEW8ej-OqryIdQ_4_7"></a><a id="Tc_s5sijFm9DE-dWvqvUVGPLA_4_10"></a><a id="Tc_yrcCTUapeEuNjYI2ur9kBQ_4_13"></a><a id="Tc_pRBj8ZKuOEGElu1zCPKrBQ_5_0"></a><a id="Tc_RXHg_xEAzESc9dhu2Iph6Q_5_4"></a><a id="Tc_QMSYRC8ez0m76t4NioSTdA_5_7"></a><a id="Tc_ExIzA_WfaEK99M6mVIOJew_5_10"></a><a id="Tc_jDDsUAzIeU2rd3yE7nuaVA_5_13"></a><a id="Tc__FPF-0u3qEmPiJ1gUe0x8Q_6_0"></a><a id="Tc_iVOsX4gs2Ui8ysEZQwIIQg_6_11"></a><a id="Tc_xHZMF3t_q0WyGAY1QdvsLA_7_0"></a><a id="Tc_ZDmq2AtLhU218ENo45Lu9w_7_11"></a><a id="Tc_uTXRW1FekUeBgIU-wOH0og_7_14"></a><a id="Tc_CjXhV-lF5Uqt3Lve6DEr0A_8_0"></a><a id="Tc_65F6D5NuU0KqMm39lzrsMg_8_2"></a><a id="Tc_PLLtef-NHkuL7jGGp-cd0Q_8_5"></a><a id="Tc_XR5I25y_l0aLaD17CwT1LA_8_11"></a><a id="Tc_Wv6AQrnV7kGMdC_e-yYpmQ_9_0"></a><a id="Tc_4ieRduCxcEaSCBMxVVQWOw_9_2"></a><a id="Tc_qjijRn26sEuz-MYiDfC8SA_9_5"></a><a id="Tc_Tk0DtyPWr0yk98JDkoaX9w_9_8"></a><a id="Tc_7aMX069uW02UoqMdU3nlcg_10_0"></a><a id="Tc_m9civubVrE-jvFxQSUWYQQ_10_5"></a><a id="Tc_aplh-Wjq_U6xM0moS16TiQ_10_8"></a><a id="Tc_WBDHV10UUUetwMVSaxKcXw_10_11"></a><a id="Tc_ewKdfq4zKUaKUnl2q7fr_A_10_14"></a><a id="Tc_lUUSYOAInEKMtpK84ii49g_11_0"></a><a id="Tc_qPK2o9BWSE6hD6TyRjiWqQ_11_4"></a><a id="Tc_MNmtpBkCrE6AH3lRXg_0qQ_11_7"></a><a id="Tc_DFdvCZSEgUCdJTOWFSclTA_11_10"></a><a id="Tc_kpWUINlugUqT3wcA-mrJfA_11_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended March&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional&#160;Paid-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Par&#160;value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in&#160;Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj8-kTaoPUeqeGIfHnTabg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_Aq4T4o4pV0iLLo1nLsmAPw_5_2">8,405,771</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj8-kTaoPUeqeGIfHnTabg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_tpZOmReiVUKjEg_350H47g_5_5">8,406</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bkjZN5Y5rEWwwaBWPP47cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_NEO4AWPQOEaPLf0iuKPWUg_5_8">447,641,680</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dAcdkzltg0mbv8cPmlI6WA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_X9SGYKUgm0-XcODhmHvEmg_5_11">428,049,049</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2022_dDnDDGPKLkOOtV5YB9PuYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_E7lW4N-HoUGcoUnSRDuGvQ_5_14">19,601,037</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of common stock for cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yie4PE_5UKKtvhQWc8ymQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_CwYUFWAQck6BzauOs5odqQ_6_2">212,761</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yie4PE_5UKKtvhQWc8ymQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_DfYkjLsVdkeAh7XvgFwzmQ_6_5">213</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kLbzwvujTEy1z59aTzl4IQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_Beobs0OBk0mbra-f0GFOLg_6_8">619,761</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_y6-Y4Bmp70yXYZXJrUsCXg_6_14">619,974</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"> Issuance of common stock as commitment fee for future financing </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yie4PE_5UKKtvhQWc8ymQ" decimals="INF" format="ixt:numdotdecimal" name="mrkr:IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" scale="0" id="Tc_RTNj1EDDqE-AiyPPlM4bSw_7_2">180,410</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yie4PE_5UKKtvhQWc8ymQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" scale="0" id="Tc_kLx1W3IKO0yWUfqzVBgkEg_7_5">180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kLbzwvujTEy1z59aTzl4IQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" sign="-" scale="0" id="Tc_FYTGKF2FDEKpBsobT8qaqQ_7_8">180</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kLbzwvujTEy1z59aTzl4IQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_0IJjBfHojU6t0RZaUFehAg_8_8">659,913</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_vWlZJAS13Uqa8BhEOGgbRQ_8_14">659,913</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HbuT4I4LOEWfD8qUtjixAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_Vmz-pSM3tk67G2IeDZT6vg_9_11">4,967,576</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_QIG_PccDLE-fUUGBek9xLw_9_14">4,967,576</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"> Fractional shares adjustment due to reverse split </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yie4PE_5UKKtvhQWc8ymQ" decimals="INF" format="ixt:numdotdecimal" name="mrkr:StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit" sign="-" scale="0" id="Tc_hIYUmLpu5EqtLPooG-vItA_10_2">113</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:33.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ARak6biMC0C2vE3aHgU_OA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_oiMsJvD900KksAHkACRXEg_11_2">8,798,829</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ARak6biMC0C2vE3aHgU_OA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_m3rUzgog8UuL3E34MMqa0Q_11_5">8,799</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TabWhcOewUWWAHC4rI6AMA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_7bniK7afSUOTsIiZXjZ6Vg_11_8">448,921,174</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PUYOhITdW02F2X4CUsXlkg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_qCjbZO06IkSveuTgU2fFGQ_11_11">433,016,625</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2023_N3CIHFtK7keuOQ6DeBbsBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_1NgzgRcdkUSZiE8NckN0PQ_11_14">15,913,348</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to these unaudited condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7463fb76_fd05_4ba7_9546_190ddfd3a660"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">(UNAUDITED)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2754bc31_9829_47cf_b327_8a54e3fb6fa6"></a><a id="Tc_kIMBR3W6s0W8k0orWYBnIA_1_2"></a><a id="Tc_ma4UNZ4qKEewLKsAEWO87Q_2_2"></a><a id="Tc_5VuRBuGL9UOolo_ZirsFYw_3_2"></a><a id="Tc_UH3TekVB3kqyGHyQabbcGw_3_5"></a><a id="Tc_OizZMgiz6E2xxFjeqLS3jQ_4_0"></a><a id="Tc_1CGQ0GgfmEOExn4ovXkaSw_5_0"></a><a id="Tc_mnkSnaQtp0ydMjLsJ-ixAA_5_2"></a><a id="Tc_Qt-5uAh1HU6jaI66kyqYJw_5_5"></a><a id="Tc_fc4Df5qE6kuLNfF_cPXV7w_6_0"></a><a id="Tc_Ciw9-vBK5kyvblXEStPIsg_6_3"></a><a id="Tc_-hCFDnfXnE2b0pYyt05ubg_7_0"></a><a id="Tc_Mw3whvkSVk2Di0_EC13Hyw_8_0"></a><a id="Tc_iINPRIYtjUO4lh3aSHVcxw_9_0"></a><a id="Tc_D0g0jQGpXkag5u5GWeYreQ_10_0"></a><a id="Tc_sCfnyNjhl0qzIbS6a2pozA_11_0"></a><a id="Tc_EI-hmYC9zkON-zyK5NgW8A_12_0"></a><a id="Tc_uKUIiyBntUG2NHCk6xQsxg_13_0"></a><a id="Tc_ztJhAoumQ0eOFMYcZ0dNZw_13_3"></a><a id="Tc_kE6hk6cPIEqTwG5K1U4bnA_14_0"></a><a id="Tc_SIF9CGREHkC42Pi1AzsGiQ_14_6"></a><a id="Tc_2e4f_1msnUCOgGUz9pf0fg_15_0"></a><a id="Tc_Mk-XKQyMdEKpznWqpc3Clg_16_0"></a><a id="Tc_Ln5ypBbiV0ahJZuwvPfU7g_17_0"></a><a id="Tc_hSFd1vee3k6VWU8a8tBXFA_17_3"></a><a id="Tc_QZNGwB1rm0Os8U8Ur4tKcQ_18_0"></a><a id="Tc_lGm-cgSWXEasn3ZeWcllog_19_0"></a><a id="Tc_nxAFTGFUwEyu1_M08Tnsrw_20_0"></a><a id="Tc_Vy_0Aku2FEG0YY0x3VrUDA_20_3"></a><a id="Tc_al4En32BMUSvJtQOsvuB7w_21_0"></a><a id="Tc_jGOY81ufgkWetCjdIbdW_A_21_3"></a><a id="Tc_1F6i_zu6dECGABf_dd_vBw_22_0"></a><a id="Tc_muBcBvbvPkCyddgN2Oa-XA_23_0"></a><a id="Tc_Y6LkmbtAVUGvJ4SrEj3eDw_23_3"></a><a id="Tc_eEjB0PB_kkunNezcEWWO0Q_24_0"></a><a id="Tc_6J5P4QniU0-Jz8s5YlBYQg_24_6"></a><a id="Tc_RPVN2VgvDUm2wUyl8SFdVg_25_0"></a><a id="Tc_qW2Tb9pwfUiJ_qyR_gL9Hw_26_0"></a><a id="Tc_BYmOLB-e6EWCF81lCH_dYw_27_0"></a><a id="Tc_1fX316uwCk-yDeTNPYwf3A_28_0"></a><a id="Tc_FOd2Og_kukKIx15Wq_zr0w_28_2"></a><a id="Tc_dN2kBQBF-EeWML8rxWJDSA_28_5"></a><a id="Tc_B2t0_nkmN0eN3FZYiBmFMg_30_0"></a><a id="Tc_O8qlbnAyuUid6aDUzUPoqQ_31_0"></a><a id="Tc_fQ7u_fnOtUyucu3thVR6CA_31_2"></a><a id="Tc_geyFru05akG4TLETTuKGSA_31_3"></a><a id="Tc_buOows0F_k2f26xEjYv1lg_31_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Flows from Operating Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_pIglNnSgSUiQhbb52b1zbQ_5_3">2,392,822</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_uXID9GdfDka9jltSxsuVog_5_6">4,967,576</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Less: loss from discontinued operations, net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="0" id="Tc_IfkVdqM97km8RUyUAiTpLQ_6_6">742,751</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Net loss from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="0" id="Tc_lcbyPeLfb0eT_CcPN0iQWw_7_3">2,392,822</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="0" id="Tc_oUPYmP8uoEGVUU0rN1u8Yg_7_6">4,224,825</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;"><b style="font-weight:bold;">Reconciliation of net loss to net cash used in operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_lq2JRNT8MU-vNgNxW654ZQ_9_3">79,417</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_IBQLQl-B3EiHu1zJBRWHpQ_9_6">659,913</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 12pt;"><b style="font-weight:bold;">Changes in operating assets and liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 18pt;">Prepaid expenses and deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="0" id="Tc_tCr5Hyht80-MzSA7k-19DQ_11_3">71,117</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="0" id="Tc_cpUt-5ELr0mfHdO8s6DIUw_11_6">36,452</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 18pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="0" id="Tc_OMrJdOVM0Ea3ceWWd4Fu3Q_12_3">823,647</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" sign="-" scale="0" id="Tc_-qGDVmD8dEikk5MwMk5Qyg_12_6">1,319,118</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 18pt;">Related party receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" scale="0" id="Tc_QsyPFBkQr0GRW8q8TsiAMQ_13_6">1,000,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 18pt;">Related party payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" sign="-" scale="0" id="Tc_BgXNCluRRUu7jyMxAybI5Q_14_3">975,690</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 18pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_y3hF3Hn36E2zgSYLvYOftQ_15_3">204,507</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_zjmD2agEpkeuCKaDsyia5w_15_6">111,171</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 24pt;">Net cash used in operating activities - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" sign="-" scale="0" id="Tc_hzz546DGK0m80ZEYiFDHeA_16_3">3,837,118</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" sign="-" scale="0" id="Tc_RfPvo9M5_0OjHhObc-RbMg_16_6">3,098,171</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 24pt;">Net cash used in operating activities - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" sign="-" scale="0" id="Tc_cknQWdozXEuqWpuL47uv7A_17_6">2,790,124</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_rOqCM3aFSU-cpE3EA5fotA_18_3">3,837,118</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_-tFCi7TFtkOJUEYoplS8EQ_18_6">5,888,295</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Flows from Investing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 12pt;">Net cash used in investing activities - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" sign="-" scale="0" id="Tc_6PNoe54o10KJr6CT3Powlg_20_6">112,608</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 18pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_wjZ3km3ksU-ctaPTOAAD0g_21_6">112,608</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Flows from Financing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 12pt;">Proceeds from issuance of common stock, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_UR8Htp18GUagpDbLRaMnxw_23_6">619,974</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 12pt;">Proceeds from stock options exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_NhVyLSc0AEqotu6P57Kkzw_24_3">49,096</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 18pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_bypCZ-RUo0yiQvQPLm2INA_25_3">49,096</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_rDeN8Jq9s0a4LFlpBiJeBQ_25_6">619,974</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Net decrease in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="0" id="Tc_HX2ES10j60u2j7_SBqTESw_26_3">3,788,022</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="0" id="Tc_csU2UliTIkqdmG5d0iQ5PA_26_6">5,380,929</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_la1NGz_w3EmJGDg_sH_q7g_27_3">15,111,450</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2022_dDnDDGPKLkOOtV5YB9PuYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_A45sf6pCdUWC0m5FGXkZxw_27_6">11,782,172</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents at end of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_EgjRfonGs0mWlvm05obl2g_28_3">11,323,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2023_N3CIHFtK7keuOQ6DeBbsBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_HUdnmsCeEEeyRIf0H_vZwQ_28_6">6,401,243</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental schedule of non-cash financing and investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock as commitment fee for future financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="mrkr:NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing" scale="0" id="Tc_4TLCQrmhd0OMIXhTFeYtUA_31_6">180</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to these unaudited condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e875c7e4_cea7_4a7f_8008_e180b0e4ebcf"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="NOTESTOCONDENSEDCONSOLIDATEDFINANCIALSTA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">(Unaudited)</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:NatureOfOperations" id="Tb_Dnb6G9TagEutp0uuK1JWhw" continuedAt="Tb_Dnb6G9TagEutp0uuK1JWhw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;1: NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marker Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;we&#8221;), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company&#8217;s multi tumor associated antigen (multiTAA&#8221;)-specific T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Purchase Agreement with Cell Ready</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 26, 2023, the Company completed the previously announced transaction with Cell Ready, LLC (&#8220;Cell Ready&#8221;) pursuant to a Purchase Agreement (the &#8220;Cell Ready Purchase Agreement), dated May 1, 2023, by and between the Company and Cell Ready. Mr. John Wilson is a member of the Company&#8217;s board of directors and is serving as the CEO of Cell Ready, therefore Cell Ready is a related party. Pursuant to the Cell Ready Purchase Agreement, effective as of the Closing Date, the Company (i) assigned to Cell Ready the leases for the Company&#8217;s two manufacturing facilities in Houston, Texas (the &#8220;Manufacturing Facilities&#8221;), (ii) sold to Cell Ready all of the equipment and leasehold improvements at the Manufacturing Facilities and (iii) assigned to Cell Ready its rights, title and interest in the Company&#8217;s Master Services Agreement for Product Supply (the &#8220;MSA&#8221;), dated April 7, 2023, by and between the Company, Cell Ready and Indapta Therapeutics, Inc., as well as its rights, title and interest in any contracts related to the equipment and Manufacturing Facilities (collectively, the &#8220;Purchased Assets&#8221;). Cell Ready acquired the Purchased Assets for total consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_6_26_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_XIIQwpm8KkCnK2MdeGDs6g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="6" id="Narr_kHIA40vHTkSBYESdnjdXiA">19.0</ix:nonFraction> million. In connection with the purchase of the Manufacturing Facilities, Cell Ready also extended offers of employment to approximately <ix:nonFraction unitRef="Unit_Standard_employee_YXZ7VHgYFkK0MKSPoxHTNQ" contextRef="Duration_6_26_2023_To_6_26_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_I4S7uiZnTE-bi56dzKi0tw" decimals="INF" format="ixt:numdotdecimal" name="mrkr:OffersEmploymentToNumberOfEmployees" scale="0" id="Narr_z1j6kAHJNEyA5rfU9eM6hA">50</ix:nonFraction> of the Company&#8217;s former employees in its manufacturing, development, quality, and regulatory affairs functions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Purchased Assets constituted a significant disposition. Based upon the magnitude of the disposition and because the Company is exiting certain manufacturing operations, the disposition represents a significant strategic shift that will have a material effect on the Company&#8217;s operations and financial results. Accordingly, the assets sold meet the definition of a discontinued operation, as defined by Accounting Standards Codification (&#8220;ASC&#8221;) 205-20 &#8211; Discontinued Operations, and prior comparative periods have been retroactively adjusted to reflect the current presentation. See additional discussion at Note 7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 22, 2024, we entered into a Master Services Agreement for Product Supply (the &#8220;MSA&#8221;) with Cell Ready to provide outsourced services previously performed by the Company prior to its asset sale to Cell Ready. Cell Ready, which is owned by one of our directors and shareholders, Mr. John Wilson, is a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. If the services involve the supply of product, Cell Ready is required to supply such product in conformance with the product requirements set forth in the applicable work order(s). Under the MSA, Cell Ready is to use only personnel with sufficient qualifications and experience to supply the services contemplated by the MSA, provide its personnel with adequate training and assume full responsibility for its personnel&#8217;s compliance with the MSA. Further, Cell Ready is required to provide the Company with assistance and cooperation in order for the Company to obtain and maintain all necessary regulatory approvals, at the Company&#8217;s expense.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Dnb6G9TagEutp0uuK1JWhw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Organizational Changes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 2023, the Company implemented changes to its organizational structure due to the transaction with Cell Ready and to reduce operational costs. In connection with these changes, the Company reduced headcount, including the separation of its former Chief Executive Officer, Peter Hoang, in May 2023, and its former Chief Accounting Officer, Michael Loiacono, in June 2023. During the second quarter of 2023, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_4_1_2023_To_6_30_2023_wZXVoXh7Q0KniAnmTI3IqA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SeveranceCosts1" scale="6" id="Narr_7xd0VSYl_E-Q8DH5eoVDxg">0.9</ix:nonFraction> million of severance and termination-related costs. The payments of these costs were completed in July of 2023. Effective May 1, 2023, the Company&#8217;s board of directors appointed Dr. Juan Vera as the Company&#8217;s President and Chief Executive Officer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective June 30, 2023, the board of directors appointed Eliot M. Lurier as the Company&#8217;s Interim Chief Financial Officer, whereby Mr. Lurier provided consulting services to the Company pursuant to a consulting agreement between the Company and Danforth Advisors, LLC (&#8220;Danforth&#8221;) and received no compensation directly from the Company. On November 17, 2023, the Company terminated the consulting agreement between the Company and Danforth, effective January 16, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 17, 2023, Mr. Lurier ceased serving as the Company&#8217;s Interim Chief Financial Officer and Dr. Vera was appointed as the Company&#8217;s Principal Financial and Accounting Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 26, 2023, the Company effected a one-for-ten (<ix:nonNumeric contextRef="Duration_1_26_2023_To_1_26_2023_awyJo1ParUe6ER8qP8Er1Q" name="us-gaap:StockholdersEquityReverseStockSplit" id="Narr_myqp_mw2dEqXRMoMkAvWUA">1-for-10</ix:nonNumeric>) reverse stock split of its common stock (the &#8220;Reverse Stock Split&#8221;) and a corresponding reduction in the total number of authorized shares of its common stock from <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_1_26_2023_srt_RangeAxis_srt_MaximumMember_e2_Hkwej-0-x0rfYttNybA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_CRoFtsxdq02OoXPHz1oEsg">300,000,000</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_1_26_2023_srt_RangeAxis_srt_MinimumMember_PkV5_ayFjkm8F2rhSnUmqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_w9XXpVf7xUm1SP5kpIExmw">30,000,000</ix:nonFraction>. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:BasisOfAccounting" id="Tb_fhnX5OfzDEeUylhYbx0UJQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;2: BASIS OF PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (&#8220;SEC&#8221;) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results (see Note 7 for information on discontinued operations).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The results for the unaudited condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2024, or for any future interim period. The condensed consolidated balance sheet at December 31, 2023 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2023 and notes thereto included in the Company&#8217;s annual report on Form 10-K filed on March 26, 2024.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock" id="Tb_SqWBMw6gkEu9DKEC7mEFHA" continuedAt="Tb_SqWBMw6gkEu9DKEC7mEFHA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3: LIQUIDITY AND FINANCIAL CONDITION </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March 31, 2024, the Company had cash and cash equivalents of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_z5NWMk1A_kWpL31Se-1WuA">11.3</ix:nonFraction> million. The Company&#8217;s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing; successfully progress its product candidates through preclinical and clinical development; obtain regulatory approval of one or more of its product candidates; maintain and enforce intellectual property rights; develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity, debt financings and grants. In August 2021, the Company entered into a Controlled Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;ATM Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and RBC Capital Markets, LLC (the &#8220;Sales Agents&#8221;), pursuant to which the Company can offer and sell, from time to time at its sole discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_8_31_2021_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_090YrRTZKEOoBAZPdsIihw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesSubscriptions" scale="6" id="Narr_caFjhUT3wUaLlOzeuorGMQ">75.0</ix:nonFraction> million. Any shares of its common stock sold will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-258687), which the SEC declared effective on August 19, 2021. However, our use of the shelf registration statement on Form S-3 will be limited for so long as we are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement and in accordance with the ATM agreement. The Sales Agents are entitled to compensation under the Sales Agreement at a commission rate equal to <ix:nonFraction unitRef="Unit_Standard_pure_Qbvl_Q3p3U-i5knuHKFQlQ" contextRef="Duration_8_1_2021_To_8_31_2021_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_fMwy5Q-88kG0ISyjxlel4A" decimals="3" format="ixt:numdotdecimal" name="mrkr:CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" scale="-2" id="Narr_GzeD-3FilEqwwHaiZORhsA">3.0</ix:nonFraction>% of the gross sales price per share sold under the ATM Agreement, and we have provided each of the Sales Agents with indemnification and contribution rights. During the three months ended March 31, 2023, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2023_To_3_31_2023_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_OIylfIWvwk61OIbrkzAtLg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_KeFSKWHGkEqYJSgB6m-LlA">200,261</ix:nonFraction> shares of its common stock under the ATM Agreement for proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_OIylfIWvwk61OIbrkzAtLg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_i5Ct3d1ysk6pTxG3FaRrig">0.6</ix:nonFraction> million. There was <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2024_To_3_31_2024_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_h4ZLvIQokUOG-qQCkBlAeA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_IL_gWvZON0-BgmQeLA_RdQ">no</ix:nonFraction> common stock issued under the ATM Agreement during the three months ended March 31, 2024. In April 2024, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_4_1_2024_To_4_30_2024_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_sE3cONnYgEmmcMHZ2wUk0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_pm9uA5-6F0OH-s23ZH5eHg">8,178</ix:nonFraction> shares of its common stock under the ATM Agreement resulting in net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_4_1_2024_To_4_30_2024_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_sE3cONnYgEmmcMHZ2wUk0g" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_28ix_zWqmkG_bG65y2TUXA">0.04</ix:nonFraction> million, after deducting agent commissions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_8_31_2021_To_8_31_2021_wLINgxwAtEqXJr9cCHPb-A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="Narr_dYp3aCeg80qdUvqCh1EOuw">13.1</ix:nonFraction> million from the Cancer Prevention and Research Institute of Texas (&#8220;CPRIT&#8221;) to support the Company&#8217;s clinical investigation of MT-401. Through the date of this filing, the Company has received $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FundsReceivedFromCpritGrant" scale="6" id="Narr_GoVjXRTy2UmckfbpfvosuA">6.9</ix:nonFraction> million of funds from the CPRIT grant. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_GrantMember_dzr8lBZFQUCRXXMJiuJ70Q" decimals="-5" format="ixt:numdotdecimal" name="mrkr:RevenueFromGrantRelatedToCprit" scale="6" id="Narr_dScZaRDsTUKrpgIWIn1nRQ">0.8</ix:nonFraction> million of grant income related to the CPRIT grant as revenue for the three months ended March 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2022, the Company received notice from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) that it had awarded the Company a $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_9_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_QKfSVv0dhkacuUG8PSdyzg" decimals="-5" format="ixt:numdotdecimal" name="mrkr:GrantReceived" scale="6" id="Narr_gNeZw5grqE-lLhR1QBu_jw">2.0</ix:nonFraction> million grant from the FDA&#8217;s Orphan Products Grant program to support the Company&#8217;s clinical investigation of MT-401 for the treatment of post-transplant AML Through the date of this filing, the Company has received $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_9_n_o50vykCM5Ly004kRVQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_NVp3u1GQFUifr9ftYTrXHQ">0.8</ix:nonFraction> million from the FDA grant. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_9_n_o50vykCM5Ly004kRVQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr__p3iPRXpBkujLhywjTw2TA">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_dFfPvaLfIEikU4XiNmZE_A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_wqxWX2Yis0GYx_dSvp4Bkg">0.1</ix:nonFraction> million of grant income related to the FDA grant as revenue for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:OrphanProductsGrantProgram" scale="6" id="Narr_VvkqwOxZ0EOnkk9PF8HBhQ">0.3</ix:nonFraction> million of grant income receivable, which represented grant income earned in advance of funds to be received from the FDA. In April 2024, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_4_1_2024_To_4_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_b7OtDgPp-kyyI1YWR77jEA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_3zmf0q4t50SVXsNz79-4sA">0.3</ix:nonFraction> million of funds from the FDA grant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2023, the Company received notice of a $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_5_1_2023_To_5_31_2023_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_t3VLl29vOk-QUwtoTypBUw" decimals="-5" format="ixt:numdotdecimal" name="mrkr:GrantReceived" scale="6" id="Narr_lEd5sNbPjE2ztqM_ss-AWg">2.0</ix:nonFraction> million grant from the National Institutes of Health Small Business Innovation Research (&#8220;SBIR&#8221;) program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents. Through the date of this filing, the Company has received $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_K-XuDOatfU2spHjQPAU4OA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_eg4pXPbok0K8PDsToAfwhA">0.4</ix:nonFraction> million from SBIR. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_K-XuDOatfU2spHjQPAU4OA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_0ZPXIw4PcEiU9Hc-1lDw3g">0.2</ix:nonFraction> million of grant income related to the SBIR grant as revenue for the three months ended March 31, 2024. As of March 31, 2024, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_xgSQFi7SKUC3P-uEqMdsgQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherReceivables" scale="6" id="Narr_n2UKfHxLN0qmNkeUc51TGQ">0.2</ix:nonFraction> million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In April 2024, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_4_1_2024_To_4_30_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_YTxnqMIXBE2WBHHgARjHqg" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_Lom6d0NqRU6MbY7EEUFOHw">0.2</ix:nonFraction> million of funds from the SBIR grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As described in Note 1, on June 26, 2023, the Company completed the transaction with Cell Ready pursuant to the Cell Ready Purchase Agreement for total consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_6_26_2023_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember__S3prYqHtE6Us-UKNLgTqA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="6" id="Narr_QBrXpJ6bQ0-pz-q0v0U6og">19.0</ix:nonFraction> million. On February 22, 2024, the Company entered into a Master Services Agreement for Product Supply (the &#8220;MSA&#8221;) with Cell Ready, a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company expects to continue to incur substantial losses over the next several years during its development phase.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_SqWBMw6gkEu9DKEC7mEFHA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on the Company&#8217;s clinical and research and development plans and its timing expectations related to the progress of its programs, the Company expects that its cash and cash equivalents as of March 31, 2024, including drawdowns of available grant funds, will enable the Company to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2025. Prior to the Cell Ready transaction, there was substantial doubt regarding the Company&#8217;s ability to continue as a going concern, which was alleviated by the proceeds from the transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has based this estimate on assumptions that may prove to be wrong, and the Company could utilize its available capital resources sooner than it currently expects. Furthermore, the Company&#8217;s operating plan may change, and it may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of the Company&#8217;s product candidates and the extent to which the Company may enter into additional collaborations with third parties to participate in their development and commercialization, the Company is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated clinical trials. The Company&#8217;s future funding requirements will depend on many factors, as it: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiates or continues clinical trials of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continues the research and development of its product candidates and seeks to discover additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintains and enforces intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enters into contract manufacturing arrangements with Cell Ready or other contract manufacturing organizations for clinical manufacturing supply;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishes sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluates strategic transactions the Company may undertake; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enhances operational, financial and information management systems and hires additional personnel, including personnel to support development of product candidates and, if a product candidate is approved, commercialization efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has sufficient cash available to meet its operating requirements for at least the next twelve months from the issuance of these financial statements. However, the Company does not have sufficient sources of revenue to provide incoming cash flows to sustain its future operations beyond the fourth quarter of 2025. As outlined above, its ability to pursue its long-term planned business activities is dependent upon its successful efforts to raise additional capital and grant income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The current macro-economic environment of decades-high inflation and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company&#8217;s ability to access capital, which could in the future negatively affect the Company&#8217;s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company&#8217;s business and the value of its common stock.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_VPBE6sfnFkKok_OC3GT0NQ" continuedAt="Tb_VPBE6sfnFkKok_OC3GT0NQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;4: SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_GEwIZdV0VUKQykMWgmdJKQ" continuedAt="Tb_GEwIZdV0VUKQykMWgmdJKQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Principles of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals Inc. &#8211; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada, Inc. All significant intercompany balances and transactions are eliminated upon consolidation.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_VPBE6sfnFkKok_OC3GT0NQ_cont1" continuedAt="Tb_VPBE6sfnFkKok_OC3GT0NQ_cont2"><ix:continuation id="Tb_GEwIZdV0VUKQykMWgmdJKQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:UseOfEstimates" id="Tb_EAfUA6JwfkiVuL-CgEfFyg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results may differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies, controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense and income taxes.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_mCGdelzC8kGxJryU5U2H0w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at March 31, 2024 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits of $250,000. As of March 31, 2024, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:CashAtFinancialInstitutions" scale="6" id="Narr_3jfdukdB9kubSrcAkORkaw">1.4</ix:nonFraction> million in cash at financial institutions and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:USGovernmentAgenciesSecuritiesAtCarryingValue" scale="6" id="Narr_l4ijpHzo_0qqbPj_ihAzkQ">9.9</ix:nonFraction> million in U.S. government agency securities, for aggregate cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_mjdQQuYzPk-bD4XmmGWEOg">11.3</ix:nonFraction> million. As of December 31, 2023, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:CashAtFinancialInstitutions" scale="6" id="Narr_GHAdnjAXVEyssLu_yfYijQ">1.4</ix:nonFraction> million in cash at financial institutions and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:USGovernmentAgenciesSecuritiesAtCarryingValue" scale="6" id="Narr_A_yFgu05tUigR1KRd61Hvw">13.7</ix:nonFraction> million in U.S. government agency securities, for aggregate cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_84fAV0AonkS9NQXWAuOohQ">15.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event cash is received from grants in advance of incurring qualifying costs, it is recorded as restricted cash until it is earned and recorded to grant income.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:DiscontinuedOperationsPolicyTextBlock" id="Tb_LY3tGopLiE6_RXH9ruToDQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Discontinued Operations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Purchased Assets sold to Cell Ready pursuant to the Cell Ready Purchase Agreement constituted a significant disposition and as such, the Company concluded that the disposition of its Purchased Assets represented a strategic shift that had a major effect on its operations and financial results. Therefore, the Purchased Assets, related party revenue, service revenue and related expenses are classified as discontinued operations for all periods presented herein. See Note 7 for further information.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="mrkr:RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" id="Tb_26zc2tPuFEG7qHdQm20WqQ" continuedAt="Tb_26zc2tPuFEG7qHdQm20WqQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Standards Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Improvements to Reporetable Segment Disclosures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounitng Standards Update (&#8220;ASU&#8221;) No. 2023-07, Segement Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, among other provisions. The ASU is effective for fiscal year periods beginning after December15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the ASU requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the standard to determine the impact of adoption to its consolidated financial statements and disclosures.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_VPBE6sfnFkKok_OC3GT0NQ_cont2"><ix:continuation id="Tb_26zc2tPuFEG7qHdQm20WqQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Improvements to Income Tax Disclosures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregtion of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption the guidance can be applied prospectively or retrospectively. We do not expect the adoption of this guiadance to have a material impact on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its consolidated financial position or results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There have been no material changes in the Company&#8217;s significant accounting policies to those previously disclosed in the Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 26, 2024.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_dcd17db5_eaa8_4484_a536_453fc66b03e3"></a><a id="Tc_6-8Cb0BTLEuAQ9Nn-Yj6_Q_1_2"></a><a id="Tc_o7qRuTCtO0iyvbi6vnLJ4A_2_2"></a><a id="Tc_XEVlbaW6D0urYJZtnNLKzA_3_2"></a><a id="Tc_VWvI9dByx0-j9ThrRb4n1Q_3_5"></a><a id="Tc_3PHyQXZXm0Wp3WxvykpdIQ_4_0"></a><a id="Tc_zHAJ9H4HhU2STfHpOsHozw_5_0"></a><a id="Tc_T5YCuFh5hEC3T4PRp3ucqw_5_2"></a><a id="Tc_vX7Gz_ztMkiiZI_wGcZFjg_5_5"></a><a id="Tc_P_wwBUxn7kCjN7LHxmE9Ww_6_0"></a><a id="Tc_XJjLglis6keLaBHkn0aiXw_6_2"></a><a id="Tc_Dk3STojNZUWdqLODNvSTaw_6_3"></a><a id="Tc_rJHX91J6EEijd_L7B1LLaw_6_5"></a><a id="Tc_9YnFpSCnyUWWaorzQr2WVg_7_0"></a><a id="Tc_-1oq5d9RuEGq04sNb7HzRQ_7_2"></a><a id="Tc_0ujWhyUqU0yFT0_0OpX5Qw_7_5"></a><a id="Tc_p1CM5pguY0uxTRpJZERmkw_9_0"></a><a id="Tc_w9bJvHzOS0uudhL1C2bOjw_10_0"></a><a id="Tc_YWiKyRwtn0W12F0xHVVodw_11_0"></a><a id="Tc_gBAdm9De0kyC_VlNGeln9Q_13_0"></a><a id="Tc_IFkPByNqeUyn5TVI7VVJaw_14_0"></a><a id="Tc_MpCKyQ_1-0q0zXJhlN-5kw_14_2"></a><a id="Tc_bAKIfvg0c0SkHt3CiFUqhA_14_5"></a><a id="Tc_hxeTlECx5UisOTNXYpKHZg_15_0"></a><a id="Tc_RXmiBsCBfEeWhkqxIHogHA_15_2"></a><a id="Tc_nNX94vupvkSk5vHd4y_MXw_15_3"></a><a id="Tc_KwvY5nywrke-vuwuKddVYw_15_5"></a><a id="Tc_bezhMZEBOECIN954ehA9ng_16_0"></a><a id="Tc_0LD6GtMzzU2gc628SfN0bw_16_2"></a><a id="Tc__15mBAh0NUilBJ9Q2ycTDw_16_5"></a><a id="_a5b1bf5a_1a84_47d8_9fe7_666187e4feb9"></a><a id="Tc_Vxweqw2mAEWAtQSmFWqzdw_1_2"></a><a id="Tc_CnR7XYz5QkO84rR93RXotw_2_2"></a><a id="Tc_90M0ED1XFEGo-C8t-PbqJQ_3_2"></a><a id="Tc_ROMsYRRcHk2OWUmsbR377w_3_4"></a><a id="Tc_R6-x9ZCfUk6ufJC7qeBBrg_4_0"></a><a id="Tc_1dBud5-PS0y6FFx_ObjNUA_5_0"></a><a id="Tc_sRHHf7_Ckke6OPGP88F4QQ_5_2"></a><a id="Tc_Uoct0dm_6EWd3KXLQjFuug_6_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:MinorityInterestDisclosureTextBlock" id="Tb_oOZAo9eZV0a1kq68PPfPXg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;5: NET LOSS PER SHARE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth the computation of net loss per share for the three months ended March 31, 2024 and 2023, respectively:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_AOWvAvlIGU2RjwW29ApRng" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="0" id="Tc_lj0jrUbL1ES_VoYLn1twhg_5_3">2,392,822</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="0" id="Tc_BFUh4z-_Pky9r5r146HRtg_5_6">4,224,825</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="0" id="Tc_-xL7INOxkk-ARyuhjuLP7w_6_6">742,751</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_H6Dzq24v3EaCV93Vs_Tivg_7_3">2,392,822</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_aTKbLUJU30qhLUa2oERYeg_7_6">4,967,576</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_2nC5U1mDqk6Mz9FMn_s8FQ_10_3">8,901,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_2mABBukpukC4Ohot4IGDJQ_10_6">8,721,031</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_1-7zsTrFbEG2QWyUKVjTyg_11_3">8,901,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_G4T6iF7ts0K3s4CJrUOGLg_11_6">8,721,031</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net earnings (loss) per share:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from continuing operations, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_q-0_2XmY6USw8sVHreOyLA_14_3">0.27</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_zPOr3yDRX0y8LRIpVvxpPw_14_6">0.48</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_wqRcIkapzEShMmCn2PX7tA_15_6">0.09</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_M4So9eSkx0itoikB8O10MA_16_3">0.27</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_4GntlMQphUi_hpYWWVfPtQ_16_6">0.57</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following securities, rounded to the nearest thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="mrkr:NetLossPerShareTableTextBlock" id="Tb_HBDv7Y9jq0OQI19YlZbKmw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_W07D8lnky0aimmBd-R3YIg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_1d42pasvyEarPqtVO-JTLg_4_2">639,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_65JWbw2x0UWpZJA7_fd3rA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_pPO_8iERvk-OBXYG1JBHdw_4_4">1,297,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Common stock purchase warrants</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BuQkUd2NSUCXfasuFdBgPA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_zrpthvJsZU67KarEwNlUjQ_5_4">1,848,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Potentially dilutive securities</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_vlPpw9d950Wnr6g-e8RRqA_6_2">639,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_pj6qC4GHIkuHVFdG7Ibi_A_6_4">3,145,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="Tb_iRLyX7mPSEukaa97wr-WVg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 6: OTHER RECEIVABLE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_hcxj8tGJMUufaz5d7_ww7g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TenantImprovements" scale="6" id="Narr_ZMSwoW5vqkK4-owyQT3NnQ">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_7HG6TYGhSkuj85Yk7cyx0g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TenantImprovements" scale="6" id="Narr_2HYOyWU6MkyrGFA6liUljA">1.2</ix:nonFraction> million of grant income related to the CPRIT grant for the three months ended March 31, 2024 and 2023, respectively. At March 31, 2024, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_hcxj8tGJMUufaz5d7_ww7g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="Narr_xHCiXMIYjU2DYOHcWC9GCQ">1.2</ix:nonFraction> million of grant income receivable related to the CPRIT grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Additionally, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_9_n_o50vykCM5Ly004kRVQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:RevenueFromOrphanProductsGrantProgram" scale="6" id="Narr_huog3dC6NkqPQFCyhLbbpA">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_K-XuDOatfU2spHjQPAU4OA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:RevenueFromOrphanProductsGrantProgram" scale="6" id="Narr_EdCrK7QxnECUc64n76AsAA">0.2</ix:nonFraction> million of grant income related to the FDA and SBIR grants, respectively, for the three months ended March 31, 2024. At March 31, 2024, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember__N7KeTtie0WOfM9lUAInzQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:OrphanProductsGrantProgram" scale="6" id="Narr_o_5sSG9WvEub6LOZp6RNSQ">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_xgSQFi7SKUC3P-uEqMdsgQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:OrphanProductsGrantProgram" scale="6" id="Narr_Y7F4AGASEUinPpGhmylPNg">0.2</ix:nonFraction> million of grant income receivable related to the FDA and SBIR grants, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company received $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_4_1_2024_To_4_30_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_0K6azYZMnkS3HVng864fgA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_RwtuyXir5k2Ixa_G-AcknQ">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_4_1_2024_To_4_30_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_YTxnqMIXBE2WBHHgARjHqg" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_Z7AY1CJKL0a3eHYqrvpjMQ">0.2</ix:nonFraction> million of funds from FDA and SBIR in April 2024, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_7QEz2Lfb1EGVpWyjNmVA-w_1_2"></a><a id="Tc_FDSeGesj_0W5pIcuNNHeRw_2_2"></a><a id="Tc_WBlF2r2Ak0GgYEvexUUBvg_3_3"></a><a id="Tc_maaXe075Gkitiq5Rd07-iA_4_0"></a><a id="Tc_q0bvc3eJoUqHhF6j6HhSTQ_5_0"></a><a id="Tc_n_Iem0GvqUyzBWW46kpAkQ_5_2"></a><a id="Tc_P0FicLKYa0q62y_iFqPXmQ_6_0"></a><a id="Tc_d_ztwucwE0WwafCOf31VYA_7_0"></a><a id="Tc_N7eEGLs36UOdV87dNp6Rgw_8_0"></a><a id="Tc_SciszqcDSUW3iM_MzgUaxA_9_0"></a><a id="Tc_WEiaR09fl0m3ShGbIdoA0Q_10_0"></a><a id="Tc_KIMJE59v7kWfC0tnXrdOsA_11_0"></a><a id="Tc_t2L1RUiL5kymPOLxaoH_8g_11_2"></a><a id="Tc_M1JtcOCBsEmfsDygiFOiMA_1_2"></a><a id="Tc_bAkTmpgp3Ei3vvq8y9DSFg_2_2"></a><a id="Tc_ElFlzSX8zkO6ee39X2FAuQ_3_2"></a><a id="Tc_mEh2GzyZmEmVF2JKvYFlKQ_4_0"></a><a id="Tc_ejS9Iv61HE6zu-IXsQGkUw_5_0"></a><a id="Tc_22Up3o-CgkeCT-bN8GsSIg_6_0"></a><a id="Tc_zs1TJZ66wEKnHAceiZpq-g_7_0"></a><a id="Tc_9ZtSrMIzYE67zJT_F1X1YA_7_2"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="Tb_AT3lwiBXZ0GwOLtCeby0qg" continuedAt="Tb_AT3lwiBXZ0GwOLtCeby0qg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 7: DISCONTINUED OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As discussed in Note 1, on June 26, 2023, the Company completed the previously announced transaction with Cell Ready for cash consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_6_26_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_XIIQwpm8KkCnK2MdeGDs6g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="6" id="Narr_yXQeoB4i4kybeijP2iMQwQ">19.0</ix:nonFraction> million, resulting in derecognition of the Purchased Assets and a gain on sale of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_6_26_2023_To_6_26_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_I4S7uiZnTE-bi56dzKi0tw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" scale="6" id="Narr_TM6Sdo1WkUuPUSoUp-qNDA">8.7</ix:nonFraction> million, net of $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_6_26_2023_To_6_26_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_I4S7uiZnTE-bi56dzKi0tw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" scale="0" id="Narr_gNDFB5kuHEWXHk7Sn5Zfxg">63,000</ix:nonFraction> in tax. There were no remaining assets and liabilities classified in discontinued operations as of March 31, 2024 or December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company had no activity related to discontinued operations for the three months ended March 31, 2024. Net loss from discontinued operations for the three months ended March 31, 2023, was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="Group_wgrvcA1ucky9_DHVPtiLIg" continuedAt="Group_wgrvcA1ucky9_DHVPtiLIg_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three&#160;Months&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenues:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Related party service revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_HuG04-O0U0-9tr34MqB3RA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="0" id="Tc_6MLpgD2OPkqvT1LimFd4aw_5_3">3,500,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_12_31_2023_0E4EMJOdr0W3g33PvIH_sQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="0" id="Tc_HquRAuZrUkePQxJhrODvdQ_6_3">3,500,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_caUp8WmODEqDoW7woCj3OA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="0" id="Tc_Z5lUWu2e1kSrL7MpJrFz-g_8_3">3,894,245</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_csS-ol7uukaNejaEqG1D1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="0" id="Tc_SXrqhDJyUEK0KIdLCbMJSg_9_3">348,506</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_12_31_2023_0E4EMJOdr0W3g33PvIH_sQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="0" id="Tc_eHNCm0ZnOUiL3-Q-4USh5Q_10_3">4,242,751</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_12_31_2023_0E4EMJOdr0W3g33PvIH_sQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" sign="-" scale="0" id="Tc_74PfVAEoJkueUlyF8gVtNA_11_3">742,751</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes our cash flows related to discontinued operations for the three months ended March 31, 2023:</p><ix:continuation id="Group_wgrvcA1ucky9_DHVPtiLIg_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three&#160;Months&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Discontinued operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_u5io9Qini0SROgijz_sG3Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" sign="-" scale="0" id="Tc_-6zuHicpWUOBIhH8jag-AQ_5_3">2,790,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_u5io9Qini0SROgijz_sG3Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" sign="-" scale="0" id="Tc_OKbLuuLCjk6kDyUPRZK8Vg_6_3">113,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Net decrease in cash and cash equivalents from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInDiscontinuedOperations" sign="-" scale="0" id="Tc_lxQ7hYCwKkKUL-7CcvmCTw_7_3">2,903,000</ix:nonFraction>)</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Related Party Service Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In April 2022, the Company entered into a binding services agreement (&#8220;Wilson Wolf Agreement&#8221;) with Wilson Wolf Manufacturing Corporation (&#8220;Wilson Wolf&#8221;). Mr. John Wilson is a member of the Company&#8217;s board of directors and is serving as the CEO of Wilson Wolf. Wilson Wolf is in the business of creating products and services intended to simplify and expedite the transition of cell therapies and gene-modified cell therapies to mainstream society (the &#8220;Wilson Wolf Mission&#8221;). Pursuant to the Wilson Wolf Agreement, Wilson Wolf made a cash payment to the Company in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_4_1_2022_To_4_30_2022_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_wPOXGWAUdk2rreQDgrYe6A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingIncome" scale="6" id="Narr_rLs5nHQDPk-GZqDc2FUMCg">8.0</ix:nonFraction> million, as consideration for certain training and research services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In March 2023, the Company recognized the final $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_3_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_K0gVoKOl8EymtFxIsG-9UQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_pdUtCUlIfkSvN3c6DbBuHw">2.5</ix:nonFraction> million of revenue pursuant to this $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_3_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_K0gVoKOl8EymtFxIsG-9UQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingIncome" scale="6" id="Narr_aNgglSjFMUeRwrehMyvbDg">8.0</ix:nonFraction> million agreement and an additional $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_3_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_K0gVoKOl8EymtFxIsG-9UQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:AdditionalRevenueRecognized" scale="6" id="Narr_VcsyjXcwBUG9O3ayLWMMSg">1.0</ix:nonFraction> million because certain agreed milestones were met. The additional $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_FeJJ4O0CM0OwiGmy1OureA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:AdditionalRevenueRecognized" scale="6" id="Narr_QD9aucCubUiJpSGz6_cvpQ">1.0</ix:nonFraction> million of service fee revenue recognized during the three months ended March 31, 2023 was received in May 2023.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_AT3lwiBXZ0GwOLtCeby0qg_cont1"></ix:continuation><a id="Tc_4eFSBjeE6ESwNdOwfvdFTg_1_2"></a><a id="Tc_UNginFpGsUadecb9kCmiog_1_5"></a><a id="Tc_KG5v2qgFgk6fCaF9qpczdg_2_2"></a><a id="Tc_N7kpxr3lBEKAGAGR_8-OqA_2_5"></a><a id="Tc_mjnA9gxVuk-UDrCYn1RmLA_3_0"></a><a id="Tc_ubh58LhJp0avV76YWXuxpA_3_2"></a><a id="Tc_-n97Q1qbNkaoI5k35Sl7Yg_3_5"></a><a id="Tc_gMx19UfhqEam7hoyXW-XHg_4_0"></a><a id="Tc_vq-r1IiGKU-9ppVh4-IozA_5_0"></a><a id="Tc_JFGETfSXokq0BxdxkmRAkQ_6_0"></a><a id="Tc_Y4as1Mlk_kyJ2NrvHqgRDQ_7_0"></a><a id="Tc_qXSF1a6gCEqJ2u9L_PA38A_8_0"></a><a id="Tc_NRHyBF424E6MuaMoZrIPOA_9_0"></a><a id="Tc_njMVjzYDhkm9wY5H3JisTQ_10_0"></a><a id="Tc_4r1moXbYEkit9xiKif04Hg_10_2"></a><a id="Tc_mQeZcPO3ikahDeaquujcDA_10_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_w7hYwIIYbkqR5-aWkKnemQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;8: ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accounts payable, accrued liabilities, and related party payable consist of the following as of March 31, 2024 and December 31, 2023, respectively:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="Tb_WnCc29b4V0ChvdpGo7JEkg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_33nSZgW9_EylgtpxLMsmKA_3_3">1,202,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_QaJYEj7s50uT4tRQcz9ozQ_3_6">961,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_XFewb_yd0UefBObKp2PMhQ_4_3">57,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_ALrrLO5P9UWiio1UGexI7w_4_6">57,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_y9-XM6HTNkG1KPAIxmwlzw_5_3">297,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_oXAie1mTNki_VRnvBmTdoQ_5_6">303,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Related party payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_rN0rRwNYAECik7lJYjcBDA_6_3">354,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_j3lMUkSf9U-tFzw3B9X5mw_6_6">1,330,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Property taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="0" id="Tc_4lNdtpmFS0SulDgUES4SKQ_7_3">65,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="0" id="Tc_SKNFMjaqZEiRBWn_eZazbA_7_6">116,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:OtherTaxesPayableCurrent" scale="0" id="Tc_TNcMMBblfEiWiPRLFjThrA_8_3">126,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="mrkr:OtherTaxesPayableCurrent" scale="0" id="Tc__W9e3lvInESRP79ICBWxag_8_6">103,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_b509-iI3Ckuc27k1a0lN-A_9_3">203,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_5lurzNqBL0WoYBDEHLXbwQ_9_6">205,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable, accrued liabilities and related party payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" scale="0" id="Tc_5Ur4MhyQj0e2soNhjiXNvA_10_3">2,304,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA" decimals="0" format="ixt:numdotdecimal" name="mrkr:AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" scale="0" id="Tc_HbKOYpOCNEeTWXpl-AKi3g_10_6">3,075,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_07W_qsYgcEudbi5GDRWobg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="Narr_lvRdiJCYRkuhY0N-K__L3g">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8ps6npQK00elvbaMdGpAAw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="Narr_4JZU2sqg10ChKzVPr1b3xw">1.3</ix:nonFraction> million related-party payable as of March 31, 2024 and December 31, 2023, respectively, reflects amounts payable to Cell Ready for outsourced product development and manufacturing services. See Note 13: Related Party Transactions.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_JPDWAj3NFkmRfgJ_XdDEVg" continuedAt="Tb_JPDWAj3NFkmRfgJ_XdDEVg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;9: STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reverse Stock Split</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 26, 2023, the Company effected the Reverse Stock Split and a corresponding reduction in the total number of authorized shares of its common stock from <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_1_25_2023_UtL_c0KyKEWg0Dz7B0kqYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr__QusnTbF5ke897agqGoRYw">300,000,000</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_1_26_2023_lWBBv-azxUmgoxtZqB0QnQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_ruHger4Z7EqsyvTqriJSjA">30,000,000</ix:nonFraction>. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All historical share and per share amounts reflected in this report have been adjusted to reflect the Reverse Stock Split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Common Stock Transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance of Stock Pursuant to ATM Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company did <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_N9zarOSsVEuBpoYtfzkupQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr__7fDki4BKkqg_ozcNRy8fQ">no</ix:nonFraction>t issue any common stock under the ATM Agreement for the three months ended March 31, 2024. During the three months ended March 31, 2023, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_v0PCHlsRw0uzmua5_m8DQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_hb6LdPcFuEW_OVMLLYuUZQ">200,261</ix:nonFraction> shares of its common stock under the ATM Agreement for proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_v0PCHlsRw0uzmua5_m8DQg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_xPQexOuO7kaVYp84bH7R_Q">0.6</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Purchase Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2022, the Company entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) with Lincoln Park which provides that, upon the terms and subject to the conditions of the agreement, the Company has the right, but not the obligation, to sell to Lincoln Park up to $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_12_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_qmoIEv97Rk2jUyIAWQnjTA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Narr_unxEqLBqdEmgysLojX6IWA">25,000,000</ix:nonFraction> of shares of its common stock (the &#8220;Purchase Shares&#8221;) from time to time over a <ix:nonNumeric contextRef="Duration_12_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_qmoIEv97Rk2jUyIAWQnjTA" format="ixt-sec:durwordsen" name="mrkr:StockPurchaseAgreementTimeToTimeTermToPurchaseShares" id="Narr_w_GixDNrL0y_BZJ40jq2aQ">24-month</ix:nonNumeric> term, at a variable price with certain market-based terms as defined in the Purchase Agreement. The Purchase Agreement does not exhibit any of the characteristics for liability classification under ASC Topic 480, Distinguishing Liabilities from Equity. Instead, the purchase agreement is indexed to the Company&#8217;s own stock under ASC Subtopic 815-40, <i style="font-style:italic;">Contracts in Entity&#8217;s Own Equity</i>, and classified as equity. In January 2023, Lincoln Park was issued <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_RKze1ypjXU6RtzdpbC9cRQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_lSyDXDJ54kOyPA9GakBnlw">180,410</ix:nonFraction> shares of stock as a commitment fee at a value of $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_RKze1ypjXU6RtzdpbC9cRQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:CommitmentFee" scale="6" id="Narr_WDgGZ_HjxEWFOGsoX3eIdw">0.5</ix:nonFraction> million. During the three months ended March 31, 2023, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_n7CziHvjvE--LojpNufD4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Jhpt2yap-UWiQBVxcTl3Xw">12,500</ix:nonFraction> shares of its common stock under the Purchase Agreement for proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_n7CziHvjvE--LojpNufD4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_QTtV6o6BDk6X8_DH0SJPfA">33,000</ix:nonFraction>. The Company terminated the Purchase Agreement with Lincoln Park on February 29, 2024 effective March 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Stock Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2024, certain outstanding options were exercised for <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_BgWQx1joRUqgQ_5hQ3A-og">19,497</ix:nonFraction> shares of common stock, providing aggregate proceeds to the Company of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Narr__8TrozsV6EmRovvSTZmITg">49,000</ix:nonFraction>.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_JPDWAj3NFkmRfgJ_XdDEVg_cont1"></ix:continuation><a id="Tc_Vj3CwPM3IUmqFRljf2D5Zg_1_10"></a><a id="Tc_R5qs4BdwQ0GHQp7Aea3sgg_2_10"></a><a id="Tc_RHWR3I0lQEqT58x8-Frh8A_3_4"></a><a id="Tc_dCMG-vpE7E69wFFfoY85gA_3_10"></a><a id="Tc_11ceBmw9H02N0PEPVQj7cw_4_2"></a><a id="Tc_RGQlyMd2402R0dzLFfiBSA_4_4"></a><a id="Tc_KULnovcakEarUVsAheUl0A_4_7"></a><a id="Tc_5o_FG8648ke2CTp4ijsXNg_4_10"></a><a id="Tc_e2QeF3nsGEqeW4z_l67NBA_5_0"></a><a id="Tc_FIsEJJp0ZEO32Q7yt41tYg_5_4"></a><a id="Tc_RvrrwzPjvkCSABtXzoZ_sw_5_7"></a><a id="Tc_khl1tnsg70KvDugkPEQtug_6_0"></a><a id="Tc_48QBl5qsfkKCLnq1fPWHlg_6_8"></a><a id="Tc_n1rbugJPmES_ygMOiQFkuw_6_10"></a><a id="Tc_oMZl5-Fnfku-KAfW9LjVIA_7_0"></a><a id="Tc_77umS6VHmEKa5atD406dZA_7_8"></a><a id="Tc_AeNjN_WYUkC01BiLhuWwrA_7_10"></a><a id="Tc_yIYvO5O8BEmgL-e5a3J0UA_8_0"></a><a id="Tc__TuCOdmQqki0quUtzk2ZyA_8_4"></a><a id="Tc_emqW99rnHUaos9DLd3CGMw_8_7"></a><a id="Tc_hKuaHaX26EeHtFFTRI1gtw_9_0"></a><a id="Tc_CW-4kZARr0mzo5W_lhbEyQ_9_4"></a><a id="Tc_Y8-q7fP35U2DdT9s23k-OQ_9_7"></a><a id="Tc_bSZQF3aFM0yUduaDad80jA_1_2"></a><a id="Tc_sso-lUKHtkelZ3gfS-Y3sA_2_2"></a><a id="Tc_vkk3qHSuS0i8CtGwhrvFJQ_3_2"></a><a id="Tc_pg2btLQ6dkmwSLiHgxmLrQ_3_5"></a><a id="Tc_JQ_wotRXPE6i0dU0YFvtsQ_4_0"></a><a id="Tc_vYNedHfjU0iM2kSUO9FUJQ_5_0"></a><a id="Tc_ry7ULIHoNEu_FcWhXFo1lA_5_2"></a><a id="Tc_uuXkJW8aqEa74kzGfWzE7g_5_5"></a><a id="Tc_0Ot-5i00nEWXYFvn-na0GQ_6_0"></a><a id="Tc_rV57M2ZSjkK5tTTXjTdO_g_7_0"></a><a id="Tc_3H1MHjzvaU-Vwhf036JSMQ_8_0"></a><a id="Tc_02x0QDlH8kCdU6CY1w0vyw_8_3"></a><a id="Tc_yNOTlRxRR0e-MHGRzkTDbA_9_0"></a><a id="Tc_Egl2c7PQd06EHEBLTMQc4A_9_2"></a><a id="Tc_EJoaoX8fPUeA9lyKeLeRHA_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_H6wexY840Uyz4koETLKTeg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;10: STOCK-BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2024 Equity Incentive Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_EJkZoSsgwU-FvgKTJSx59w">no</ix:nonFraction> equity incentive awards issued during the three months ended March 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A summary of the Company&#8217;s stock option activity for the three months ended March 31, 2024 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="Tb_AJJdH-W4K0C8vvJL9EUFGg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Intrinsic Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_uiVzVsnzbEO2OvPv-3o_Jg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_2lMdMprpSEuFZrYLlCvQoA_5_2">737,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_uiVzVsnzbEO2OvPv-3o_Jg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_NMcYmTKZ706cdM7GZ-gdHg_5_5">25.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_uiVzVsnzbEO2OvPv-3o_Jg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc__NYfYw3tqkOJd3pzyjqttw_5_8">1,317,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_JNor-YkRMES_vEoMGuLiUQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_kpSopFFGf0O7zSwjDmnn9Q_5_10"> 7.6</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_X9phuL_RxUqyj7QCXMC4zg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_64wW9VoJm0WyzEDzCEFqBA_6_2">19,497</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_X9phuL_RxUqyj7QCXMC4zg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_B6JR19wirUWCSbb97N8irw_6_5">2.52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Canceled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_X9phuL_RxUqyj7QCXMC4zg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_Y_DFfZfK3kWnfjteg_Fg5g_7_2">79,196</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_X9phuL_RxUqyj7QCXMC4zg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_-7wJT7Ph0EigpE9Q0V5X6A_7_5">52.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of March&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_M8QVuqpUVkWUQBZalnnUIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_SLgHJDFuRkifKj1OT99KoA_8_2">639,202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="As_Of_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_M8QVuqpUVkWUQBZalnnUIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_eRp3ajsiGkmcWmQWfc1t2Q_8_5">22.71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_M8QVuqpUVkWUQBZalnnUIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_d4gHLthxuUyseqSv2uGKtw_8_8">720,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_X9phuL_RxUqyj7QCXMC4zg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_fxAxzTHYCkqJXmpwNKG8Yw_8_10"> 7.5</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="As_Of_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_M8QVuqpUVkWUQBZalnnUIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_X7JgPNtJ8E2n4MLSeOHOHA_9_2">329,916</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA" contextRef="As_Of_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_M8QVuqpUVkWUQBZalnnUIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_Rcv0HeKF90aK8E-XcCei5w_9_5">41.17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_M8QVuqpUVkWUQBZalnnUIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="Tc_aIRpchtf20ivy9EQdwQtWA_9_8">113,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_X9phuL_RxUqyj7QCXMC4zg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_bFd99-4msUuqpPiP8win1w_9_10"> 6.2</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth stock-based compensation expenses recorded during the respective periods:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="mrkr:StockBasedCompensationExpensesTableTextBlock" id="Tb_7ZnqRKT-HUag_DkrE9MkKw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock Compensation expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_MCdjUbOPBEuJBGWUJszvmQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:StockCompensationInContinuingOperations" scale="0" id="Tc_eoFqVYAMLkWX1RV38XEutQ_5_3">6,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_YwRyxwQa5U2Ym0Gma3rUFg" decimals="0" format="ixt:numdotdecimal" name="mrkr:StockCompensationInContinuingOperations" scale="0" id="Tc_LAowT3cuC0yGM0qO16Ji5w_5_6">151,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_vBXDcg9tlkOH2-yBzo50cg" decimals="0" format="ixt:numdotdecimal" name="mrkr:StockCompensationInContinuingOperations" scale="0" id="Tc_CdlWXVyIb0aMBK8pIJpSHw_6_3">73,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_XBUskIaJ10C-ReGlI38TAw" decimals="0" format="ixt:numdotdecimal" name="mrkr:StockCompensationInContinuingOperations" scale="0" id="Tc_Htm-wSqKdEiJUNVdLK03sA_6_6">221,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock compensation in continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="mrkr:StockCompensationInContinuingOperations" scale="0" id="Tc_8mqDIVlyGEGLrijWjhIjhw_7_3">79,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="mrkr:StockCompensationInContinuingOperations" scale="0" id="Tc_P_KBlcOiTUGIS8ziGpVtiw_7_6">372,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock compensation in discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="mrkr:StockCompensationInDiscontinuedOperations" scale="0" id="Tc_kBEcqqn4pEuuKVrkEHDJsQ_8_6">288,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total stock compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_FocWY9Tte0u31dcdfa0Mlw_9_3">79,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_wVH6Ja4tEkSirkWWmb0Phg_9_6">660,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of March 31, 2024, the total stock-based compensation cost related to unvested awards not yet recognized was $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_8fY37ErtVEODZD6EKS7IJw">0.3</ix:nonFraction> million. The expected weighted average period compensation costs to be recognized was approximately <ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_3-hC5KU8HkisMZ3cRqnRUg">1.8</ix:nonNumeric> years. Future option grants will impact the compensation expense recognized.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="Tb_JbJC7yO950qBb57sGadHVQ" continuedAt="Tb_JbJC7yO950qBb57sGadHVQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;11: GRANT INCOME</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CPRIT</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_8_1_2021_To_8_31_2021_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_up4ngz1fg02kE_1r6itooQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:ReceiptOfProductDevelopmentResearchAward" scale="6" id="Narr_HCVP6F6E8Ea8tWi2GMaHhQ">13.1</ix:nonFraction> million from CPRIT to support the Company&#8217;s clinical investigation of MT-401.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If restricted cash received from grants in advance of incurring qualifying costs, it is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. There was <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_aZw1rDA380KfM4Tw_qsCzw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RestrictedCash" scale="0" id="Narr_4vLd-j2J70q9WwEqiZ7rww"><ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_12_31_2023_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_j4d_NUsf-U6y0TlpBZ0hiA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RestrictedCash" scale="0" id="Narr_WlBjdtv4a0yiiUfTcHjEtA">no</ix:nonFraction></ix:nonFraction> restricted cash recorded as of March 31, 2024 and December 31, 2023. If qualifying grant income is earned in advance of cash received from grants, it is recognized as revenue and recorded as other receivable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_aF3HC3hiPEGwEVjTVodC_Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_OX4NRv87nkaNtFxOa6AatA">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_SJSbS_G9j0aQNGKHeaocXQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_H8IznaTIH0q6dtUphGO3wg">1.2</ix:nonFraction> million of grant income related to the CPRIT grant as revenue for the three months ended March 31, 2024, and 2023, respectively. As of March 31, 2024, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_aZw1rDA380KfM4Tw_qsCzw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="6" id="Narr_vpRJKVMJnEerehfRr_6lMg">1.2</ix:nonFraction> million as other receivable, which represented grant income earned in advance of funds to be received from CPRIT.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4b89080b_7a0f_4209_85d5_11c6bcdefd07"></a><ix:continuation id="Tb_JbJC7yO950qBb57sGadHVQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDA</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In September 2022, the Company received notice from the FDA that it had awarded the Company a $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_9_30_2022_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_o77qs3ys40OOa0GfLhRa-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="6" id="Narr_LN_qKDdgRU2zAJIcY9KaRg">2.0</ix:nonFraction> million grant from the FDA&#8217;s Orphan Products Grant program to support the Company&#8217;s clinical investigation of MT-401 for the treatment of post-transplant AML. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_9_n_o50vykCM5Ly004kRVQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_dVBP-EflcEieIMYR6wXPrQ">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_dFfPvaLfIEikU4XiNmZE_A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_SM6Xnpk5RUq3O3wZ2faaqQ">0.1</ix:nonFraction> million of grant income related to the FDA grant as revenue for the three months ended March 31, 2024 and March 31, 2023, respectively. As of March 31, 2024, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember__N7KeTtie0WOfM9lUAInzQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="6" id="Narr_SPNUVa4mukqkFy93pMjWtA">0.3</ix:nonFraction> million as other receivable, which represented grant income earned in advance of funds to be received from the FDA. In April 2024, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_4_1_2024_To_4_30_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_0K6azYZMnkS3HVng864fgA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_AwHLa7B_oUa4VjCDZvJL0g">0.3</ix:nonFraction> million of funds from the FDA grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SBIR</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In May 2023, the Company announced it had received a $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_5_31_2023_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_nozZmEEAxEWXLrXsS0VZYA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="6" id="Narr_Y5GqFGQN9E-zz_qCJ7mgkQ">2.0</ix:nonFraction> million grant from the National Institutes of Health Small Business Innovation Research program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_K-XuDOatfU2spHjQPAU4OA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_q1wxzTKNSEqFQ6d6xhR-pg">0.2</ix:nonFraction> million of grant income related to the SBIR grant as revenue for the three months ended March 31, 2024. As of March 31, 2024, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_xgSQFi7SKUC3P-uEqMdsgQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="6" id="Narr_FBsKqzLbCEKbwiSoYYlNMg">0.2</ix:nonFraction> million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In April 2024, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_4_1_2024_To_4_30_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_YTxnqMIXBE2WBHHgARjHqg" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_TbjoB76cVkezYmxjEl8kMQ">0.2</ix:nonFraction> million of funds from the SBIR grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="Tb_fnPviX9dnU6YOU0Tt-zh_Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 12: LEGAL PROCEEDINGS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time, the Company may be party to ordinary, routine litigation incidental to their business. The Company knows of no material, active or pending legal proceedings against the Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of the Company&#8217;s directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to the Company&#8217;s interest.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_2vodr_jRNES4J8yie8JDKQ_1_2"></a><a id="Tc_dNa1BZnmpU-87T3tzVaJkA_2_2"></a><a id="Tc_D4K72j6sgEiYTvG26H9OkA_3_2"></a><a id="Tc_zwpOMWSM50m_jPjAHuLnHA_3_5"></a><a id="Tc_20e_4h-Yv0Sr-Y0Ugr9DYA_4_0"></a><a id="Tc_O7Gwxfoen0q8C9ewWuwvoA_4_2"></a><a id="Tc_KUILpKBUy0e3vrySRlfrkQ_4_3"></a><a id="Tc_Gu2oQBrmoU-CreidWJWXdQ_4_5"></a><a id="Tc_ZdtGdWGvF0atVV-C5pRjOA_5_0"></a><a id="Tc_8OZ7SM-330y49TK2Cmz5Mg_5_6"></a><a id="Tc_NdvRs-nasEaz7MDS6OjuSg_6_0"></a><a id="Tc_xoJhgWFKH0ayOaBiysEl9A_6_3"></a><a id="Tc_VS5AD3FLRkuYS7fXZxr8ng_7_0"></a><a id="Tc_7-LCqOJJekWZgCSdcJCqyQ_7_2"></a><a id="Tc_BSo6dMoTZEeEgkr5RGxUug_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_B24qhzlVnUyDkgAdVptL1A" continuedAt="Tb_B24qhzlVnUyDkgAdVptL1A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;13: RELATED PARTY EXPENSES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth related party transaction expenses recorded for the three months ended March 31, 2024 and 2023, respectively.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="Group_5NasPDwdlkaGPfstEmhSBg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Baylor College of Medicine</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_H1facwiFj0qZIcr4nQ49VQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" id="Tc_Lm4PbPyxe0SWu23m7M0p4g_4_6">11,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cell Ready</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_CellReadyMember_IthHVQzVkEC_BWostaNF4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" id="Tc_1-twrCeDBkeWqnPtlRfyVA_5_3">1,186,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Wilson Wolf Manufacturing Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_awaPZGwxYkOh-Kh6ZKEEGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" id="Tc_17I8e1WyYU-P8m6MOXQxlA_6_6">204,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" id="Tc_1Q61ayXmLkanEm-k3XHNbg_7_3">1,186,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" id="Tc_GJJpWTAbdEa0KR2ywvLw-w_7_6">215,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="As_Of_3_31_2024_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_07W_qsYgcEudbi5GDRWobg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="Narr_QmCwfbkga0W4cr1LAu1Z7w">0.4</ix:nonFraction> million of related party transactions are included in accounts payable and accrued liabilities as of March 31, 2024. See Note 8 for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreements with The Baylor College of Medicine (&#8220;BCM&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2018, January 2020 and February 2020, the Company entered in Sponsored Research Agreements with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM&#8217;s Center for Cell and Gene Therapy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2019, May 2020 and July 2021, the Company entered into Clinical Supply Agreements with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2019, the Company entered in a Workforce Grant Agreement with BCM, which provided for BCM to provide to the Company manpower costs of projects for manufacturing, quality control testing and validation run activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2020, the Company entered into a Clinical Trial Agreement with BCM, which provided for BCM to provide to the Company investigator-initiated research studies.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_B24qhzlVnUyDkgAdVptL1A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has also entered into a Clinical Site Agreement with BCM, which provided for BCM to conduct clinical trials for the Company and is a part of continuing operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">BCM owns shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchases from Wilson Wolf</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 2023, the Company utilized Wilson Wolf for the purchases of cell culture devices called G-Rexes. Mr. John Wilson is a member of the Company&#8217;s board of directors and is serving as the CEO of Wilson Wolf Manufacturing Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchases from Cell Ready, LLC</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is currently utilizing Cell Ready, LLC for its clinical manufacturing supply and product development. Mr. John Wilson is a member of the Company&#8217;s board of directors and is serving as the CEO of Cell Ready, LLC. On February 22, 2024, we entered into a Master Services Agreement for Product Supply (the &#8220;MSA&#8221;) with Cell Ready. Cell Ready, which is owned by one of our directors and shareholders, Mr. John Wilson, is a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. If the services involve the supply of product, Cell Ready is required to supply such product in conformance with the product requirements set forth in the applicable work order(s). Under the MSA, Cell Ready is to use only personnel with sufficient qualifications and experience to supply the services contemplated by the MSA, provide its personnel with adequate training and assume full responsibility for its personnel&#8217;s compliance with the MSA. Further, Cell Ready is required to provide the Company with assistance and cooperation in order for the Company to obtain and maintain all necessary regulatory approvals, at the Company&#8217;s expense. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2024, the Company entered into Work Order #1 under the MSA, pursuant to which Cell Ready agreed to provide the Company with GMP drug product for Marker MT-401 and/or MT-601. The services include the delivery of final drug product and quality control testing. The Company also requested Cell Ready to provide general support services in connection therewith. During the three months ended March 31, 2024, the Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_wgAA0Ldo_UOtaTkJBKsynw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="6" id="Narr_n9DLzIIdBE-wiHE85ic5Wg">1.2</ix:nonFraction> million is expenses related to the &#160;services and manufacturing costs and paid $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_wgAA0Ldo_UOtaTkJBKsynw" decimals="-5" format="ixt:numdotdecimal" name="mrkr:InvoicesReceivedForServicesAndManufacturingCosts" scale="6" id="Narr__dhqDA1e_0a2R84Z7i22Zg">2.2</ix:nonFraction> million for invoices received. Additional Work Orders are expected to be generated for the remainder of 2024.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w" name="us-gaap:SubsequentEventsTextBlock" id="Tb_AqcfKkLDu0eddCPy4F_6FA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 14: SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In April 2024, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ" contextRef="Duration_4_1_2024_To_4_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_dqKTucMUbUGZUuzFK_dOyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_xBeQGgcTekCvALqPS4P1Zw">8,178</ix:nonFraction> shares of its common stock under the ATM Agreement resulting in net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ" contextRef="Duration_4_1_2024_To_4_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_dqKTucMUbUGZUuzFK_dOyg" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_f_UolWrmK0aNUTTL8znOBw">0.04</ix:nonFraction> million, after deducting agent commissions.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0089bcf7_a0a5_4481_8156_8e6352095b87"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, that involve risks and uncertainties. All statements other than statements relating to historical matters including statements to the effect that we &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;anticipate&#8221;, &#8220;plan&#8221;, &#8220;target&#8221;, &#8220;intend&#8221; and similar expressions should be considered forward-looking statements. Our actual results could differ materially from those discussed in the forward-looking statements as a result of a number of important factors, including factors discussed in this section and elsewhere in this Quarterly Report on Form 10-Q, and the risks discussed in our other filings with the SEC. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its potential impact on our business and the global economy. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management&#8217;s analysis, judgment, belief, or expectation only as the date hereof. We assume no obligation to update these forward-looking statements to reflect events or circumstance that arise after the date hereof.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">As used in this quarterly report: (i) the terms &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, &#8220;Marker&#8221; and the &#8220;Company&#8221; mean Marker Therapeutics, Inc. and its wholly owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals Inc. which wholly owns GeneMax Pharmaceuticals Canada Inc., unless the context otherwise requires; (ii) &#8220;SEC&#8221; refers to the Securities and Exchange Commission; (iii) &#8220;Securities Act&#8221; refers to the Securities Act of 1933, as amended; (iv) &#8220;Exchange Act&#8221; refers to the Securities Exchange Act of 1934, as amended; and (v) all dollar amounts refer to United States dollars unless otherwise indicated.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following should be read in conjunction with our unaudited condensed consolidated interim financial statements and related notes included in this Quarterly Report on Form 10-Q.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Company Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our multi tumor associated antigen (&#8220;multiTAA&#8221;)-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumor-associated antigens, or TAAs. This approach selectively expands tumor-specific T cells from a patient&#8217;s/donor&#8217;s blood and is able to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Targeting multiple antigens simultaneously exploits the natural capacity of T cells to recognize and kill tumor targets via native T cell receptors (&#8220;TCR&#8221;), while limiting tumor adaptation/escape by antigen-negative selection or antigen down-regulation. When infused into a patient with cancer, the multiTAA-specific T cells are designed to kill cancer cells expressing the TAA and potentially recruit the patient&#8217;s immune system to participate in the cancer killing process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We licensed the underlying technology for multiTAA-specific T cell therapy from Baylor College of Medicine, or BCM, in March 2018. BCM had utilized the therapy in seven exploratory clinical trials. In these studies, BCM treated over 150 patients suffering from a variety of cancers including lymphoma, multiple myeloma, acute myeloid leukemia, or AML, acute lymphoblastic leukemia, or ALL, pancreatic cancer, breast cancer and various sarcomas. In those studies, BCM saw evidence of clinical benefit, expansion of infused cells, and decreased toxicity compared to other cellular therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are advancing two product candidates for 3 clinical indications as part of our multiTAA-specific T cell program for:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Off-the-Shelf (OTS) product in various indications (e.g., MT-401-OTS)</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not genetically engineer our multiTAA-specific T cell therapies and we believe that our product candidates are superior to T cells engineered with chimeric antigen receptors, or CAR-T, for several reasons including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Multiple targets &#8594; enhanced tumoricidal effect&#8594; minimized tumor immune escape</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical safety &#8594; no treatment-related side effects, including cytokine release syndrome (CRS) or other severe adverse effects (SAEs), were attributed to the use of multiTAA-specific T cell therapies to date</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:237.6pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-genetically engineered T cell products &#8594; selective expansion of tumor-specific T cells from a patient&#8217;s or donor&#8217;s blood capable of recognizing a broad range of tumor antigens &#8594; no risk of mutagenesis and reduced manufacturing complexity &#8594; lower cost</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="mrkr-20240331x10q002.jpg" alt="Graphic" style="display:inline-block;height:125.33pt;left:0%;padding-bottom:0.7pt;position:relative;top:0pt;width:513.36pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For these reasons, we believe our endogenous T cell receptor-based therapies may provide meaningful clinical benefit and safety to patients with both hematological and solid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that the simplicity of our manufacturing process allows additional modifications to expand multiTAA-specific T cell recognition of cancer targets. For example, we are assessing the potential of combining multiTAA-specific T cell products with other products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 8, 2024, we issued a press release announcing that Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA, was invited to present his clinical experience from the APOLLO study at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada (April 2-7, 2024). Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024 and reported that study participants tolerated initial dose level well and demonstrated durable objective responses after MT-601 treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our clinical-stage pipeline is set forth below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="mrkr-20240331x10q003.jpg" alt="Graphic" style="display:inline-block;height:237.6pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:473.72pt;"/></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recent Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On February 22, 2024, we entered into a Master Services Agreement for Product Supply (the &#8220;MSA&#8221;) with Cell Ready LLC (&#8220;Cell Ready&#8221;) to provide services previously performed by the company until the disposition of its contract development and manufacturing operations. Cell Ready, which is owned by one of our directors and shareholders, Mr. John Wilson, is a contract development and manufacturing organization (CDMO).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. If the services involve the supply of product, Cell Ready is required to supply such product in conformance with the product requirements set forth in the applicable work order(s). The MSA contains customary representations, warranties and indemnification provision. The initial term of the MSA is three years and may be extended upon the mutual written agreement of the parties. Either party may terminate the MSA (a) for material breach by the other party if such breach has not been cured within 30 days following notice of termination or (b) if the other party is the subject of an insolvency event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under the MSA, Cell Ready is to use only personnel with sufficient qualifications and experience to supply the services contemplated by the MSA, provide its personnel with adequate training and assume full responsibility for its personnel&#8217;s compliance with the MSA. Further, Cell Ready is required to provide the Company with assistance and cooperation in order for the Company to obtain and maintain all necessary regulatory approvals, at the Company&#8217;s expense. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">With regard to intellectual property, the MSA provides that each party will solely and exclusively own all right, title and interest in and to their Background IP and all inventions derived from such background IP (such invention being referred to as Foreground IP). Background IP means all intellectual property either (a) owned or controlled by a party prior to the effective date of the MSA or (b) developed or acquired by a party independently from performance under the MSA without the use of, reliance on, or access to the other parties confidential information. Furthermore, pursuant to the MSA, Cell Ready grants to the Company a non-exclusive, perpetual, irrevocable, transferable, assignable, fully-paid up, royalty-free, worldwide license to and under any of Cell Ready&#8217;s Background IP and Foreground IP to the extent they are incorporated or embedded in any deliverables provided to the Company or in the process of generating or manufacturing such deliverables and reasonably necessary or useful for the Company to make, have made, manufacture, have manufactured, use, have used, offer for sale, sell, import, and otherwise exploit such deliverables. The Company grants to Cell Ready until the termination or expiry of any applicable Work Order and for a period not exceeding the term of the MSA, a non-exclusive, fully paid-up, non-transferable, non-sublicensable limited license under and to the Company&#8217;s Background IP made available to Cell Ready pursuant to a Work Order solely to the extent required for Cell Ready to provide the services under such Work Order.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">During the three months ended March 31, 2024, the Company incurred $1.2 million is expenses related to the services and manufacturing costs, and paid $2.2 million related to invoices received. Additional Work Orders are expected to be generated for the remainder of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The above description of the MSA does not purport to be complete and is qualified in their entirety by reference to the full text of the MSA and Work Oder #1, copies of which are attached hereto as Exhibits 10.8 and 10.9 and are incorporated herein by reference. The MSA has been filed as an exhibit to the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 26, 2024, to provide investors with information regarding the terms of the MSA and is not intended to modify or supplement any factual disclosures about the Company in its public reports filed with the SEC. In particular, the MSA is not intended to be, and should not be relied upon as, disclosure regarding any facts and circumstances relating to the Company. The representations, warranties, and covenants contained in the MSA have been made solely for the purposes of the MSA and as of specific dates; were solely for the benefit of the parties to the MSA; are not intended as statements of fact to be relied upon by the parties&#8217; shareholders; may no longer be true as of a given date; and may apply standards of materiality in a way that is different from what may be viewed as material by shareholders. Security holders are not third-party beneficiaries under the MSA and should not rely on the representations, warranties, and covenants or any descriptions thereof as characterizations of any actual state of facts or of the condition of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organizational Changes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In 2023, the Company implemented changes to its organizational structure due to the transaction with Cell Ready and to reduce operational costs. In connection with these changes, the Company reduced headcount, including the separation of its former Chief Executive Officer, Peter Hoang, in May 2023 and its former Chief Accounting Officer, Michael Loiacono, in June 2023. During the second quarter of 2023, the Company recorded $0.9 million of severance and termination-related costs. The payments of these costs </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">were completed in July of 2023. Effective May 1, 2023, the Company&#8217;s board of directors appointed Dr. Juan Vera as the Company&#8217;s President and Chief Executive Officer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective June 30, 2023, the board of directors appointed Eliot M. Lurier as the Company&#8217;s Interim Chief Financial Officer, whereby Mr. Lurier provided consulting services to the Company pursuant to a consulting between the Company and Danforth Advisors, LLC (&#8220;Danforth&#8221;) and received no compensation directly from the Company. On November 17, 2023, the Company terminated the consulting agreement between the Company and Danforth, effective January 16, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 17, 2023, Mr. Lurier ceased serving as the Company&#8217;s Interim Chief Financial Officer and Dr. Vera was appointed as the Company&#8217;s Principal Financial and Accounting Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 26, 2023, the Company effected a one-for-ten (1-for-10) reverse stock split of its common stock (the &#8220;Reverse Stock Split&#8221;) and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In this discussion of our results of operations and financial condition, amounts in financial tables, other than per-share amounts, have been rounded to the nearest thousand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the Three months Ended March 31, 2024 and 2023</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the results of our continuing operations for the three months ended March 31, 2024 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Revenues:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,244,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,234,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,244,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,234,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,575,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,376,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (801,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (24)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,218,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,167,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (949,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (44)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,793,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,543,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,750,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (32)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,549,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,309,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,760,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (41)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Other income (expenses):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 156,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 85,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 71,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 84</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Loss from continuing operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (2,393,000)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (4,224,000)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,831,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (43)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We did not generate any revenue during the three months ended March 31, 2024 and 2023, respectively, from the sales or licensing of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, we received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (&#8220;CPRIT&#8221;) to support the clinical investigation of MT-401. During the three months ended March 31, 2024 and 2023, we recognized $0.8 million and $1.2 million of revenue, respectively, associated with the CPRIT grant.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2022, we received notice from the FDA that it had awarded us a $2.0 million grant from the FDA&#8217;s Orphan Products Grant program to support the clinical investigation of MT-401 for the treatment of post-transplant AML. During the three months ended March 31, 2024 and 2023, we recognized $0.3 million and $0.1 million of revenue, respectively associated with the FDA grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2023, we received notice of a $2.0 million grant from the National Institutes of Health Small Business Innovation Research (&#8220;SBIR&#8221;) program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents. During the three months ended March 31, 2024 we recognized $0.2 million of revenue associated with the SBIR grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All funding agencies have agreed to continue their financial support and to shift funds to the MT-401-OTS program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating expenses incurred during the three months ended March 31, 2024 were $3.8 million compared to $5.5 million during the same period ended March 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Significant changes and expenditures in operating expenses are outlined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Research and Development Expenses </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses decreased by 24% to $2.6 million for the three months ended March 31, 2024, compared to $3.4 million for the three months ended March 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The decrease of $0.8 million in 2024 was primarily attributable to the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease of $0.7 million in process development expenses,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease of $0.8 million in clinical trial expenses,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease of $0.6 million in headcount-related expenses, offset by</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase of $0.1 million in other expenses, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase of $1.2 million in Cell Ready (outsourced) clinical manufacturing costs and process development expenses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses decreased by 44% to $1.2 million for the three months ended March 31, 2024, compared to $2.2 million during the same period ended March 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The decrease of $1.0 million in 2024 was primarily attributable to the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease of $0.4 million in headcount-related expenses, including stock-based compensation expense,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease of $0.4 million in legal and professional fees, </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease of $0.1 million in insurance expense, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease of $0.1 million in other expenses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Income (Expense)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interest Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest income was $0.2 million and $0.1 million for the three months ended March 31, 2024 and 2023, respectively, and was attributable to interest income relating to funds that are held in U.S. Treasury notes and U.S. government agency-backed securities.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss from continuing operations</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The decrease in our net loss from continuing operations during the three months ended March 31, 2024 compared to the three months ended March 31, 2023 was primarily due to cost reductions in our research and development activities, as well as cost reductions in general and administrative expenses. We anticipate that we will continue to incur net losses in the future as we continue to invest in research and development activities, including clinical development of our multiTAA T cell product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not generated any revenues from the sales or licensing of our product candidates since inception and only have limited revenue associated with grants to fund research. We have financed our operations primarily through public and private offerings of our stock and debt including warrants and the exercise thereof, grants, and more recently through the cash proceeds received from the Cell Ready transaction and additional grants to fund research.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Working Capital</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth our cash and cash equivalents and working capital as of March 31, 2024 and December 31, 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,323,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,111,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Working capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,788,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,053,000</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes our cash flows for the three months ended March 31, 2024 and 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Continuing operations:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,837,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,098,000)</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 49,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 620,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Discontinued operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,790,000)</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (113,000)</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,788,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,381,000)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Continuing Operations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities from continuing operations during the three months ended March 31, 2024 was $3.8 million. The use of cash primarily related to our net loss from continuing operations of $2.4 million offset by $0.1 million of non-cash stock-based compensation, and a $1.5 million decrease from changes in assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities from continuing operations during the three months ended March 31, 2023 was $3.1 million. The use of cash primarily related to our net loss from continuing operations of $4.2 million offset by $0.7 million of non-cash stock-based compensation, and further offset by a $0.4 million increase from changes in assets and liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $0.1 million and $0.6 million during the three months ended March 31, 2024 and March 31, 2023, respectively, due to the net proceeds from sale of common stock as well as the exercise of stock options.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Discontinued Operations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities from discontinued operations during the three months ended March 31, 2023 was $2.8 million, which was comprised of $0.7 million of net loss and $2.1 million of cash used for other operating activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities from discontinued operations during the three months ended March 31, 2023 was $0.1 million, which related to capital expenditures for lab equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Future Capital Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, we have not generated any revenues from the commercial sale of approved drug products, and we do not expect to generate substantial revenue for at least the next several years. If we fail to complete the development of our product candidates in a timely manner or fail to obtain their regulatory approval, our ability to generate future revenue will be compromised. We do not know when, or if, we will generate any revenue from our product candidates, and we do not expect to generate significant revenue unless and until we obtain regulatory approval of, and commercialize, our product candidates. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue or initiate clinical trials of and seek marketing approval for our product candidates. In addition, if we obtain approval for any of our product candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from the CPRIT to support the Company&#8217;s clinical investigation of MT-401. Through the date of this filing, the Company has received $6.9 million of funds from the CPRIT grant. The Company recorded $0.8 million of grant income related to the CPRIT grant as revenue during the three months ended March 31, 2024 and at March 31, 2024, the Company recorded $1.2 million of grant income receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 13, 2022, the Company received notice from the FDA that it had awarded the Company a $2.0 million grant from the FDA&#8217;s Orphan Products Grant program to support the clinical investigation of MT-401 for the treatment of post-transplant AML. Through the date of this filing, the Company has received $0.8 million from the FDA grant. The Company recorded $0.3 million of grant income related to the FDA grant as revenue during the three months ended March 31, 2024 and at March 31, 2024, the Company recorded $0.3 million of grant income receivable. In April 2024, the Company received $0.3 million of funds from the FDA grant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2023, the Company announced that it had received a $2.0 million grant from the National Institutes of Health Small Business Innovation Research (&#8220;SBIR&#8221;) program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents. Through the date of this filing, the Company has received $0.4 million from SBIR. The Company recorded $0.2 million of grant income related to the SBIR grant as revenue during the three months ended March 31, 2024 and at March 31, 2024, the Company recorded $0.2 million of grant income receivable. In April 2024, the Company received $0.2 million of funds from the SBIR grant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All funding agencies have agreed to continue their financial support and to shift funds to the MT-401-OTS program.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March 31, 2024, we had working capital of $11.8 million, compared to working capital of $14.1 million as of December 31, 2023, and as of March 31, 2024 we had cash and cash equivalents of $11.3 million compared to $15.1 million as of December 31, 2023. Operating expenses incurred during the three months ended March 31, 2024 were $3.8 million compared to $5.5 million during the equivalent prior year period. Based on our clinical plans and our timing expectations related to the progress of our programs, we expect that, together with drawdowns of available grant funds, our cash and cash equivalents as of March 31, 2024 will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Furthermore, our operating plan may change, and we may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates and the extent to which we may enter into additional collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials. Our future funding requirements will depend on many factors, as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate or continue clinical trials of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue the research and development of our product candidates and seek to discover additional product candidates; seek regulatory approvals for our product candidates if they successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue development of our manufacturing capabilities and our manufacturing facility;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluate strategic transactions we may undertake; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enhance operational, financial and information management systems and hire additional personnel, including personnel to support development of our product candidates and, if a product candidate is approved, our commercialization efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because all of our product candidates are in the early stages of clinical and preclinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of product candidates or whether, or when, we may achieve profitability. Until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to continue to fund our operations and capital funding needs through equity and/or debt financing. We may also consider new collaborations or selectively partner our technology. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our existing stockholders&#8217; common stock. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates or grant licenses on terms unfavorable to us. We may also be required to pay damages or have liabilities associated with litigation or other legal proceedings involving our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the foregoing, high inflation and concerns about an economic recession in the United States or other major markets have resulted in, among other things, volatility in the capital markets that may have the effect of reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction due to these factors could materially affect our business and the value of our common stock.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">ATM Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In August 2021, we entered into a Controlled Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald &amp; Co. and RBC Capital Markets, LLC, or the Sales Agents, pursuant to which we can offer and sell, from time to time at our sole discretion through the Sales Agents, shares of our common stock having an aggregate offering price of up to $75.0 million. Any shares of our common stock sold will be issued pursuant to our shelf registration statement on Form S-3 (File No. 333-258687), which the SEC declared effective on August 19, 2021. However, our use of the shelf registration statement on Form S-3 will be limited for so long as we are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement and in accordance with the ATM agreement. The Sales Agents will be entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and we have provided each of the Sales Agents with indemnification and contribution rights. During the three months ended March 31, 2024, the Company did not sell any shares of its common stock under the ATM agreement. In April 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement resulting in net proceeds of $0.04 million, after deducting agent commissions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stock Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On December 12, 2022, we entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, which provides that, upon the terms and subject to the conditions of the agreement, we have the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of our common stock, or the Purchase Shares, from time to time over a 24-month term, at a variable price with certain market-based terms as defined in the agreement. The purchase agreement does not exhibit any of the characteristics for liability classification under ASC Topic 480, Distinguishing Liabilities from Equity. In January 2023, Lincoln Park was issued 180,410 shares of stock as a commitment fee at a value of $0.5 million. On February 29, 2024, we terminated the Purchase Agreement with Lincoln Park effective March 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Critical Accounting Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. There have not been any critical accounting estimates made by management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2569333a_4b3b_4b56_80ef_24831b6d65e8"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 10pt 0.7pt;"><b style="font-weight:bold;">Item 3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p><a id="_f5cb70a5_bdb8_4094_bc1c_3f4618981ce4"></a><a id="Item4ControlsandProcedures_453239"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 10pt 0.7pt;"><b style="font-weight:bold;">Item 4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0.7pt;"><span style="display:inline-block;text-indent:0pt;width:18.1pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></span><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We have established disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure. Our management, with participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of as of the end of the period covered by this report. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in recording, processing, summarizing, and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In designing and evaluating the disclosure controls and procedures, management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Our management, including our Chief Executive Officer and Principal Financial and Accounting Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0.7pt;"><span style="display:inline-block;text-indent:0pt;width:18.1pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></span><b style="font-weight:bold;">Changes in Internal Control Over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There were no changes in our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal quarter ended March 31, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_fb194b0e_a04c_488d_8d89_a42864719a37"></a><a id="PARTIIOTHERINFORMATION_786639"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_798737"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0.7pt;"><b style="font-weight:bold;">Item 1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results, or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9eb16ab4_fb14_456a_8f32_39c156cb2d03"></a><a id="Item1ARiskFactors_449487"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0.7pt;"><b style="font-weight:bold;">Item 1A. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. In addition to the other information set forth in this quarterly report on Form 10-Q, you should carefully consider the factors described in Part I, Item 1A. &#8220;Risk Factors&#8221; of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on March 26, 2024. There have been no material changes to the risk factors described in that report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7e61cb52_d5c5_484b_8922_e606763b4729"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0.7pt;"><b style="font-weight:bold;">Item 2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 0.7pt;">We did not record any issuances of unregistered securities during the three months ended March 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_df96c916_015c_40bd_9078_13c857f9cd13"></a><a id="Item3DefaultsUponSeniorSecurities_390946"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0.7pt;"><b style="font-weight:bold;">Item 3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 0.7pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_735a43b4_3e9b_416d_bf8e_d0fa9ff88018"></a><a id="Item4MineSafetyDisclosure_210061"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_37c6f124_7d4d_4198_a1a1_3728432b2aee"></a><a id="Item5OtherInformation_200318"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0.7pt;"><b style="font-weight:bold;">Item 5. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 0.7pt;">Not applicable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0584e5c8_fe6b_421d_8e26_01dd486f918b"></a><a id="Item6Exhibits_556633"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 6. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following exhibits are included with this Quarterly Report on Form 10-Q:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br/><b style="font-weight:bold;">number</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;width:37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit description</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;no.</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">date</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">herewith</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054209/tv504951_ex3-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation (Delaware).</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/17/18</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.1.1</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312522162322/d480537dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to Certificate of Incorporation.</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/27/2022</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.1.2</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465923007019/tm234466d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to Amended and Restated Certificate of Incorporation</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/26/2023</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054209/tv504951_ex3-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of Marker Therapeutics, Inc.</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.6</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/17/18</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000141057824000297/mrkr-20231231xex10d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Master Services Agreement for Product Supply between Marker Therapeutics, Inc. and Cell Ready LLC dated February 22, 2024**</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/26/2024</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20240331xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1933, as amended.</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">32.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">*</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20240331xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer Pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">32.2<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">*</sup></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:37%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20240331xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exhibit 101</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">101.INS - XBRL Instance Document</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">101.SCH - XBRL Taxonomy Extension Schema Document</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">101.CAL - XBRL Taxonomy Extension Calculation Linkbase Document</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">101.DEF - XBRL Taxonomy Extension Definition Linkbase Document</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">101.LAB - XBRL Taxonomy Extension Label Linkbase Document</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">101.PRE - XBRL Taxonomy Extension Presentation Linkbase Document</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">104&#160;&#160;&#160;&#160;&#160;&#160;&#160; - Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101 filed herewith).</p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Furnished herewith and not deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Confidential treatment has been granted as to certain portions of this exhibit pursuant to Rule 406 of the Securities Act of 1933, as amended, or Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b8879143_b464_4415_99a7_6ed66ff6edaf"></a><a id="SIGNATURES_208803"></a><a id="SIGNATURES_772915"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Date: May 15, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">MARKER THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">/s/ Juan Vera</i></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Juan Vera</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">President, Chief Executive Officer and Treasurer (Principal Executive Officer and Principal Financial and Accounting Officer)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>mrkr-20240331xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 5/15/2024 04:51:38 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">I, Juan Vera, certify that:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Quarterly Report on Form 10-Q of Marker Therapeutics, Inc.;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(3)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(4)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurances regarding the reliability of financial reporting in the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(5)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;&#160;&#160;&#160;May 15, 2024</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Juan Vera</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Juan Vera</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:&#160;&#160;&#160;President, Chief Executive Officer and Treasurer (Principal Executive Officer)</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>mrkr-20240331xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 5/15/2024 04:51:39 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">I, Juan Vera, certify that:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Quarterly Report on Form 10-Q of Marker Therapeutics, Inc.;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(3)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(4)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurances regarding the reliability of financial reporting in the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(5)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;&#160;&#160;&#160;May 15, 2024</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Juan Vera</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Juan Vera</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:&#160;&#160;&#160;&#160;President, Chief Executive Officer and Treasurer (Principal Financial and Accounting Officer)</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>mrkr-20240331xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 5/15/2024 04:51:38 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The undersigned, Juan Vera, the Chief Executive Officer of Marker Therapeutics, Inc. (the &#8220;Company&#8221;) hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge, the Quarterly Report on Form 10-Q for the period ended March 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 15, 2024</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Juan Vera</i></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Juan Vera</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Treasurer </p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>mrkr-20240331xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 5/15/2024 04:51:38 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The undersigned, Juan Vera, the Principal Financial Officer of Marker Therapeutics, Inc. (the &#8220;Company&#8221;) hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge, the Quarterly Report on Form 10-Q for the period ended March 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 15, 2024</p></td><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Juan Vera</i></p></td><td style="vertical-align:bottom;width:50.82%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Juan Vera</b></p></td><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Treasurer </p></td><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td><td style="vertical-align:bottom;width:50.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>mrkr-20240331x10q001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20240331x10q001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !D 5X# 2(  A$! Q$!_\0
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MV?I_Q\+_ (T*E745RHR5:E&7+<U"@D0CO3XX]BTR.2-P61@PQG(ITDR(H);
M;H:;BN:_4U?+\2';E%&T'D5BR>)])5B#J5H"IP0;A>/UJS8ZW8WS[+>]MYW'
M58I58_H:?LZ\?>:T,8XB#?+<ORH'7!IF\1@ 4YY K8ZU7NM2LK*(27-S#;(3
M@-,X7G\:CEE+2.QO._+H]"VK';0WS5F'Q-H_(_M6R&./^/A/\:8?%>D+D+J=
MF2.N)U_QK7V4Y:.)BZM.$=9&J0.AJ,0H#D&JT&LV%UCRKN&?/'[N0-_*K0*O
M]T].M9RARZSC8M2IST3'$X;I1L4L3FLR7Q1I5NY1M1M RG:0TR@@^G6K=MJ%
MM>0":VGCGC/\4;AA^E5.DW%.I$<:D)RY(O5%O:,>U,;8*KW>I6]E"99IDBC'
M5Y&"J/Q-9Z>*M%F_YB=D#_U\+_C3]G4M[BT,G5I*?)-ZFVF".*"#FL\ZW80V
MHN/MEN("<"0R@(?QJ+_A)])W\ZK9#OC[0O\ C35.=BO:4[V3-48/:@)60_BC
M21_S$[/_ +_K_C2CQ7H^ IU6R!/3-PG^-"IU;:Q$J].]N8U' 8$'I2Q@+TK/
MDUK3H(U>:_MXHY/N-)*%#?3)YJ,>*-'0?\A2R_\  A/\:(4YVLUJ5*K&+MS:
M&KQFD8!NM9/_  D^CYYU6T!_Z[K_ (U=M-1M+X'[/=0SXZ^7(&_E2<*D=91"
M-2#^"2+B@ "EQ4:N&Z&E5\DX-9\SZHUW%)' J"[E6*)B_"@9)/:E$RLA<9(J
MKJ!AN;5X93L69"G7L1BM(;V8N:,/?GL?+7Q"_;]\#>!?&EUH!L]0O1;3"&ZN
M8$S&#[&M?]H?QE\,_''PTTZX\0ZREG9WD8DLIT;]XA(]/YU\M?&C]C#Q)H?C
MC5;R+4;=]!U6[WQ7$T@5HP3D\'K79?&_]C:\UGP+X3F\,ZY;7Z:;%MD^TR@1
M L,$\\5]%1H4TH5=;/8^AAB,LI3A>JDSI_A]^SD/"W@74_&GAK6/^$CU66W9
M[ QMD*.VWWKC?V<]4\5GXD77_"7+=#P^R.^H7.HC]TK#MD]*J_$(_$3]E_X.
M^'O#OA2^?4VO'$]S?6:&9$8_\L@1T%>LZ?I/B;X^?LWZ?INHWEIH'CB\YDMV
MQ$\R+V*]>1WK>[IMR;T?7L>Y'$)Q]YIQ>TET*?QGT/4?%&K6%_X9\O5O#B@)
M:?V:WW']>*[;Q?\ "[PYJOP8@U?QW(L^HZ=;L6O(CE^G"M[UROP-\"_\*^\"
M^)O!,?B&.7Q8X9X[$2 FV/L>U;?P=\&:WHWAOQ8?'4@N/#8B;S+>23S>@Y-8
MXB7M*=[Z1_$\C/84\9EE1-K]VM&UN<7^S]\>]*L;&_\ #^A>'$T^18&DMIU'
MS7!YY->;6/QI\9Z?XW^W)J%Q-=/>;&L^<!=W3%>F_L]7GPFA\0ZQ=^&[:XEO
MK4.\7FL64)SP!VJGX'^*_A#5_C'&&\*K";N<HDQ((# D9(KQXTW5LX['\T3J
M8F7LXTZRBK[)'VMX7OIM4T.QNYT*32PJ[*>Q(K9!Z U\V^/OVWO /PX\7+X8
MD=KF\BVK*T0_=QCZ^U>[^%?%FG>-?#]KK.CSK=V5RF^.13P:>(PE>A%5:D&H
MO8_8L)7IU(*$9\S2-S HP*C$IXR,4\/7%TN>C9GQU_P49O;K2_A]I]Q;7,UL
MQE*EH6(/Z5^?,.JZH;5##KFHH6Y?,K?XU]__ /!21VB^'FD!#C]^<YKX)T+3
M;G7]46QM5WW,J_NT ZG%?O7"6$PU;+H5:RV;OZ7/R3B&O4CBO9TGJ?9?_!.S
MXI7-Q/K?@W4]0DO)D(FLVG;)9?XNM?<&H7T>GV5U>SGRDA1BS-TP!G-?D#\"
M_&UQ\,?C'H6LL?*:"X^QSQ],!FPQ-?H-^V3\65\(? ZY;3YE^T:V@@M95;H"
M 2U?(\193SYS&&'C[E1JS_/\#W\JS",L#.=27O06I^>_QB^)^K^/_BQKFLPZ
MI=KIC2M%!''(0!M)'K7)Z3J^K-KNEK'?WQ8W4>\&5L$;A[TGAOPW>^(+>YDL
MT9X;=#-(XZ CEL_C5316-QKNDR*S1R?:HSG/4;A7ZO/"X.A@71I1NTCXIXJO
M+$^TO[MS]LO"J9\/Z=@$$VT>[/\ NBN%_:/^(2_#7X2:YJHD"W"PLD0SR21C
MBNX\*2._AS33T/V>/(_X"*^%O^"C7Q(^UZWHOA"*4[86\Z=4;AP>@/TK\"R;
M+UF&:0I2VOKZ'Z?B<5'#8'VK>Z/CK^W]4U*,WL^HWZ37#L77S6[G/K7L'[*/
MQ:O/AY\:]+DU.\N9]*U,BV;SI"0AZ+U-:7[)7P8B^+WB?Q#%?PM/IMK9M'%*
MO19L<5XCKUE<>%?$VI64@=+K3;QMN>HV'Y37[G4IX+&UJV612]V/Z'YS1Q.*
MI5%B9KW&]S]O8YA(JD'L#^=?(W_!12[GM?AG9307$UK*LX ,3%2>?:O:?V;/
M'_\ PL7X1>'=4EE66]^SA+O!R5D'&#^%>,_\%'+>*?X:V'F'"B7(P<9-?AF1
MX>6&SI4:RT4FC]&QM1XC .I2E;0_/9-5UB9V_P!.O7FE7$<8E;<Q_.K F\40
MX8G5X,_>;+]JZS]GB-+SXW^#(YT26W:\ DCFY4+COFOUM?P]X42'$MAI17'&
MZ..OUS/\WI9)7A1^K*7,K_UH?"Y=@*F8PE.=:R1^/GA/XI>-O".I"^T;Q!=6
MTBM\]O<.?G(]C7Z,?LG?M%O\=/!5W%>@VFMZ?\D^/^6G'45\>_ML:9X9TCXQ
M+'X;6!/,M]TR6Q&T2=QQTK=_X)X27,/QAU 0LRV/V23[3&3QYF.*\[.\'A\?
ME"S&G2Y7N;9?B:M#'NE*5XK0\3^+.O:M_P +3\6E=7O5CCO90(DD;"?K7W_^
MP+>/<? N.:\NI;AO,+&:9B< >YK\]_BT&M_B?XU6+K)J$N2>>]>V>'?V@A\-
M/V9[7PIH$H_X2'4"49\X\M#U-=&;Y8LTRK#QPU*S=E?\QX+,)87&U:E1]['1
M_ML?M-3^*-:/@;PE,RZ=;-_IMQ$V&+ ^H[5XW\ _A5XF^.?CJ+2[:^U*/2H&
M#WE^)&V<?P@YKD/A]\/M=^*?B^VT/18I;K6+J7%U>9.T1Y^8D_2OUG^!_P '
M-'^#'@VVT/2H\84&XF(^:23N<UYV=2P/#V7PPE!WK/?_ #9UX"G5S?%2Q%1V
MB?/7[;'A_P#X5[^SYI^DZ=-<1V]LZH98W.\GU)S7P/;ZWK,SPQ_VG=R33/L7
M;*V3Q]:_1#_@HS&R_!Z/8Y5C, 3VQFO@GX2ZE8Z%\1O#-UK#+%I<5ZK/YB[O
ME]379PS0I5,I>,G'FE=_/J<^=*4,0J,9\J,IV\4)*\<LNL<$@;2_-07<WBDV
MT<DZ:N##*HB52^3\PZU^HMM\?_@FJ@-<Z5N']ZW3-/D_:&^!Y=<W.EN[D*!]
MG4_2N.MQ'7<'36!:7I_P#IH9;2Y4Y8C4^5_VO=1U.'X7?#%C=2V5P]GEHED9
M2W'4U\PIJ6L74\5M;WU]+.XSMBE8G^=?8G_!1BXMM4TOP9=Z?$DEE)$S1,OR
MA5]J\=_8R-K=_'72H[E(9[3ROF%P@P#CWKT\G]C3RB>.E2O-.3M^AY..IU%B
MU0]K[KMJ>1BX\1N2LS:U&\8/[Q2^!]:Z'P'\;/'/P^U*'4=,UZX@$#YDLY7)
M\X#L0:_76Z\/>$6M9/.L=)2!E(9F2,?K7Y5?M*Z7X>T?XV:C;>$WC>S.3-R"
M@/?::SR7-*&?UWAZ^'LC;'9?5RN"JTZU[^9^D/[.GQMM_CCX#MM4*+:ZC'@7
M5LI^XU>MQG>2PZ&O@+_@FE<RB_\ %4$7F-:&3=N<YVGTK[Y=WB4%%W9K\ESS
M"T\'C:E&&D4]#[_*Z\ZU"$I[V(YF.[S,X7LOK7P)\>OC-XSD^(M_:V&H26$%
MD_R1 XW &OOO/G*KH SCC!Z 5Y'\5_A9X!UE;[7]6L8KO4K6%I/+BD 9RHR!
M@5U\/8VC@L6I8BESWTM:YY'$&%Q.)PO-@ZJAU=^I\Y>,_#/C3XZ^!O#_ (CM
M(KJYEMEV?8D) 8_WC6_'\$O%>I?!R'P^NJJ^L0R-+/8M+P W13@]JP/A/^U7
MJNI^+;/PM%IT=A97VZWLK:/[T!R0":M?#[X2?$#P7\6]4U_6]8:Q\/QF:274
M9K@D-GI\I/:OML3&OA)RA/DII>]%;W\O^&/@:5.C62<N;FV;\_(Z.)O%7[/O
MPHL[0:5'XBFGN TEO*/,$.<<#K4T7[.NJ^,/C%I'Q>O/$,VB6PMT,FCS2;%C
MP.PZ5H? 'PWJMKXE\3>*[[Q3%XD\+2*Y#,XD 89.['\)KY!_:,_:(\0_%_Q;
M?V<.H3:?X=M)FBM[6UD*?=.-Q(ZYKQX9?7SK$3HP2[RDEWZ6/L\/F57):*FY
M-KHF?:OAKX.?#K_A9VL>*M"\5"X\07RLCPM/D*V,<<UD:Y->?LU?#WQ'J?C2
MZN/$NG:K.88[>WRQ56__ %U^<MKJ>H:?=1W%KJ-W!<1\K)',0<CIGUK[W_9&
M^-MS\;_#=SX-\;VT.HZA9+FWFD4-YR =2.Q%=>=\+8O*,,ZU*;E&RNFMNS.Z
MGQ7B,SPU3"5/M[>=AND:;X&^!W@=?'VAV%[+)KL?EQVTP^2//)S6E\%;?X>:
MC:W_ (\F3^SHH25E^V<1(QY)6M'PWX4\2:QK/B31O'6FP_\ " V>Z2R_A*J.
M>/PKRGQYXF\"?'_P#>?"OX8S2:;J>GW'VB*WD'EK=[#RN[ODU\7@L)'%N,^5
MZ;OL?&QPRG455+EC'2W=GE/BC]G;5_B?\0M6U'X?WD/B'0+VY=WF)W-#N/./
M:OT._9[^&TOPH^%>@>&;B<O/9Q8<YSR3FOB_X6Z%XL_8VTG5/$WB:%8;O74^
MS6VE0R;HH67D-]:]U_9M_:KU'XA>*/\ A&O$-HBW[QF6.9>R^E?89[2QF+PR
ME0M*C#:7>RU^X]K*IX6A7]G5E:?8^K5Y')!-+WJ*!EV\<'-/=MM?F"C)JTC]
M%34OA9\;_P#!2A<_#O1S_P!-Z^0/V9UCE^/OA&*4!HGN K!NAR,5]@?\%)&5
MOAUI!R?]?P,5\@?LU!9/C_X/C*,K"[4GBOWKAZJX\-5(VZ2_4_*,W3_M=::7
M7Z$_[4_@)OAE\:M<M!$4M+QS<VK@<98YXK/^*GQFO_B7X5\-Z3=.PBT6W$?)
MZL.]?7'_  49^')O_"VF>+[:V\R739-DQ4<D'I7PUHF@R^*?$.E:';Q$W&IS
MJ$*^F1FO2X>QL,9@XXRM%.5)?C:QPYA"IA,1*A26E1GT?\(OAS-X5_9/\9^)
M[B$"XU-2UL6'(4#G%?+V@*5N]#DSE_.B+#T^<5^FWQY\*V_@?]E.XT6R3RUM
M;9%V_P"UMY_6OS(\/Y?5-*4[HW:YC+<?>^<5CD./J8_"XRK;5MV^XZ,QHJA4
MHTXKM<_:FUU6W\.> X=1N6"06]BDK$].$%?CU\6O&UUX\^)>OZY</]I\ZX>.
MUR<X7/%??_[8/Q6_X03]GNVMK:9DO-5@BME0#YF0J 37YMVUK)Y4$$4)GNSS
M'''\S'UXKRN",'[#VN.K+1Z)^AWY_BXRIPPRZ6/TC_8;TO0OAO\ ".&>[U.V
M34-4;[3.&< J>F*^5?VV?"FEZ/\ &2;4]%N(9K'4HP\@B8$!^IZ5XTVD^*8%
M9?L?B"VB)W(L4;[?PJ*\TC6TC+7UCJS11#?YUY&W&?<U[>5Y72P^:SS!U[\U
M]/Z['EXC&UIY?&@Z=DNI]<?\$YOB8MCK^L^#;R?"W7^E0*QZ'T%>B_\ !1N-
MC\,K-B?E2< _G7PY\*?&DWPY^).@Z^F"L-POGR(>JY]*^U?^"@&M0Z]\#](O
MH<-'=/'("#_>YKYW,L#+#\04L53C[LV[>J1Z^%Q5/$97*DI:QW/@6SU"?2Y?
MM=L\EM*O$-Q%]X-[5L_\+.\93111GQ;?MYN<"1B#6_\  33(]0^-WA.RO(5G
MM)KI8S#(,J>.XK[6_;)_9PT?4/A=-J_AS2X;'4]._>9MXP,IWZ5];FN<8;#X
MZAA\93NVM^Q\_@,%4KT9U:,[*.Y^?-CIFK^(M:CL[))=7URZ?Y'8EB2:_1G]
MCK]G&[^$7AG4-;UF+&MZF [1]T&.E?GE\/\ QK??#KQ7HVOZ< EQ9S"1Y'Y#
M#."F*_83X;_$'3_B/X%TS7[&0/'=09.WD!L?,/SKY?C3%XFE2A2HQM1E_5CV
MN'\-AZDISK2]Y'Y%?%1?L_Q6\7!FWA]0D_X#S7,20F/Y/LDT\</!NHP2J9[$
MUT?Q;41_%?QTT0=T:]DW9'0YK[4_8R^#_AWQM^S[J=M?VB23ZGN5[B1<LAQ@
M$5]76S1Y/E6'Q-2-XNVAX]#!+&XVI2C+>]CY_P#V.?CA8_"'QVUMJ=M'_9&I
ML(Y=08?-$>V#7ZGV5Y%J-O'<V\BRVTRAXY$.0P-?C5\6OA5J/PC\>7_AO5(F
M7RV+6<G\,J'H1ZFOK/\ 8>_:;:X:#X<^([PK=0<6%S*?OK_SSSZU\'Q3DG]H
MT?[5PFL6KOT[GT60YC'!5)8"LK.^YW7_  477_BT$*_]-Q_.OSFT_3[C6M0M
MM/L;>:]O)R(XHU_O>U?HQ_P43FB_X5%!O+*// &!WS7P'\-?$%KX2^('AO7+
MR606EC>++*%7J!7T/!U6=#)9.C&\DWH>;Q%%2S"*F]&CH&_9D^)VY ?!%[(&
M_B -,?\ 9<^*#.K#P9>0*KI\Q!XPPK[O@_X*$_#"&/:\UV"F =L1-%W_ ,%#
M_A?'"S127DIR%*M"1U.*\FOG>?SO&6$LO0[Z.7Y7%*7MM3P;]N:RETCP-\,K
M2\CFBGCL_+>(_P![: <U\JZ=JFH:+=13V5S)I]R@PLEOG=^E?7W_  4%\16G
MC#1_ >JV+2&VNHVDCW+C@\UX]^QWH5EK_P ;;2RU&T6[LI/O1S#</UKW,EQ=
M3#9'.M5AHG*Z^;;/%S"C"OCXT82Z+4\R;XD>+M0C>UF\3ZA=+G#P.Y!.>],\
M/>#]9\?ZY%H_A^UDU75)C\['DQ^Y-?9?[>'P T[2?#EEXT\.:=':+I_[NZBM
MD"[LG[QQZ5\J_!#XKS_!_P"(^C^(81Y]@[JMX .75CC]*[\NS*CBLKJ5\#3M
M4UT\R,9@YX?%PIXB=XGZ0_LG_ =O@EX"6VOMKZU?$2W3+V/I7NJN =O4 =:R
MO#FL6?B33+/6+202P7$*O'(IR-I&:ODK;KGJ&.<U_.N.K5<16E.K\3>I^NX.
MG3C22AMT.8^(-_=Z;X$UF\TQ"MY%;.R+U.0.U?F=IWQ%\63>,_/.H75Q?23J
M)+5]Q7:6P01]*_55U\])%:%6 X"GHWUKQ'XDVGPN^%5S/K6L16FG:I>(R^;M
M!9=PQG'M7U_#&;PPL:E!T/:2GMIJCY3B#)YXV4:D)\L8]#S2\M?AAI$6L-X8
MNM/C^)\UGOM86/*3E>@]#G->5_LZ^%OB;\0KCQ9I/Q FU3_A';B)_M5S<N?+
MCD )^3VKC/A[^RWXE\9?%6'Q%HFM1W_AJ/4?/.J>9^\DCSG']*]Z^)'QE\6^
M&/B9#X6M+*2+39=EL(HXLK,IX9B?<5Z>88I9?&5*,O:3E;XM7'T/$J8B%*$/
M:1LH]NIK?L_>!_!/AKX9>+/!O@77Y=4U"\61[CS7+*C\C*^@K\\-4LY=)UW4
M[*>%H)X+J1&CD&&)!Z_C7Z#:WJB?L[?$'0]+\(^#7N(];P]]=0@L%R>034_Q
MX_9)\*_&W47UG0]7CT7Q28P\L4&"6..A7L:GA_.XX'$REBMI[V[EU,+6SBE:
MDKN.Z['YVX$N>,'O7U!_P3RT"_O/BOJ6KP!QI%A;M'<R/]TL1Q@U?TK_ ()X
M^)_M5O)K.NV^GZ>IS<7(8;RO?BO>-2UOP#^R_P"#M'\*:4C2V^LAHGO+<;B<
M\,[$=Z^JS[B*EF%)X7"/F<U;T1S9=D^+P-1XFM'W(G')X4\;:C\=]8UV\\>0
MWGP\B9S=V2RC"1$8\O'J*YG0O OPV^$UWXE^('@+56\0:U:;T@LW;<L.XDDX
M_&N\\-_!CP3X2CUO3)/%LD[^)X-T*32D!-W0_7)JA\,OACX,_9]\1WR>)/$,
M-_=:C&8FM>" AZ%AVX[U\S2]G"+5Y-)*T5&W,EOT^38ZE:HJCII*,9;NZ=F<
M'\-/%&M_M.ZB?"GBW%TB%KF"\B4XB<C[N?:OH7X%_LHV'PAUNXUR[O3?W\@*
M1EN=BUY!\4_B18_!K73I'PWT^TTUI(5NI;S@^:K=@:]V_9G^,EW\5_"UTVJ?
M/>VDHC=P.#Q3SFKC8X+VN%C[.A+[/7S]+CR:65RQCIU)<]1=>A[7!LV?(<U/
MN##!%0P(D*D)TJ4L%YK\J4G'WZC/U)**=J>Q\W_MI?!?Q)\9O"FFV'AS;YEO
M)O8&OG7X)_L=?$?P?\8/#GB#5!$MC9W :;'7;7VG\3OCYX/^$%S:Q>);_P"Q
M-=?<)'%</)^V?\-#.K'6SY?487C'K7UV#S?&T<*\-2^!I_B<,\D6+K>UMKO]
MQZG\3?!5MX]\$:OH<Z+(+J!E0,/X\?*?SKXZ_9>_8V\2^ OBU_;OBE5DLK#)
MM-W/.:^E/ W[2O@;XD>((]!TC53+JKQM,%"\;%YSFNM\$_$C1O'\M_\ V+=F
M\2QG-M/GH''45R83,<7@Z%3#TW[LUJ7/+:=>HJDX?#J<[^T9X"U'XA?"S5=$
MTE,WMQC97P)IO["WQ0M[JQE:)!]GN(Y03Z!@3^E?J4S\J X'M2*025P16^ S
MO%9=2E1H[2.7$9;3KS4Y+4^'/VI_V??B-\7?%FC?V2BG1]-LDAC0]"X49/YU
M1_9@_8T\2^#_ (DKK?BZ&UDM[=,K&5SDFOO%=J>O':E9@RY0_/V!K:/$&,IX
M1X2GI%G/_8U&=15:JNS*'A[2UXDL[<1CY5_=BL'QW\.-+\6^%]2TPV5MYLT#
M*A,8X..*[ .#(=NUD'WCGD-Z4]9%;^\/J*^>I8C$0DI<^J/4GA:52#IN.A^6
MM_\ L$?%".ZNXX8X'M7D9D9!\PYR*]O\;?L[_$#QK^S9H'A.^3=KEA-\Q)YV
M \5]N&0[MO0'HU)M^0,V-XXZU]-/B7&U)4Y3L^3;\CR%D>'IIQ@K7/SA^#?[
M&_Q%\(_%KPWK]_&/L5C="5OI7Z*:IIUMJFG2VEW&'MYE*,C#(.:MACC&1O\
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M7)?MFLP\"^!%4I%(]]!DD#/45WW[6 5?V:/$*!0-UE&&8#'9>:Z.2*4%YO\
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M^Z2:D\H(@"_*/2DJC5Q1K-?,^1OB'\-?B9\5O'G@?Q%J6F1:;IFD7Z7#:8)
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E110 FP,N",BD6-57IGZT44 .5 O08IU%%4@"BBBF 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>mrkr-20240331x10q002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20240331x10q002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "G JP# 2(  A$! Q$!_\0
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M_*FBMO[&POG]Y'UZKY'ZK?\ #RGX1?W-?_\  %?_ (Y1_P /*?A%_<U__P
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M,0QHP)VH&+@=>E:_4L#H[2LVETZV^?57)]O7[H^G_P#AY3\(O[FO_P#@"O\
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M_P *O[NN?^ 2_P#Q=?F+11_9&&\_O#_5_!^?W_\  /TZ_P"'A_PJ_NZY_P"
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M5V:YMEO?;LUIWT.\_P"'B'PISC;K>?\ KR7_ .+H_P"'A_PJ_NZY_P" 2_\
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M4]9\%6LE_/I$5I->W,NJLM]:B0*'^UV,L:E 6/RE"?Q%?,U=-++<)6CS1O\
M>==#)\!B(N4>;3NT?IU_P\/^%7]W7/\ P"7_ .+H_P"'A_PJ_NZY_P" 2_\
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M^=<S11[-!_KGC/\ GU'\?\SITO[9F"B="2< 9ZU^R_[-_P#R0/X??]@2T_\
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M!_OK_.OVZ_9P_P"2!_#_ /[ EI_Z*6OQ%M/^/N#_ 'U_G7[=?LX?\D#^'_\
MV!+3_P!%+7RV??PX>I]3E_\ N,_\:_\ 26?.?[%TNW]G'PR,_P#+:\_]*)*]
MN\[WKP?]C63;^SMX;'_36[_]*'KVKS:[)PO-^I\TI6+WG>]'G>]4?-H\VHY
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MX:<IQO\ ?N]M=M+:?,BL[6SG\<V=]H&LWVEZ%<2RPRA2D<A",)(H9"P/RY+
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MW^]?ZGO7A'APX_8VLS_U4<_^A&O7I+L^8_S#J:\2NKRE_BE^A];-_P"PX?\
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M:_*UC,5*+DGH?K[PU!-)H]Y\3?M%W T6#2I-)NM)UK5)/(MKB%OM-J/[[JP
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MT]Q*JA0SGJ<#@5U<G[Q3\O\ +_@F=_=L4K3_ (^X/]]?YU^W7[.'_) _A_\
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M7M^EA9S7,F=D2,Y /)P,X'OQ7.>"_';>+78"WC\L6Z7'GV\OF1KO)Q$W (D
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MF!$LZW#B20'J&;.3[YK1BT'6CI4%Z?,@T^6WDNK>2:X$:2I#(%;RP3\Q5VX
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M0YC7O+O=9SC(Y0BF?#CQA;>#M7OVO[6:\TO4]-N-*O8[9PDZQ3+@O&S @,"
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M+23O8/:R[ER0VIUDFR$RV7G_ +@7!!E";OEWE>-V,9QQFOVS_9P_Y('\/_\
ML"6G_HI:_$:S!:\@ &3O'\Z_;S]G:"2V^!'@&*5&CD71+3*L,$?NEKY_/OX<
M%YGTN7_[C/\ QK_TD^,?C]\%OB!^S-XW\0>/?A[);7?@C59VN[S3KAUV6\C$
ML5,;,"0"3M9.0#@CCGQ?_AM_QC_T!-%_[YD_^*HHKMRK$5,10O/=:'@8RA3A
M4T6X?\-O^,?^@)HO_?,G_P 51_PV_P",?^@)HO\ WS)_\5117LW.#V<>P?\
M#;_C'_H":+_WS)_\51_PV_XQ_P"@)HO_ 'S)_P#%4447'[./8/\ AM_QC_T!
M-%_[YD_^*H_X;?\ &/\ T!-%_P"^9/\ XJBBBXO9Q[!_PV_XQ_Z FB_]\R?_
M !5'_#;_ (Q_Z FB_P#?,G_Q5%%%P]G'L'_#;_C'_H":+_WS)_\ %4?\-O\
MC'_H":+_ -\R?_%4447#V<>P?\-O^,?^@)HO_?,G_P 51_PV_P",?^@)HO\
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M>\8@8_L31?\ OF3_ .*H_P"&W_&/_0$T7_OF3_XJBBM;F?LX]@_X;?\ &/\
MT!-%_P"^9/\ XJC_ (;?\8_] 31?^^9/_BJ**+A[./8/^&W_ !C_ - 31?\
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M8GLON_X)7LL)_P! \?OG_P#)!_PP+\7/^@+#_P"!]M_\<H_X8%^+G_0%A_\
M ^V_^.444?VUB>R^[_@A[+"?] \?OG_\D'_# OQ<_P"@+#_X'VW_ ,<H_P"&
M!?BY_P! 6'_P/MO_ (Y111_;6)[+[O\ @A[+"?\ 0/'[Y_\ R0G_  P)\7/^
M@+%_X'VW_P <I?\ A@7XN?\ 0%A_\#[;_P".444?VUB>R^[_ ((>RPG_ $#Q
M^^?_ ,D'_# OQ<_Z L/_ ('VW_QRC_A@7XN?] 6'_P #[;_XY111_;6)[+[O
M^"'LL)_T#Q^^?_R0?\,"_%S_ * L/_@?;?\ QRC_ (8%^+G_ $!8?_ ^V_\
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M+?\ T!(?_ ^V_P#CE%%']M8GLON_X(>RPG_0/'[Y_P#R0?\ # ?Q;_Z D/\
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M!]M_\<H_X8#^+?\ T!(?_ ^V_P#CE%%']M8GLON_X(>RPG_0/'[Y_P#R0?\
M# ?Q;_Z D/\ X'VW_P <H_X8#^+?_0$A_P# ^V_^.444?VUB>R^[_@A[+"?]
M \?OG_\ )!_PP'\6_P#H"0_^!]M_\<H_X8#^+?\ T!(?_ ^V_P#CE%%']M8G
MLON_X(>RPG_0/'[Y_P#R0?\ # ?Q;_Z D/\ X'VW_P <H_X8#^+?_0$A_P#
M^V_^.444?VUB>R^[_@A[+"?] \?OG_\ )'JGP,_X)Q>)+CQ):ZAX]D@TS1H'
M#O:P3K+/< '[@*$J@/0MG..@[U^CEK;165M%;P1K%!$@CCC08"J!@ #T HHK
;R,5BZN+DI57L*=1.*IPBHQ6R6WF^K;\VS__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>mrkr-20240331x10q003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20240331x10q003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %" H(# 2(  A$! Q$!_\0
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MZ# ^M?44N&<1*+E5ERV3=K-O22C^-[GA3SRBG:FKZI7O9:IO]#[KHKX:^/\
MXN\4>%$^%S>$?$GBB&T@TB\U>>/5[N5+J[CA=92MR,C<VW(PV<#BK^N?%SQ#
MXR_:N\)7.A^(+Z/P0=0M-+-I;7;K;W,C6XGD+(#AO]8%.1_#1#AJM4IJM&HN
M5QG+9Z<CM9^<NGS[#EG5.$W3<'=.*_\  E>_HNI]K45\@_M2_$WQ9<?$6ZT[
MP5X@?28O VEKKFIQ1W7E"\D,B,+=E!&_$0+;3D$$C'-._:8GN-5^$=I\6?"_
MC?Q3I,FIBP$5A8:J\5G&LF%;]VN/FZY.>H-84<@J5%AW4J*/MM%HW9NW*G_B
M3NGV-:N;0A[90@W[/5ZI72O=KT:LSZ\HKY3^(>E:]X)USP)\*O#_ (Y\2AO&
M-Y-<WVO:G?FXO;>"*-<Q0.WW-W)XYS]35[['KG[.WQL\!Z+:>+-:\3^%?%LD
MUG-9:_=FZEMIE4%9(W/(!+#(Z=>O&,5DZG!.%9.4HRE%6:O&-[^2?NNRZVZ7
M1H\R<9-2IM)-1D[K1RM;UW5WYGT]17AO[(OB75O%'@;Q-<:QJ5UJD\/B6^MX
MY;N5I&2-=FU 2>%&3@=LURCV>N_M$?'#QUH=SXLUKPQX4\(-!:166@W9MI;J
M>16)DD<#. 5/'TZ<YQ_LEPQ%:C5J)1I*\I6;ZI*RW;;:-/[04J-*I"#;J;+Y
M-ZOT3/IVBOCM?C;XM^#7A3XS^';W5YO$U[X,-H-)U:_ DG*W1"H)3_$4R#D]
M>>U,\4Z1%\'X/#>K:U\=_$&E>-+U([^=M4,UWIMRA(WIY"*55<D@<_EU'<N'
MZG-RRJ+WG:-HRES>ZIWLE=*THWTOKMHSE>;PY;J&WQ7:5O><;7;LW=.VO3<^
MQZ*^2O$7QFUSP9\3?CMJMOJ5Q?V6D:!IUUIEE-*SVT,LL48#K&3@ LX8]"><
MUO>"_@?XXO/#OA;QE8_%;7CXJO%@U"^CU&<S:;-'(H=H1;C   .!CWZ=L)Y-
M[&FJN(K*"DHVNF[MQ4[.RTLFDWW>QK',O:S<*--R:O?5;*3C?7>[3LCZ7HKY
MJ_;9U+Q3;:#X*L?"NN7^AZCJ&K/"9=/N'A:0"!V"G:02,CI7C/Q6^/7B?QQJ
M7PTOO#>OW^FZ?;V>ER:RMA=O&LES<RE6C<*1NQY3CGU-;X'AZMCZ-.M":2GS
M7WTMHK_XFK(RQ6<4\)4G2E!MQM\[[V]%JS[[HKYD_:T\9>)-4\0:#\/O!6OO
MX?UJ6TN=:N[N&[^SLL42,(H]P(/[Q\C&>PK/\??&O4O&/[,/@?Q=H^J7&G:E
M>:M86M[)9S&-O,#E)D)&."RDX[@BN>CD5>M2H55)+VKM_AO?E;_Q<KMZ>9M4
MS6E3J5:=G[BOZVM=+TNK^I]5T5YU^T/JM[H?P-\:ZAIUW/8WUOIDLD-S;R&.
M2-@."K#D'W%>'IXB\3_%77?AA\-H?%6J:!9W'A*#7]9U2QE*WMYE541B4\C)
MY)[Y/I7/@\JEBZ/UCG48IRO>^BC'F;TWWLEW-L3CXX>I[+E;DTK>;;LE^OH?
M6M%?+?PF\4Z3HWB;Q?X>T#XLZAXMLETRXEM]'UF.>2^LYH@0SK<.H!4>GN,=
M.?(?!OQ\\8Z=^SMXIT#Q/K5_#XBN-)76O#VMM=/Y]Q;F8+(@ESG>A5N,YP2.
MPKTZ?#=>M*4:<MG!:J47:=];-)^[;6U]+M-I'#/.J5.*<X[J3T::O'I==^GW
M,_0*BOF#X^^,_$.J^'?AOX!\,>()=$\2^([=;VYU071A>*WA@WDF3<"-[\=>
M=I'>L#QA\9M;\8_L3IX@T_5KK3?%5O<6NEWEU:W!BE6Y6X2-R74Y&\$,<'H]
M<U+(:U6%&IS)*I-1ZZ7;2D_)N,ON\T;5,UI4Y5(<K?)%R];)-I>:37W^1]?4
M5\>Z;\;_ !!XFO\ X4:'J5_=:3XMTOQ.=%\26,4S1_:"L?RNP&-Z.!GGC.?:
MM/P3X>\2?M-7GC;Q'>>//$/AA-.U:XTO1;#0[PV\-N(L8DE4?ZPG(R#[\],7
M/(9X>+J8FHH16[LWO)Q5K;IVYD]K?<3#-H5FH4(.4GTT71-WOM:]K=SZOHKY
MIUS4/&?A+XP_ CP[K7BB?4KF>/4(]4EM"T$%^4BRC21@X8@8Y/?)XS7A?P^\
M8+X@M=7N/$OBCXQ7&H1ZK<0H?#-Q/)9K$K#:N0?O#G(^E:T.'IUZ?M553C9/
M1-WO*<?+^2_S1%7.(TI^S<+.]M6ELHOS_FM\C]"J*^1OCY<^(=(\9Z#)K5QX
M^_X5BFC1)%=^%)RETEWWDNR.6.W!Y/7IWKV']F77_P#A(/AA!*OC0^.XXKB2
M*/4IX&AN408(BG5N3(N>2>N1UZUY^(RF5#!QQBGS)VV3LKWTOM=6U3L^USKH
MY@JN)EAN6S7FO+IO;71J_G8]8HHHKP3U@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCOB_X"?XH?#;7O"T=X
MM@^I0"(7+)O"?,&SC(STKL:*VHU9T*D:M-VE%IKU6J,ZE.-6$J<]FK/YGD_Q
M&^"$WCOP3X(T%-66T;PY?6-XTS1%A/\ 9UVXQGC/Z5RI^ OQ"\/^/?&'B#P?
M\0;+0[?Q'>B\FM9](6Y*D A1N8]MQZ5]!45Z5+-L51@Z::<7?1QBUJU)Z-/J
MDSAJ9?AZDN=IIZ:IM/1-='V;/$]2^ >L^+M>\*ZQXJ\2P:K?:7I>I:;>O#9"
M$70NHV0,%!PNT$?7%<Q\//V0#X"L? L*:_'<2^'M<GUFXD%MM^U;T1%0?-Q@
M(.>>IKZ3HK2.=8Z%/V49VCV227VO+^_+^DB7EF%E/VDHW?>[O]GS_NK^FSP'
M0?V/O"5]J/B/6?'EO!XQU[6-2EO3=R*\2PQM@+$JANBX//T]*J3?LK7\GP,N
M_AJ/$R&Q35A>Z?<O;DM;VXD$@A8;OF(.[GWZ5]$T4_[<S#F3=5NSBTG9I..U
MELK>7S%_9>#LTH6NFGW:>]WN_F>8?&CX*+\4[30[RPUB;P[XIT"?[3I>KP1B
M3RG( 964_>5L#(]NXR#SW@SX">(KCXBZ=XW^(_BZ/Q9J^D1/%I5K9V2VMM;%
MAAI"H^\Q&?T]!CW"BN>GFF*I4/J\9+ELULKI/=*5KI/JD^K[LVG@:$ZOMI+7
M1[NS:V;5[-KI='S?X1_9[^)_PZBU6S\+?$RPT[3+[49M1^SS:(DS*\A&?F8Y
MZ 5M>)O@#XHL_'%QXT\!>,XO#?B'4[:*#68[FP6>UO71<"79_"WY]^F3GW:B
MNB6=8N51U7RW:L_<C[R=OBT][9/6]GJ8K+,/&"@KV6J]Z6GIKIOT/%/!_P"S
M'IFG^#O&&F^*=5G\4:SXO(?6=5=!"SD?<$:C.T(3D>_MQ7&:O^RSX]\5>'(/
M!>O_ !/2_P# T&R,1KI,8OY(8V#1QM,2>A5>?89STKZ>HHAG>.IS=133;:>L
M8NS2LG&Z]VR22M;1+L@EE>%G%0<79*VC:NF[M/76[UUON^YXS;_LWZ?-XU\?
M:EJ5[]MT7Q5I-KI+6&S;)"D,*Q[M_=OE!!QP:Y73?V9?&TEOHGAK6_B;/?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN6IA*M*C"O*W++LT]=[-+;3N;PQ%.I5E25[KR:^[N:E%%%<1TA1110 4444
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M_:&HZ8\06*:(J0XV@$.Q]Z]5_P"$BO\ _H7K_P#[[B_^+H_X2*__ .A>O_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[M-(OHW97:14VLP)"GYL\]<&OE?]JCX1WG@?PG\:]4M]!M-+\-:II?ABRL1
M$CAFFBNU$BE5Z8W*"2.AJUXS^ 'CSXBZ/\4]7TOX?Q>"4U7PSI^@V?AZ&XMQ
M_:%Q%=++)<'RSM"A,A2>2!0!]E>$?BIX3\;V%W<Z/XCTJ_\ L,:R7RVU['+]
MCRNX^80?EQSR?0^E1:1\9/ ?B#1=3UC3?&6A7VE:9_Q_7MOJ$3Q6WO(P;"CW
M/6OE_P")G[+7BGQ%K7Q%L?"NDV>@V&L^ =.TJUEB9((9KV&Z$DD+!.1NC786
M(QANM<YXL^ OCKXCV7CC6M*^&D/PZCD\#CPS#X?AN+?=J=W]H23S,1G:(T52
M%9CN/'T !]<3_'KX;6T-W++X]\.1QVDZVT[G5(<1RMT1OFX)P?R/I5[Q'\7O
M _A#4K'3M;\7:)I-]?*KVUO>7\4;RJQPK*"W0G@'H:^6O$'[+&HS>*O&EQ9^
M"].-C<_#"+0].Q'"!_:0R&4#L^ /G_6N$^*W[/\ \7/%7A%O#*^#S<)_PAVE
MV-G<Z:]E&SW$"*9X[V>4&5MK [%C(!..1S0!^AH((!!R#WI:R/"-K/9>$]%M
M[I#%=0V4$<J,<E7$:A@3]<UKT %%%% !1110!\V_M._M'^)?@QXJTO3=%L]-
MN+>ZL_M#M>Q.[!M[+QM=>,+7C7_#>GCW_H%Z!_X#3?\ QVM']OS_ )'_ ,/?
M]@W_ -JO7RU7L4:4)03:/Y[XAS[,\+FM>C1KRC&+T2Z:(^E/^&]/'W_0+T#_
M ,!YO_CM'_#>GC[_ *!>@?\ @/-_\=KS9_@;J!^#%K\0H;^&>":X\DZ<L9\U
M!YICWYZ8W8_[Z%:WCG]GN/X:>(-"T[Q+XLL]-@U.S>Z-Y]FDD6!EP/+(7DG)
MQD>E:*%"]K')_:'$O)[1U9*-HN[<4K3^%W??_ASL?^&]?'W_ $"] _\  :;_
M ..TI_;U\?#_ )A>@?\ @--_\=KSCXO_  =T_P"$SBS?Q=::OK(,;/I\%K(C
M+$ZEEDW'C&,<=>:9X0^"<OB/PG;:_J7B+3?#=K?2RP:<-0#_ .E/&,N2R@A$
M!XW-WK14\.X\W+H2\RXB5>6&=>7/'=<T=.FKV6NF^^AZ3_PWMX^_Z!>@?^ T
MW_QV@_M[>/A_S"] _P# :;_X[7 Z'^SUJFM^$K?5!J]A;ZK>VEQJ%AHK[S-=
MV\!^=U8#:,\[0>N*R9?@IK5I\)[CQY?/%96(EA6WM'.9ITD8J), _*N0<9ZX
M-:QIX9NUD-YCQ(H\SJSMRN739*[;[:-:/75=T>IG]O;Q\/\ F%Z!_P" TW_Q
MVD_X;W\??] K0/\ P&F_^.U\UMTI*[%A*'\B/,_UESC_ *"9'TI_PWQX^_Z!
M6@?^ TW_ ,=H_P"&^?'_ /T"O#__ (#3?_':^:?6DKHC@L._L(:XDSC_ *"9
M'TK_ ,-]^/\ _H%>'_\ P&F_^.T']OOQ^/\ F%>'_P#P&F_^.U\STC=*ZHX#
M"O\ Y=HO_63-_P#H)D?3!_;]\?\ _0*\/_\ @--_\=II_;^^( _YA7A__P !
MIO\ X[7S.::>]=4,NPCWIHI<1YO_ -!$CZ8/_!0#X@#_ )A/A_\ \!IO_CM(
M?^"@/Q!'_,)\/_\ @--_\=KYE/2FGK79'*\$_P#ETBUQ'FW_ $$2/IH_\% _
MB"/^85X?_P# :;_X[33_ ,%!?B#_ - GP]_X#3?_ !VOF1N],/:NN.48![TD
M6N(LV_Z")'TX?^"@WQ"_Z!/A[_P&F_\ CU-/_!0CXAC_ )A/A[_P&F_^/5\Q
M'I3&Z5UQR;+W_P N46N(<U_Z")'T\?\ @H5\0Q_S"?#O_@--_P#'J:?^"AGQ
M#'_,)\._^ TW_P >KY@;K4;=#77'),M?_+A&BX@S7_H(D?4)_P""AWQ$_P"@
M3X=_\!IO_CU(?^"B'Q%_Z!'AW_P&F_\ CU?+OI3#UKICD66/_EQ$T7$&:?\
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M\/\ X[^&IO"GA^WN=4@\&VFBZA=3WN@1VKW$6H6<N6$$9(.>6*X8^_:O#/\
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MMF_^)KLA6I?SK[T6L%BO^?4O_ 7_ )'"'I33UKNS\"_B'C_D2=?_ /!;-_\
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MBBBN<W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"I=:197U[97EQ:Q375DS/;3.H+0EE
M*L5/;*D@^U6Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S/$VOVWA7P[JFM7F\VF
MGVTEU*(U+,512Q"@=3QP* .=T[XR^#M5^*.I?#NUUJ*7QAI]JM[<Z<$;*1';
MSNQM)^=25!R PR*S= _:&\ ^)M?\::+8:ZLFH^#A(=;BDMY8Q:B,L'.YE <
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M:\W_ ),=3XCXEBW&5-W2O_#Z=]MCZU_X> >"O^@%K7Y1?_%TT_\ !0/P4/\
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M6)(;:SNI(AL9)!S][<N3ZBFZ1X,U?X,_"3XDQ^-I+>T_MNWBL]/T\W:2O=W
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MPS8>(]"O-'NXRMA=KLGC@/E[U)!921V8#!]02*U:* &QQI#&L<:A$4!551@
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M &;>OJRSD6D-F\.!@S2,K?D%-0>;X@_Y]]._[_2?_$ULT4 8WF^(/^??3O\
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M )]]._[_ $G_ ,36S10!C>;X@_Y]]._[_2?_ !-'F^(/^??3O^_TG_Q-;-%
M&-YOB#_GWT[_ +_2?_$T>;X@_P"??3O^_P!)_P#$ULT4 8WF^(/^??3O^_TG
M_P 31YOB#_GWT[_O])_\36S10!C>;X@_Y]]._P"_TG_Q-'F^(/\ GWT[_O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV;(W#JI'4$>AK<KP/]F6-=4\5_%'Q-I5G+9>$];U>*72Q);F!9RL(6694(!
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MD53J-B57&U3*N!CIBKO]E67_ #YV_P#WZ7_"C^RK+_GSM_\ OTO^% %"37]
MFE25[^P>1/N.TB$K]#VIR^)-#1V==1LE=OO,)5R?KS5W^RK+_GSM_P#OTO\
MA1_95E_SYV__ 'Z7_"@"@=?T [\W]@=YRV9$Y/J:<WB31'=7;4K(LOW6,JY'
MTYJ[_95E_P ^=O\ ]^E_PH_LJR_Y\[?_ +]+_A0!0.O: ;@3_;K#SP,>;YB;
ML?7K3AXDT169AJ5D&;[Q$JY/UYJ[_95E_P ^=O\ ]^E_PH_LJR_Y\[?_ +]+
M_A0!3C\2Z)"@2/4K)$'15E4 ?K3O^$IT?_H*6?\ W^7_ !JU_95E_P ^=O\
M]^E_PH_LJR_Y\[?_ +]+_A0!5_X2G1_^@I9_]_E_QH_X2G1_^@I9_P#?Y?\
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M2:&C%EU&R5B "1*H)QT[U&VM^'G55:\T]E7[H+I@?2M'^RK+_GSM_P#OTO\
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M\^=O_P!^E_PH'<H/K^@21JCWU@R+]U6D0@?040^(-!M\^5?V$6>NR1!FK_\
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M^U*^DJ*/[0Q/\WX+_(?]K8S^?\%_D?-+?L;%O^9J'_@ ?_CE0/\ L7%_^9L
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#Q7XHZI>VGBV>."[GA01I\L<K*/NCL#7(_P!NZE_T$+O_
M +_M_C110 ?V[J7_ $$+O_O^W^-']NZE_P!!"[_[_M_C110 ?V[J7_00N_\
MO^W^-']NZE_T$+O_ +_M_C110 ?V[J7_ $$+O_O^W^-']NZE_P!!"[_[_M_C
M110 ?V[J7_00N_\ O^W^-']NZE_T$+O_ +_M_C110 ?V[J7_ $$+O_O^W^-'
M]NZE_P!!"[_[_M_C110 ?V[J7_00N_\ O^W^-']NZE_T$+O_ +_M_C110 ?V
M[J7_ $$+O_O^W^-']NZE_P!!"[_[_M_C110 ?V[J7_00N_\ O^W^-']NZE_T
M$+O_ +_M_C110 ?V[J7_ $$+O_O^W^-']NZE_P!!"[_[_M_C110 ?V[J7_00
MN_\ O^W^-']NZE_T$+O_ +_M_C110 ?V[J7_ $$+O_O^W^-']NZE_P!!"[_[
M_M_C110 ?V[J7_00N_\ O^W^-']NZE_T$+O_ +_M_C110 ?V[J7_ $$+O_O^
MW^-']NZE_P!!"[_[_M_C110 ?V[J7_00N_\ O^W^-']NZE_T$+O_ +_M_C11
M0 ?V[J7_ $$+O_O^W^-']NZE_P!!"[_[_M_C110 ?V[J7_00N_\ O^W^-']N
MZE_T$+O_ +_M_C110 ?V[J7_ $$+O_O^W^-']NZE_P!!"[_[_M_C110 ?V[J
M7_00N_\ O^W^-']NZE_T$+O_ +_M_C110 ?V[J7_ $$+O_O^W^-']NZE_P!!
M"[_[_M_C110 ?V[J7_00N_\ O^W^-']NZE_T$+O_ +_M_C110 ?V[J7_ $$+
MO_O^W^-']NZE_P!!"[_[_M_C110 ?V[J7_00N_\ O^W^-']NZE_T$+O_ +_M
M_C110 ?V[J7_ $$+O_O^W^-']NZE_P!!"[_[_M_C110 ?V[J7_00N_\ O^W^
M-']NZE_T$+O_ +_M_C110 ?V[J7_ $$+O_O^W^-']NZE_P!!"[_[_M_C110
M?V[J7_00N_\ O^W^-']NZE_T$+O_ +_M_C110 ?V[J7_ $$+O_O^W^-']NZE
M_P!!"[_[_M_C110 ?V[J7_00N_\ O^W^-']NZE_T$+O_ +_M_C110 ?V[J7_
M $$+O_O^W^-']NZE_P!!"[_[_M_C110 ?V[J7_00N_\ O^W^-']NZE_T$+O_
M +_M_C110 ?V[J7_ $$+O_O^W^-']NZE_P!!"[_[_M_C110 ?V[J7_00N_\
EO^W^-=-\.M5O;GQ=8QS7EQ*A9LJ\K$'Y&[$T44 >Y4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>mrkr-20240331.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/15/2024 4:51:51 PM-->
<!--Modified on: 5/15/2024 4:51:51 PM-->
<xsd:schema targetNamespace="http://www.tapimmune.com/20240331" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:mrkr="http://www.tapimmune.com/20240331" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt="http://fasb.org/srt/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:attributeFormDefault="unqualified" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" id="StatementCondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" id="StatementCondensedConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureCondensedConsolidatedStatementsOfCashFlowsCalc2" id="DisclosureCondensedConsolidatedStatementsOfCashFlowsCalc2">
        <link:definition>00400 - Disclosure - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" id="StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails" id="DisclosureDiscontinuedOperationsOperationsDetails">
        <link:definition>40702 - Disclosure - DISCONTINUED OPERATIONS - Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails" id="DisclosureDiscontinuedOperationsCashFlowsDetails">
        <link:definition>40703 - Disclosure - DISCONTINUED OPERATIONS - Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" id="DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails">
        <link:definition>40801 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" id="StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>31003 - Disclosure - STOCK BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails" id="DisclosureNatureOfOperationsDetails">
        <link:definition>40101 - Disclosure - NATURE OF OPERATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails" id="DisclosureLiquidityAndFinancialConditionDetails">
        <link:definition>40301 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails" id="DisclosureNetLossPerShareComputationOfLossPerShareDetails">
        <link:definition>40501 - Disclosure - NET LOSS PER SHARE - Computation of loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails" id="DisclosureNetLossPerShareDilutiveSecuritiesDetails">
        <link:definition>40502 - Disclosure - NET LOSS PER SHARE - Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" id="DisclosureOtherReceivableDetails">
        <link:definition>40601 - Disclosure - OTHER RECEIVABLE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails" id="DisclosureDiscontinuedOperationsAdditionalInformationDetails">
        <link:definition>40701 - Disclosure - DISCONTINUED OPERATIONS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails" id="DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails">
        <link:definition>40901 - Disclosure - STOCKHOLDERS' EQUITY - Reverse Stock Split And ATM Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails" id="DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails">
        <link:definition>40902 - Disclosure - STOCKHOLDERS' EQUITY - Stock Purchase Agreement And Exercise of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockBasedCompensationStockOptionActivityDetails">
        <link:definition>41001 - Disclosure - STOCK-BASED COMPENSATION - Stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails" id="DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails">
        <link:definition>41002 - Disclosure - STOCK-BASED COMPENSATION - Stock-based compensation expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" id="DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>41003 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureGrantIncomeDetails" id="DisclosureGrantIncomeDetails">
        <link:definition>41101 - Disclosure - GRANT INCOME (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails" id="DisclosureRelatedPartyExpensesDetails">
        <link:definition>41301 - Disclosure - RELATED PARTY EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41401 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNatureOfOperations" id="DisclosureNatureOfOperations">
        <link:definition>10101 - Disclosure - NATURE OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>10201 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialCondition" id="DisclosureLiquidityAndFinancialCondition">
        <link:definition>10301 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>10501 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivable" id="DisclosureOtherReceivable">
        <link:definition>10601 - Disclosure - OTHER RECEIVABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureDiscontinuedOperations" id="DisclosureDiscontinuedOperations">
        <link:definition>10701 - Disclosure - DISCONTINUED OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable" id="DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable">
        <link:definition>10801 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10901 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>11001 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureGrantIncome" id="DisclosureGrantIncome">
        <link:definition>11101 - Disclosure - GRANT INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLegalProceedings" id="DisclosureLegalProceedings">
        <link:definition>11201 - Disclosure - LEGAL PROCEEDINGS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyExpenses" id="DisclosureRelatedPartyExpenses">
        <link:definition>11301 - Disclosure - RELATED PARTY EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11401 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>30503 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsTables" id="DisclosureDiscontinuedOperationsTables">
        <link:definition>30703 - Disclosure - DISCONTINUED OPERATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables" id="DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables">
        <link:definition>30803 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesTables" id="DisclosureRelatedPartyExpensesTables">
        <link:definition>31303 - Disclosure - RELATED PARTY EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="mrkr-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mrkr-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mrkr-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mrkr-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:element name="StockBasedCompensationExpensesTableTextBlock" id="mrkr_StockBasedCompensationExpensesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccountsPayableAndAccruedLiabilitiesTable" id="mrkr_AccountsPayableAndAccruedLiabilitiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccountsPayableAndAccruedLiabilitiesLineItems" id="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BasisOfPresentationAbstract" id="mrkr_BasisOfPresentationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightExerciseAxis" id="mrkr_ClassOfWarrantOrRightExerciseAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightExerciseDomain" id="mrkr_ClassOfWarrantOrRightExerciseDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" id="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" id="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing" id="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" id="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LiquidityFinancialConditionAndGoingConcernAbstract" id="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LiquidityFinancialConditionAndGoingConcernTextBlock" id="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ControlledEquityOfferingSalesAgreementMember" id="mrkr_ControlledEquityOfferingSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" id="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" id="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FundsReceivedFromCpritGrant" id="mrkr_FundsReceivedFromCpritGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="FundsReceivedFromGrant" id="mrkr_FundsReceivedFromGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ReceiptOfProductDevelopmentResearchAward" id="mrkr_ReceiptOfProductDevelopmentResearchAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="WilsonWolfManufacturingCorporationMember" id="mrkr_WilsonWolfManufacturingCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RevenueFromGrantRelatedToCprit" id="mrkr_RevenueFromGrantRelatedToCprit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="BindingServicesAgreementMember" id="mrkr_BindingServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockBasedCompensationTable" id="mrkr_StockBasedCompensationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockBasedCompensationLineItems" id="mrkr_StockBasedCompensationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GrantIncomeTable" id="mrkr_GrantIncomeTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GrantIncomeLineItems" id="mrkr_GrantIncomeLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GrantReceived" id="mrkr_GrantReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CancerPreventionAndResearchInstituteOfTexasMember" id="mrkr_CancerPreventionAndResearchInstituteOfTexasMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" id="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" id="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LincolnParkMember" id="mrkr_LincolnParkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AtmAgreementMember" id="mrkr_AtmAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FinancialConditionGoingConcernAndManagementPlansTable" id="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FinancialConditionGoingConcernAndManagementPlansLineItems" id="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NetLossPerShareTableTextBlock" id="mrkr_NetLossPerShareTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentFee" id="mrkr_CommitmentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="RevenueFromOrphanProductsGrantProgram" id="mrkr_RevenueFromOrphanProductsGrantProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="OrphanProductsGrantProgram" id="mrkr_OrphanProductsGrantProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="StockPurchaseAgreementMember" id="mrkr_StockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockPurchaseAgreementTimeToTimeTermToPurchaseShares" id="mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit" id="mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CellReadyAgreementMember" id="mrkr_CellReadyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OffersEmploymentToNumberOfEmployees" id="mrkr_OffersEmploymentToNumberOfEmployees" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CpritGrantMember" id="mrkr_CpritGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FdaGrantMember" id="mrkr_FdaGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract" id="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RelatedPartyServiceMember" id="mrkr_RelatedPartyServiceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IndaptaMember" id="mrkr_IndaptaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdditionalRevenueRecognized" id="mrkr_AdditionalRevenueRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockCompensationInContinuingOperations" id="mrkr_StockCompensationInContinuingOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="StockCompensationInDiscontinuedOperations" id="mrkr_StockCompensationInDiscontinuedOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CellReadyMember" id="mrkr_CellReadyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" id="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" id="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CashAtFinancialInstitutions" id="mrkr_CashAtFinancialInstitutions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" id="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OtherTaxesPayableCurrent" id="mrkr_OtherTaxesPayableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="InvoicesReceivedForServicesAndManufacturingCosts" id="mrkr_InvoicesReceivedForServicesAndManufacturingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>mrkr-20240331_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/15/2024 4:51:51 PM-->
<!--Modified on: 5/15/2024 4:51:51 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#StatementCondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#StatementCondensedConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureCondensedConsolidatedStatementsOfCashFlowsCalc2" roleURI="http://www.tapimmune.com/role/DisclosureCondensedConsolidatedStatementsOfCashFlowsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureDiscontinuedOperationsOperationsDetails" roleURI="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureDiscontinuedOperationsCashFlowsDetails" roleURI="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638513887098132828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638513887098132828" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638513887098132828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638513887098132828" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638513887098132828" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638513887098132828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638513887098132828" xlink:to="us-gaap_PrepaidExpenseCurrent_638513887098132828" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_638513887098132828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638513887098132828" xlink:to="us-gaap_OtherReceivablesNetCurrent_638513887098132828" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638513887098132828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638513887098132828" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638513887098132828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638513887098132828" xlink:to="us-gaap_LiabilitiesCurrent_638513887098132828" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638513887098142828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638513887098132828" xlink:to="us-gaap_OtherLiabilitiesCurrent_638513887098142828" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638513887098142828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638513887098132828" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638513887098142828" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638513887098142828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638513887098142828" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638513887098142828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638513887098142828" xlink:to="us-gaap_PreferredStockValue_638513887098142828" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638513887098142828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638513887098142828" xlink:to="us-gaap_CommonStockValue_638513887098142828" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638513887098142828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638513887098142828" xlink:to="us-gaap_AdditionalPaidInCapital_638513887098142828" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638513887098142828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638513887098142828" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638513887098142828" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638513887098152826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638513887098152826" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_638513887098152826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638513887098152826" xlink:to="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_638513887098152826" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_638513887098152826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638513887098152826" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_638513887098152826" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_638513887098152826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperations_638513887098152826" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638513887098152826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations_638513887098152826" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638513887098152826" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638513887098152826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638513887098152826" xlink:to="us-gaap_InvestmentIncomeInterest_638513887098152826" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638513887098152826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638513887098152826" xlink:to="us-gaap_OperatingIncomeLoss_638513887098152826" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638513887098152826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638513887098152826" xlink:to="us-gaap_OperatingExpenses_638513887098152826" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638513887098152826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638513887098152826" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638513887098152826" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638513887098162826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638513887098152826" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638513887098162826" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638513887098162826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638513887098152826" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638513887098162826" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureCondensedConsolidatedStatementsOfCashFlowsCalc2" xlink:type="extended" xlink:title="00400 - Disclosure - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (calc 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638513887098162826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638513887098162826" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638513887098162826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638513887098162826" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638513887098162826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638513887098162826" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_638513887098162826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638513887098162826" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_638513887098162826" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638513887098162826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_638513887098162826" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638513887098162826" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_638513887098172827" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_638513887098162826" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_638513887098172827" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_638513887098172827" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_638513887098162826" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_638513887098172827" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_638513887098172827" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_638513887098162826" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_638513887098172827" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638513887098172827" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_638513887098162826" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638513887098172827" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638513887098172827" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_638513887098162826" xlink:to="us-gaap_ShareBasedCompensation_638513887098172827" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638513887098172827" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_638513887098162826" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638513887098172827" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_638513887098172827" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638513887098162826" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_638513887098172827" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638513887098172827" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638513887098172827" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_638513887098172827" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638513887098172827" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_638513887098172827" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638513887098182828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638513887098182828" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638513887098182828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638513887098182828" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638513887098182828" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638513887098182828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638513887098182828" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638513887098182828" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - DISCONTINUED OPERATIONS - Operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_638513887098182828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_638513887098182828" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638513887098182828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638513887098182828" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - DISCONTINUED OPERATIONS - Cash Flows (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_638513887098182828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_638513887098182828" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_638513887098182828" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_638513887098182828" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" xlink:type="extended" xlink:title="40801 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638513887098192832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638513887098192832" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638513887098192832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638513887098192832" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638513887098192832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638513887098192832" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638513887098192832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_638513887098192832" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638513887098192832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_638513887098192832" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_638513887098192832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_638513887098192832" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OtherTaxesPayableCurrent" xlink:label="mrkr_OtherTaxesPayableCurrent_638513887098192832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:to="mrkr_OtherTaxesPayableCurrent_638513887098192832" order="7" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>mrkr-20240331_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/15/2024 4:51:51 PM-->
<!--Modified on: 5/15/2024 4:51:51 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#StatementCondensedConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" roleURI="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureNatureOfOperationsDetails" roleURI="http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureLiquidityAndFinancialConditionDetails" roleURI="http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureNetLossPerShareDilutiveSecuritiesDetails" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureOtherReceivableDetails" roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureDiscontinuedOperationsAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureDiscontinuedOperationsOperationsDetails" roleURI="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureDiscontinuedOperationsCashFlowsDetails" roleURI="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureGrantIncomeDetails" roleURI="http://www.tapimmune.com/role/DisclosureGrantIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureRelatedPartyExpensesDetails" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.tapimmune.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_1" xlink:title="us-gaap_RelatedPartyMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyDomain_1" xlink:to="us-gaap_RelatedPartyMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_RelatedPartyDomain_1 To us-gaap_RelatedPartyMember_1" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_IndaptaMember" xlink:label="mrkr_IndaptaMember_1" xlink:title="mrkr_IndaptaMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyMember_1" xlink:to="mrkr_IndaptaMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_RelatedPartyMember_1 To mrkr_IndaptaMember_1" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_1" xlink:title="mrkr_WilsonWolfManufacturingCorporationMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyMember_1" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_RelatedPartyMember_1 To mrkr_WilsonWolfManufacturingCorporationMember_1" order="2" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="OptionIndexedToIssuersEquityTypeAxis" xlink:title="OptionIndexedToIssuersEquityTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="OptionIndexedToIssuersEquityTypeDomain" xlink:title="OptionIndexedToIssuersEquityTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OptionIndexedToIssuersEquityTypeAxis" xlink:to="OptionIndexedToIssuersEquityTypeDomain" xlink:title="definition: OptionIndexedToIssuersEquityTypeAxis to OptionIndexedToIssuersEquityTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="AssetAcquisitionAxis" xlink:title="AssetAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain" xlink:title="AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain" xlink:title="definition: AssetAcquisitionAxis to AssetAcquisitionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:title="CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProjectMember" xlink:label="ProjectMember" xlink:title="ProjectMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="ProjectMember" xlink:title="definition: CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis to ProjectMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="RestatementAxis" xlink:title="RestatementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="RestatementDomain" xlink:title="RestatementDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestatementAxis" xlink:to="RestatementDomain" xlink:title="definition: RestatementAxis to RestatementDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:title="DerivativeInstrumentsGainLossByHedgingRelationshipAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="HedgingRelationshipDomain" xlink:title="HedgingRelationshipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="HedgingRelationshipDomain" xlink:title="definition: DerivativeInstrumentsGainLossByHedgingRelationshipAxis to HedgingRelationshipDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis to ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain" xlink:title="definition: BalanceSheetLocationAxis to BalanceSheetLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis" xlink:label="RestructuringPlanAxis" xlink:title="RestructuringPlanAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain" xlink:label="RestructuringPlanDomain" xlink:title="RestructuringPlanDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestructuringPlanAxis" xlink:to="RestructuringPlanDomain" xlink:title="definition: RestructuringPlanAxis to RestructuringPlanDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="GranteeStatusAxis" xlink:title="GranteeStatusAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="GranteeStatusDomain" xlink:title="GranteeStatusDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="GranteeStatusAxis" xlink:to="GranteeStatusDomain" xlink:title="definition: GranteeStatusAxis to GranteeStatusDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VestingAxis" xlink:to="VestingDomain" xlink:title="definition: VestingAxis to VestingDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_ClassOfWarrantOrRightExerciseAxis" xlink:label="ClassOfWarrantOrRightExerciseAxis" xlink:title="ClassOfWarrantOrRightExerciseAxis" />
    <link:loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_ClassOfWarrantOrRightExerciseDomain" xlink:label="ClassOfWarrantOrRightExerciseDomain" xlink:title="ClassOfWarrantOrRightExerciseDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightExerciseAxis" xlink:to="ClassOfWarrantOrRightExerciseDomain" xlink:title="definition: ClassOfWarrantOrRightExerciseAxis to ClassOfWarrantOrRightExerciseDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis_1" xlink:title="us-gaap_DisposalGroupClassificationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_1" xlink:title="us-gaap_DisposalGroupClassificationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DisposalGroupClassificationAxis_1" xlink:to="us-gaap_DisposalGroupClassificationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DisposalGroupClassificationAxis_1 To us-gaap_DisposalGroupClassificationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract" xlink:label="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract" xlink:to="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" xlink:label="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" xlink:label="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit" xlink:label="mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails" xlink:type="extended" xlink:title="40101 - Disclosure - NATURE OF OPERATIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CellReadyAgreementMember" xlink:label="mrkr_CellReadyAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_CellReadyAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OffersEmploymentToNumberOfEmployees" xlink:label="mrkr_OffersEmploymentToNumberOfEmployees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="mrkr_OffersEmploymentToNumberOfEmployees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails" xlink:type="extended" xlink:title="40301 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_ControlledEquityOfferingSalesAgreementMember" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_ControlledEquityOfferingSalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_BindingServicesAgreementMember" xlink:label="mrkr_BindingServicesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_BindingServicesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CellReadyAgreementMember" xlink:label="mrkr_CellReadyAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_CellReadyAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_LincolnParkMember" xlink:label="mrkr_LincolnParkMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_LincolnParkMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FdaGrantMember" xlink:label="mrkr_FdaGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GrantMember" xlink:to="mrkr_FdaGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_CommonStockSharesSubscriptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_OtherReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_FundsReceivedFromGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FundsReceivedFromCpritGrant" xlink:label="mrkr_FundsReceivedFromCpritGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_FundsReceivedFromCpritGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_GrantReceived" xlink:label="mrkr_GrantReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_GrantReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OrphanProductsGrantProgram" xlink:label="mrkr_OrphanProductsGrantProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_OrphanProductsGrantProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_RevenueFromGrantRelatedToCprit" xlink:label="mrkr_RevenueFromGrantRelatedToCprit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_RevenueFromGrantRelatedToCprit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40502 - Disclosure - NET LOSS PER SHARE - Dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" xlink:type="extended" xlink:title="40601 - Disclosure - OTHER RECEIVABLE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:label="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CancerPreventionAndResearchInstituteOfTexasMember" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProjectMember" xlink:to="mrkr_CancerPreventionAndResearchInstituteOfTexasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FdaGrantMember" xlink:label="mrkr_FdaGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_FdaGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesWithImputedInterestLineItems" xlink:label="us-gaap_ReceivablesWithImputedInterestLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="us-gaap_TenantImprovements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_RevenueFromOrphanProductsGrantProgram" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="mrkr_RevenueFromOrphanProductsGrantProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OrphanProductsGrantProgram" xlink:label="mrkr_OrphanProductsGrantProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="mrkr_OrphanProductsGrantProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="mrkr_FundsReceivedFromGrant" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - DISCONTINUED OPERATIONS - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_RelatedPartyServiceMember" xlink:label="mrkr_RelatedPartyServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_RelatedPartyServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CellReadyAgreementMember" xlink:label="mrkr_CellReadyAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_CellReadyAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_BindingServicesAgreementMember" xlink:label="mrkr_BindingServicesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_BindingServicesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyMember" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncome" xlink:label="us-gaap_OtherOperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_OtherOperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_AdditionalRevenueRecognized" xlink:label="mrkr_AdditionalRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="mrkr_AdditionalRevenueRecognized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - DISCONTINUED OPERATIONS - Operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_RelatedPartyServiceMember" xlink:label="mrkr_RelatedPartyServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_RelatedPartyServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - DISCONTINUED OPERATIONS - Cash Flows (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" xlink:type="extended" xlink:title="40801 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesTable" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CellReadyMember" xlink:label="mrkr_CellReadyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mrkr_CellReadyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OtherTaxesPayableCurrent" xlink:label="mrkr_OtherTaxesPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mrkr_OtherTaxesPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails" xlink:type="extended" xlink:title="40901 - Disclosure - STOCKHOLDERS' EQUITY - Reverse Stock Split And ATM Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_AtmAgreementMember" xlink:label="mrkr_AtmAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mrkr_AtmAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - STOCKHOLDERS' EQUITY - Stock Purchase Agreement And Exercise of Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockPurchaseAgreementMember" xlink:label="mrkr_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mrkr_StockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_LincolnParkMember" xlink:label="mrkr_LincolnParkMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_LincolnParkMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares" xlink:label="mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CommitmentFee" xlink:label="mrkr_CommitmentFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mrkr_CommitmentFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41001 - Disclosure - STOCK-BASED COMPENSATION - Stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockBasedCompensationTable" xlink:label="mrkr_StockBasedCompensationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_StockBasedCompensationTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockBasedCompensationLineItems" xlink:label="mrkr_StockBasedCompensationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="mrkr_StockBasedCompensationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="41002 - Disclosure - STOCK-BASED COMPENSATION - Stock-based compensation expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockBasedCompensationTable" xlink:label="mrkr_StockBasedCompensationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_StockBasedCompensationTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockBasedCompensationLineItems" xlink:label="mrkr_StockBasedCompensationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="mrkr_StockBasedCompensationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockCompensationInContinuingOperations" xlink:label="mrkr_StockCompensationInContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="mrkr_StockCompensationInContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockCompensationInDiscontinuedOperations" xlink:label="mrkr_StockCompensationInDiscontinuedOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="mrkr_StockCompensationInDiscontinuedOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureGrantIncomeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - GRANT INCOME (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_GrantIncomeTable" xlink:label="mrkr_GrantIncomeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_GrantIncomeTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="mrkr_GrantIncomeTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CpritGrantMember" xlink:label="mrkr_CpritGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GrantMember" xlink:to="mrkr_CpritGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FdaGrantMember" xlink:label="mrkr_FdaGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GrantMember" xlink:to="mrkr_FdaGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_GrantMember" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_GrantIncomeLineItems" xlink:label="mrkr_GrantIncomeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_GrantIncomeLineItems" xlink:to="mrkr_GrantIncomeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_ReceiptOfProductDevelopmentResearchAward" xlink:label="mrkr_ReceiptOfProductDevelopmentResearchAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_GrantIncomeLineItems" xlink:to="mrkr_ReceiptOfProductDevelopmentResearchAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_GrantIncomeLineItems" xlink:to="us-gaap_RestrictedCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_GrantIncomeLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_GrantIncomeLineItems" xlink:to="us-gaap_GrantsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_GrantIncomeLineItems" xlink:to="mrkr_FundsReceivedFromGrant" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - RELATED PARTY EXPENSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CellReadyMember" xlink:label="mrkr_CellReadyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_CellReadyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mrkr_CellReadyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CellReadyAgreementMember" xlink:label="mrkr_CellReadyAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_CellReadyAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_InvoicesReceivedForServicesAndManufacturingCosts" xlink:label="mrkr_InvoicesReceivedForServicesAndManufacturingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mrkr_InvoicesReceivedForServicesAndManufacturingCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_ControlledEquityOfferingSalesAgreementMember" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mrkr_ControlledEquityOfferingSalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>mrkr-20240331_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/15/2024 4:51:51 PM-->
<!--Modified on: 5/15/2024 4:51:51 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liability, Current, Related Party, Type [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value, 30 million shares authorized, 8.9 million shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively (see Note 9)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock par value (in $ per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock par value (in $ per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity, Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Including Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expenses):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from continuing operations before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from continuing operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from continuing operations</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract" xlink:label="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract" xlink:to="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discontinued Operation, Income (Loss) from Discontinued Operation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discontinued operations:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from discontinued operations, net of tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on disposal of discontinued operations, Net of tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: loss from discontinued operations, net of tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net earnings (loss) per share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations, Per Basic Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from continuing operations, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from discontinued operations, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations, Per Diluted Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from continuing operations, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from discontinued operations, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of common shares outstanding, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of common shares outstanding, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid- in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance, Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate proceeds from shares issued under the purchase agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for cash (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock from exercise of stock options (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock from exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" xlink:label="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" xlink:to="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">It represents value of common stock as commitment fee for future financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance Of Common Stock , Value, As Commitment Fee For Future Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock as commitment fee for future financing</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" xlink:label="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" xlink:to="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">It represents number of common stock issued as commitment fee for future financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance Of Common Stock, Shares, As Commitment Fee For Future Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock as commitment fee for future financing (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit" xlink:label="mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit" xlink:to="mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in the number of shares during the period as a result of a fractional shares adjustment due to reverse split.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Fractional Shares Adjustment Due to Reverse Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fractional shares adjustment due to reverse split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Operating Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss from continuing operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Interest Receivable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Due from Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities - continuing operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Provided by (Used in) Operating Activities, Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities - discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Investing Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Provided by (Used in) Investing Activities, Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities - discontinued operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Financing Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from stock options exercise</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net decrease in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental schedule of non-cash financing and investing activities:</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing" xlink:label="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing" xlink:to="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of Issuance of common stock as commitment fee for future financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Cash Issuance Of Common Stock As Commitment Fee For Future Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock as commitment fee for future financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_BasisOfPresentationAbstract" xlink:label="mrkr_BasisOfPresentationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_BasisOfPresentationAbstract" xlink:to="mrkr_BasisOfPresentationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_BasisOfPresentationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_BasisOfPresentationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIS OF PRESENTATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIS OF PRESENTATION</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:to="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIQUIDITY AND FINANCIAL CONDITION</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" xlink:to="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity Financial Condition And Going Concern Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity Financial Condition And Going Concern [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIQUIDITY AND FINANCIAL CONDITION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="us-gaap_NoncontrollingInterestAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_NoncontrollingInterestAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncontrolling Interest Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER RECEIVABLE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER RECEIVABLE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DISCONTINUED OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DISCONTINUED OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GRANT INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GRANT INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LEGAL PROCEEDINGS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Matters and Contingencies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LEGAL PROCEEDINGS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principles of Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discontinued Operations, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discontinued Operations</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:label="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:to="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for recently issued accounting standards not yet adopted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Standards Not yet Adopted [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Standards Not Yet Adopted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of computation of net loss per share</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_NetLossPerShareTableTextBlock" xlink:label="mrkr_NetLossPerShareTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NetLossPerShareTableTextBlock" xlink:to="mrkr_NetLossPerShareTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NetLossPerShareTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of net loss per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NetLossPerShareTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_NetLossPerShareTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of anti-dilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposal Groups, Including Discontinued Operations [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of income statement information and summary of cash flows for discontinued operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accounts payable, accrued liabilities and related party payable</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockBasedCompensationTable" xlink:label="mrkr_StockBasedCompensationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockBasedCompensationTable" xlink:to="mrkr_StockBasedCompensationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockBasedCompensationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This table lists the stock-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockBasedCompensationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation [Table]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockBasedCompensationLineItems" xlink:label="mrkr_StockBasedCompensationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="mrkr_StockBasedCompensationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockBasedCompensationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent stock-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockBasedCompensationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockBasedCompensationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of the company's stock option activity</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockBasedCompensationExpensesTableTextBlock" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockBasedCompensationExpensesTableTextBlock" xlink:to="mrkr_StockBasedCompensationExpensesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of stock based compensation expenses recorded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based Compensation Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of related party transaction expenses</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information about organization, consolidation and presentation of financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CellReadyAgreementMember" xlink:label="mrkr_CellReadyAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CellReadyAgreementMember" xlink:to="mrkr_CellReadyAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CellReadyAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Cell Ready Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CellReadyAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cell Ready Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CellReadyAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cell Ready Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposal Group Classification [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupClassificationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposal Group Classification [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discontinued Operations, Disposed of by Sale [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposed by sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discontinued Operations, Disposed of by Sale</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposal Group, Including Discontinued Operation, Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration for purchased assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration for purchased assets</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OffersEmploymentToNumberOfEmployees" xlink:label="mrkr_OffersEmploymentToNumberOfEmployees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OffersEmploymentToNumberOfEmployees" xlink:to="mrkr_OffersEmploymentToNumberOfEmployees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OffersEmploymentToNumberOfEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of employees extended for employment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OffersEmploymentToNumberOfEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offers Employment to Number of Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_OffersEmploymentToNumberOfEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of former employees offered employment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance and termination-related costs</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Condition Going Concern And Management Plans [Table]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_ControlledEquityOfferingSalesAgreementMember" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ControlledEquityOfferingSalesAgreementMember" xlink:to="mrkr_ControlledEquityOfferingSalesAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to controlled equity offering sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Controlled Equity Offering Sales Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM Agreement</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_BindingServicesAgreementMember" xlink:label="mrkr_BindingServicesAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_BindingServicesAgreementMember" xlink:to="mrkr_BindingServicesAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_BindingServicesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for binding services agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_BindingServicesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Binding Services Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_BindingServicesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Binding Services Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" xlink:to="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Cantor Fitzgerald &amp; Co and RBC Capital Markets, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cantor Fitzgerald Co. And Rbc Capital Markets Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Agents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_LincolnParkMember" xlink:label="mrkr_LincolnParkMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_LincolnParkMember" xlink:to="mrkr_LincolnParkMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_LincolnParkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The information pertaining to Lincoln Park.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_LincolnParkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lincoln Park [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_LincolnParkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lincoln Park</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to National Institutes of Health Small Business Innovation Research.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">National Institutes of Health Small Business Innovation Research [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SBIR grant</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FdaGrantMember" xlink:label="mrkr_FdaGrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FdaGrantMember" xlink:to="mrkr_FdaGrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FdaGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award of money not required to be repaid for FDA grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FdaGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FDA Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FdaGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FDA grant</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIQUIDITY AND FINANCIAL CONDITION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscriptions" xlink:to="us-gaap_CommonStockSharesSubscriptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Subscriptions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" xlink:to="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percent of calculation of compensation rate by using gross sales price per share sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Commission Rate Calculation on Gross Sales Price per Share, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commission rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FundsReceivedFromGrant" xlink:to="mrkr_FundsReceivedFromGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FundsReceivedFromGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funds received from grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FundsReceivedFromGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funds Received From Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FundsReceivedFromGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funds received from grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of notice received</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FundsReceivedFromCpritGrant" xlink:label="mrkr_FundsReceivedFromCpritGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FundsReceivedFromCpritGrant" xlink:to="mrkr_FundsReceivedFromCpritGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FundsReceivedFromCpritGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funds received from grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FundsReceivedFromCpritGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funds Received From CPRIT Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FundsReceivedFromCpritGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funds received from CPRIT grant</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_GrantReceived" xlink:label="mrkr_GrantReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GrantReceived" xlink:to="mrkr_GrantReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GrantReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of grant income transfer product and service to customer for which consideration has been received or is receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GrantReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_GrantReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income received</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OrphanProductsGrantProgram" xlink:label="mrkr_OrphanProductsGrantProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OrphanProductsGrantProgram" xlink:to="mrkr_OrphanProductsGrantProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OrphanProductsGrantProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of receivable from Orphan Products Grant program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OrphanProductsGrantProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Orphan Products Grant Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_OrphanProductsGrantProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income receivable</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_RevenueFromGrantRelatedToCprit" xlink:label="mrkr_RevenueFromGrantRelatedToCprit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RevenueFromGrantRelatedToCprit" xlink:to="mrkr_RevenueFromGrantRelatedToCprit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RevenueFromGrantRelatedToCprit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from grant related to CPRIT.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RevenueFromGrantRelatedToCprit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue From Grant Related to CPRIT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_RevenueFromGrantRelatedToCprit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from CPRIT</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CashAtFinancialInstitutions" xlink:label="mrkr_CashAtFinancialInstitutions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CashAtFinancialInstitutions" xlink:to="mrkr_CashAtFinancialInstitutions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CashAtFinancialInstitutions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash held at financial institutions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CashAtFinancialInstitutions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash at Financial Institutions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CashAtFinancialInstitutions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash at financial institutions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue" xlink:label="us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue" xlink:to="us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Government Agencies Securities, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government agency securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potentially dilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:label="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:to="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Receivables with Imputed Interest [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Project [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProjectMember" xlink:to="us-gaap_ProjectMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProjectMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Project [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CancerPreventionAndResearchInstituteOfTexasMember" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CancerPreventionAndResearchInstituteOfTexasMember" xlink:to="mrkr_CancerPreventionAndResearchInstituteOfTexasMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The information pertaining to cancer Prevention And Research Institute Of Texas.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancer Prevention And Research Institute Of Texas [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancer Prevention And Research Institute Of Texas</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesWithImputedInterestLineItems" xlink:label="us-gaap_ReceivablesWithImputedInterestLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="us-gaap_ReceivablesWithImputedInterestLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesWithImputedInterestLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables with Imputed Interest [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesWithImputedInterestLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER RECEIVABLE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursements</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_RevenueFromOrphanProductsGrantProgram" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RevenueFromOrphanProductsGrantProgram" xlink:to="mrkr_RevenueFromOrphanProductsGrantProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of revenue recognized for grant from Orphan Products Grant program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue From Orphan Products Grant Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposal Groups, Including Discontinued Operations [Table]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_RelatedPartyServiceMember" xlink:label="mrkr_RelatedPartyServiceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RelatedPartyServiceMember" xlink:to="mrkr_RelatedPartyServiceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RelatedPartyServiceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for related party service.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RelatedPartyServiceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Service [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_RelatedPartyServiceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party service revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_WilsonWolfManufacturingCorporationMember" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Clinical Trial Agreement with Wilson Wolf Manufacturing Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Wilson Wolf Manufacturing Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Wilson Wolf Manufacturing Corporation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DISCONTINUED OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax on gain on disposal of discontinued operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncome" xlink:label="us-gaap_OtherOperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncome" xlink:to="us-gaap_OtherOperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Operating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash payment</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_AdditionalRevenueRecognized" xlink:label="mrkr_AdditionalRevenueRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AdditionalRevenueRecognized" xlink:to="mrkr_AdditionalRevenueRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AdditionalRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of additional revenue recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AdditionalRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_AdditionalRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional revenue recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposal Group, Including Discontinued Operation, Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposal Group, Including Discontinued Operation, Operating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net decrease in cash and cash equivalents from discontinued operations</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesTable" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesTable" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This table lists the accounts payable and accrued liabilities. The line items identify information about the accounts payable and accrued liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable And Accrued Liabilities [Table]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CellReadyMember" xlink:label="mrkr_CellReadyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CellReadyMember" xlink:to="mrkr_CellReadyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CellReadyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Cell Ready.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CellReadyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cell Ready [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CellReadyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cell Ready</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable And Accrued Liabilities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrual for Taxes Other than Income Taxes, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property taxes</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OtherTaxesPayableCurrent" xlink:label="mrkr_OtherTaxesPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OtherTaxesPayableCurrent" xlink:to="mrkr_OtherTaxesPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OtherTaxesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the value of accounts payable, accrued liabilities and related payable of other taxes payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OtherTaxesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Taxes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_OtherTaxesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other taxes payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Including Related party payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accounts payable, accrued liabilities and related party payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_AtmAgreementMember" xlink:label="mrkr_AtmAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AtmAgreementMember" xlink:to="mrkr_AtmAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AtmAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The member stands for  ATM agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AtmAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_AtmAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockPurchaseAgreementMember" xlink:label="mrkr_StockPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockPurchaseAgreementMember" xlink:to="mrkr_StockPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This Member represents stock purchase agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares" xlink:label="mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares" xlink:to="mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The time to time term to purchase shares in stock purchase sgreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement, Time to Time Term to Purchase Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Time to time term to purchase shares (in months)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CommitmentFee" xlink:label="mrkr_CommitmentFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CommitmentFee" xlink:to="mrkr_CommitmentFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CommitmentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of commitment fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CommitmentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CommitmentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Indexed to Issuer's Equity, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Indexed to Issuer's Equity, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares Outstanding, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares, Cancelled / Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares, Options vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share, Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share, Outstanding, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share, Cancelled / Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Options vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Intrinsic Value Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Intrinsic Value, Options vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Life, Outstanding (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Life, Options vested and exercisable (in years)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockCompensationInContinuingOperations" xlink:label="mrkr_StockCompensationInContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockCompensationInContinuingOperations" xlink:to="mrkr_StockCompensationInContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockCompensationInContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense for Stock compensation in continuing operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockCompensationInContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Compensation In Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockCompensationInContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation in continuing operations</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockCompensationInDiscontinuedOperations" xlink:label="mrkr_StockCompensationInDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockCompensationInDiscontinuedOperations" xlink:to="mrkr_StockCompensationInDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockCompensationInDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense for Stock compensation in discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockCompensationInDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Compensation In Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_StockCompensationInDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation in discontinued operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock compensation expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, grants in period, gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equity incentive awards issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock-based compensation cost related to unvested awards not yet recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected weighted average period of recognition of unrecognized compensation costs (in years)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_GrantIncomeTable" xlink:label="mrkr_GrantIncomeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GrantIncomeTable" xlink:to="mrkr_GrantIncomeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GrantIncomeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This table lists the grant income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GrantIncomeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income [Table]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CpritGrantMember" xlink:label="mrkr_CpritGrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CpritGrantMember" xlink:to="mrkr_CpritGrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CpritGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award of money not required to be repaid for CPRIT grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CpritGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CPRIT Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CpritGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CPRIT grant</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_GrantIncomeLineItems" xlink:label="mrkr_GrantIncomeLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GrantIncomeLineItems" xlink:to="mrkr_GrantIncomeLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GrantIncomeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represents grant income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GrantIncomeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_GrantIncomeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GRANT INCOME</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_ReceiptOfProductDevelopmentResearchAward" xlink:label="mrkr_ReceiptOfProductDevelopmentResearchAward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ReceiptOfProductDevelopmentResearchAward" xlink:to="mrkr_ReceiptOfProductDevelopmentResearchAward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ReceiptOfProductDevelopmentResearchAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipt of product development research award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ReceiptOfProductDevelopmentResearchAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipt Of Product Development Research Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ReceiptOfProductDevelopmentResearchAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipt of product development research award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash recorded</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xlink:to="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Clinical Trial Agreement with Baylor College of Medicine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical Trial Agreement with Baylor College of Medicine [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Baylor College of Medicine</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service and manufacturing costs</label>
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_InvoicesReceivedForServicesAndManufacturingCosts" xlink:label="mrkr_InvoicesReceivedForServicesAndManufacturingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_InvoicesReceivedForServicesAndManufacturingCosts" xlink:to="mrkr_InvoicesReceivedForServicesAndManufacturingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_InvoicesReceivedForServicesAndManufacturingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Invoices for the cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_InvoicesReceivedForServicesAndManufacturingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Invoices Received for Services and Manufacturing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_InvoicesReceivedForServicesAndManufacturingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid invoices</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>mrkr-20240331_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/15/2024 4:51:51 PM-->
<!--Modified on: 5/15/2024 4:51:51 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#StatementCondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#StatementCondensedConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" roleURI="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureNatureOfOperations" roleURI="http://www.tapimmune.com/role/DisclosureNatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureBasisOfPresentation" roleURI="http://www.tapimmune.com/role/DisclosureBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureLiquidityAndFinancialCondition" roleURI="http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialCondition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureNetLossPerShare" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureOtherReceivable" roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureDiscontinuedOperations" roleURI="http://www.tapimmune.com/role/DisclosureDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureStockholdersEquity" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureStockBasedCompensation" roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureGrantIncome" roleURI="http://www.tapimmune.com/role/DisclosureGrantIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureLegalProceedings" roleURI="http://www.tapimmune.com/role/DisclosureLegalProceedings" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureRelatedPartyExpenses" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureSubsequentEvents" roleURI="http://www.tapimmune.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureDiscontinuedOperationsTables" roleURI="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureRelatedPartyExpensesTables" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureNatureOfOperationsDetails" roleURI="http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureLiquidityAndFinancialConditionDetails" roleURI="http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureNetLossPerShareComputationOfLossPerShareDetails" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureNetLossPerShareDilutiveSecuritiesDetails" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureOtherReceivableDetails" roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureDiscontinuedOperationsAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureDiscontinuedOperationsOperationsDetails" roleURI="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureDiscontinuedOperationsCashFlowsDetails" roleURI="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureStockBasedCompensationAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureGrantIncomeDetails" roleURI="http://www.tapimmune.com/role/DisclosureGrantIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureRelatedPartyExpensesDetails" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20240331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638513887098762836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638513887098762836" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638513887098762836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638513887098762836" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638513887098762836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638513887098762836" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638513887098762836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638513887098762836" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638513887098762836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638513887098762836" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638513887098762836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638513887098762836" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638513887098762836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638513887098762836" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638513887098772836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638513887098772836" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638513887098772836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638513887098772836" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638513887098772836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638513887098772836" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638513887098772836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638513887098772836" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638513887098772836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638513887098772836" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638513887098772836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638513887098772836" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638513887098772836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638513887098772836" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638513887098772836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638513887098772836" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638513887098772836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638513887098772836" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638513887098772836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638513887098772836" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638513887098772836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638513887098772836" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638513887098782839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638513887098782839" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638513887098782839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638513887098782839" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638513887098782839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638513887098782839" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638513887098782839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638513887098782839" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638513887098782839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638513887098782839" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638513887098782839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638513887098782839" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638513887098782839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638513887098782839" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638513887098782839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638513887098782839" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638513887098782839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638513887098782839" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638513887098792836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638513887098792836" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638513887098792836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638513887098792836" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638513887098792836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638513887098792836" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638513887098792836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638513887098792836" xlink:to="us-gaap_AssetsCurrentAbstract_638513887098792836" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638513887098792836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638513887098792836" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638513887098792836" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638513887098792836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638513887098792836" xlink:to="us-gaap_PrepaidExpenseCurrent_638513887098792836" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_638513887098792836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638513887098792836" xlink:to="us-gaap_OtherReceivablesNetCurrent_638513887098792836" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638513887098792836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638513887098792836" xlink:to="us-gaap_AssetsCurrent_638513887098792836" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638513887098792836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638513887098792836" xlink:to="us-gaap_Assets_638513887098792836" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638513887098802839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638513887098802839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638513887098802839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638513887098802839" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638513887098802839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638513887098802839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638513887098802839" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638513887098802839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638513887098802839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638513887098802839" xlink:to="us-gaap_OtherLiabilitiesCurrent_638513887098802839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_638513887098802839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrent_638513887098802839" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_638513887098802839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638513887098802839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638513887098802839" xlink:to="us-gaap_LiabilitiesCurrent_638513887098802839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638513887098802839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638513887098802839" xlink:to="us-gaap_Liabilities_638513887098802839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638513887098802839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638513887098802839" xlink:to="us-gaap_StockholdersEquityAbstract_638513887098802839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638513887098802839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638513887098802839" xlink:to="us-gaap_PreferredStockValue_638513887098802839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638513887098802839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638513887098802839" xlink:to="us-gaap_CommonStockValue_638513887098802839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638513887098802839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638513887098802839" xlink:to="us-gaap_AdditionalPaidInCapital_638513887098802839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638513887098802839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638513887098802839" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638513887098802839" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638513887098812837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638513887098802839" xlink:to="us-gaap_StockholdersEquity_638513887098812837" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638513887098812837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638513887098812837" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638513887098812837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638513887098812837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638513887098812837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638513887098812837" xlink:to="srt_RangeAxis_638513887098812837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638513887098812837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638513887098812837" xlink:to="srt_RangeMember_638513887098812837" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638513887098812837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638513887098812837" xlink:to="srt_MinimumMember_638513887098812837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638513887098812837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638513887098812837" xlink:to="srt_MaximumMember_638513887098812837" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638513887098812837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638513887098812837" xlink:to="us-gaap_StatementLineItems_638513887098812837" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638513887098812837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098812837" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638513887098812837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638513887098822835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098812837" xlink:to="us-gaap_PreferredStockSharesAuthorized_638513887098822835" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638513887098822835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098812837" xlink:to="us-gaap_PreferredStockSharesIssued_638513887098822835" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638513887098822835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098812837" xlink:to="us-gaap_PreferredStockSharesOutstanding_638513887098822835" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638513887098822835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098812837" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638513887098822835" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638513887098822835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098812837" xlink:to="us-gaap_CommonStockSharesAuthorized_638513887098822835" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638513887098822835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098812837" xlink:to="us-gaap_CommonStockSharesIssued_638513887098822835" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638513887098822835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098812837" xlink:to="us-gaap_CommonStockSharesOutstanding_638513887098822835" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_638513887098822835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098812837" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_638513887098822835" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638513887098822835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_StatementTable_638513887098822835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638513887098822835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638513887098822835" xlink:to="srt_ProductOrServiceAxis_638513887098822835" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638513887098832842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638513887098822835" xlink:to="srt_ProductsAndServicesDomain_638513887098832842" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_638513887098832842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638513887098832842" xlink:to="us-gaap_GrantMember_638513887098832842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638513887098832842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638513887098822835" xlink:to="us-gaap_StatementLineItems_638513887098832842" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_638513887098832842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098832842" xlink:to="us-gaap_RevenuesAbstract_638513887098832842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638513887098832842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638513887098832842" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638513887098832842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_638513887098832842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098832842" xlink:to="us-gaap_CostsAndExpensesAbstract_638513887098832842" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638513887098832842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638513887098832842" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638513887098832842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638513887098832842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638513887098832842" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638513887098832842" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638513887098832842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638513887098832842" xlink:to="us-gaap_OperatingExpenses_638513887098832842" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638513887098832842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638513887098832842" xlink:to="us-gaap_OperatingIncomeLoss_638513887098832842" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638513887098832842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098832842" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638513887098832842" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638513887098832842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638513887098832842" xlink:to="us-gaap_InvestmentIncomeInterest_638513887098832842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638513887098832842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638513887098832842" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638513887098832842" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_638513887098842835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638513887098832842" xlink:to="us-gaap_IncomeLossFromContinuingOperations_638513887098842835" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract" xlink:label="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract_638513887098842835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638513887098832842" xlink:to="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract_638513887098842835" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_638513887098842835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract_638513887098842835" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_638513887098842835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_638513887098842835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract_638513887098842835" xlink:to="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_638513887098842835" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638513887098842835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract_638513887098842835" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638513887098842835" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638513887098842835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098832842" xlink:to="us-gaap_NetIncomeLoss_638513887098842835" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638513887098842835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098832842" xlink:to="us-gaap_EarningsPerShareAbstract_638513887098842835" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638513887098842835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638513887098842835" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638513887098842835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638513887098842835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638513887098842835" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638513887098842835" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638513887098852904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638513887098842835" xlink:to="us-gaap_EarningsPerShareBasic_638513887098852904" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638513887098852904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638513887098842835" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638513887098852904" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638513887098852904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638513887098842835" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638513887098852904" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638513887098852904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638513887098842835" xlink:to="us-gaap_EarningsPerShareDiluted_638513887098852904" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638513887098852904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098832842" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638513887098852904" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638513887098852904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098832842" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638513887098852904" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638513887098852904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638513887098852904" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638513887098862835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638513887098852904" xlink:to="us-gaap_StatementEquityComponentsAxis_638513887098862835" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638513887098862835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638513887098862835" xlink:to="us-gaap_CommonStockMember_638513887098862835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638513887098862835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638513887098862835" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638513887098862835" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638513887098862835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638513887098862835" xlink:to="us-gaap_RetainedEarningsMember_638513887098862835" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638513887098862835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638513887098862835" xlink:to="us-gaap_EquityComponentDomain_638513887098862835" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638513887098862835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638513887098852904" xlink:to="us-gaap_StatementLineItems_638513887098862835" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638513887098862835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098862835" xlink:to="us-gaap_StockholdersEquity_638513887098862835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638513887098862835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098862835" xlink:to="us-gaap_SharesIssued_638513887098862835" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638513887098862835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098862835" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638513887098862835" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638513887098862835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098862835" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638513887098862835" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638513887098862835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098862835" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638513887098862835" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638513887098862835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098862835" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638513887098862835" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" xlink:label="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing_638513887098862835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098862835" xlink:to="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing_638513887098862835" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" xlink:label="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing_638513887098872841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098862835" xlink:to="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing_638513887098872841" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638513887098872841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098862835" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638513887098872841" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638513887098872841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098862835" xlink:to="us-gaap_NetIncomeLoss_638513887098872841" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit" xlink:label="mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit_638513887098872841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098862835" xlink:to="mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit_638513887098872841" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638513887098872841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098862835" xlink:to="us-gaap_StockholdersEquity_638513887098872841" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638513887098872841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638513887098862835" xlink:to="us-gaap_SharesIssued_638513887098872841" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638513887098872841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638513887098872841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638513887098872841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638513887098872841" xlink:to="us-gaap_ProfitLoss_638513887098872841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638513887098882839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638513887098872841" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638513887098882839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638513887098882839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638513887098872841" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638513887098882839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638513887098882839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638513887098872841" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638513887098882839" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638513887098882839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638513887098882839" xlink:to="us-gaap_ShareBasedCompensation_638513887098882839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638513887098882839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638513887098872841" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638513887098882839" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638513887098882839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638513887098882839" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638513887098882839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_638513887098882839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638513887098882839" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_638513887098882839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_638513887098882839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638513887098882839" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_638513887098882839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_638513887098882839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638513887098882839" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_638513887098882839" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638513887098882839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638513887098882839" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638513887098882839" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_638513887098882839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638513887098872841" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_638513887098882839" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_638513887098882839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638513887098872841" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_638513887098882839" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638513887098892836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638513887098872841" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638513887098892836" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638513887098892836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638513887098892836" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_638513887098892836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638513887098892836" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_638513887098892836" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638513887098892836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638513887098892836" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638513887098892836" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638513887098892836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638513887098892836" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638513887098892836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638513887098892836" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638513887098892836" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638513887098892836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638513887098892836" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638513887098892836" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638513887098892836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638513887098892836" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638513887098892836" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638513887098892836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638513887098892836" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638513887098892836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638513887098892836" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638513887098902841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638513887098902841" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638513887098902841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638513887098902841" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing" xlink:label="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing_638513887098902841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638513887098902841" xlink:to="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing_638513887098902841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNatureOfOperations" xlink:type="extended" xlink:title="10101 - Disclosure - NATURE OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638513887098902841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_638513887098902841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="10201 - Disclosure - BASIS OF PRESENTATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_BasisOfPresentationAbstract" xlink:label="BasisOfPresentationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting_638513887098902841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisOfPresentationAbstract" xlink:to="us-gaap_BasisOfAccounting_638513887098902841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialCondition" xlink:type="extended" xlink:title="10301 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:label="LiquidityFinancialConditionAndGoingConcernAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_638513887098912837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityFinancialConditionAndGoingConcernAbstract" xlink:to="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_638513887098912837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638513887098912837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638513887098912837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="10501 - Disclosure - NET LOSS PER SHARE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="NoncontrollingInterestAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_638513887098912837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_638513887098912837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureOtherReceivable" xlink:type="extended" xlink:title="10601 - Disclosure - OTHER RECEIVABLE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_638513887098912837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_638513887098912837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureDiscontinuedOperations" xlink:type="extended" xlink:title="10701 - Disclosure - DISCONTINUED OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_638513887098922839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_638513887098922839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable" xlink:type="extended" xlink:title="10801 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638513887098922839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638513887098922839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10901 - Disclosure - STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638513887098922839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638513887098922839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="11001 - Disclosure - STOCK-BASED COMPENSATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638513887098922839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638513887098922839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureGrantIncome" xlink:type="extended" xlink:title="11101 - Disclosure - GRANT INCOME" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_638513887098922839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_638513887098922839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureLegalProceedings" xlink:type="extended" xlink:title="11201 - Disclosure - LEGAL PROCEEDINGS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="DisclosureTextBlockSupplementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_638513887098932837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_638513887098932837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyExpenses" xlink:type="extended" xlink:title="11301 - Disclosure - RELATED PARTY EXPENSES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638513887098932837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638513887098932837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11401 - Disclosure - SUBSEQUENT EVENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638513887098932837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638513887098932837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_638513887098932837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_638513887098932837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638513887098942836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638513887098942836" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638513887098942836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638513887098942836" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock_638513887098942836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_DiscontinuedOperationsPolicyTextBlock_638513887098942836" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:label="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_638513887098942836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_638513887098942836" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="30503 - Disclosure - NET LOSS PER SHARE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="NoncontrollingInterestAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638513887098942836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638513887098942836" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_NetLossPerShareTableTextBlock" xlink:label="mrkr_NetLossPerShareTableTextBlock_638513887098942836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestAbstract" xlink:to="mrkr_NetLossPerShareTableTextBlock_638513887098942836" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsTables" xlink:type="extended" xlink:title="30703 - Disclosure - DISCONTINUED OPERATIONS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_638513887098942836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_638513887098942836" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables" xlink:type="extended" xlink:title="30803 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_638513887098952841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_638513887098952841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="31003 - Disclosure - STOCK BASED COMPENSATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_638513887098952841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_638513887098952841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockBasedCompensationExpensesTableTextBlock" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock_638513887098952841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="mrkr_StockBasedCompensationExpensesTableTextBlock_638513887098952841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesTables" xlink:type="extended" xlink:title="31303 - Disclosure - RELATED PARTY EXPENSES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_638513887098952841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_1" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_638513887098952841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails" xlink:type="extended" xlink:title="40101 - Disclosure - NATURE OF OPERATIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638513887098952841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638513887098952841" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638513887098952841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638513887098952841" xlink:to="srt_RangeAxis_638513887098952841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638513887098952841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638513887098952841" xlink:to="srt_RangeMember_638513887098952841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638513887098962840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638513887098952841" xlink:to="srt_MaximumMember_638513887098962840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638513887098962840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638513887098952841" xlink:to="srt_MinimumMember_638513887098962840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638513887098962840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638513887098952841" xlink:to="us-gaap_TypeOfArrangementAxis_638513887098962840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638513887098962840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638513887098962840" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638513887098962840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CellReadyAgreementMember" xlink:label="mrkr_CellReadyAgreementMember_638513887098962840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638513887098962840" xlink:to="mrkr_CellReadyAgreementMember_638513887098962840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis_638513887098962840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638513887098952841" xlink:to="us-gaap_DisposalGroupClassificationAxis_638513887098962840" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_638513887098962840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis_638513887098962840" xlink:to="us-gaap_DisposalGroupClassificationDomain_638513887098962840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_638513887098962840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain_638513887098962840" xlink:to="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_638513887098962840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638513887098962840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638513887098952841" xlink:to="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638513887098962840" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_638513887098962840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638513887098962840" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_638513887098962840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638513887098962840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638513887098962840" xlink:to="us-gaap_CommonStockSharesAuthorized_638513887098962840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_638513887098962840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638513887098962840" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_638513887098962840" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OffersEmploymentToNumberOfEmployees" xlink:label="mrkr_OffersEmploymentToNumberOfEmployees_638513887098972839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638513887098962840" xlink:to="mrkr_OffersEmploymentToNumberOfEmployees_638513887098972839" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1_638513887098972839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638513887098962840" xlink:to="us-gaap_SeveranceCosts1_638513887098972839" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails" xlink:type="extended" xlink:title="40301 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:label="LiquidityFinancialConditionAndGoingConcernAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638513887098972839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityFinancialConditionAndGoingConcernAbstract" xlink:to="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638513887098972839" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638513887098972839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638513887098972839" xlink:to="us-gaap_TypeOfArrangementAxis_638513887098972839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638513887098972839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638513887098972839" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638513887098972839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_ControlledEquityOfferingSalesAgreementMember" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember_638513887098972839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638513887098972839" xlink:to="mrkr_ControlledEquityOfferingSalesAgreementMember_638513887098972839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_BindingServicesAgreementMember" xlink:label="mrkr_BindingServicesAgreementMember_638513887098972839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638513887098972839" xlink:to="mrkr_BindingServicesAgreementMember_638513887098972839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CellReadyAgreementMember" xlink:label="mrkr_CellReadyAgreementMember_638513887098972839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638513887098972839" xlink:to="mrkr_CellReadyAgreementMember_638513887098972839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638513887098972839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638513887098972839" xlink:to="srt_CounterpartyNameAxis_638513887098972839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638513887098972839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638513887098972839" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638513887098972839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_638513887098982842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638513887098972839" xlink:to="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_638513887098982842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638513887098982842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638513887098972839" xlink:to="us-gaap_SubsequentEventTypeAxis_638513887098982842" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638513887098982842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638513887098982842" xlink:to="us-gaap_SubsequentEventTypeDomain_638513887098982842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638513887098982842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638513887098982842" xlink:to="us-gaap_SubsequentEventMember_638513887098982842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638513887098982842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638513887098972839" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638513887098982842" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638513887098982842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638513887098982842" xlink:to="us-gaap_RelatedPartyDomain_638513887098982842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_LincolnParkMember" xlink:label="mrkr_LincolnParkMember_638513887098982842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638513887098982842" xlink:to="mrkr_LincolnParkMember_638513887098982842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638513887098982842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638513887098972839" xlink:to="srt_ProductOrServiceAxis_638513887098982842" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638513887098982842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638513887098982842" xlink:to="srt_ProductsAndServicesDomain_638513887098982842" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_638513887098982842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638513887098982842" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_638513887098982842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_638513887098982842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638513887098982842" xlink:to="us-gaap_GrantMember_638513887098982842" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FdaGrantMember" xlink:label="mrkr_FdaGrantMember_638513887098992838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GrantMember_638513887098982842" xlink:to="mrkr_FdaGrantMember_638513887098992838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638513887098992838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638513887098972839" xlink:to="us-gaap_StatementEquityComponentsAxis_638513887098992838" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638513887098992838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638513887098992838" xlink:to="us-gaap_EquityComponentDomain_638513887098992838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638513887098992838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638513887098992838" xlink:to="us-gaap_CommonStockMember_638513887098992838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638513887098992838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638513887098972839" xlink:to="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638513887098992838" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638513887098992838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638513887098992838" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638513887098992838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions_638513887098992838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638513887098992838" xlink:to="us-gaap_CommonStockSharesSubscriptions_638513887098992838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_638513887098992838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638513887098992838" xlink:to="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_638513887098992838" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638513887098992838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638513887098992838" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638513887098992838" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638513887099002839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638513887098992838" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638513887099002839" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables_638513887099002839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638513887098992838" xlink:to="us-gaap_OtherReceivables_638513887099002839" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant_638513887099002839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638513887098992838" xlink:to="mrkr_FundsReceivedFromGrant_638513887099002839" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_638513887099002839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638513887098992838" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_638513887099002839" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FundsReceivedFromCpritGrant" xlink:label="mrkr_FundsReceivedFromCpritGrant_638513887099002839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638513887098992838" xlink:to="mrkr_FundsReceivedFromCpritGrant_638513887099002839" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_GrantReceived" xlink:label="mrkr_GrantReceived_638513887099102840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638513887098992838" xlink:to="mrkr_GrantReceived_638513887099102840" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OrphanProductsGrantProgram" xlink:label="mrkr_OrphanProductsGrantProgram_638513887099102840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638513887098992838" xlink:to="mrkr_OrphanProductsGrantProgram_638513887099102840" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_RevenueFromGrantRelatedToCprit" xlink:label="mrkr_RevenueFromGrantRelatedToCprit_638513887099102840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638513887098992838" xlink:to="mrkr_RevenueFromGrantRelatedToCprit_638513887099102840" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638513887099102840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638513887098992838" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638513887099102840" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_638513887099112842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638513887098992838" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_638513887099112842" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CashAtFinancialInstitutions" xlink:label="mrkr_CashAtFinancialInstitutions_638513887099112842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mrkr_CashAtFinancialInstitutions_638513887099112842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue" xlink:label="us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue_638513887099112842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue_638513887099112842" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638513887099112842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638513887099112842" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails" xlink:type="extended" xlink:title="40501 - Disclosure - NET LOSS PER SHARE - Computation of loss per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="NoncontrollingInterestAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_638513887099112842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_638513887099112842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_638513887099112842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_638513887099112842" xlink:to="us-gaap_IncomeLossFromContinuingOperations_638513887099112842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638513887099112842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_638513887099112842" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638513887099112842" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638513887099122838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_638513887099112842" xlink:to="us-gaap_NetIncomeLoss_638513887099122838" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638513887099122838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638513887099122838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638513887099122838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638513887099122838" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638513887099122838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638513887099122838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638513887099122838" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638513887099122838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638513887099122838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_638513887099122838" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638513887099122838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638513887099122838" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638513887099122838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638513887099122838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638513887099122838" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638513887099122838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638513887099122838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638513887099122838" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638513887099122838" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638513887099122838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638513887099122838" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638513887099122838" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638513887099122838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638513887099122838" xlink:to="us-gaap_EarningsPerShareBasic_638513887099122838" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638513887099122838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638513887099122838" xlink:to="us-gaap_EarningsPerShareDiluted_638513887099122838" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40502 - Disclosure - NET LOSS PER SHARE - Dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="NoncontrollingInterestAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638513887099132838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638513887099132838" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638513887099132838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638513887099132838" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638513887099132838" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638513887099132838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638513887099132838" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638513887099132838" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638513887099132838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638513887099132838" xlink:to="us-gaap_EmployeeStockOptionMember_638513887099132838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638513887099132838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638513887099132838" xlink:to="us-gaap_WarrantMember_638513887099132838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638513887099132838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638513887099132838" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638513887099132838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638513887099132838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638513887099132838" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638513887099132838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" xlink:type="extended" xlink:title="40601 - Disclosure - OTHER RECEIVABLE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:label="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_638513887099132838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReceivablesAbstract" xlink:to="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_638513887099132838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638513887099132838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_638513887099132838" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638513887099132838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_638513887099132838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638513887099132838" xlink:to="us-gaap_ProjectMember_638513887099132838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CancerPreventionAndResearchInstituteOfTexasMember" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasMember_638513887099132838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember_638513887099132838" xlink:to="mrkr_CancerPreventionAndResearchInstituteOfTexasMember_638513887099132838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638513887099142838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_638513887099132838" xlink:to="srt_ProductOrServiceAxis_638513887099142838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638513887099142838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638513887099142838" xlink:to="srt_ProductsAndServicesDomain_638513887099142838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FdaGrantMember" xlink:label="mrkr_FdaGrantMember_638513887099142838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638513887099142838" xlink:to="mrkr_FdaGrantMember_638513887099142838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_638513887099142838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638513887099142838" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_638513887099142838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638513887099142838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_638513887099132838" xlink:to="us-gaap_SubsequentEventTypeAxis_638513887099142838" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638513887099142838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638513887099142838" xlink:to="us-gaap_SubsequentEventTypeDomain_638513887099142838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638513887099142838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638513887099142838" xlink:to="us-gaap_SubsequentEventMember_638513887099142838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesWithImputedInterestLineItems" xlink:label="us-gaap_ReceivablesWithImputedInterestLineItems_638513887099142838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_638513887099132838" xlink:to="us-gaap_ReceivablesWithImputedInterestLineItems_638513887099142838" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements_638513887099142838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems_638513887099142838" xlink:to="us-gaap_TenantImprovements_638513887099142838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_638513887099142838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems_638513887099142838" xlink:to="us-gaap_OtherReceivablesNetCurrent_638513887099142838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_RevenueFromOrphanProductsGrantProgram" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram_638513887099142838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems_638513887099142838" xlink:to="mrkr_RevenueFromOrphanProductsGrantProgram_638513887099142838" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OrphanProductsGrantProgram" xlink:label="mrkr_OrphanProductsGrantProgram_638513887099142838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems_638513887099142838" xlink:to="mrkr_OrphanProductsGrantProgram_638513887099142838" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant_638513887099152840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems_638513887099142838" xlink:to="mrkr_FundsReceivedFromGrant_638513887099152840" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - DISCONTINUED OPERATIONS - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638513887099152840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638513887099152840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis_638513887099152840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638513887099152840" xlink:to="us-gaap_DisposalGroupClassificationAxis_638513887099152840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_638513887099152840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis_638513887099152840" xlink:to="us-gaap_DisposalGroupClassificationDomain_638513887099152840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_638513887099152840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain_638513887099152840" xlink:to="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_638513887099152840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638513887099152840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638513887099152840" xlink:to="srt_ProductOrServiceAxis_638513887099152840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638513887099152840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638513887099152840" xlink:to="srt_ProductsAndServicesDomain_638513887099152840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_RelatedPartyServiceMember" xlink:label="mrkr_RelatedPartyServiceMember_638513887099152840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638513887099152840" xlink:to="mrkr_RelatedPartyServiceMember_638513887099152840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638513887099152840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638513887099152840" xlink:to="us-gaap_TypeOfArrangementAxis_638513887099152840" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638513887099152840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638513887099152840" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638513887099152840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CellReadyAgreementMember" xlink:label="mrkr_CellReadyAgreementMember_638513887099162838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638513887099152840" xlink:to="mrkr_CellReadyAgreementMember_638513887099162838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_BindingServicesAgreementMember" xlink:label="mrkr_BindingServicesAgreementMember_638513887099162838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638513887099152840" xlink:to="mrkr_BindingServicesAgreementMember_638513887099162838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638513887099162838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638513887099152840" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638513887099162838" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638513887099162838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638513887099162838" xlink:to="us-gaap_RelatedPartyDomain_638513887099162838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638513887099162838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638513887099162838" xlink:to="us-gaap_RelatedPartyMember_638513887099162838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_638513887099162838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyMember_638513887099162838" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember_638513887099162838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099162838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638513887099152840" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099162838" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_638513887099162838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099162838" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_638513887099162838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_638513887099162838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099162838" xlink:to="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_638513887099162838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_638513887099162838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099162838" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_638513887099162838" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncome" xlink:label="us-gaap_OtherOperatingIncome_638513887099162838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099162838" xlink:to="us-gaap_OtherOperatingIncome_638513887099162838" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638513887099172838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099162838" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638513887099172838" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_AdditionalRevenueRecognized" xlink:label="mrkr_AdditionalRevenueRecognized_638513887099172838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099162838" xlink:to="mrkr_AdditionalRevenueRecognized_638513887099172838" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - DISCONTINUED OPERATIONS - Operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638513887099172838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638513887099172838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638513887099172838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638513887099172838" xlink:to="srt_ProductOrServiceAxis_638513887099172838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638513887099172838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638513887099172838" xlink:to="srt_ProductsAndServicesDomain_638513887099172838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_RelatedPartyServiceMember" xlink:label="mrkr_RelatedPartyServiceMember_638513887099172838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638513887099172838" xlink:to="mrkr_RelatedPartyServiceMember_638513887099172838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638513887099172838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638513887099172838" xlink:to="us-gaap_IncomeStatementLocationAxis_638513887099172838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638513887099172838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638513887099172838" xlink:to="us-gaap_IncomeStatementLocationDomain_638513887099172838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638513887099172838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638513887099172838" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638513887099172838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638513887099172838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638513887099172838" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638513887099172838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099182839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638513887099172838" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099182839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638513887099182839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099182839" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638513887099182839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_638513887099182839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099182839" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_638513887099182839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_638513887099182839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099182839" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_638513887099182839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - DISCONTINUED OPERATIONS - Cash Flows (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638513887099182839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638513887099182839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis_638513887099182839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638513887099182839" xlink:to="us-gaap_DisposalGroupClassificationAxis_638513887099182839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_638513887099182839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis_638513887099182839" xlink:to="us-gaap_DisposalGroupClassificationDomain_638513887099182839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:label="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_638513887099182839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain_638513887099182839" xlink:to="us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_638513887099182839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099182839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638513887099182839" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099182839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_638513887099182839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099182839" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_638513887099182839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_638513887099182839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099182839" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_638513887099182839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_638513887099192840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638513887099182839" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_638513887099192840" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" xlink:type="extended" xlink:title="40801 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesTable" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesTable_638513887099192840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesTable_638513887099192840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638513887099192840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesTable_638513887099192840" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638513887099192840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638513887099192840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638513887099192840" xlink:to="us-gaap_RelatedPartyDomain_638513887099192840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638513887099192840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638513887099192840" xlink:to="us-gaap_RelatedPartyMember_638513887099192840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638513887099192840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesTable_638513887099192840" xlink:to="srt_CounterpartyNameAxis_638513887099192840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638513887099192840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638513887099192840" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638513887099192840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CellReadyMember" xlink:label="mrkr_CellReadyMember_638513887099192840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638513887099192840" xlink:to="mrkr_CellReadyMember_638513887099192840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638513887099192840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesTable_638513887099192840" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638513887099192840" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638513887099192840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638513887099192840" xlink:to="us-gaap_AccountsPayableCurrent_638513887099192840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638513887099192840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638513887099192840" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638513887099192840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638513887099202840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638513887099192840" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638513887099202840" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638513887099202840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638513887099192840" xlink:to="us-gaap_OtherLiabilitiesCurrent_638513887099202840" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_638513887099202840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638513887099192840" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_638513887099202840" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_638513887099202840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638513887099192840" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_638513887099202840" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_OtherTaxesPayableCurrent" xlink:label="mrkr_OtherTaxesPayableCurrent_638513887099202840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638513887099192840" xlink:to="mrkr_OtherTaxesPayableCurrent_638513887099202840" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638513887099202840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638513887099192840" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638513887099202840" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent_638513887099202840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638513887099192840" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent_638513887099202840" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails" xlink:type="extended" xlink:title="40901 - Disclosure - STOCKHOLDERS' EQUITY - Reverse Stock Split And ATM Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638513887099202840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_638513887099202840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638513887099202840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638513887099202840" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638513887099202840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638513887099212841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638513887099202840" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638513887099212841" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_AtmAgreementMember" xlink:label="mrkr_AtmAgreementMember_638513887099212841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638513887099212841" xlink:to="mrkr_AtmAgreementMember_638513887099212841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638513887099212841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638513887099202840" xlink:to="us-gaap_ClassOfStockLineItems_638513887099212841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638513887099212841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638513887099212841" xlink:to="us-gaap_CommonStockSharesAuthorized_638513887099212841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638513887099212841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638513887099212841" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638513887099212841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638513887099212841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638513887099212841" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638513887099212841" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - STOCKHOLDERS' EQUITY - Stock Purchase Agreement And Exercise of Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638513887099212841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638513887099212841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638513887099212841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638513887099212841" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638513887099212841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638513887099212841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638513887099212841" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638513887099212841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockPurchaseAgreementMember" xlink:label="mrkr_StockPurchaseAgreementMember_638513887099212841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638513887099212841" xlink:to="mrkr_StockPurchaseAgreementMember_638513887099212841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638513887099212841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638513887099212841" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638513887099212841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638513887099222841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638513887099212841" xlink:to="us-gaap_RelatedPartyDomain_638513887099222841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_LincolnParkMember" xlink:label="mrkr_LincolnParkMember_638513887099222841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638513887099222841" xlink:to="mrkr_LincolnParkMember_638513887099222841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638513887099222841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638513887099212841" xlink:to="us-gaap_SubsequentEventTypeAxis_638513887099222841" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638513887099222841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638513887099222841" xlink:to="us-gaap_SubsequentEventTypeDomain_638513887099222841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638513887099222841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638513887099222841" xlink:to="us-gaap_SubsequentEventMember_638513887099222841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638513887099222841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638513887099212841" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638513887099222841" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638513887099222841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638513887099222841" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638513887099222841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares" xlink:label="mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares_638513887099222841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638513887099222841" xlink:to="mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares_638513887099222841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638513887099222841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638513887099222841" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638513887099222841" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CommitmentFee" xlink:label="mrkr_CommitmentFee_638513887099222841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638513887099222841" xlink:to="mrkr_CommitmentFee_638513887099222841" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638513887099222841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638513887099222841" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638513887099222841" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638513887099222841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638513887099222841" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638513887099222841" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638513887099232839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638513887099222841" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638513887099232839" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41001 - Disclosure - STOCK-BASED COMPENSATION - Stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockBasedCompensationTable" xlink:label="mrkr_StockBasedCompensationTable_638513887099232839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="mrkr_StockBasedCompensationTable_638513887099232839" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_638513887099232839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationTable_638513887099232839" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_638513887099232839" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638513887099232839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis_638513887099232839" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638513887099232839" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638513887099232839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638513887099232839" xlink:to="us-gaap_EmployeeStockOptionMember_638513887099232839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockBasedCompensationLineItems" xlink:label="mrkr_StockBasedCompensationLineItems_638513887099232839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationTable_638513887099232839" xlink:to="mrkr_StockBasedCompensationLineItems_638513887099232839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638513887099232839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099232839" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638513887099232839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638513887099232839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099232839" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638513887099232839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638513887099232839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099232839" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638513887099232839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6385138870992328391" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099232839" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6385138870992328391" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638513887099242845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099232839" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638513887099242845" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638513887099242845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099232839" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638513887099242845" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638513887099242845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099232839" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638513887099242845" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638513887099242845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099232839" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638513887099242845" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6385138870992428451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099232839" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6385138870992428451" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638513887099242845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099232839" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638513887099242845" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638513887099242845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099232839" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638513887099242845" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638513887099242845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099232839" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638513887099242845" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638513887099242845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099232839" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638513887099242845" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_638513887099242845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099232839" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_638513887099242845" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="41002 - Disclosure - STOCK-BASED COMPENSATION - Stock-based compensation expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockBasedCompensationTable" xlink:label="mrkr_StockBasedCompensationTable_638513887099252843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="mrkr_StockBasedCompensationTable_638513887099252843" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638513887099252843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationTable_638513887099252843" xlink:to="us-gaap_IncomeStatementLocationAxis_638513887099252843" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638513887099252843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638513887099252843" xlink:to="us-gaap_IncomeStatementLocationDomain_638513887099252843" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638513887099252843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638513887099252843" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638513887099252843" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638513887099252843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638513887099252843" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638513887099252843" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockBasedCompensationLineItems" xlink:label="mrkr_StockBasedCompensationLineItems_638513887099252843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationTable_638513887099252843" xlink:to="mrkr_StockBasedCompensationLineItems_638513887099252843" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockCompensationInContinuingOperations" xlink:label="mrkr_StockCompensationInContinuingOperations_638513887099252843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099252843" xlink:to="mrkr_StockCompensationInContinuingOperations_638513887099252843" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_StockCompensationInDiscontinuedOperations" xlink:label="mrkr_StockCompensationInDiscontinuedOperations_638513887099252843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099252843" xlink:to="mrkr_StockCompensationInDiscontinuedOperations_638513887099252843" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638513887099252843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638513887099252843" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638513887099252843" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="extended" xlink:title="41003 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638513887099252843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638513887099252843" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638513887099262841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638513887099262841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638513887099262841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638513887099262841" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureGrantIncomeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - GRANT INCOME (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_GrantIncomeTable" xlink:label="mrkr_GrantIncomeTable_638513887099262841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="mrkr_GrantIncomeTable_638513887099262841" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638513887099262841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeTable_638513887099262841" xlink:to="srt_ProductOrServiceAxis_638513887099262841" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638513887099262841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638513887099262841" xlink:to="srt_ProductsAndServicesDomain_638513887099262841" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_638513887099262841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638513887099262841" xlink:to="us-gaap_GrantMember_638513887099262841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CpritGrantMember" xlink:label="mrkr_CpritGrantMember_638513887099262841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GrantMember_638513887099262841" xlink:to="mrkr_CpritGrantMember_638513887099262841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FdaGrantMember" xlink:label="mrkr_FdaGrantMember_638513887099262841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GrantMember_638513887099262841" xlink:to="mrkr_FdaGrantMember_638513887099262841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_638513887099262841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GrantMember_638513887099262841" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_638513887099262841" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638513887099262841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeTable_638513887099262841" xlink:to="us-gaap_SubsequentEventTypeAxis_638513887099262841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638513887099262841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638513887099262841" xlink:to="us-gaap_SubsequentEventTypeDomain_638513887099262841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638513887099262841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638513887099262841" xlink:to="us-gaap_SubsequentEventMember_638513887099262841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_GrantIncomeLineItems" xlink:label="mrkr_GrantIncomeLineItems_638513887099272841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeTable_638513887099262841" xlink:to="mrkr_GrantIncomeLineItems_638513887099272841" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_ReceiptOfProductDevelopmentResearchAward" xlink:label="mrkr_ReceiptOfProductDevelopmentResearchAward_638513887099272841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeLineItems_638513887099272841" xlink:to="mrkr_ReceiptOfProductDevelopmentResearchAward_638513887099272841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_638513887099272841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeLineItems_638513887099272841" xlink:to="us-gaap_RestrictedCash_638513887099272841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638513887099272841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeLineItems_638513887099272841" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638513887099272841" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable_638513887099272841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeLineItems_638513887099272841" xlink:to="us-gaap_GrantsReceivable_638513887099272841" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant_638513887099272841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeLineItems_638513887099272841" xlink:to="mrkr_FundsReceivedFromGrant_638513887099272841" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - RELATED PARTY EXPENSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638513887099272841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_2" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638513887099272841" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638513887099272841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638513887099272841" xlink:to="us-gaap_TypeOfArrangementAxis_638513887099272841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638513887099272841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638513887099272841" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638513887099272841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CellReadyAgreementMember" xlink:label="mrkr_CellReadyAgreementMember_638513887099282840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638513887099272841" xlink:to="mrkr_CellReadyAgreementMember_638513887099282840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638513887099282840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638513887099272841" xlink:to="srt_CounterpartyNameAxis_638513887099282840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638513887099282840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638513887099282840" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638513887099282840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CellReadyMember" xlink:label="mrkr_CellReadyMember_638513887099282840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638513887099282840" xlink:to="mrkr_CellReadyMember_638513887099282840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638513887099282840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638513887099272841" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638513887099282840" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638513887099282840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638513887099282840" xlink:to="us-gaap_RelatedPartyDomain_638513887099282840" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_638513887099282840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638513887099282840" xlink:to="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_638513887099282840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_CellReadyMember" xlink:label="mrkr_CellReadyMember_6385138870992828401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638513887099282840" xlink:to="mrkr_CellReadyMember_6385138870992828401" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_638513887099282840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638513887099282840" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember_638513887099282840" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638513887099282840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638513887099282840" xlink:to="us-gaap_RelatedPartyMember_638513887099282840" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638513887099282840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638513887099272841" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638513887099282840" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses_638513887099282840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638513887099282840" xlink:to="us-gaap_OperatingCostsAndExpenses_638513887099282840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638513887099282840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638513887099282840" xlink:to="us-gaap_OtherLiabilitiesCurrent_638513887099282840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_638513887099292843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638513887099282840" xlink:to="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_638513887099292843" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_InvoicesReceivedForServicesAndManufacturingCosts" xlink:label="mrkr_InvoicesReceivedForServicesAndManufacturingCosts_638513887099292843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638513887099282840" xlink:to="mrkr_InvoicesReceivedForServicesAndManufacturingCosts_638513887099292843" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638513887099292843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_638513887099292843" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638513887099292843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638513887099292843" xlink:to="us-gaap_SubsequentEventTypeAxis_638513887099292843" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638513887099292843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638513887099292843" xlink:to="us-gaap_SubsequentEventTypeDomain_638513887099292843" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638513887099292843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638513887099292843" xlink:to="us-gaap_SubsequentEventMember_638513887099292843" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638513887099292843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638513887099292843" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638513887099292843" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638513887099292843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638513887099292843" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638513887099292843" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20240331.xsd#mrkr_ControlledEquityOfferingSalesAgreementMember" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember_638513887099292843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638513887099292843" xlink:to="mrkr_ControlledEquityOfferingSalesAgreementMember_638513887099292843" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638513887099292843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638513887099292843" xlink:to="us-gaap_SubsequentEventLineItems_638513887099292843" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638513887099302842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638513887099292843" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638513887099302842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638513887099302842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638513887099292843" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638513887099302842" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979677937296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MARKER THERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-4497941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9350 Kirby Drive, Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-6400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRKR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,919,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001094038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979679055328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,323,428<span></span>
</td>
<td class="nump">$ 15,111,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and deposits</a></td>
<td class="nump">917,009<span></span>
</td>
<td class="nump">988,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">1,851,462<span></span>
</td>
<td class="nump">1,027,815<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">14,091,899<span></span>
</td>
<td class="nump">17,127,391<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">14,091,899<span></span>
</td>
<td class="nump">17,127,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,949,700<span></span>
</td>
<td class="nump">1,745,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party payable</a></td>
<td class="nump">$ 353,965<span></span>
</td>
<td class="nump">1,329,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration', window );">Other Liability, Current, Related Party, Type [Extensible Enumeration]</a></td>
<td class="text">Related Party [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">$ 2,303,665<span></span>
</td>
<td class="nump">3,074,848<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,303,665<span></span>
</td>
<td class="nump">3,074,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 30 million shares authorized, 8.9 million shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively (see Note 9)</a></td>
<td class="nump">8,910<span></span>
</td>
<td class="nump">8,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">450,458,009<span></span>
</td>
<td class="nump">450,329,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(438,678,685)<span></span>
</td>
<td class="num">(436,285,863)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">11,788,234<span></span>
</td>
<td class="nump">14,052,543<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 14,091,899<span></span>
</td>
<td class="nump">$ 17,127,391<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of related party for liability classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979677875232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in $ per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in $ per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="nump">8,900,000<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">8,900,000<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979679188624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,244,061<span></span>
</td>
<td class="nump">$ 1,234,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,575,015<span></span>
</td>
<td class="nump">3,376,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,218,063<span></span>
</td>
<td class="nump">2,167,318<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,793,078<span></span>
</td>
<td class="nump">5,543,815<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,549,017)<span></span>
</td>
<td class="num">(4,309,479)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">156,195<span></span>
</td>
<td class="nump">84,654<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations</a></td>
<td class="num">(2,392,822)<span></span>
</td>
<td class="num">(4,224,825)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract', window );"><strong>Discontinued operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(742,751)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(742,751)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,392,822)<span></span>
</td>
<td class="num">$ (4,967,576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Loss from continuing operations, basic</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Loss from discontinued operations, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">(0.27)<span></span>
</td>
<td class="num">(0.57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Loss from continuing operations, diluted</a></td>
<td class="num">(0.27)<span></span>
</td>
<td class="num">(0.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Loss from discontinued operations, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic</a></td>
<td class="nump">8,901,962<span></span>
</td>
<td class="nump">8,721,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted</a></td>
<td class="nump">8,901,962<span></span>
</td>
<td class="nump">8,721,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,244,061<span></span>
</td>
<td class="nump">$ 1,234,336<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979677657344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid- in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 8,406<span></span>
</td>
<td class="nump">$ 447,641,680<span></span>
</td>
<td class="num">$ (428,049,049)<span></span>
</td>
<td class="nump">$ 19,601,037<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning Balance, Shares at Dec. 31, 2022</a></td>
<td class="nump">8,405,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash</a></td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">619,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (in shares)</a></td>
<td class="nump">212,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing', window );">Issuance of common stock as commitment fee for future financing</a></td>
<td class="nump">$ 180<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing', window );">Issuance of common stock as commitment fee for future financing (in shares)</a></td>
<td class="nump">180,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,967,576)<span></span>
</td>
<td class="num">(4,967,576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit', window );">Fractional shares adjustment due to reverse split</a></td>
<td class="num">(113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 8,799<span></span>
</td>
<td class="nump">448,921,174<span></span>
</td>
<td class="num">(433,016,625)<span></span>
</td>
<td class="nump">15,913,348<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, Shares at Mar. 31, 2023</a></td>
<td class="nump">8,798,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 8,891<span></span>
</td>
<td class="nump">450,329,515<span></span>
</td>
<td class="num">(436,285,863)<span></span>
</td>
<td class="nump">14,052,543<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning Balance, Shares at Dec. 31, 2023</a></td>
<td class="nump">8,891,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">49,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in shares)</a></td>
<td class="nump">19,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,392,822)<span></span>
</td>
<td class="num">(2,392,822)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 8,910<span></span>
</td>
<td class="nump">$ 450,458,009<span></span>
</td>
<td class="num">$ (438,678,685)<span></span>
</td>
<td class="nump">$ 11,788,234<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, Shares at Mar. 31, 2024</a></td>
<td class="nump">8,910,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents number of common stock issued as commitment fee for future financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents value of common stock as commitment fee for future financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a fractional shares adjustment due to reverse split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979678381648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (2,392,822)<span></span>
</td>
<td class="num">$ (4,967,576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Less: loss from discontinued operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(742,751)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss from continuing operations</a></td>
<td class="num">(2,392,822)<span></span>
</td>
<td class="num">(4,224,825)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">79,417<span></span>
</td>
<td class="nump">659,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="nump">71,117<span></span>
</td>
<td class="nump">36,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Other receivables</a></td>
<td class="num">(823,647)<span></span>
</td>
<td class="nump">1,319,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent', window );">Related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="num">(975,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">204,507<span></span>
</td>
<td class="nump">111,171<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities - continuing operations</a></td>
<td class="num">(3,837,118)<span></span>
</td>
<td class="num">(3,098,171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in operating activities - discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,790,124)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,837,118)<span></span>
</td>
<td class="num">(5,888,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash used in investing activities - discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(112,608)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(112,608)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercise</a></td>
<td class="nump">49,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">49,096<span></span>
</td>
<td class="nump">619,974<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(3,788,022)<span></span>
</td>
<td class="num">(5,380,929)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">15,111,450<span></span>
</td>
<td class="nump">11,782,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">$ 11,323,428<span></span>
</td>
<td class="nump">6,401,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing', window );">Issuance of common stock as commitment fee for future financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of Issuance of common stock as commitment fee for future financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979675114608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;1: NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marker Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;we&#8221;), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company&#8217;s multi tumor associated antigen (multiTAA&#8221;)-specific T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Purchase Agreement with Cell Ready</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 26, 2023, the Company completed the previously announced transaction with Cell Ready, LLC (&#8220;Cell Ready&#8221;) pursuant to a Purchase Agreement (the &#8220;Cell Ready Purchase Agreement), dated May 1, 2023, by and between the Company and Cell Ready. Mr. John Wilson is a member of the Company&#8217;s board of directors and is serving as the CEO of Cell Ready, therefore Cell Ready is a related party. Pursuant to the Cell Ready Purchase Agreement, effective as of the Closing Date, the Company (i) assigned to Cell Ready the leases for the Company&#8217;s two manufacturing facilities in Houston, Texas (the &#8220;Manufacturing Facilities&#8221;), (ii) sold to Cell Ready all of the equipment and leasehold improvements at the Manufacturing Facilities and (iii) assigned to Cell Ready its rights, title and interest in the Company&#8217;s Master Services Agreement for Product Supply (the &#8220;MSA&#8221;), dated April 7, 2023, by and between the Company, Cell Ready and Indapta Therapeutics, Inc., as well as its rights, title and interest in any contracts related to the equipment and Manufacturing Facilities (collectively, the &#8220;Purchased Assets&#8221;). Cell Ready acquired the Purchased Assets for total consideration of $19.0 million. In connection with the purchase of the Manufacturing Facilities, Cell Ready also extended offers of employment to approximately 50 of the Company&#8217;s former employees in its manufacturing, development, quality, and regulatory affairs functions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Purchased Assets constituted a significant disposition. Based upon the magnitude of the disposition and because the Company is exiting certain manufacturing operations, the disposition represents a significant strategic shift that will have a material effect on the Company&#8217;s operations and financial results. Accordingly, the assets sold meet the definition of a discontinued operation, as defined by Accounting Standards Codification (&#8220;ASC&#8221;) 205-20 &#8211; Discontinued Operations, and prior comparative periods have been retroactively adjusted to reflect the current presentation. See additional discussion at Note 7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 22, 2024, we entered into a Master Services Agreement for Product Supply (the &#8220;MSA&#8221;) with Cell Ready to provide outsourced services previously performed by the Company prior to its asset sale to Cell Ready. Cell Ready, which is owned by one of our directors and shareholders, Mr. John Wilson, is a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. If the services involve the supply of product, Cell Ready is required to supply such product in conformance with the product requirements set forth in the applicable work order(s). Under the MSA, Cell Ready is to use only personnel with sufficient qualifications and experience to supply the services contemplated by the MSA, provide its personnel with adequate training and assume full responsibility for its personnel&#8217;s compliance with the MSA. Further, Cell Ready is required to provide the Company with assistance and cooperation in order for the Company to obtain and maintain all necessary regulatory approvals, at the Company&#8217;s expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Organizational Changes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 2023, the Company implemented changes to its organizational structure due to the transaction with Cell Ready and to reduce operational costs. In connection with these changes, the Company reduced headcount, including the separation of its former Chief Executive Officer, Peter Hoang, in May 2023, and its former Chief Accounting Officer, Michael Loiacono, in June 2023. During the second quarter of 2023, the Company recorded $0.9 million of severance and termination-related costs. The payments of these costs were completed in July of 2023. Effective May 1, 2023, the Company&#8217;s board of directors appointed Dr. Juan Vera as the Company&#8217;s President and Chief Executive Officer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective June 30, 2023, the board of directors appointed Eliot M. Lurier as the Company&#8217;s Interim Chief Financial Officer, whereby Mr. Lurier provided consulting services to the Company pursuant to a consulting agreement between the Company and Danforth Advisors, LLC (&#8220;Danforth&#8221;) and received no compensation directly from the Company. On November 17, 2023, the Company terminated the consulting agreement between the Company and Danforth, effective January 16, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 17, 2023, Mr. Lurier ceased serving as the Company&#8217;s Interim Chief Financial Officer and Dr. Vera was appointed as the Company&#8217;s Principal Financial and Accounting Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 26, 2023, the Company effected a one-for-ten (1-for-10) reverse stock split of its common stock (the &#8220;Reverse Stock Split&#8221;) and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979679754304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_BasisOfPresentationAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;2: BASIS OF PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (&#8220;SEC&#8221;) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results (see Note 7 for information on discontinued operations).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The results for the unaudited condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2024, or for any future interim period. The condensed consolidated balance sheet at December 31, 2023 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2023 and notes thereto included in the Company&#8217;s annual report on Form 10-K filed on March 26, 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979677777312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY AND FINANCIAL CONDITION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_LiquidityFinancialConditionAndGoingConcernAbstract', window );"><strong>LIQUIDITY AND FINANCIAL CONDITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock', window );">LIQUIDITY AND FINANCIAL CONDITION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3: LIQUIDITY AND FINANCIAL CONDITION </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March 31, 2024, the Company had cash and cash equivalents of approximately $11.3 million. The Company&#8217;s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing; successfully progress its product candidates through preclinical and clinical development; obtain regulatory approval of one or more of its product candidates; maintain and enforce intellectual property rights; develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity, debt financings and grants. In August 2021, the Company entered into a Controlled Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;ATM Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and RBC Capital Markets, LLC (the &#8220;Sales Agents&#8221;), pursuant to which the Company can offer and sell, from time to time at its sole discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $75.0 million. Any shares of its common stock sold will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-258687), which the SEC declared effective on August 19, 2021. However, our use of the shelf registration statement on Form S-3 will be limited for so long as we are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement and in accordance with the ATM agreement. The Sales Agents are entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and we have provided each of the Sales Agents with indemnification and contribution rights. During the three months ended March 31, 2023, the Company sold 200,261 shares of its common stock under the ATM Agreement for proceeds of $0.6 million. There was no common stock issued under the ATM Agreement during the three months ended March 31, 2024. In April 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement resulting in net proceeds of $0.04 million, after deducting agent commissions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (&#8220;CPRIT&#8221;) to support the Company&#8217;s clinical investigation of MT-401. Through the date of this filing, the Company has received $6.9 million of funds from the CPRIT grant. The Company recorded $0.8 million of grant income related to the CPRIT grant as revenue for the three months ended March 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2022, the Company received notice from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) that it had awarded the Company a $2.0 million grant from the FDA&#8217;s Orphan Products Grant program to support the Company&#8217;s clinical investigation of MT-401 for the treatment of post-transplant AML Through the date of this filing, the Company has received $0.8 million from the FDA grant. The Company recorded $0.3 million and $0.1 million of grant income related to the FDA grant as revenue for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, the Company recorded $0.3 million of grant income receivable, which represented grant income earned in advance of funds to be received from the FDA. In April 2024, the Company received $0.3 million of funds from the FDA grant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2023, the Company received notice of a $2.0 million grant from the National Institutes of Health Small Business Innovation Research (&#8220;SBIR&#8221;) program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents. Through the date of this filing, the Company has received $0.4 million from SBIR. The Company recorded $0.2 million of grant income related to the SBIR grant as revenue for the three months ended March 31, 2024. As of March 31, 2024, the Company recorded $0.2 million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In April 2024, the Company received $0.2 million of funds from the SBIR grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As described in Note 1, on June 26, 2023, the Company completed the transaction with Cell Ready pursuant to the Cell Ready Purchase Agreement for total consideration of $19.0 million. On February 22, 2024, the Company entered into a Master Services Agreement for Product Supply (the &#8220;MSA&#8221;) with Cell Ready, a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company expects to continue to incur substantial losses over the next several years during its development phase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on the Company&#8217;s clinical and research and development plans and its timing expectations related to the progress of its programs, the Company expects that its cash and cash equivalents as of March 31, 2024, including drawdowns of available grant funds, will enable the Company to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2025. Prior to the Cell Ready transaction, there was substantial doubt regarding the Company&#8217;s ability to continue as a going concern, which was alleviated by the proceeds from the transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has based this estimate on assumptions that may prove to be wrong, and the Company could utilize its available capital resources sooner than it currently expects. Furthermore, the Company&#8217;s operating plan may change, and it may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of the Company&#8217;s product candidates and the extent to which the Company may enter into additional collaborations with third parties to participate in their development and commercialization, the Company is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated clinical trials. The Company&#8217;s future funding requirements will depend on many factors, as it: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiates or continues clinical trials of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continues the research and development of its product candidates and seeks to discover additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintains and enforces intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enters into contract manufacturing arrangements with Cell Ready or other contract manufacturing organizations for clinical manufacturing supply;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishes sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluates strategic transactions the Company may undertake; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enhances operational, financial and information management systems and hires additional personnel, including personnel to support development of product candidates and, if a product candidate is approved, commercialization efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has sufficient cash available to meet its operating requirements for at least the next twelve months from the issuance of these financial statements. However, the Company does not have sufficient sources of revenue to provide incoming cash flows to sustain its future operations beyond the fourth quarter of 2025. As outlined above, its ability to pursue its long-term planned business activities is dependent upon its successful efforts to raise additional capital and grant income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The current macro-economic environment of decades-high inflation and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company&#8217;s ability to access capital, which could in the future negatively affect the Company&#8217;s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company&#8217;s business and the value of its common stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_LiquidityFinancialConditionAndGoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_LiquidityFinancialConditionAndGoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity Financial Condition And Going Concern Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979679493520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;4: SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Principles of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals Inc. &#8211; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada, Inc. All significant intercompany balances and transactions are eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results may differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies, controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense and income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at March 31, 2024 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits of $250,000. As of March 31, 2024, the Company had approximately $1.4 million in cash at financial institutions and approximately $9.9 million in U.S. government agency securities, for aggregate cash and cash equivalents of $11.3 million. As of December 31, 2023, the Company had approximately $1.4 million in cash at financial institutions and approximately $13.7 million in U.S. government agency securities, for aggregate cash and cash equivalents of $15.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event cash is received from grants in advance of incurring qualifying costs, it is recorded as restricted cash until it is earned and recorded to grant income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Discontinued Operations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Purchased Assets sold to Cell Ready pursuant to the Cell Ready Purchase Agreement constituted a significant disposition and as such, the Company concluded that the disposition of its Purchased Assets represented a strategic shift that had a major effect on its operations and financial results. Therefore, the Purchased Assets, related party revenue, service revenue and related expenses are classified as discontinued operations for all periods presented herein. See Note 7 for further information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Standards Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Improvements to Reporetable Segment Disclosures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounitng Standards Update (&#8220;ASU&#8221;) No. 2023-07, Segement Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, among other provisions. The ASU is effective for fiscal year periods beginning after December15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the ASU requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the standard to determine the impact of adoption to its consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Improvements to Income Tax Disclosures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregtion of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption the guidance can be applied prospectively or retrospectively. We do not expect the adoption of this guiadance to have a material impact on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its consolidated financial position or results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There have been no material changes in the Company&#8217;s significant accounting policies to those previously disclosed in the Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 26, 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979764846208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;5: NET LOSS PER SHARE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth the computation of net loss per share for the three months ended March 31, 2024 and 2023, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,392,822)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,224,825)</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (742,751)</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,392,822)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,967,576)</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,901,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,721,031</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,901,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,721,031</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net earnings (loss) per share:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from continuing operations, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.48)</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.09)</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.57)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following securities, rounded to the nearest thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 639,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,297,000</p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Common stock purchase warrants</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,848,000</p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Potentially dilutive securities</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 639,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,145,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979679517632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER RECEIVABLE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">OTHER RECEIVABLE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 6: OTHER RECEIVABLE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. The Company recorded $0.8 million and $1.2 million of grant income related to the CPRIT grant for the three months ended March 31, 2024 and 2023, respectively. At March 31, 2024, the Company recorded $1.2 million of grant income receivable related to the CPRIT grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Additionally, the Company recorded $0.3 million and $0.2 million of grant income related to the FDA and SBIR grants, respectively, for the three months ended March 31, 2024. At March 31, 2024, the Company recorded $0.3 million and $0.2 million of grant income receivable related to the FDA and SBIR grants, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company received $0.3 million and $0.2 million of funds from FDA and SBIR in April 2024, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//310-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979676033408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>DISCONTINUED OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISCONTINUED OPERATIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 7: DISCONTINUED OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As discussed in Note 1, on June 26, 2023, the Company completed the previously announced transaction with Cell Ready for cash consideration of $19.0 million, resulting in derecognition of the Purchased Assets and a gain on sale of approximately $8.7 million, net of $63,000 in tax. There were no remaining assets and liabilities classified in discontinued operations as of March 31, 2024 or December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company had no activity related to discontinued operations for the three months ended March 31, 2024. Net loss from discontinued operations for the three months ended March 31, 2023, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three&#160;Months&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenues:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Related party service revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,500,000</p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,500,000</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,894,245</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 348,506</p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,242,751</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (742,751)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes our cash flows related to discontinued operations for the three months ended March 31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three&#160;Months&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Discontinued operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,790,000)</p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (113,000)</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Net decrease in cash and cash equivalents from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,903,000)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Related Party Service Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In April 2022, the Company entered into a binding services agreement (&#8220;Wilson Wolf Agreement&#8221;) with Wilson Wolf Manufacturing Corporation (&#8220;Wilson Wolf&#8221;). Mr. John Wilson is a member of the Company&#8217;s board of directors and is serving as the CEO of Wilson Wolf. Wilson Wolf is in the business of creating products and services intended to simplify and expedite the transition of cell therapies and gene-modified cell therapies to mainstream society (the &#8220;Wilson Wolf Mission&#8221;). Pursuant to the Wilson Wolf Agreement, Wilson Wolf made a cash payment to the Company in the amount of $8.0 million, as consideration for certain training and research services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In March 2023, the Company recognized the final $2.5 million of revenue pursuant to this $8.0 million agreement and an additional $1.0 million because certain agreed milestones were met. The additional $1.0 million of service fee revenue recognized during the three months ended March 31, 2023 was received in May 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979782639936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;8: ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accounts payable, accrued liabilities, and related party payable consist of the following as of March 31, 2024 and December 31, 2023, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,202,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 961,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 297,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 303,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Related party payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 354,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,330,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Property taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 116,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 126,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 203,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 205,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable, accrued liabilities and related party payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,304,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,075,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The $0.4 million and $1.3 million related-party payable as of March 31, 2024 and December 31, 2023, respectively, reflects amounts payable to Cell Ready for outsourced product development and manufacturing services. See Note 13: Related Party Transactions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979676240240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;9: STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reverse Stock Split</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 26, 2023, the Company effected the Reverse Stock Split and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All historical share and per share amounts reflected in this report have been adjusted to reflect the Reverse Stock Split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Common Stock Transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance of Stock Pursuant to ATM Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company did not issue any common stock under the ATM Agreement for the three months ended March 31, 2024. During the three months ended March 31, 2023, the Company sold 200,261 shares of its common stock under the ATM Agreement for proceeds of $0.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Purchase Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2022, the Company entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) with Lincoln Park which provides that, upon the terms and subject to the conditions of the agreement, the Company has the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of its common stock (the &#8220;Purchase Shares&#8221;) from time to time over a 24-month term, at a variable price with certain market-based terms as defined in the Purchase Agreement. The Purchase Agreement does not exhibit any of the characteristics for liability classification under ASC Topic 480, Distinguishing Liabilities from Equity. Instead, the purchase agreement is indexed to the Company&#8217;s own stock under ASC Subtopic 815-40, <i style="font-style:italic;">Contracts in Entity&#8217;s Own Equity</i>, and classified as equity. In January 2023, Lincoln Park was issued 180,410 shares of stock as a commitment fee at a value of $0.5 million. During the three months ended March 31, 2023, the Company sold 12,500 shares of its common stock under the Purchase Agreement for proceeds of approximately $33,000. The Company terminated the Purchase Agreement with Lincoln Park on February 29, 2024 effective March 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Stock Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2024, certain outstanding options were exercised for 19,497 shares of common stock, providing aggregate proceeds to the Company of approximately $49,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979679437248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;10: STOCK-BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2024 Equity Incentive Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no equity incentive awards issued during the three months ended March 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A summary of the Company&#8217;s stock option activity for the three months ended March 31, 2024 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Intrinsic Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,317,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.6</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,497)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Canceled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (79,196)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of March&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 639,202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 720,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.5</p></td></tr><tr><td style="vertical-align:top;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 329,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 113,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.2</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth stock-based compensation expenses recorded during the respective periods:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock Compensation expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 151,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 221,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock compensation in continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 372,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock compensation in discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 288,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total stock compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 660,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of March 31, 2024, the total stock-based compensation cost related to unvested awards not yet recognized was $0.3 million. The expected weighted average period compensation costs to be recognized was approximately 1.8 years. Future option grants will impact the compensation expense recognized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979675158224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GRANT INCOME<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>GRANT INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">GRANT INCOME</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;11: GRANT INCOME</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CPRIT</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from CPRIT to support the Company&#8217;s clinical investigation of MT-401.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If restricted cash received from grants in advance of incurring qualifying costs, it is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. There was no restricted cash recorded as of March 31, 2024 and December 31, 2023. If qualifying grant income is earned in advance of cash received from grants, it is recognized as revenue and recorded as other receivable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recorded $0.8 million and $1.2 million of grant income related to the CPRIT grant as revenue for the three months ended March 31, 2024, and 2023, respectively. As of March 31, 2024, the Company recorded $1.2 million as other receivable, which represented grant income earned in advance of funds to be received from CPRIT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDA</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In September 2022, the Company received notice from the FDA that it had awarded the Company a $2.0 million grant from the FDA&#8217;s Orphan Products Grant program to support the Company&#8217;s clinical investigation of MT-401 for the treatment of post-transplant AML. The Company recorded $0.3 million and $0.1 million of grant income related to the FDA grant as revenue for the three months ended March 31, 2024 and March 31, 2023, respectively. As of March 31, 2024, the Company recorded $0.3 million as other receivable, which represented grant income earned in advance of funds to be received from the FDA. In April 2024, the Company received $0.3 million of funds from the FDA grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SBIR</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In May 2023, the Company announced it had received a $2.0 million grant from the National Institutes of Health Small Business Innovation Research program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents. The Company recorded $0.2 million of grant income related to the SBIR grant as revenue for the three months ended March 31, 2024. As of March 31, 2024, the Company recorded $0.2 million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In April 2024, the Company received $0.2 million of funds from the SBIR grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979675190544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>LEGAL PROCEEDINGS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">LEGAL PROCEEDINGS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 12: LEGAL PROCEEDINGS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time, the Company may be party to ordinary, routine litigation incidental to their business. The Company knows of no material, active or pending legal proceedings against the Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of the Company&#8217;s directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to the Company&#8217;s interest.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979676608448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY EXPENSES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY EXPENSES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;13: RELATED PARTY EXPENSES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth related party transaction expenses recorded for the three months ended March 31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Baylor College of Medicine</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,000</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cell Ready</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,186,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Wilson Wolf Manufacturing Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 204,000</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,186,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 215,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$0.4 million of related party transactions are included in accounts payable and accrued liabilities as of March 31, 2024. See Note 8 for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreements with The Baylor College of Medicine (&#8220;BCM&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2018, January 2020 and February 2020, the Company entered in Sponsored Research Agreements with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM&#8217;s Center for Cell and Gene Therapy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2019, May 2020 and July 2021, the Company entered into Clinical Supply Agreements with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2019, the Company entered in a Workforce Grant Agreement with BCM, which provided for BCM to provide to the Company manpower costs of projects for manufacturing, quality control testing and validation run activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2020, the Company entered into a Clinical Trial Agreement with BCM, which provided for BCM to provide to the Company investigator-initiated research studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has also entered into a Clinical Site Agreement with BCM, which provided for BCM to conduct clinical trials for the Company and is a part of continuing operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">BCM owns shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchases from Wilson Wolf</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 2023, the Company utilized Wilson Wolf for the purchases of cell culture devices called G-Rexes. Mr. John Wilson is a member of the Company&#8217;s board of directors and is serving as the CEO of Wilson Wolf Manufacturing Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchases from Cell Ready, LLC</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is currently utilizing Cell Ready, LLC for its clinical manufacturing supply and product development. Mr. John Wilson is a member of the Company&#8217;s board of directors and is serving as the CEO of Cell Ready, LLC. On February 22, 2024, we entered into a Master Services Agreement for Product Supply (the &#8220;MSA&#8221;) with Cell Ready. Cell Ready, which is owned by one of our directors and shareholders, Mr. John Wilson, is a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. If the services involve the supply of product, Cell Ready is required to supply such product in conformance with the product requirements set forth in the applicable work order(s). Under the MSA, Cell Ready is to use only personnel with sufficient qualifications and experience to supply the services contemplated by the MSA, provide its personnel with adequate training and assume full responsibility for its personnel&#8217;s compliance with the MSA. Further, Cell Ready is required to provide the Company with assistance and cooperation in order for the Company to obtain and maintain all necessary regulatory approvals, at the Company&#8217;s expense. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2024, the Company entered into Work Order #1 under the MSA, pursuant to which Cell Ready agreed to provide the Company with GMP drug product for Marker MT-401 and/or MT-601. The services include the delivery of final drug product and quality control testing. The Company also requested Cell Ready to provide general support services in connection therewith. During the three months ended March 31, 2024, the Company incurred $1.2 million is expenses related to the &#160;services and manufacturing costs and paid $2.2 million for invoices received. Additional Work Orders are expected to be generated for the remainder of 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979764772736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 14: SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In April 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement resulting in net proceeds of $0.04 million, after deducting agent commissions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979767691952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Principles of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals Inc. &#8211; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada, Inc. All significant intercompany balances and transactions are eliminated upon consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results may differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies, controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense and income taxes.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at March 31, 2024 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits of $250,000. As of March 31, 2024, the Company had approximately $1.4 million in cash at financial institutions and approximately $9.9 million in U.S. government agency securities, for aggregate cash and cash equivalents of $11.3 million. As of December 31, 2023, the Company had approximately $1.4 million in cash at financial institutions and approximately $13.7 million in U.S. government agency securities, for aggregate cash and cash equivalents of $15.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event cash is received from grants in advance of incurring qualifying costs, it is recorded as restricted cash until it is earned and recorded to grant income.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Discontinued Operations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Purchased Assets sold to Cell Ready pursuant to the Cell Ready Purchase Agreement constituted a significant disposition and as such, the Company concluded that the disposition of its Purchased Assets represented a strategic shift that had a major effect on its operations and financial results. Therefore, the Purchased Assets, related party revenue, service revenue and related expenses are classified as discontinued operations for all periods presented herein. See Note 7 for further information.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock', window );">Recently Issued Accounting Standards Not Yet Adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Standards Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Improvements to Reporetable Segment Disclosures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounitng Standards Update (&#8220;ASU&#8221;) No. 2023-07, Segement Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, among other provisions. The ASU is effective for fiscal year periods beginning after December15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the ASU requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the standard to determine the impact of adoption to its consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Improvements to Income Tax Disclosures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregtion of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption the guidance can be applied prospectively or retrospectively. We do not expect the adoption of this guiadance to have a material impact on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its consolidated financial position or results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There have been no material changes in the Company&#8217;s significant accounting policies to those previously disclosed in the Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 26, 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recently issued accounting standards not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480781/205-20-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979764751968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,392,822)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,224,825)</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (742,751)</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,392,822)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,967,576)</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,901,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,721,031</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,901,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,721,031</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net earnings (loss) per share:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from continuing operations, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.48)</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.09)</p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.57)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_NetLossPerShareTableTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 639,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,297,000</p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Common stock purchase warrants</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,848,000</p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Potentially dilutive securities</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 639,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,145,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_NetLossPerShareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of net loss per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_NetLossPerShareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979764846208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>DISCONTINUED OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of income statement information and summary of cash flows for discontinued operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three&#160;Months&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenues:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Related party service revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,500,000</p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,500,000</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,894,245</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 348,506</p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,242,751</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (742,751)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three&#160;Months&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Discontinued operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,790,000)</p></td></tr><tr><td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (113,000)</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Net decrease in cash and cash equivalents from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,903,000)</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979678111296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable, accrued liabilities and related party payable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,202,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 961,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 297,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 303,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Related party payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 354,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,330,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Property taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 116,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 126,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 203,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 205,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable, accrued liabilities and related party payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,304,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,075,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979767190336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of the company's stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Intrinsic Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,317,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.6</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,497)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Canceled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (79,196)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of March&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 639,202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 720,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.5</p></td></tr><tr><td style="vertical-align:top;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 329,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 113,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.2</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationExpensesTableTextBlock', window );">Schedule of stock-based compensation expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock Compensation expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 151,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 221,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock compensation in continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 372,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock compensation in discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 288,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total stock compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 660,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockBasedCompensationExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of stock based compensation expenses recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockBasedCompensationExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979676721024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party transaction expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Baylor College of Medicine</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,000</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cell Ready</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,186,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Wilson Wolf Manufacturing Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 204,000</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,186,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 215,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979673039152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 26, 2023 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Jan. 26, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 25, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and termination-related costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_CellReadyAgreementMember', window );">Cell Ready Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration for purchased assets | $</a></td>
<td class="nump">$ 19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_CellReadyAgreementMember', window );">Cell Ready Purchase Agreement | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration for purchased assets | $</a></td>
<td class="nump">$ 19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OffersEmploymentToNumberOfEmployees', window );">Number of former employees offered employment | employee</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OffersEmploymentToNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of employees extended for employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OffersEmploymentToNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_CellReadyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_CellReadyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979673311264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY AND FINANCIAL CONDITION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>LIQUIDITY AND FINANCIAL CONDITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,323,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,111,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 619,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Amount of notice received</a></td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromCpritGrant', window );">Funds received from CPRIT grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrphanProductsGrantProgram', window );">Grant income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,244,061<span></span>
</td>
<td class="nump">$ 1,234,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>LIQUIDITY AND FINANCIAL CONDITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember', window );">SBIR grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>LIQUIDITY AND FINANCIAL CONDITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantReceived', window );">Grant income received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrphanProductsGrantProgram', window );">Grant income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>LIQUIDITY AND FINANCIAL CONDITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RevenueFromGrantRelatedToCprit', window );">Revenue from CPRIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,244,061<span></span>
</td>
<td class="nump">$ 1,234,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_FdaGrantMember', window );">FDA grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>LIQUIDITY AND FINANCIAL CONDITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantReceived', window );">Grant income received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrphanProductsGrantProgram', window );">Grant income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>LIQUIDITY AND FINANCIAL CONDITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | SBIR grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>LIQUIDITY AND FINANCIAL CONDITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | FDA grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>LIQUIDITY AND FINANCIAL CONDITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_ControlledEquityOfferingSalesAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>LIQUIDITY AND FINANCIAL CONDITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate offering price</a></td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_ControlledEquityOfferingSalesAgreementMember', window );">ATM Agreement | Sales Agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>LIQUIDITY AND FINANCIAL CONDITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent', window );">Commission rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_ControlledEquityOfferingSalesAgreementMember', window );">ATM Agreement | Sales Agents | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>LIQUIDITY AND FINANCIAL CONDITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_CellReadyAgreementMember', window );">Cell Ready Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>LIQUIDITY AND FINANCIAL CONDITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration for purchased assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percent of calculation of compensation rate by using gross sales price per share sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FundsReceivedFromCpritGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds received from grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FundsReceivedFromCpritGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FundsReceivedFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds received from grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FundsReceivedFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of grant income transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OrphanProductsGrantProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable from Orphan Products Grant program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OrphanProductsGrantProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RevenueFromGrantRelatedToCprit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from grant related to CPRIT.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RevenueFromGrantRelatedToCprit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_FdaGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_FdaGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_ControlledEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_ControlledEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_CellReadyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_CellReadyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979677924464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CashAtFinancialInstitutions', window );">Cash at financial institutions</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue', window );">Government agency securities</a></td>
<td class="nump">9,900,000<span></span>
</td>
<td class="nump">13,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,323,428<span></span>
</td>
<td class="nump">$ 15,111,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_CashAtFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash held at financial institutions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_CashAtFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt securities issued by a United States government agency such as Government National Mortgage Association (Ginnie Mae), Federal Home Loan Mortgage Corporation (Freddie Mac), and Federal National Mortgage Association (Fannie Mae), which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979679272032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Computation of loss per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations</a></td>
<td class="num">$ (2,392,822)<span></span>
</td>
<td class="num">$ (4,224,825)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(742,751)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,392,822)<span></span>
</td>
<td class="num">$ (4,967,576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">8,901,962<span></span>
</td>
<td class="nump">8,721,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">8,901,962<span></span>
</td>
<td class="nump">8,721,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net earnings (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Loss from continuing operations, basic</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Loss from continuing operations, diluted</a></td>
<td class="num">(0.27)<span></span>
</td>
<td class="num">(0.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Loss from discontinued operations, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Loss from discontinued operations, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">(0.27)<span></span>
</td>
<td class="num">(0.57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToParentDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979679284784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">639,000<span></span>
</td>
<td class="nump">3,145,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">639,000<span></span>
</td>
<td class="nump">1,297,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,848,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979678275232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER RECEIVABLE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,851,462<span></span>
</td>
<td class="nump">$ 1,027,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrphanProductsGrantProgram', window );">Grant income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_FdaGrantMember', window );">FDA grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RevenueFromOrphanProductsGrantProgram', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrphanProductsGrantProgram', window );">Grant income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_FdaGrantMember', window );">FDA grant | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember', window );">SBIR grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RevenueFromOrphanProductsGrantProgram', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrphanProductsGrantProgram', window );">Grant income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember', window );">SBIR grant | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_CancerPreventionAndResearchInstituteOfTexasMember', window );">Cancer Prevention And Research Institute Of Texas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FundsReceivedFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds received from grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FundsReceivedFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OrphanProductsGrantProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable from Orphan Products Grant program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OrphanProductsGrantProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RevenueFromOrphanProductsGrantProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized for grant from Orphan Products Grant program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RevenueFromOrphanProductsGrantProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesWithImputedInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesWithImputedInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_FdaGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_FdaGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_CancerPreventionAndResearchInstituteOfTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_CancerPreventionAndResearchInstituteOfTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979671022080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 26, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>DISCONTINUED OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,244,061<span></span>
</td>
<td class="nump">$ 1,234,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_CellReadyAgreementMember', window );">Cell Ready Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>DISCONTINUED OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration for purchased assets</a></td>
<td class="nump">$ 19,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_RelatedPartyServiceMember', window );">Related party service revenue | Binding Services Agreement | Wilson Wolf Manufacturing Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>DISCONTINUED OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_AdditionalRevenueRecognized', window );">Additional revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Disposed by sale | Cell Ready Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>DISCONTINUED OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration for purchased assets</a></td>
<td class="nump">19,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Gain on disposal of discontinued operations, Net of tax</a></td>
<td class="nump">8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">Tax on gain on disposal of discontinued operations</a></td>
<td class="nump">$ 63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_AdditionalRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_AdditionalRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_CellReadyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_CellReadyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_RelatedPartyServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_RelatedPartyServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_BindingServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_BindingServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_WilsonWolfManufacturingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_WilsonWolfManufacturingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979678402544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS - Operations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>DISCONTINUED OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,242,751<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">$ (742,751)<span></span>
</td>
<td class="num">(742,751)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>DISCONTINUED OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,894,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>DISCONTINUED OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_RelatedPartyServiceMember', window );">Related party service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>DISCONTINUED OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_RelatedPartyServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_RelatedPartyServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979679143600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS - Cash Flows (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>DISCONTINUED OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in operating activities</a></td>
<td class="num">$ (2,790,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash provided used in investing activities</a></td>
<td class="num">(112,608)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations', window );">Net decrease in cash and cash equivalents from discontinued operations</a></td>
<td class="num">(2,903,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Disposed by sale</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>DISCONTINUED OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(2,790,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash provided used in investing activities</a></td>
<td class="num">$ (113,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in cash associated with the entity's discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979679068048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_AccountsPayableAndAccruedLiabilitiesLineItems', window );"><strong>ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 1,202,000<span></span>
</td>
<td class="nump">$ 961,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">57,000<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">297,000<span></span>
</td>
<td class="nump">303,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party payable</a></td>
<td class="nump">$ 353,965<span></span>
</td>
<td class="nump">1,329,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration', window );">Other Liability, Current, Related Party, Type [Extensible Enumeration]</a></td>
<td class="text">Related party<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Property taxes</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="nump">116,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OtherTaxesPayableCurrent', window );">Other taxes payable</a></td>
<td class="nump">126,000<span></span>
</td>
<td class="nump">103,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">203,000<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent', window );">Total accounts payable, accrued liabilities and related party payable</a></td>
<td class="nump">2,304,000<span></span>
</td>
<td class="nump">3,075,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Cell Ready</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_AccountsPayableAndAccruedLiabilitiesLineItems', window );"><strong>ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party payable</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_AccountsPayableAndAccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_AccountsPayableAndAccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OtherTaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the value of accounts payable, accrued liabilities and related payable of other taxes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OtherTaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of related party for liability classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrkr_CellReadyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrkr_CellReadyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979668390736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Reverse Stock Split And ATM Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 26, 2023</div></th>
<th class="th"><div>Jan. 25, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 619,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrkr_AtmAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrkr_AtmAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrkr_AtmAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979668372992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Stock Purchase Agreement And Exercise of Stock Options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate proceeds from shares issued under the purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 619,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 619,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrkr_StockPurchaseAgreementMember', window );">Stock Purchase Agreement | Lincoln Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate proceeds from shares issued under the purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares', window );">Time to time term to purchase shares (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (in shares)</a></td>
<td class="nump">180,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommitmentFee', window );">Commitment fee</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_CommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of commitment fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_CommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The time to time term to purchase shares in stock purchase sgreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrkr_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrkr_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_LincolnParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_LincolnParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979674300784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock option activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="num">(19,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Beginning Balance</a></td>
<td class="nump">737,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="num">(19,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Cancelled / Expired</a></td>
<td class="num">(79,196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Ending Balance</a></td>
<td class="nump">639,202<span></span>
</td>
<td class="nump">737,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Options vested and exercisable</a></td>
<td class="nump">329,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Outstanding, Beginning Balance</a></td>
<td class="nump">$ 25.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Exercised</a></td>
<td class="nump">2.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Cancelled / Expired</a></td>
<td class="nump">52.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Outstanding, Ending Balance</a></td>
<td class="nump">22.71<span></span>
</td>
<td class="nump">$ 25.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and exercisable</a></td>
<td class="nump">$ 41.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Total Intrinsic Value Outstanding</a></td>
<td class="nump">$ 720,000<span></span>
</td>
<td class="nump">$ 1,317,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Total Intrinsic Value, Options vested and exercisable</a></td>
<td class="nump">$ 113,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding (in years)</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Options vested and exercisable (in years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockBasedCompensationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockBasedCompensationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979679015328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock-based compensation expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockCompensationInContinuingOperations', window );">Stock compensation in continuing operations</a></td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="nump">$ 372,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockCompensationInDiscontinuedOperations', window );">Stock compensation in discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expenses</a></td>
<td class="nump">79,000<span></span>
</td>
<td class="nump">660,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockCompensationInContinuingOperations', window );">Stock compensation in continuing operations</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">151,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockCompensationInContinuingOperations', window );">Stock compensation in continuing operations</a></td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="nump">$ 221,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockBasedCompensationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockBasedCompensationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockCompensationInContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for Stock compensation in continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockCompensationInContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockCompensationInDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for Stock compensation in discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockCompensationInDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979679745504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of equity incentive awards issued (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total stock-based compensation cost related to unvested awards not yet recognized | $</a></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period of recognition of unrecognized compensation costs (in years)</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979672688096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GRANT INCOME (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantIncomeLineItems', window );"><strong>GRANT INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,244,061<span></span>
</td>
<td class="nump">$ 1,234,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantIncomeLineItems', window );"><strong>GRANT INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantIncomeLineItems', window );"><strong>GRANT INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,244,061<span></span>
</td>
<td class="nump">1,234,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_CpritGrantMember', window );">CPRIT grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantIncomeLineItems', window );"><strong>GRANT INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ReceiptOfProductDevelopmentResearchAward', window );">Receipt of product development research award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_FdaGrantMember', window );">FDA grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantIncomeLineItems', window );"><strong>GRANT INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_FdaGrantMember', window );">FDA grant | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantIncomeLineItems', window );"><strong>GRANT INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember', window );">SBIR grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantIncomeLineItems', window );"><strong>GRANT INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember', window );">SBIR grant | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantIncomeLineItems', window );"><strong>GRANT INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FundsReceivedFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds received from grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FundsReceivedFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represents grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ReceiptOfProductDevelopmentResearchAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receipt of product development research award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ReceiptOfProductDevelopmentResearchAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_CpritGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_CpritGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_FdaGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_FdaGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979673216400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total Research and development</a></td>
<td class="nump">$ 1,186,000<span></span>
</td>
<td class="nump">$ 215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party payable</a></td>
<td class="nump">353,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,329,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember', window );">Baylor College of Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_CellReadyMember', window );">Cell Ready</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total Research and development</a></td>
<td class="nump">1,186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_WilsonWolfManufacturingCorporationMember', window );">Wilson Wolf Manufacturing Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrkr_CellReadyMember', window );">Cell Ready | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party payable</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_CellReadyAgreementMember', window );">Cell Ready Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Service and manufacturing costs</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_InvoicesReceivedForServicesAndManufacturingCosts', window );">Paid invoices</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_InvoicesReceivedForServicesAndManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Invoices for the cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_InvoicesReceivedForServicesAndManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_CellReadyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_CellReadyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_WilsonWolfManufacturingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_WilsonWolfManufacturingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrkr_CellReadyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrkr_CellReadyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_CellReadyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_CellReadyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139979677977392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 619,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">8,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">$ 40,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrkr_ControlledEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrkr_ControlledEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &> KU@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !G@*]8W Q[*.\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O31;%4*7%\6G"8(#Q;>0W+9@TX3DI-VWMZU;A^@'\#%W__SN
M=W"-B=*$A,\I1$SD,-\,ONVR-''#CD11 F1S1*]S.2:ZL;D/R6L:G^D 49L/
M?4 0G-^"1])6DX8)6,2%R%1CC30)-85TQENSX.-G:F>8-8 M>NPH0U56P-0T
M,9Z&MH$K8((1)I^_"V@7XES]$SMW@)V30W9+JN_[LE_-N7&'"MZ>MB_SNH7K
M,NG.X/@K.TFGB!MVF?RZNG_8/3(EN%@7O"ZJ>B>XY$+6=^^3ZP^_J[ /UNW=
M/S:^"*H&?MV%^@)02P,$%     @ 9X"O6)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MFYO5ZG&#+M:8029B$"3$R27Z@CXA$_%8CG+/%')VY6&&U4S7Y4SVB9F^8S9
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M3!7(ZUM*Q6M''6WUFXS_#U!+ P04    " !G@*]8LS*M<# %  "8&   &
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M-99Y8G+S^#"]?9C=3H$\FSW^N)M>O<B+V8L\W-\^O,S XS?P^'3[?/5R)P/
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M=WU2RDUIVO%YT[JPXYO9@^R HU.C'A+XK47.EJB")7N5_\)G')]18SREVQE
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M/DN*+5H6H/.5H0BT"S;0O3JG_P!02P,$%     @ 9X"O6-@FC 0G#   :R(
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ME!;\X.ON&T\%I1\F0_<H RLR:*!>"O\U:.$4%!D:!)PV3 B9PJR*X?V4+.$
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M,E]2W.B\#;).5:?FOF9CN$0]4>SFL37,\1XG[ED(U&[D.NGDBP%S'[)O&8
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M(";#YDNP%?^<8&I#L"5_7"#%*4<;\'QF;6B^T 7M[TO._@M02P,$%     @
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M<D@[Y85JR56"T+7(?]GO2,+^A/GG)X<P?X_.1R0RB7O<3[Q)Q[V>]?/[!K1
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M\Z<]X>)GH'@1[)H_O<QL"';%/Y<@[LK1 CR?6W#%=$$*\K>XT_\"4$L#!!0
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M:_RG 88,<'ZI,<*Z0PLT_UWF_P%02P,$%     @ 9X"O6#5^X1SJ @  T <
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MPBGOL&C]'-F62Z\R44GKE\);63H9LTA]0SEPRF%+:BQ<313"@YV?6Z5$$:-
M410(^#"=-TX4LLSHX: +8E<ISL=\V1,_/3L:#@Z._[7_=S6B.T;4CLM'6]<(
M5RN,E%"*"[G,P0GYGJN9$F8J1BK3*2S=;'[.3\GPN+62)-W!8""HT(A;E,GE
M(Z%)-SEZS9N>TH"X?=&Y@[&_F!Q"91FFL'ZPY*I+8RMC)?MB%_7V^G!PR-+N
MC)>$R2G6FMR1*;C 5*BROJU" _"Y&":O-J ^'_0.48CRG!# )CM#Q0EIE=!E
MF@>RO*8*G)I0(L@JN>2((P18M '?<RTG.M=>([:D8VMO1$]/C.',S\8K<<0Q
M)[-,DQRHI,O8G?#6$^<S>)T4<BBEB&4*]3VN?$&*#0?'%Y<C?DJ.?Q8?2@AZ
M4,5$6<A.CKKB(YR GD5(!@S[G9K89J7+X79IBDJ62\2^5S9J/*Y@!T,OC=6W
MX4%N5RSF&I\J:QYT.Z524V8A]=',-?WJVTK:9"E2" !#+7/R@[((G5+E0GI1
M*Y7\<NP0D(2+Z3DV28OWJJ0T4596R$.H/5:5;_3^M0L?M'3^&')^2W;IZXVX
M1"72*7PR#E6%[=^K+M8%R.LU>FR+*-!CM?"A(+]#TYDJ!540/=4IT9"5'"MP
MG7JSAK_#+1*99>\A-E7B/2+6KV'^$$I95F8!X:EQGD,8&_]"G>.R2I_7B=P5
M7X-$N"_)R=ZB[WOE/&4X6?H!G[*8Y#;4HPNG!NMX'F88#/9&'I#)M2_N+&+C
MW]%1EP^$<R:]L2_!'E%'V=^$I_,A8YQW+:(Y$EJBHNT$.-9(ZW^&;Y4;Z8J'
M)R7=H_P@<VJ(YP)%/B%[ZS*0J3':QE(*O,36+%"UW!QUB[W78M-D46H*M#BH
M:=+[GK@)T%E2.YQ:4VR4;?@I]KHVF.!1XOZ&(NV=*\15PXQ04HJF"/N (HHJ
MK5.L0TU*\?<O;]4WLO$((])',R]7[%C/(N;O#OP3(VU&'S.-#@XGNI6%:)3A
M^'.1\.J:MGU7)WIDB'7SZXI/GRXW@@&BTF M_)RO#,+LMDC(*AJ9T_AW(WUP
MB.#R0MCK_&_WLO_$-%N(>^*Z;+6%86Q;"&&U'?8CZ:@2CXDKN74=^*3T3:U.
M74!?D,2Z1XW&YTV/XAQ90^AMP(EI ^2(:,A%CS EMST3[)9Z'.YSDV?H&]UM
MLW6CW;A$R4T3,_&F3W TE*7^.]:M%Y=O1]<_]\1OF+MB? ,]^'EFB11,=<6E
MHS4H+3!64 .C;@ZQ"ZH_#])JA3()\&YE,#)3 -HX7)!HNV.HZ3X!$PV HL?$
M<D 6V:HA',XN4%^HJQ]#WRSUR[55MERQ3F@J6ZZ>DT@/$US3K:+Q&XTH:SQ.
MNRR1_B=U.8^(L4JG6T$CMW6/G?\AAG3##V7:Y \J+L9 BNV(9'?;8#6-\E^#
MIOB$E'JS"['L<B3"8-"51ZP2'9.%U_KQ]YH^=GF<(NI#!,AHEP1#&)?FO;4*
M+]SCT-@$!2S!(69+H%G/-"S;A2GZOJ8@Y":*%UE/G+ IG5 0,H1TK<^&<<AQ
MJJCBW#I9KA&L>A[5G2V9,H.2(* )%\%2]VGI7("OI@'(Z4P##)JGV&53OQH^
M[18"BVR:$N)[XEV V93=YYZF*[=B,>)S3CO/3 E8:IK>1GY@FS]JC>!G)E[2
M0,1)@C#C%P@O%0SEJ)!9-0LY=?LE>1+BD2!=FBV?*J'UZ; GWL94^ZYSX9X9
MAL8T<<W@GR4B;,9+U4K26/!:=I-44_>;[/WH1F0VS)HX)OL VCV$C.Y>'@X2
MLDO?\-OK01)GFE:*\<F&^68JQUG6<I)--1U)-AB3>7>,>YN#$@])Y&]\W"R-
M+44P_,*U>5/$6HB(>UG?=U$H*5+T1[P!):E79^)YTALVQS[MVO< ,8_J2MF
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M'Y*<05.RU[1*CA)>,CV&23R")$K2(WR3(<>)YYO\3XX]1?HVA;/&S+0LQT5
MM6]0/V&0??H0GT:?CPA,!X'I,?9_$WB<XNK[[1KB= 9_<<&%A&6KN?#/.0);
M(YRKIF7R!8P2!4Q'\=D43,TH,5 E<&L@5TU#GJ'RRQ^AH_^J/6YY>PG+2B.2
M+2UYTE#M<UD!ER"I@;1:Y8B%9_D8C:.4*E8(,M\(6&F)@^JCRSV"#$\,[AIN
MG,'-^*UW# \*NT%=>?LZ=9VT?8T/NT.'6/;&^!W>MQ<JJHI+ P)+@D;CLY,
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MM\5']Y]NOQZKW4#\!DYAA;$AW3%$PQO9? R)SLJH #'C Y3,MU2YELRWU<]
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M<K0 [^<6G#9](07YM]N+_P-02P,$%     @ 9X"O6#_XP:)Y P  @@H  !D
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M"-((X/U&(,-F8PRT8^?R!U!+ P04    " !G@*]8K&[/AR4#   U"   &0
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M<84#W&P3?#%!: ">QYRK2M $]1O<_PM02P,$%     @ 9X"O6-4CBGK6 P
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M)(8E*U/](#9_P,X>2S 2J;)/LJGN=O!R5"HMLITP,LAX7KW9=N>'AD#?^XD
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M _44+Z0)+_ZC;5EV,#!0N.&"IE6P;$$:9^4G?JU>Q%Y QSX0X%0!SH< YU!
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M\NC=N^;RVI(PJ8WR2C5L::SM2575_A*^9WV4":CY"4KS0&D^*"V HC5ELG-
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M/*^>GC0=/.3%E\WJ3/\/4$L#!!0    ( &> KU@?,Z+7<@(  &L&   9
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MSDT$?N3-=-8L)-OH >>%21B7].,:)EK*E0!\7S(F]PNU03<CI_\#4$L#!!0
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M?W>I7)HGA-5+*KFX0F7S"B<(<TX$[W-Y_'X@.;.JG^Z(L] &'^H@)"R$A$5
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M3OKH Z_2PZH@6:DSK$<F,5_3KTM,J8&K!OA]SIC<%50'=9(>_0-02P,$%
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MEF1]U6XHDRB%M7;%YUV]-**L<J6A>&XKRXHK7:=L,]%_!B#, /U]S;G:&R9
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M*2#>[PGAEX6\QY??;=YW4$L#!!0    ( &> KUB.$$0"> ,  '(1   9
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MMDP3CB9YA":W5VBRH #BV>+HR ..DY0="\7=S$-'+X]')A>CDFPS+$=P7HS
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MIQUU''C,;WTP%P[!RK('*@N,C\!:+5UVS=4N[,#C#ZC:L;89+4L?J*Y]GJG
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MYB%A' D32)@$P32G?:B=]N&D3O(#TFE(&$/"/"2,(V$""9,@F.8T9] D9P/
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MOR>!HYNHE(W(X\7;'Y4R-V\"]SQ[=W;6>;R\V;=?U, E";VD_2-(KSH=G!A
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( &> KUC<#'LH[P   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( &>
MKUB97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ 9X"O6/K!MFS:!0  _1X  !@
M ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( &>
MKUC*-WM0#04  .L2   8              " @1X.  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " !G@*]8WLO] Y\"  #5"   &
M        @(%A$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ 9X"O6+,RK7 P!0  F!@  !@              ("!-A8  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( &> KUBQ8.X^E@4  &0=   8
M              " @9P;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " !G@*]8\+C1\Q<&  !.&P  &               @(%H(0  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 9X"O6-.BIKFH"P
MR!X  !@              ("!M2<  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( &> KUCNFTMH7@0  ($*   8              " @9,S
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !G@*]8V":,
M!"<,  !K(@  &               @($G.   >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ 9X"O6&2)%2B&"@  EQL  !D
M ("!A$0  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !G
M@*]8.&UWS74$  #'#   &0              @(%!3P  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( &> KU@U?N$<Z@(  - '   9
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M970Q-BYX;6Q02P$"% ,4    " !G@*]8.Z3&YZD$  "N#0  &0
M    @($F:P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M &> KUCG7V/H[0(  *(&   9              " @09P  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ 9X"O6'>WMW\%"   I14  !D
M             ("!*G,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " !G@*]8ZD N0%\"  !#!0  &0              @(%F>P  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( &> KUC_?TO*S0H
M ,<=   9              " @?Q]  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ 9X"O6#_XP:)Y P  @@H  !D              ("!
M (D  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !G@*]8
MK&[/AR4#   U"   &0              @(&PC   >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( &> KU@!!5WT]0(  (\'   9
M      " @0R0  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ 9X"O6-4CBGK6 P  Z0H  !D              ("!.),  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !G@*]8OT&M?ZX"  !5!@
M&0              @(%%EP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( &> KUAXTCU/* 4  -XI   9              " @2J:  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 9X"O6"!HN'Y8
M"P  "J$  !D              ("!B9\  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " !G@*]8'S.BUW("  !K!@  &0
M@($8JP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( &>
MKUC"-$LPN0,  "\/   9              " @<&M  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ 9X"O6*<X3UC6 @   PL  !D
M         ("!L;$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    " !G@*]8T;=W(R %  !9*P  &0              @(&^M   >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( &> KUBKY7\CRP0  . @
M   9              " @16Z  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ 9X"O6++SLE9O P  L \  !D              ("!%[\
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !G@*]8;/]#
MDM("  !W"   &0              @(&]P@  >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( &> KUBT!I"-L0,  ,,-   9
M  " @<;%  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
M9X"O6(X01 )X P  <A$  !D              ("!KLD  'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " !G@*]8RTM&_$4$  "W%P  &0
M            @(%=S0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( &> KU@[Y+SU;@0  -84   9              " @=G1  !X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 9X"O6!0+G^<R P
MO@P  !D              ("!?M8  'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " !G@*]8_P31S]H"  "1!@  &0              @('G
MV0  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( &> KUA:
MJ"I1S@8  "=-   9              " @?C<  !X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ 9X"O6"%X-KA0!   ^QH  !D
M     ("!_>,  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &> KUA''&"YI $  )L:   :
M          "  1OT  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( &> KU@NTOC K@$  ,H:   3              "  ??U  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     T #0 (PX  -;W      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>92</ContextCount>
  <ElementCount>182</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialCondition</Role>
      <ShortName>LIQUIDITY AND FINANCIAL CONDITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - OTHER RECEIVABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureOtherReceivable</Role>
      <ShortName>OTHER RECEIVABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - DISCONTINUED OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureDiscontinuedOperations</Role>
      <ShortName>DISCONTINUED OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable</Role>
      <ShortName>ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - GRANT INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureGrantIncome</Role>
      <ShortName>GRANT INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - LEGAL PROCEEDINGS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureLegalProceedings</Role>
      <ShortName>LEGAL PROCEEDINGS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - RELATED PARTY EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureRelatedPartyExpenses</Role>
      <ShortName>RELATED PARTY EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>20402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30503 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30703 - Disclosure - DISCONTINUED OPERATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsTables</Role>
      <ShortName>DISCONTINUED OPERATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureDiscontinuedOperations</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30803 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables</Role>
      <ShortName>ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>31003 - Disclosure - STOCK BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>STOCK BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>31303 - Disclosure - RELATED PARTY EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesTables</Role>
      <ShortName>RELATED PARTY EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureRelatedPartyExpenses</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40101 - Disclosure - NATURE OF OPERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails</Role>
      <ShortName>NATURE OF OPERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureNatureOfOperations</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40301 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails</Role>
      <ShortName>LIQUIDITY AND FINANCIAL CONDITION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialCondition</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40501 - Disclosure - NET LOSS PER SHARE - Computation of loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Computation of loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40502 - Disclosure - NET LOSS PER SHARE - Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails</Role>
      <ShortName>NET LOSS PER SHARE - Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40601 - Disclosure - OTHER RECEIVABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureOtherReceivableDetails</Role>
      <ShortName>OTHER RECEIVABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureOtherReceivable</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40701 - Disclosure - DISCONTINUED OPERATIONS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails</Role>
      <ShortName>DISCONTINUED OPERATIONS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40702 - Disclosure - DISCONTINUED OPERATIONS - Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails</Role>
      <ShortName>DISCONTINUED OPERATIONS - Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40703 - Disclosure - DISCONTINUED OPERATIONS - Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails</Role>
      <ShortName>DISCONTINUED OPERATIONS - Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40801 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails</Role>
      <ShortName>ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40901 - Disclosure - STOCKHOLDERS' EQUITY - Reverse Stock Split And ATM Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Reverse Stock Split And ATM Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40902 - Disclosure - STOCKHOLDERS' EQUITY - Stock Purchase Agreement And Exercise of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Stock Purchase Agreement And Exercise of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>41001 - Disclosure - STOCK-BASED COMPENSATION - Stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>41002 - Disclosure - STOCK-BASED COMPENSATION - Stock-based compensation expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock-based compensation expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>41003 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>41101 - Disclosure - GRANT INCOME (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureGrantIncomeDetails</Role>
      <ShortName>GRANT INCOME (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureGrantIncome</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>41301 - Disclosure - RELATED PARTY EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails</Role>
      <ShortName>RELATED PARTY EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mrkr-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>41401 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityIncorporationStateCountryCode, us-gaap:CommonStockSharesIssued, us-gaap:PreferredStockSharesOutstanding -  mrkr-20240331x10q.htm 9</Log>
  </Logs>
  <InputFiles>
    <File>mrkr-20240331.xsd</File>
    <File>mrkr-20240331_cal.xml</File>
    <File>mrkr-20240331_def.xml</File>
    <File>mrkr-20240331_lab.xml</File>
    <File>mrkr-20240331_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="mrkr-20240331x10q.htm">mrkr-20240331x10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mrkr-20240331x10q001.jpg</File>
    <File>mrkr-20240331x10q002.jpg</File>
    <File>mrkr-20240331x10q003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="297">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mrkr-20240331x10q.htm": {
   "nsprefix": "mrkr",
   "nsuri": "http://www.tapimmune.com/20240331",
   "dts": {
    "schema": {
     "local": [
      "mrkr-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "mrkr-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrkr-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mrkr-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrkr-20240331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "mrkr-20240331x10q.htm"
     ]
    }
   },
   "keyStandard": 156,
   "keyCustom": 26,
   "axisStandard": 13,
   "axisCustom": 0,
   "memberStandard": 13,
   "memberCustom": 15,
   "hidden": {
    "total": 13,
    "http://xbrl.sec.gov/dei/2023": 6,
    "http://fasb.org/us-gaap/2023": 7
   },
   "contextCount": 92,
   "entityCount": 1,
   "segmentCount": 31,
   "elementCount": 300,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 297,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "report": {
    "R1": {
     "role": "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj8-kTaoPUeqeGIfHnTabg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj8-kTaoPUeqeGIfHnTabg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.tapimmune.com/role/DisclosureNatureOfOperations",
     "longName": "10101 - Disclosure - NATURE OF OPERATIONS",
     "shortName": "NATURE OF OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.tapimmune.com/role/DisclosureBasisOfPresentation",
     "longName": "10201 - Disclosure - BASIS OF PRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialCondition",
     "longName": "10301 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION",
     "shortName": "LIQUIDITY AND FINANCIAL CONDITION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies",
     "longName": "10401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShare",
     "longName": "10501 - Disclosure - NET LOSS PER SHARE",
     "shortName": "NET LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.tapimmune.com/role/DisclosureOtherReceivable",
     "longName": "10601 - Disclosure - OTHER RECEIVABLE",
     "shortName": "OTHER RECEIVABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.tapimmune.com/role/DisclosureDiscontinuedOperations",
     "longName": "10701 - Disclosure - DISCONTINUED OPERATIONS",
     "shortName": "DISCONTINUED OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable",
     "longName": "10801 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE",
     "shortName": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquity",
     "longName": "10901 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.tapimmune.com/role/DisclosureStockBasedCompensation",
     "longName": "11001 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.tapimmune.com/role/DisclosureGrantIncome",
     "longName": "11101 - Disclosure - GRANT INCOME",
     "shortName": "GRANT INCOME",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.tapimmune.com/role/DisclosureLegalProceedings",
     "longName": "11201 - Disclosure - LEGAL PROCEEDINGS",
     "shortName": "LEGAL PROCEEDINGS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyExpenses",
     "longName": "11301 - Disclosure - RELATED PARTY EXPENSES",
     "shortName": "RELATED PARTY EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.tapimmune.com/role/DisclosureSubsequentEvents",
     "longName": "11401 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "20402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareTables",
     "longName": "30503 - Disclosure - NET LOSS PER SHARE (Tables)",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsTables",
     "longName": "30703 - Disclosure - DISCONTINUED OPERATIONS (Tables)",
     "shortName": "DISCONTINUED OPERATIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables",
     "longName": "30803 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)",
     "shortName": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables",
     "longName": "31003 - Disclosure - STOCK BASED COMPENSATION (Tables)",
     "shortName": "STOCK BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesTables",
     "longName": "31303 - Disclosure - RELATED PARTY EXPENSES (Tables)",
     "shortName": "RELATED PARTY EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
     "longName": "40101 - Disclosure - NATURE OF OPERATIONS (Details)",
     "shortName": "NATURE OF OPERATIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_26_2023_To_1_26_2023_awyJo1ParUe6ER8qP8Er1Q",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_26_2023_To_1_26_2023_awyJo1ParUe6ER8qP8Er1Q",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
     "longName": "40301 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION (Details)",
     "shortName": "LIQUIDITY AND FINANCIAL CONDITION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_31_2021_To_8_31_2021_wLINgxwAtEqXJr9cCHPb-A",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "longName": "40401 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ",
      "name": "mrkr:CashAtFinancialInstitutions",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ",
      "name": "mrkr:CashAtFinancialInstitutions",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails",
     "longName": "40501 - Disclosure - NET LOSS PER SHARE - Computation of loss per Share (Details)",
     "shortName": "NET LOSS PER SHARE - Computation of loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails",
     "longName": "40502 - Disclosure - NET LOSS PER SHARE - Dilutive Securities (Details)",
     "shortName": "NET LOSS PER SHARE - Dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:NetLossPerShareTableTextBlock",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:NetLossPerShareTableTextBlock",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
     "longName": "40601 - Disclosure - OTHER RECEIVABLE (Details)",
     "shortName": "OTHER RECEIVABLE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_9_n_o50vykCM5Ly004kRVQ",
      "name": "mrkr:RevenueFromOrphanProductsGrantProgram",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
     "longName": "40701 - Disclosure - DISCONTINUED OPERATIONS - Additional Information (Details)",
     "shortName": "DISCONTINUED OPERATIONS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_K0gVoKOl8EymtFxIsG-9UQ",
      "name": "us-gaap:OtherOperatingIncome",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails",
     "longName": "40702 - Disclosure - DISCONTINUED OPERATIONS - Operations (Details)",
     "shortName": "DISCONTINUED OPERATIONS - Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_0E4EMJOdr0W3g33PvIH_sQ",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_0E4EMJOdr0W3g33PvIH_sQ",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails",
     "longName": "40703 - Disclosure - DISCONTINUED OPERATIONS - Cash Flows (Details)",
     "shortName": "DISCONTINUED OPERATIONS - Cash Flows (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w",
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w",
      "name": "us-gaap:NetCashProvidedByUsedInDiscontinuedOperations",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
     "longName": "40801 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Details)",
     "shortName": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails",
     "longName": "40901 - Disclosure - STOCKHOLDERS' EQUITY - Reverse Stock Split And ATM Agreement (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Reverse Stock Split And ATM Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_N9zarOSsVEuBpoYtfzkupQ",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails",
     "longName": "40902 - Disclosure - STOCKHOLDERS' EQUITY - Stock Purchase Agreement And Exercise of Stock Options (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Stock Purchase Agreement And Exercise of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_12_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_qmoIEv97Rk2jUyIAWQnjTA",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
     "longName": "41001 - Disclosure - STOCK-BASED COMPENSATION - Stock option activity (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Stock option activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_X9phuL_RxUqyj7QCXMC4zg",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails",
     "longName": "41002 - Disclosure - STOCK-BASED COMPENSATION - Stock-based compensation expenses (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Stock-based compensation expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "mrkr:StockCompensationInContinuingOperations",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:StockBasedCompensationExpensesTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "mrkr:StockCompensationInContinuingOperations",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:StockBasedCompensationExpensesTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
     "longName": "41003 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
      "unitRef": "Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
      "unitRef": "Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
     "longName": "41101 - Disclosure - GRANT INCOME (Details)",
     "shortName": "GRANT INCOME (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_1_2021_To_8_31_2021_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_up4ngz1fg02kE_1r6itooQ",
      "name": "mrkr:ReceiptOfProductDevelopmentResearchAward",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails",
     "longName": "41301 - Disclosure - RELATED PARTY EXPENSES (Details)",
     "shortName": "RELATED PARTY EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:OperatingCostsAndExpenses",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w",
      "name": "us-gaap:OperatingCostsAndExpenses",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails",
     "longName": "41401 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2024_To_4_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_dqKTucMUbUGZUuzFK_dOyg",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20240331x10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities Including Related party payable, Current",
        "totalLabel": "Total accounts payable, accrued liabilities and related party payable"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_AccountsPayableAndAccruedLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "AccountsPayableAndAccruedLiabilitiesLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts Payable And Accrued Liabilities [Line Items]",
        "verboseLabel": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_AccountsPayableAndAccruedLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "AccountsPayableAndAccruedLiabilitiesTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This table lists the accounts payable and accrued liabilities. The line items identify information about the accounts payable and accrued liabilities.",
        "label": "Accounts Payable And Accrued Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails": {
       "parentTag": "mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r442"
     ]
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails": {
       "parentTag": "mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for Taxes Other than Income Taxes, Current",
        "terseLabel": "Property taxes",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r38",
      "r427"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails": {
       "parentTag": "mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r442",
      "r506"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid- in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r353",
      "r472",
      "r473",
      "r474",
      "r487",
      "r507"
     ]
    },
    "mrkr_AdditionalRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "AdditionalRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional revenue recognized.",
        "label": "Additional Revenue Recognized",
        "terseLabel": "Additional revenue recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Reconciliation of net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Share-based Compensation Expense",
        "verboseLabel": "Total stock compensation expenses",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r259"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "NET LOSS PER SHARE",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r125",
      "r143",
      "r173",
      "r179",
      "r183",
      "r188",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r267",
      "r271",
      "r283",
      "r321",
      "r377",
      "r442",
      "r455",
      "r481",
      "r482",
      "r490"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r131",
      "r143",
      "r188",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r267",
      "r271",
      "r283",
      "r442",
      "r481",
      "r482",
      "r490"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_AtmAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "AtmAgreementMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member stands for  ATM agreement.",
        "label": "ATM Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccounting": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccounting",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting [Text Block]",
        "verboseLabel": "BASIS OF PRESENTATION",
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "mrkr_BasisOfPresentationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "BasisOfPresentationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "BASIS OF PRESENTATION"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_BindingServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "BindingServicesAgreementMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for binding services agreement.",
        "label": "Binding Services Agreement [Member]",
        "terseLabel": "Binding Services Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_CancerPreventionAndResearchInstituteOfTexasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "CancerPreventionAndResearchInstituteOfTexasMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The information pertaining to cancer Prevention And Research Institute Of Texas.",
        "label": "Cancer Prevention And Research Institute Of Texas [Member]",
        "terseLabel": "Cancer Prevention And Research Institute Of Texas"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Cantor Fitzgerald &amp; Co and RBC Capital Markets, LLC.",
        "label": "Cantor Fitzgerald Co. And Rbc Capital Markets Llc [Member]",
        "terseLabel": "Sales Agents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Project [Axis]",
        "documentation": "Information by project."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r124",
      "r425"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash, Cash Equivalents and Credit Risk",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "mrkr_CashAtFinancialInstitutions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "CashAtFinancialInstitutions",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash held at financial institutions.",
        "label": "Cash at Financial Institutions",
        "terseLabel": "Cash at financial institutions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r85",
      "r140"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r85"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of non-cash financing and investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Net cash used in investing activities - discontinued operations",
        "verboseLabel": "Net cash provided used in investing activities",
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r85"
     ]
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Net cash used in operating activities - discontinued operations",
        "verboseLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r85"
     ]
    },
    "mrkr_CellReadyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "CellReadyAgreementMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Cell Ready Agreement.",
        "label": "Cell Ready Agreement [Member]",
        "terseLabel": "Cell Ready Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_CellReadyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "CellReadyMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Cell Ready.",
        "label": "Cell Ready [Member]",
        "terseLabel": "Cell Ready"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r172",
      "r210",
      "r211",
      "r212",
      "r214",
      "r217",
      "r222",
      "r224",
      "r344",
      "r345",
      "r346",
      "r347",
      "r436",
      "r462",
      "r470"
     ]
    },
    "mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Clinical Trial Agreement with Baylor College of Medicine.",
        "label": "Clinical Trial Agreement with Baylor College of Medicine [Member]",
        "terseLabel": "Baylor College of Medicine"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_CommitmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "CommitmentFee",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of commitment fees.",
        "label": "Commitment Fee",
        "terseLabel": "Commitment fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r472",
      "r473",
      "r487",
      "r505",
      "r507"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock par value (in $ per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r364"
     ]
    },
    "mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percent of calculation of compensation rate by using gross sales price per share sold.",
        "label": "Common Stock, Shares, Commission Rate Calculation on Gross Sales Price per Share, Percent",
        "terseLabel": "Commission rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r70",
      "r364",
      "r383",
      "r507",
      "r508"
     ]
    },
    "us-gaap_CommonStockSharesSubscriptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesSubscriptions",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Subscriptions",
        "terseLabel": "Aggregate offering price",
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r70"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value, 30 million shares authorized, 8.9 million shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively (see Note 9)",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r323",
      "r442"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r431"
     ]
    },
    "mrkr_ControlledEquityOfferingSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "ControlledEquityOfferingSalesAgreementMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to controlled equity offering sales agreement.",
        "label": "Controlled Equity Offering Sales Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Service and manufacturing costs",
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r208",
      "r212",
      "r299",
      "r428",
      "r430"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_CpritGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "CpritGrantMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid for CPRIT grant.",
        "label": "CPRIT Grant [Member]",
        "terseLabel": "CPRIT grant"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r252",
      "r253",
      "r255",
      "r439"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureTextBlockSupplementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LEGAL PROCEEDINGS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax",
        "terseLabel": "Gain on disposal of discontinued operations, Net of tax",
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r55",
      "r57",
      "r66"
     ]
    },
    "mrkr_DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation [Abstract]",
        "terseLabel": "Discontinued operations:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax",
        "totalLabel": "Loss from discontinued operations",
        "verboseLabel": "Loss from discontinued operations, net of tax",
        "documentation": "Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r66"
     ]
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation",
        "terseLabel": "Tax on gain on disposal of discontinued operations",
        "documentation": "Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r57",
      "r66",
      "r486"
     ]
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "DISCONTINUED OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails",
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Disposed by sale",
        "verboseLabel": "Discontinued Operations, Disposed of by Sale",
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations, Policy [Policy Text Block]",
        "terseLabel": "Discontinued Operations",
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r13"
     ]
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails",
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails",
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Consideration for purchased assets",
        "verboseLabel": "Consideration for purchased assets",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "terseLabel": "Total operating expenses",
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Total revenues",
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r121"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "DISCONTINUED OPERATIONS",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r90"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net earnings (loss) per share:",
        "verboseLabel": "Net loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "verboseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r161",
      "r163",
      "r166",
      "r167",
      "r168",
      "r170",
      "r281",
      "r282",
      "r319",
      "r330",
      "r432"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "verboseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r163",
      "r166",
      "r167",
      "r168",
      "r170",
      "r281",
      "r282",
      "r319",
      "r330",
      "r432"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails": {
       "parentTag": "mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total stock-based compensation cost related to unvested awards not yet recognized",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected weighted average period of recognition of unrecognized compensation costs (in years)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Common stock options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r119",
      "r134",
      "r135",
      "r136",
      "r148",
      "r149",
      "r150",
      "r152",
      "r158",
      "r160",
      "r171",
      "r189",
      "r190",
      "r225",
      "r256",
      "r257",
      "r258",
      "r262",
      "r263",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r292",
      "r338",
      "r339",
      "r340",
      "r353",
      "r407"
     ]
    },
    "mrkr_FdaGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "FdaGrantMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid for FDA grant.",
        "label": "FDA Grant [Member]",
        "terseLabel": "FDA grant"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "FinancialConditionGoingConcernAndManagementPlansLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS [Line Items]",
        "terseLabel": "LIQUIDITY AND FINANCIAL CONDITION"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_FinancialConditionGoingConcernAndManagementPlansTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "FinancialConditionGoingConcernAndManagementPlansTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Financial Condition Going Concern And Management Plans [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_FundsReceivedFromCpritGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "FundsReceivedFromCpritGrant",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funds received from grant.",
        "label": "Funds Received From CPRIT Grant",
        "terseLabel": "Funds received from CPRIT grant"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_FundsReceivedFromGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "FundsReceivedFromGrant",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funds received from grant",
        "label": "Funds Received From Grant",
        "terseLabel": "Funds received from grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r387"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative [Member]",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "mrkr_GrantIncomeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "GrantIncomeLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represents grant income.",
        "label": "Grant Income [Line Items]",
        "terseLabel": "GRANT INCOME"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_GrantIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "GrantIncomeTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This table lists the grant income.",
        "label": "Grant Income [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrantMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant [Member]",
        "terseLabel": "Grant income",
        "documentation": "Award of money not required to be repaid."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "mrkr_GrantReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "GrantReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of grant income transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Grant Received",
        "terseLabel": "Grant income received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrantsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants Receivable",
        "terseLabel": "Grant receivable",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Loss from continuing operations",
        "totalLabel": "Loss from continuing operations",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r82",
      "r87",
      "r153",
      "r154",
      "r155",
      "r156",
      "r165",
      "r168"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from continuing operations before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r77",
      "r109",
      "r173",
      "r178",
      "r182",
      "r184",
      "r320",
      "r326",
      "r434"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureCondensedConsolidatedStatementsOfCashFlowsCalc2": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss from continuing operations",
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r143",
      "r151",
      "r173",
      "r178",
      "r182",
      "r184",
      "r188",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r282",
      "r283",
      "r326",
      "r434",
      "r481"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Loss from continuing operations, basic",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r108",
      "r110",
      "r137",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r163",
      "r166",
      "r167",
      "r282",
      "r319",
      "r503"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Loss from continuing operations, diluted",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r137",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r163",
      "r166",
      "r167",
      "r168",
      "r282",
      "r319",
      "r503"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.tapimmune.com/role/DisclosureCondensedConsolidatedStatementsOfCashFlowsCalc2": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Loss from discontinued operations",
        "totalLabel": "Loss from discontinued operations",
        "verboseLabel": "Less: loss from discontinued operations, net of tax",
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r66",
      "r121",
      "r264",
      "r327"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Loss from discontinued operations, basic",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r137",
      "r164",
      "r166",
      "r167",
      "r500",
      "r503"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Loss from discontinued operations, diluted",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r164",
      "r166",
      "r167"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails",
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "DISCONTINUED OPERATIONS",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails",
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r11",
      "r12",
      "r52",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r65",
      "r67",
      "r68",
      "r91"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r392"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r392"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedLabel": "Other receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDueFromRelatedPartiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Due from Related Parties, Current",
        "negatedLabel": "Related party receivable",
        "documentation": "The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Due to Related Parties, Current",
        "terseLabel": "Related party payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and deposits",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r176"
     ]
    },
    "mrkr_InvoicesReceivedForServicesAndManufacturingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "InvoicesReceivedForServicesAndManufacturingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invoices for the cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Invoices Received for Services and Manufacturing Costs",
        "terseLabel": "Paid invoices"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of common stock issued as commitment fee for future financing.",
        "label": "Issuance Of Common Stock, Shares, As Commitment Fee For Future Financing",
        "verboseLabel": "Issuance of common stock as commitment fee for future financing (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents value of common stock as commitment fee for future financing.",
        "label": "Issuance Of Common Stock , Value, As Commitment Fee For Future Financing",
        "verboseLabel": "Issuance of common stock as commitment fee for future financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLegalProceedings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "LEGAL PROCEEDINGS",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r143",
      "r188",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r268",
      "r271",
      "r272",
      "r283",
      "r363",
      "r433",
      "r455",
      "r481",
      "r490",
      "r491"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r107",
      "r325",
      "r442",
      "r471",
      "r477",
      "r488"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r123",
      "r143",
      "r188",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r268",
      "r271",
      "r272",
      "r283",
      "r442",
      "r481",
      "r490",
      "r491"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_LincolnParkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "LincolnParkMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The information pertaining to Lincoln Park.",
        "label": "Lincoln Park [Member]",
        "terseLabel": "Lincoln Park"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_LiquidityFinancialConditionAndGoingConcernAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "LiquidityFinancialConditionAndGoingConcernAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "LIQUIDITY AND FINANCIAL CONDITION"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "LiquidityFinancialConditionAndGoingConcernTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialCondition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity Financial Condition And Going Concern Text Block",
        "label": "Liquidity Financial Condition And Going Concern [Text Block]",
        "terseLabel": "LIQUIDITY AND FINANCIAL CONDITION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "OTHER RECEIVABLE",
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r239",
      "r305",
      "r337",
      "r355",
      "r356",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r422",
      "r423",
      "r435",
      "r436",
      "r438",
      "r444",
      "r483",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r239",
      "r305",
      "r337",
      "r355",
      "r356",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r422",
      "r423",
      "r435",
      "r436",
      "r438",
      "r444",
      "r483",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestDisclosureTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "NET LOSS PER SHARE",
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "NationalInstitutesOfHealthSmallBusinessInnovationResearchMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents information pertaining to National Institutes of Health Small Business Innovation Research.",
        "label": "National Institutes of Health Small Business Innovation Research [Member]",
        "verboseLabel": "SBIR grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "verboseLabel": "NATURE OF OPERATIONS",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r117"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Discontinued Operations",
        "totalLabel": "Net decrease in cash and cash equivalents from discontinued operations",
        "documentation": "Increase (decrease) in cash associated with the entity's discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash used in operating activities - continuing operations",
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r87",
      "r111",
      "r121",
      "r132",
      "r133",
      "r136",
      "r143",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r165",
      "r173",
      "r178",
      "r182",
      "r184",
      "r188",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r282",
      "r283",
      "r329",
      "r385",
      "r405",
      "r406",
      "r434",
      "r453",
      "r481"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToParentDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToParentDilutedAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent, Diluted [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_NetLossPerShareTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "NetLossPerShareTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of net loss per share.",
        "label": "Net Loss Per Share [Table Text Block]",
        "terseLabel": "Schedule of anti-dilutive securities"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of Issuance of common stock as commitment fee for future financing.",
        "label": "Non Cash Issuance Of Common Stock As Commitment Fee For Future Financing",
        "verboseLabel": "Issuance of common stock as commitment fee for future financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expenses):"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_OffersEmploymentToNumberOfEmployees": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "OffersEmploymentToNumberOfEmployees",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of employees extended for employment.",
        "label": "Offers Employment to Number of Employees",
        "terseLabel": "Number of former employees offered employment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Total Research and development",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r178",
      "r182",
      "r184",
      "r434"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r41",
      "r42",
      "r102"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Line Items]",
        "terseLabel": "NATURE OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about organization, consolidation and presentation of financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_OrphanProductsGrantProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "OrphanProductsGrantProgram",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable from Orphan Products Grant program.",
        "label": "Orphan Products Grant Program",
        "terseLabel": "Grant income receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails": {
       "parentTag": "mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails": {
       "parentTag": "mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to Related Parties, Current",
        "terseLabel": "Related party payable",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r442"
     ]
    },
    "us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liability, Current, Related Party, Type [Extensible Enumeration]",
        "documentation": "Indicates type of related party for liability classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_OtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Operating Income",
        "terseLabel": "Cash payment",
        "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables",
        "terseLabel": "Other receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r372"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_OtherTaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "OtherTaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails": {
       "parentTag": "mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of accounts payable, accrued liabilities and related payable of other taxes payable.",
        "label": "Other Taxes Payable, Current",
        "terseLabel": "Other taxes payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in $ per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r210"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r364"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r210"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r364",
      "r383",
      "r507",
      "r508"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r322",
      "r442"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and deposits",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r191",
      "r192",
      "r426"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails",
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Proceeds from stock options exercise",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r306",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r424",
      "r437",
      "r443",
      "r463",
      "r479",
      "r480",
      "r484",
      "r504"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r306",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r424",
      "r437",
      "r443",
      "r463",
      "r479",
      "r480",
      "r484",
      "r504"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureCondensedConsolidatedStatementsOfCashFlowsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r132",
      "r133",
      "r138",
      "r143",
      "r151",
      "r159",
      "r160",
      "r173",
      "r178",
      "r182",
      "r184",
      "r188",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r266",
      "r269",
      "r270",
      "r282",
      "r283",
      "r320",
      "r328",
      "r352",
      "r385",
      "r405",
      "r406",
      "r434",
      "r440",
      "r441",
      "r454",
      "r468",
      "r481"
     ]
    },
    "us-gaap_ProjectMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProjectMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Project [Domain]",
        "documentation": "Planned program of work."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r237",
      "r239",
      "r248",
      "r249",
      "r250",
      "r304",
      "r305",
      "r337",
      "r355",
      "r356",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r422",
      "r423",
      "r435",
      "r436",
      "r438",
      "r444",
      "r447",
      "r478",
      "r483",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r237",
      "r239",
      "r248",
      "r249",
      "r250",
      "r304",
      "r305",
      "r337",
      "r355",
      "r356",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r422",
      "r423",
      "r435",
      "r436",
      "r438",
      "r444",
      "r447",
      "r478",
      "r483",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "mrkr_ReceiptOfProductDevelopmentResearchAward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "ReceiptOfProductDevelopmentResearchAward",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receipt of product development research award",
        "label": "Receipt Of Product Development Research Award",
        "terseLabel": "Receipt of product development research award"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER RECEIVABLE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesWithImputedInterestLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesWithImputedInterestLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables with Imputed Interest [Line Items]",
        "terseLabel": "OTHER RECEIVABLE",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recently issued accounting standards not yet adopted.",
        "label": "Recently Issued Accounting Standards Not yet Adopted [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards Not Yet Adopted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r296",
      "r297",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r382",
      "r384",
      "r414"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r296",
      "r297",
      "r298",
      "r299",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r382",
      "r384",
      "r414"
     ]
    },
    "mrkr_RelatedPartyServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "RelatedPartyServiceMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for related party service.",
        "label": "Related Party Service [Member]",
        "terseLabel": "Related party service revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "RELATED PARTY EXPENSES",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r392"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r296",
      "r297",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r382",
      "r384",
      "r414",
      "r489"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "RELATED PARTY EXPENSES",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r297",
      "r300",
      "r349",
      "r350",
      "r351",
      "r390",
      "r391",
      "r392",
      "r411",
      "r413"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r208",
      "r212",
      "r299",
      "r429",
      "r430"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Amount of notice received",
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r260",
      "r498"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsOperationsDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash recorded",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r469",
      "r499",
      "r502"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r96",
      "r324",
      "r341",
      "r342",
      "r348",
      "r365",
      "r442"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r148",
      "r149",
      "r150",
      "r152",
      "r158",
      "r160",
      "r189",
      "r190",
      "r256",
      "r257",
      "r258",
      "r262",
      "r263",
      "r273",
      "r275",
      "r276",
      "r278",
      "r280",
      "r338",
      "r340",
      "r353",
      "r507"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "GRANT INCOME"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue recognized",
        "verboseLabel": "Total revenues",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r177",
      "r180",
      "r181",
      "r185",
      "r186",
      "r187",
      "r234",
      "r235",
      "r306"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "GRANT INCOME",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r236"
     ]
    },
    "mrkr_RevenueFromGrantRelatedToCprit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "RevenueFromGrantRelatedToCprit",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from grant related to CPRIT.",
        "label": "Revenue From Grant Related to CPRIT",
        "terseLabel": "Revenue from CPRIT"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_RevenueFromOrphanProductsGrantProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "RevenueFromOrphanProductsGrantProgram",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized for grant from Orphan Products Grant program.",
        "label": "Revenue From Orphan Products Grant Program",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails",
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of accounts payable, accrued liabilities and related party payable",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of income statement information and summary of cash flows for discontinued operations",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r11",
      "r12",
      "r52",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r65",
      "r67",
      "r68",
      "r91"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule of computation of net loss per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ScheduleOfReceivablesWithImputedInterestTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfReceivablesWithImputedInterestTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Receivables with Imputed Interest [Table]",
        "documentation": "Table for the detailed disclosure of receivables or notes with discounts or premiums resulting from the determination of present value in cash or noncash transactions, including description of the receivable, the effective interest rate, the face amount, amortization period and method."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45",
      "r46",
      "r291"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r388",
      "r389",
      "r392"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of related party transaction expenses",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of the company's stock option activity",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r36"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r94",
      "r95",
      "r96",
      "r126",
      "r127",
      "r128",
      "r172",
      "r210",
      "r211",
      "r212",
      "r214",
      "r217",
      "r222",
      "r224",
      "r344",
      "r345",
      "r346",
      "r347",
      "r436",
      "r462",
      "r470"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "terseLabel": "Severance and termination-related costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Number of Shares, Options vested and exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Options vested and exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Shares, Cancelled / Expired",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Total Intrinsic Value Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares Outstanding, Ending Balance",
        "periodStartLabel": "Number of Shares Outstanding, Beginning Balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price per Share, Outstanding, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price per Share, Outstanding, Beginning Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, grants in period, gross",
        "terseLabel": "Number of equity incentive awards issued (in shares)",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price per Share, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price per Share, Cancelled / Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Total Intrinsic Value, Options vested and exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Outstanding (in years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Options vested and exercisable (in years)",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Issued",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r141"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r20",
      "r119",
      "r134",
      "r135",
      "r136",
      "r148",
      "r149",
      "r150",
      "r152",
      "r158",
      "r160",
      "r171",
      "r189",
      "r190",
      "r225",
      "r256",
      "r257",
      "r258",
      "r262",
      "r263",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r292",
      "r338",
      "r339",
      "r340",
      "r353",
      "r407"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements",
        "verboseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r171",
      "r306",
      "r343",
      "r354",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r386",
      "r387",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r407",
      "r448"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r171",
      "r306",
      "r343",
      "r354",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r386",
      "r387",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r407",
      "r448"
     ]
    },
    "mrkr_StockBasedCompensationExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "StockBasedCompensationExpensesTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of stock based compensation expenses recorded.",
        "label": "Stock based Compensation Expenses [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expenses"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_StockBasedCompensationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "StockBasedCompensationLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent stock-based compensation.",
        "label": "Stock-Based Compensation [Line Items]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_StockBasedCompensationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "StockBasedCompensationTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This table lists the stock-based compensation.",
        "label": "Stock-Based Compensation [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_StockCompensationInContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "StockCompensationInContinuingOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for Stock compensation in continuing operations.",
        "label": "Stock Compensation In Continuing Operations",
        "terseLabel": "Stock compensation in continuing operations"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_StockCompensationInDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "StockCompensationInDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for Stock compensation in discontinued operations.",
        "label": "Stock Compensation In Discontinued Operations",
        "verboseLabel": "Stock compensation in discontinued operations"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares during the period as a result of a fractional shares adjustment due to reverse split.",
        "label": "Stock Issued During Period, Shares, Fractional Shares Adjustment Due to Reverse Split",
        "terseLabel": "Fractional shares adjustment due to reverse split"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails",
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock for cash (in shares)",
        "verboseLabel": "Number of shares issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r69",
      "r70",
      "r96",
      "r344",
      "r407",
      "r420"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Number of Shares, Exercised",
        "terseLabel": "Issuance of common stock from exercise of stock options (in shares)",
        "verboseLabel": "Issuance of common stock from exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r69",
      "r70",
      "r96",
      "r245"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for cash",
        "verboseLabel": "Aggregate proceeds from shares issued under the purchase agreement",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r69",
      "r70",
      "r96",
      "r353",
      "r407",
      "r420",
      "r454"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r69",
      "r70",
      "r96"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Issuance of common stock from exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r20",
      "r96"
     ]
    },
    "mrkr_StockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "StockPurchaseAgreementMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This Member represents stock purchase agreement",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_StockPurchaseAgreementTimeToTimeTermToPurchaseShares": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "StockPurchaseAgreementTimeToTimeTermToPurchaseShares",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The time to time term to purchase shares in stock purchase sgreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock Purchase Agreement, Time to Time Term to Purchase Shares",
        "terseLabel": "Time to time term to purchase shares (in months)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r73",
      "r74",
      "r89",
      "r366",
      "r383",
      "r408",
      "r409",
      "r442",
      "r455",
      "r471",
      "r477",
      "r488",
      "r507"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r142",
      "r209",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r225",
      "r279",
      "r410",
      "r412",
      "r421"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r302"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails",
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r302"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r302"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails",
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r302"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails",
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r302"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r303"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityReverseStockSplitAndAtmAgreementDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails",
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementAndExerciseOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursements",
        "terseLabel": "Reimbursements",
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureLiquidityAndFinancialConditionDetails",
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesSecuritiesAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Securities, at Carrying Value",
        "terseLabel": "Government agency securities",
        "documentation": "Debt securities issued by a United States government agency such as Government National Mortgage Association (Ginnie Mae), Federal Home Loan Mortgage Corporation (Freddie Mac), and Federal National Mortgage Association (Fannie Mae), which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r113",
      "r114",
      "r115",
      "r116"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Common stock purchase warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r446",
      "r449",
      "r450",
      "r451",
      "r452"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of common shares outstanding, diluted",
        "verboseLabel": "Weighted average common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r168"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding, basic",
        "verboseLabel": "Weighted average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r168"
     ]
    },
    "mrkr_WilsonWolfManufacturingCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20240331",
     "localname": "WilsonWolfManufacturingCorporationMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Clinical Trial Agreement with Wilson Wolf Manufacturing Corporation.",
        "label": "Wilson Wolf Manufacturing Corporation [Member]",
        "terseLabel": "Wilson Wolf Manufacturing Corporation"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481620/480-10-55-63"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "720",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483384/720-30-45-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "932",
   "SubTopic": "235",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-1B"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.13)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 5.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479836/810-10-S99-5"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//310-10/tableOfContent"
  },
  "r477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001410578-24-000865-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001410578-24-000865-xbrl.zip
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M9E!"28+4@5YKI!+%2YAC$3EV_>V%:K N.FW\Q+'+R-+!+4&&*>)@ UCK0MB
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MW^W.#P2?K.(%66:U9'4MOE<*8SM<&*/)'#:?PQGXMSTPO. #'5HQO)4!Q,P
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MDV6PK!'/7@3<?1J>-F6)>KSC<NWTIFMQ.":6<I:H$P@9=(QQ2MQUKG0VO]Y
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M??3$?8G]32B/[J]0R!!R_(H,XRSAWI6M6L,%,OA,-/BZ[,-_ 5!+ P04
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M?_T"("GQ 8  'P+D9M54CR,> .>% ^"<@X.?__MEZPV> 0I<Z']Z<_WVZLT
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M"HMU$O\65V:\V2<P^QG"?_T+V*+J=IV,9. I44%1\DFB';!'=]81P42XZRS
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MN@+,=O$M*\6S5ZG<*>?L%9^Y4CPRQRUR $M1&<!U IA@<P:'L<..<H9BAC\
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M]PTO[]#_!KWU@^5':Y+3CVB"/]K!./.$SU;YM@9XT"3X+4^/,6M#1>YN&="
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M<\\+92K(KHT'[LM^AI\O8^XE1_.__R]02P,$%     @ 9X"O6+(4I$W03
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MNJVG([/1;"Z-CUM&?,#2[$AEC(<H/9X;Y$%_F1R:3,/0MQ^BD"4@R+Z.A%\
MLK&#20$SX%K2L1L"!I,%EQ\555V[+Q\)VU(KN+NZF'H]#*YM5A';XL8FAYF4
M$&)@)V@1!!&V=%U-[9'-@+/YK]]\_<TW;VEF!3UQCO^,3K;CT,Z0 :^B9$3A
MT?/M/[ U0=\D']I,+BQ5ZF55ENC3@@]$.X_HN[<31$SM3VS$/38Q;;21?/K=
M!!$89\SJY#JM*^0H/;_):E)5OK2Y'0;;WD5\%=[/7(V!:^E"2I7/  MEPGJW
M<9D'(3VQ*+3O[[ZI,O#_^/K[ZZ]%IA[03B?-K1V]"C!&*R_$Z'L][\4MB[V2
M-YR-85L+=V:<;;)_$)U$"4?#=@0U7!;.4,N'PG4+=00KGP2F<!$%C&P7Q:#U
M'(+VSR9]I?*:L&F6LCF(.6YQ:-@NMN:&[Q*_$DQ-,SI%+ E]CP^V:8OVSU(3
M81NI/.]Y>ZV?!==T&]"N?EK(4: $!WJ5PX)B--=+SS F/0#[>5XM#A-&.DPZ
MQP#>;,6\5:>]X)IE!:T#I+GZ,,4SJ^XV=ZUF^:T.RL"RZ/C.(/-O6C)WR-DN
M-/QP8-[N\*/MNCVS5WMRT -C_  A*$E)0GS&47^B(IH&VZW*\MWDN09<ERM-
M>;?/,W0?]O7#Z\T)(.,8BD&GM?KV=-T3NK6K0;"-M9RGTOJ*; 1<0Q30J1[W
MQ.#0KPQ@=[>D C_,:1OY5Z9IY!__W-*NG=-G^_JVQO5W,/6JE .J3H4OX&E1
M.7EME,<.0IO6)_Z C2#R8U6BT(?5I \XWS3^FMOT6^#:5.2BH$_\*\ :=45@
MYSIU[YT,N\-;G#5:]<%V[5-T$NK5]?=P-:N4DT2W"E_"U*YR$E7U*X:&?N7P
MAKVITAL[@UF%\5QM%5?? [:*,DY2J\A_"=0J2DE45B,.3:-5],&.UMW3TG;Q
M@OPINHY<.A"FO=3S5KJ32D?!LR )6EOOJ'05[>R3)_U7'C>&O_89/1:[@;+!
M/NN?)Q"&]&38EM=,!N*[DJ*9<"VT(?V=W:@DF)#G(XZ+W[VB/7AXLT8 -RP'
MD 1+2&:7L= KVT7_BLY$".RNE9;K4$4A\,Z9T_1&F)3D2B:-R?A%/(N-_GK&
M6(Q=2'=G1AYW7LU0 ##L'KGF!IU=H&06S>]-@C%F?KVU@:32">,SXB*O=0;,
M1X_+>*]H[MIPP;QWZ(E;;K!V&9?:#%3<[%Q^UOA,5=#N7'+*N(RVRX;G(LL5
M-SO79[[]\,UMV.NNN7O+!T0--]!R,V$;= /N!2^/QK=O;D)\-^^3!M\Q-WNO
MU+<4(.Z6<^Q+;I6K9XS&S&4VR17#1V'6G6\4B^8,8V\\ +_0=L4W+%=NB<6C
M1V:LXLVP8.B(C+2CC6&9@6I]]-\SH[JWOS?LU>]]:Z:,S"9K=KU5XT=DG5WN
M^\I-M.?=;K- N#>F0>QT;Z_K;_$3]6.<][,C?*$K-Q.V!3?@OOKQW\TTN/;<
MA/@NGP?2ZJ,,#[=VQ# !*7S5O0027KF1!R6\#F+>"]?T3CB]CU)3M$X\&K89
MUW"9-UW!4+CF6D>P\B*T7NW6R\7]=#^GW6W(?S[,5_L=6K]#Z\U\.]TOR("A
M[LEN?,^*S'#M[[#_9)NBARZ"83"5LXZOY/)LV1AXZEA+J7KFGP%E3_IBN ,_
MB(DI8(\7.0$!?SPA%D'I6/!J*.;P2A=O!X)6R IR.]7*KI_4-%C'W_N&&Y8^
M(R@? 5,7*[C)K]&YK^'I7161JMK&8.EY3- ?.S8+7/04G7K";H2#FFBW9!AL
MLQ'Q52P?51P#UX"$E+;9<E& NNLJ]\:8E@K*,?)W1!-GGLL8^L4.C[.([&Q/
MV"?;$R>BR2O:99?\G[4WGJOETA#2*$Q213HE5ML$#'C#5F*FI8D@^NN@!"OZ
M3-"B!.\$I9A1@AH1W#I]A!89^=CT'MV^CJ@EDNLZF.<U9/S8D^HY'0O83F7^
M?,9N4!N=5 R'[1+K^"R>B)6/A>O<:BE6/Q0B@'DIIQBT[CBF-U;79]9CC/AA
M'(/6%-D$F!:X)BS>$[_@>&>:8(VY%;JNZCFP35.*XV)<4C$!KI'*D:V^CG+H
M<3WT%'YBN)H"BL%8MC+X6E)AV"7NPZ%=@ZV3[=K4*='B\]6&6S\+MNE*<EU(
MHU5/@6N^LH0KYZ<X?-X<NX!!JPD/R;91P*"EVVX2!"3AA4 J9>-@FZJ0LT++
MV^M!<,U13&K[ # !J:5P:?>,\5VF=Q/?:C4P?H-@Z06U)E88.1(CN^6NU,RR
M82,PM!)BVYL:!XI>4;#]]$>0MK<.^:- >-8OMCK/U6)M*\_UBNS%3J4FS2,S
M#[8E2G.>M\O:27"M5)YT59W.8TC--D;R5<]9(8GT;?\"X WL[9CS9!']2DN6
M:.$^X2"DFUW.Z\(E@3SY1""<BN&PS;B.S^(ERO*Q<(VVEF)55<T QY9*CYDX
M;$WFV2.K')#&FQU9X) <'MEN1-S0.EW[[_#!\S$?MS>><3!_)C[)\RW;-?P+
M*^]'_)=)CYT\QV$>K,:>^\0(W27T+NW;J]F]H(/LF/IG6MW@<SN&[&B=$X@R
M"M$#(S$)51B1$U0DJE>O6+OS@"SE; =C9L+U;H0;1T,AI0VFZU66_0MPA&K^
M;,QN:3#O0CP)#FDW8F*6DP%[S-7FZP>048UO .I+!V9;QOV=_-]\ZM/^],UW
MW[UE?HU^\L][.X@Q8"NEO\A@Z1!!4J<KF#"]8:<2HXZR$X!Z?:CEF1'=:C&2
M^M"&#I))K%&LRYI"(^/)L!WJ.[_NPW>4K2@PI)"'GJTM$U2R")4/U749"Z#X
M,D>L)2&G*HS[R"?+R.9(&%I'X8;U6261Q?H@OK'>$RJ8[GT(^>;#XS[PP VH
M>^56GU?DY"%&WVLO"A&G,!^S:PE208H["VNM<G^J*6,\3F%-D,MU++S1,7WK
MT'O#=BGE:Y=\??8"PUD?2@>JK#PJP$>XUBC+L'9U:0QY9.N).G]=KR"4DF3]
MH,M$3 XU5]&4GE>,NFP.$($RP1&)63F)"1W@2JL#E%@A@AHWUQ $;&>F(@]Q
MOKAZ/ES'I,1%ASGD<O=RE47.7H)N/)\%LM=YY2%/KYHEFGL6J98@M6'2^26*
M0.IFQY!"P$'P W*@1^&$W]K[S==C8"\CI1P5[D[F!\!=",K)5$YCX_ J+3'@
M26"==^J>56IWNJYW#L',(+YA;O@N6;R#I'5%S57LBN&P/48=GWGG(1H+UX_4
M4JRJF@G@K.N*[A?WO;%*K1 G[+YRF/],6ZU<G^(,Y6AZY98%+D(6@=R8(IS?
M&8%M5C64:@X%MK-2E$JSBU4%$'!=FRHC_5^YHBZ1(=;8P'EHZ=3<.IJ@!XI+
MOR>IWO@U]RG-X(W)NRA(2C4A-TJ/H\)2_ZDZ7E>E]L3@*J4'SV,-*5V)TU)M
MWNLZSF-L2\:$R5C87J>2PZK=%QL(UUM4D]O=OFO"+1?$GJL;'F^W(.4&J&NO
M-2R7<+9;][83A=AJO>&Z@@/;/2E+IO&F*P\$KEM39V68C5>,&DP@,X2$:C=?
M%L>FW[/4AG6-?4Q3B&/R-DK2:K$)&Z,'4F,*\D8,F@<;5L(2FS&-WNPZ%(Q9
MEPP<L]&PO5 -EU6;LG@H7.]11W"7&[/[4D75LS7KBL^R;4NY0>K:G@W/Z2"N
MYQ=L/QX)[BD1B?&(5Q%M-[0^W'38K<H0-84!VTTI223OO!H!@.O2U-A0-8L$
M&XK1(8Z/AC <8[X#M<[DE":Q&+%8W%0L9MRRFDO'RTM'9UI+LWP:2D6GC\T'
MN&5]ZN4$6P%EE'ZV3BH2GE8$8G2^MI:1@;RMSHA3FV@:>5R]L:IV&366S"!^
M-^W039:?F_[R-3=/9>?"]K&-))#WK%(3X?K39N2KFD%%O_;=?CW[^X_KY?U\
MN_L2S7_ZN-A_TFH"G/69=SI[+OEG4-+.77;.2%2^BN-252^;, (5KR1;.>_$
M@*(,:M<-X)MD1XL,EC:"KQL+6V<K.2SD1<L&PM71:G*[TDVM7>!G+/)ABTQE
M+_BR<;"54LA9L5ODU2"XRB@F57G]YU$O ZFW57R_O.FPJZEEL?)XAK,Q;&OA
MSHRS'1I.I8W5S8%M;U(<YVVO<@)<.Y0C6U5O,^B(@G]MNRA&H-="A^4:96SK
M:>,:DO486\D96J75"@?#-M=J'HL=6\M&PC70&GI5=30!B](S;:T&V1.74].,
M3I%CT.S8/3[8IJVE(RO/^2V"(!)>([D: MO:RO@I;.)SW\.UK%(J536- YL@
M#JX/&SJS\H%SUZJRHTYYFK.D,;HSR'P33^+#B/YXVX6&'P[&W1U^M%VWGL&!
M,H,DLN>,Q44CF41^-IP(K_!G]HTX0R@W%[A/:2*!8L908B)@+]2(?&7WQ';%
M'$U:DS:N1,M0T2NJG_F ?@I8U44 P\B!@J&VGC] 9*(Y>#XRC>"HZ<QP&.ZG
MCX\^?B31$#K[GHFQ%=_"C4\*;:X>D6MA'X5',HIP2HO7(H/,P[KZV0MDPYVU
MHG.\G3Q*[RB0@81[O)HY.O\HHK\/!YG$=C ]9->2J'61Z)6=7"[HI4VRNKOL
M6A39/9RBAQ0+0'NPR+Y;G]DKBODS]DT[$.\Y%>",TDW62T8VH"P%,CKG*<%*
MCX$F'Q)C1BEJ6*ZD1Q&)'2R-Q7",AWD=]K%W5FWJU6_HU8&KJ08T2E\C(1OI
M\.QE>!L97EJEW5[3ORUV!0&[ >^[,O5] I'M6=##!>7';8P+^WCZV?")5XII
MFJ2>**#G-9ST3GW2]UR"+MN!6?M6X5X_TKR^=SSIUSNWBWA!.6?H,?%8A-6B
M565"S/J0NW_!EO%I0#^Q6<OW=QB_\_QW41CY^)WMD@FW;SPZ  =SZ>I*3FEO
MRA:P@+>E[((S9;,*D8_/A"UVU?.)(KVQ,"-@_^9DH /&;'M^8)2@0T+*L$TL
MM<HL<47K RK<!$NW'=, 940@0@4B9"!.!TH)&=AYPY&;FH+U[+[YXM6=_Y:'
M-S8'WE!2U1Y<$M@877A3UKKQX;>OUIB-Q>G$T?CRP80G<.99*GYDSGQPP:EY
M<]")[;@J([;R^WR5I)X($$R7WUXVTKGM4BBC2S?)\-+NEE><WLX2VBRY=%=,
M+F7YIPDR#B'Q_L3>#]BF%@<IF=*KN"C*..MFY@!W%S56)CW>T7>E[!YV['^M
M_XH"Y@'O([SWMOB)RFQW=NSK=\==PX;I6GJ18!I9=@48>)39.9OJ-[JMB"&C
MZ6MZ>\>]/KVV^'$<N]G#B*1A@4'BU"!R6'E" QU2@I-)1DHRF<_ZB/F<:A10
MLH>-2L$(6^:Z2$9/4L8CHXC,8;*,B4*,JD&7!5CR?-=4[S17L)@9P?&=XWT.
MY M7E$V!N2XTX5=0IN)F/.0P4H+J%D4I[N>KW?P>592GF$UW/Z)WR_4O._3J
MXVKZ\7Y!QFC9@*UP2&6P\;TGV\+6W>4C"=T6;EP1UGV<$B-]LD,;U^F]$B#8
MUJ NFZO>I VAP+6<%KRTJ==)<:($*3W<?T7QDJCG*Y2B1AENW3T+-4B)28@Y
M,GX26R86+1W_B! .=EC1B;@P +8_N.4E;^?9MW#MMX3&-G99J)L.K85\78?B
MCF6AJZ-O?5^*]&>)?Y7\C[+WBC])\HL(9-8;,MB&WZ^,F[644<$$UR'US&^'
M#2$$S6GR;1Y@^;_V#6VTB#ZMSR[N?*.G'DZ2G AH(H0Z#=O!A<;P>Z^;G51/
MJ&"[V#[E6RS:TST>N.ZU5V[5B^6D1/&$:$P6N@DIZ=<CV_N!E'A"A\UORI/U
MRDV\+)$P_9N]\HNX8!-/2^1JZ-T\-KL!,-)3?OF3_+&=UO=X(E]U]DX#$ZK.
M\V>*5-/1._CC]2XVGCXFE-QC_M^<"XM+G]7$.8T P#;BYK*XVO1)SH9K[ H\
MM-B<,13H58+L*[IJ9=% 6G!0;R@PH$AF1^K^@JO%.PAPR#L6DI7_@2S_VA;R
M6U%L?'PV;"OVT=(2O)DV-K]0SG>U-RC.&9,/$%#>L>7'6'I9\(M/.)N9>\?<
M)VQB#H];MH7/7F"'NE+/5QQ/3=./Z&Z&)X/(O@/;3S1=1#9 TF*K 3(VBY>1
M2;7]5T$8DS>0XJ-CWQ#C3%.M*,/*DK=@G$6OPEF'1^PC/X4)Q%W<1YCFGK>8
MU6O=&#X-4&:1[Y-]G+3@:H",S5W(R*3:751!&).[D.*C8W=!+VFR@X<8*XK1
M3E",&(R_Z%4Z"?=G O:2\QM@W ;-K;9T&F(0(W09-?*H=1B"^2-S%W5<]. L
MV '& *Y"/>G0HUR*;N)L7.#X"!).>9$;!AM.U-2UX@!KF:5"FL1F,L#&YC>:
MR*AVAU(+:4R^I!$_W>]8&&X4(V?;_&0;D\.OJ>B0)F&E4CGGI&+$4DDR(K O
MT)==L1$(N350V*ZH&YFI7;(O@PC7-77$UX"7[R?E-^6T7/$%(+W:BQ7H-9Q+
M;I+"NK>#F&1LU;JRMC!A>[).)%9HZ-@&(%P_U@U;K5['-'%A>3KZ=F*UO26U
MBD[6AUEYB0F]V%!!Z@AD!CM6;;V@@O?<S66A%F_"]<D*/ P81P(/&/_;.8F%
M^X2#+EZ$5P,:I=.0D(V$\ZB ,CHG(L-+3\XD13W<JP")B$2#G*[?A)<)1LMM
M0$E!M-YF-H$)V^]T(K&Z;:8T0+C>J!NV>MAFEMD>_&WF<**[B8;L5& CVV9J
MD-DY4;DJX<$.)5NOFN!=>'-9J(6,<)VS @\#AHB0]IM]B:36PP)R$FF)[+;[
MS6I HW0:$K*1<!X54$;G1&1XZ<F9I*@!O4+7(*7KW6:96'15(&.-K^EMV=)2
M_0(9RLR#[3VD.;\J8U8]":YOD"==_0E6OHEZOO="OFF%%I-_R<Q+;,6&9M\6
M]-V8T'(:NMU<DSZM,O/&X^:DN[#63AJ'F^NGRV-1U6%U;QZ:^V(?RZ3#)>R-
M4NNH$+S--Y>%VH8(KA=0X&' #1"D;$I?(BGF7HE(LJY:>C,J5 CT_^>_1_:3
MX=!:9%M,MGFV&6*+?C%UK>('N9&\'\3U+?_Y<UP*DOS!:HULC1#/#P<LS,8,
M3@1LAZ7G-[D^\AN. KB.4Y,<VN15)MS]YNB8H(Q$Q(?0!S%7'Q9G<-I1R;,C
MVO4]*5V;L( H#X@SH<6;C^QWHBN"%>.AZ76V.M#?A/V!,])&MR+T\?N\;'_=
MN?M]H=X4C'/LP\'QAFMSM[*N@W[QE?HH9(0(D\^]0ZYW7']"VH6&'XY43 _X
MT79=]G:K0EB#>7EZ A,70,U.D5VK9 ]$;Z4X7A#YN.9<M0.P\'U]%W*[=O=M
M8,+V^)UPUOJD,2OUFUWHH&9:>B*;$:+[<%:[ '?1^>RP8LFT^:)YQ%;DL(,,
MUW-?,WGF,AFN57I31.4H5]#1E\B!BJ3TU*:V@?J5C#L!"--;=2>KM&%O*VC
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MG+LHL%T<! O7]9[8T"T.,+',H]A]M <)V-ET)*_4-;6$!]R1=<5=%]=)_.Q
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MHVKHIVI#BVO65" :^R>-0#IZ2D16;5"6-3?7Y6?#=+R*4B@6;)2:"C=F:,J
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M6$M2?SI6A^9DO/#U0?%WZ72%:$C#"UXC5"4!8I4H/:EXL>O$T#]5@Y7BY1V
M:$C<R6,?^0K1[:_0TQ'*"UT/.A8 A,1=X;AEI+X?R,]2([T7?EBS<$/?=@/;
M_)F6W.X_,7B#[V7[]5I)]W0$4T3V<GUW/<L0O'4A"YW2B1BA>M[Q@Q4[+QY^
M):.\ +7YVX=Z<3W4+V5%<;VM^GWZ0C@"C]NKK&]<;B_8@/O<?GF&X'0+(?(
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MH-7]5\NQMN$6J_W<]]+IG]"L/ +58BBPF5X%I?Y"AC+[O<)05HJA?,#583Z
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M,$>DD93H6OG9.N.(C;J0YJ-/K"@_QAT =ZYW%P:A!Y)+O@O;TDVK4YX]K2B
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MWLMWDJ.9P?(ZN1!^6*DEFE3+W/*E2!==,^$;L)XV2%'H_I8GD%[U$\> SL+
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MN> GH$6&F2":G![;BO.<0S1. F^'9)OJ6]SIW[)BLN#+=<1G$E:ZLUH58"_
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M7W__?SB.:9UDHX2IEN*-@>EBB@UD%ZC87'.'MUC+FDQD$RL#V]8, TO:FCH
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M#INZ-XJQ79U7E@L"(NBZ-\ 'M<TO346_^QJP,9^2X* ?F\H7=RWGIP]OJG/
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MT^]825YF1OHXEJ'L8=,4Q]/0C2)R A]Z<?4;_=SIQOE0C#RA3GIQ5.3%UJ@
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M></!;HSAS\WAY<P-<_XQW>=D?SSIK4%]P/A6-?4^5&\A6/-W<85W#VVA]^6
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M;ONCBXLKEF'9MQOPV^K4,* 1Y>/@ . ]&\@Z+O?A>V]E8RXOG74G8[$;BMD
MZ^T#@"(R8.Q-+/9?[/$K(L8>)<?R M^BUXY3$SRUN>0#YN::Y6A(U&]M8$!
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M_.>%AN^ZP@:"3_0?OQ?B-K!L4Y%L(*,_<+I\^$%@9!-2SY"/BW#S&TEST*;
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M0@"3P<H,\T"5/,\&RFUW]M?@WCT9;Y&:,E<\+X]E4)I!HOQK@$\JRQG-< S
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ME/A0$64#6%'<@7PT!J6/7Z[7)5%Y;K2G%M1J8V>@XE^>)$W0B_ M',M%ZWU
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MKLHM0Q4:Q>BRE5.S&@=>362*0M,9[>P::AT6T"\HXN7J<-);/3?J=#0[F;=
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M"J$6%] RB4>F2RYI12!\2:3,-RHF7!,W5',J0BU1 @Y6E2TR ,,/ TT.J!K
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M=$@F/ U4UP,7A<=5P%!!%J\?R_[1]:O9]AO9\F[9'."4VW!/+#CT7IW66$D
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M2W*Y%S91Y%;[I-=2G8T)UVPXLK] AXP&R%='AX:T,<!%@)V30[PXY54!ZX;
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MWF.S+)1*B9[2YZ2V5*T7TZ/FT$ UW5#2,_T1ZOG:[FN['R6ZH>5SJKIWVW'
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M6G85#W%.34,L5'C=!,_>A\UYH@B".T?D<PJ.M^T%?W"P@K<MS;O@A"KPE:V
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M;30G5WZ;0P!%1%&T&4IHP10C3&"92&ZL(9P/E+, 9CJ4[;5@$&"./L-Y&4!
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MX8R]X\,/\<+7SWEP8AIWEO+PCB"<31SPHG'_TN"+OR_^1\3_P?T.IW9H'9@
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MXKIW\07S)/;C6YOU%? =Y.U4K^<++Z6\RD$C8MBO&]V(4OJ(MP=0]0F:*I*
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MPT[^PD+2 #,]OY[75-W1:]G[53]B\+UI6._BA@1(,:4(%&XD2RE4ACW?<33
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MJ;9(IT1U-/2OCE2'?RV3*'X"-@23'6V!^GCHGBFF1$6"\_A?08.($<NY=?Q
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M+,3EV!^FM%J"O^()&6/UR^LKA?1MGG2;;DAQM>G[?)3>3AV2Q;M6L7HRBV-
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M06&(AXT!6L5\9>)91A75,\%+E8+&"*^"3KO?7O.6EW<^PF)K%69XS0)'%Q[
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MC6/=4$0*3.;W!Y@$I4^A0PT\Z,]3T*:O+T#/(J=%$Z'ST-QJ%FV"1>:#0SW
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MI4]W] PRO>L="'$RIXM$,.F1)1M1^UA9K:QV5)A2^H9^M+OWO[UA%?F,/+)
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MUI]4$@E;&5.I*!$4UJ'6\AHY6']Y-:O:@,PESY7V,;N((ES,4<=49L8=/-0
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M#)DG"KGZT _QO,*CVI4[2A# Z;(@Y<X!%=HEY0VXF+$X!YM[I),%?<\/;Z,
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MGR@4 D:Y0U&[=J/YDX(U& 1@#U%&15(9>$=,34PXQ4OF>%&6>9&AF$_K$0X
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M(6KQOG2NR5 L/74135^V"ZT1@ML'J!L!+1B1H)#G@1X#$5 &B<[%R:V<&'*
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M8?#G?T]TTYO"%@Y.-%'C #U 6B(;AT=.K/<!ZCS/_8(EED+F6\IXW['=&HU
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M,K6XER&<Y5R_^+J\Z$VM@2.SA;+Q:.05&C8Q%:W!*BC7YA>QG!&8<F!+9D6
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MJ ]BX7RM.T-X\8D3W#FS1%%YO]'J_'0ZB&(/_M14NT(X6-U&O_^35?R(T%@
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M-[EL.F=,+,#^(_P_ZYT[I@=&E1NUE.EFYVY6G0'"^NDA& (7J:N>#,.-$LX
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MG@$8M6$Y ?9WH9L-YQXXUHQZR[T_T1I5Q",RKODN&[7^"/A\7_G:*>,-W#M
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M*T8_]]LI2^&Z+(N%4B0N++I-2 >G\_Y-7WC'7>+<O=2Z9$'@;<KF,GF$+[;
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M+*J L 7B>!,*FIUR[+P=9R8=-MQVB'A(UH;S*&LY[5H01^P\CU]^FUE_5;S
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M"+FX J1!UL%)@(7+) #V%_ _]0E%.=7$KK;3\V5H(#SNK)0$8!3!J9WWPT@
M@ D)$*/WGW\P6=%A@=F^@! Q9T=@@2,+(J\!)A*?2@(0 >1)KQ<_)P%:U8(Y
M+,VT Q@RT"DE:+EXM+*8MSWTCPKU&CAA+1]Z@@GJ2.T@<N(,%D@ V0[R C[3
M&8*=^=QBMX^ 5[;B-!L_P?D-VJ\&NW0PH2*6.U:^.C+IW"+",-PR^1'%>I/(
MEF-J$B#D,^1V#,U:D!M3'O.RAIA#B\!2V2B2FG><G:!4L,A^(DT"$"C 1'FP
MDK_DPD#"$IWDNV8V[#.47SUTM1CM%-1GH5W--HR@[Y9I@;:8>75;7N[&2+:
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M3C)G7\P?U#]PAFB!G\7V/XZW+,V]UY&OV3*+8'87VP']#=[,6T;,^B$51R2
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M>.]%?.0AO+@WL6AP;/\>DD4M)T)L/58.HJ>TGZ=7%, 3(AJ3E_!6;*A1#:\
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MU:2\80=_+$J& #+(AE_3KQQV*3UR*+5K_@2ICN_GM'U]783BTXT=2J6C?H>
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MGB")E *+/_WNA95]S"]6IS/R![&\(.%,I_@2AZ(Q;Z-LX1S?YHRSTD-\;,1
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M'NZJ::[(P&&"9X"I:*?SGZ.0&Y(R+UNY%&!2WF$4/<T$?&=0$>K^>O[R@+G
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M)&S3@%>X_\%+18AKRH.$XA16R<U*MY6#Y&6OT/"]T8 &?FD._Q'Q>T#[//V
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M!I072XA1>Q%0T66S8+EO5QLO34 N^UZ,Y1W5^4,JS2"E(S UD+^<;]KQV0G
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M[1H"+MT#(@4)\>D\[OX]+4U86-B75YFV2A-E W1P?B@UT:P#4$99+4W2TV*
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MV;O^@$13#(+7_SFFU$]7BN8#5]..PZ$+W[=(]>9[P!677CBT"-52M S>Q^C
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MRYO9!FI@OBS?P&07F7X]TKH'V*.\D!^HO^JF#5]!:^X!,I1&]<EO/T5NDUT
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MVUF-_"(@6K:6!B ;N:),^@2,[NK<;ZA0<:2S"29V(FG:!60BS2XA:L*<+?;
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MZ[B[2XYI]C%6S9/"EKFL!CX$BRNI;X36!5BTA.-Z),/ZO]<F;;T 4YVHMR*
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MRX=DQ@-I^YZ:TO*EL'+%9PV5S:VCCLW8[A62ETH1W?#-ILW?9:5"0R!6]:*
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MP&L S37@]T/%:T";S34 6?0C(F*VO_)_*%:Q^_]/+C/2&XO>H41C0G^8HCZ
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MLG_GG.<\][F+S#]8F7..=[QCSCG>L=83T@_2/."RCH:V!H""$@"@(/\!2#,
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MU7Z!3\(8R_+4:^0B*[_D@@#NMVM_>/;?<RST?\JSOQW[+[^F ;14%.3@43$
ME &G)KG1.YCI($L$]O +\,JZG.-63Q;4PYE')-V2UDL#TLUNSA46NU?Y28PZ
M&F80ZN?M$KS=P[)>REQD5K932%SV'G.&12L$G^CKH@TO0NZ.UJJ@M]C,W*SU
MX@^(ZQ/6CRH3*1Q,;F$^W9%MWYBHWD>PUN?@\M"VF0BT8?3UZ4Y3AD<S^'OH
M9Z',5Y=MJ,)7;RO5[3,W.C$(-9FEBB7ZU7AH"Q&EFQ8,%7(S2LK6DS&.I1Y[
M2ANY< X\"8#&,(.-E-BD7T.TT5%N5T?%I0(6Q[>7=<L:%WR3*KY^_3GC=7OJ
M"QJVD<6FH+8H/MW282''&R6>AU49$Y.L<7'SV_#PYK-^LR3Z<@$Q<5:6M_.!
MC&N=CFNMZRT+]@&G(KZZK$_-D!,ZRW$9?>0+?P,1$H#2 I&['ERA#@D[,2;H
MXQQ[NZPKY-OMK@;?$*=R 56Z>FKZ+M/TT49US"8Q(!@H9PQ4SL1Z&YP6"C:.
MAS!,0RRQB#B"27Y?20P%2WA$*<ZRI_J)]2$H(;W2(##LD='7FZ:/_(US$^I'
MG&?3&VY"T09K!U)EZ:H\4ZJ73A3M2FQ%9F$:Y<,P(5@2\=J:U6&H[S EY":6
M!(B'Z'#V2"?:H$#3&4>-;0VA0I-W[F\=2GN!5Y1-+."]E2%#*$X%ZMQI<(T5
M3CD<8LT_X6T).GRV;NV2K&+)Y_WUS.>O:Y.P*]T.ZR\,6!*3\H35+<MZI!'O
M0S:J-]Q3-1+N>B8:%X[J:QAL:(I83_KZ_PI65 =[;,:@;:V[><[AI'JJ2FQ=
M$SO1UAO@Y9;D?(<X/[?[V@L:!M3/)X4. C%;#+C.7BONX1@I&"W8I./2V7QS
MJTM3]2GK 2QOWFM2R9PUY#7XM,*[F4JK[BKE*L"ALY.<OOZ^>K9^6I+XW3A/
M)__J3$GUD739GMZQ7S1^*^0>OF%^,EQ) N]W:)'>-0FGO1>F/0[[\MZKX<'-
M"X8XYJ^RB@%;>CB#=VSM> 7I,A"0FZ!2 ![=YT-DU*E)S:5[O8Y;6[J>;-9W
MU?O(EWL@<MW;JS_W,"//N=]F;CUC,WFT-B]8O'):(OD7=KDY L4R;7[XR<UO
M<Q99WR:MU)L+U\&Q];AYMV<QA<B[UA\G=Y^FO,MVF;1R3!JMF5$3K=*@*G>8
MIQRZLB?X:>(PE$B-1^]VPEEQR0G=;F!\*>[QF'C>F).$2XWF]4AG]<8O *I7
M"2$9GS/U-UU*&Z/[+^K<:W;?ZC88&M"]D1@\UU/UK:W\IQ#2R_5P_'G^8K!_
MB\'78[OHH[*#J;%6$[=L_,W>CN9E8F3Q.D=-AR-RFX?U[7GNT(Q\QKMR%K$$
M<_P^&LKE"KPDWBH-0ZTU![=EIMZHKF?SX.CS]A8VC^MXU\)C$A^L[_%J8?W'
ML>2&JHOP+C!8+!>!3ZN^V^W$C$T6U'GHUH.2QWBHERF=Y,(=3BL4'-'Z)ET<
M])V8LR#,PJFKM6Z&Z_8V)Z*FNIOQ=K3BE["3WJ\]01>'<8<];;H]RC7TKPBV
M>>NI''X% 66/K.;ZG.[$M7Y9OJ&J(2.:O]AXO6EUR6S#.,=,6]QUB\B)2D;@
MO%H" ])-!UU,2LPSLAIA&R!;<=VRXRRS$3O?$[7UAF;>+RB.=0[?GP?2$\<.
MU6K>'M?BM7[07?R\Q.MIQY-Y':?<;>N_$-GI##$K=6;UYV$, T[XZK+KS,TY
MFCUX:O*U;RGS2"EY.*R_("9O/][W2I'(W+%0[\<VZ;D^_WM=BXN1)9M-UHDZ
M<VXM L?'O%8C0#'"#9Q!8AXXO9O(\UU)=)U'K-KV+MHZF-<R/D"\_%?4Y:$&
MNFP6GLQ%;MD=WG,$""X^XT0>7'0?IU0'I8^JE$R>:%6LJ$,>';+^>EQ]-55V
M+MPZ=N5,?$>;'$3:KK: PVNJW;6 S05E+9G5XN86? OIPB4Q5&(2[1V_;JB1
MUAIHZ[]V*+%W,?HH;!$32U KQ?LO(%Y"[J O^!@RXN-G/=Q]57R>@"L6P@)N
MZ'^)P_3:^;V;^ZSP!)=NC4O8-,B\BMP'54AWFQ^R-MLNCU>T1YLU6;^.Z_.5
MY6RG?1&HZ&W\%606SO&I[V:BT4;!C(YA7^/ ]J[&N(25Z;(Q5\6.^L!$W[W4
M-/U@HN;DF$5OLT</"7 9G$8"+&A$E@!G793$1@D&/D#&1]T2F@>A583*+_:!
M,NPKL2O3M02F!0QC"-(B\QZ.>R5!06WA-;(.%">N_OD[YE+K/;3H4VU3:+D@
MW]63722;0@08W/PA+9K!ND6Z]9-91;/?+T-0<%?GO?!G.:ITQL&2MDS^\(FV
MBI_'\.BC(ILQ!:<%\5AE2@7Y"G!NL,XO\/[Y?6TW&I6S1UK5<?R/%Z*N+!WV
M+4HM0.E;'\.OUHUO*^BB$V(M.%X'5G0)020\%5) C)^GFZ@Q=%Y*R15T/!F!
M(>-F!O<,'\QBA'L'CL1W'Y@-\>F$#'8,'8P75,?L$D&0A.^E(DL>":E*UT85
MG++[*FS )T26:.<1?HL0YD\%H[:'[S?C'VVU+^VOS;5%'CA.DAFZBG]RIFQ1
M;;$1W?A>:%]XWMG=Z-SY:%]WO9A,[8UWDQ4!^-A"T]N>/<*[@FZ)U6U[\$GS
M<7FE2;G57Q<K;SQRMY;ZU=KLX>;C2O13?!HM!#NS'QHME$WYO[,U8F*(E-!H
MWDMU&!I-<#U]R?WK;*+I'9#VFEBR".B)GHZS_%["43M;P)JV;Y4GE[1HSEBD
MF%9SE&F(XYQ_/2>/-0R59!Y/&6F5#;8'(R757Y, 3K:-/>#A-9L2/ V.II.H
MB(N,4N#%G1M0:\!QK[:F301?<]=Y>]ZH*<&MMR#XK'J@:<USLRMR+D5LP5Q/
M)RJT5Y'KB3*NCOC ]RLN184EM7OZ/L'I"H;&>.IR?(L=MK(*#6-L+T6Y!-H5
M%,ZUWE-E\+F5YT#+S'7KN^8DRS>(PNE;^I?E$)J+(-Q/W84MK^!G:!6WABWK
M$8:'D)^/KZYD%L(3<VOC?>/#E1W9IQ7?:P?#Q#$#QUJI*4\<E5V$9@];$%.[
MQ'5BN@*URFE"JT!P,3[!$K?<RG-GLBY.QQKI?[U5E];M9=7-B-5&A5/%F_FH
MZCI"%M4M(D<"T[4J_4=V:X?B[KK6,V_.A+)RPI_2;0<?6XQ(FA!_?I--]+6N
MB=&>RE^L2^F? ]Z!.LYOCH97I@5/!\UN$YT^0)SQ0@CF+4GY@4M//>CP1?>S
MMN3L8&>>&@I_I4A..EU^3IO@OGAU=XX6?P$MDA#5[!]'Y,,W*[.Z'C\P9$T&
M.3G4UT]T1W"HYF'NL)\JGE/LB%XI2GM:\O"XU:'I^43_FN)H<F7B>N+Z28W+
MO+,!K/[]I&9+#>C9^.;TF@\$M< [A4%#.XOKK)5I('J?D;4#6QINFIN[SF\D
M1+YJA#R373WK!DZ?IX\6)7AZ+AI2@(?$+^$C3>JC+SV33S^;.;$_\D)@BB!V
M=+B6F.67VRR0\739:!S2X#K\,Z$U RZFN)4X<1#XH;R&_HJ0R)1KVYK+6F7Z
MGH)).PE0P_.Q""_?P^$1[6M),"K'MT9.^%JHT,CROM#(DU=E>H?9ZO9,0VS6
M+*)8P%[T9S=( *91$N#+]^>Q&LUZ3XE:]H]'>I",@2QVP1'>H_#,W"@G\+JW
M+S/2K:C\Z>9HM6?SX?/W.A,CM[X*)"\XL5"S.53DN:ZUU.Y/8&P]6K;!@XA-
M5-'@(I#7U2H9,^,#9'&YUZS[Z/D,OS"M",_6Z<SR&:X7H&0D]!F04]LC%PRR
MQJ<KD@ O:UT64Z9[YKZJ!-S5@/HS)U)E9'OV>F3WCC*;=LKV=+H4Y=:-^BW;
ME)15<-<VCWD-O*@^43QPL]O>DE<T.U:DHT([=1SB7U6">4[%4P859,LJ"T=J
M@PA8YLKV8>[ 73NI?&)7E7,F[[CD#/"R!@>FRZ^Y7\_-P/@\37(8Q@L*#CA8
M QH;F40.W6G4<8UCGY9S<1QINI4Q<[/>-KS+<-HT#E6V7G'$UUE) C@"Z?"]
M:,WH5NO%VLANPY)6[:+IKS".1^T<\U<[(5U8[>/CR3O%(;V']XCT.+;P6GI&
M]8+5U+0ECKF/'@(UN@?4>ML&UK^HEWM/VG:!>D96:@K?A*?'?6SJK22;W$!B
M*;.LS2B_!]6M7!BP*\9_?-?#OP6UC+3O%(=?ANCC+"(4M+/Q,+1 1%61:_/S
M>A<NN;OWGR97U:OV>]T'X%"2X)B#%ZU9VEA%3*2"D6!DJ]N"HI*B',K"VE-4
M^LZ9BR,## HE2R<.1)X5]6<U$!NK)1?^F>I8XW'+68%G:2.%=6++/P($OZ4'
M_TP/E"^3G[7<!$N'0IT4_69ZFK/BR-H%OX]AM%GS6KLL%A=J-:-"LW0Z,L#U
M/LA7(7-*Z>YI?#G$"2O20:1N&K=/L,)BKT]:6D-B)1A7+62G5;B<2L. FB-6
MHAA>CG=E%Z:Z"\O?ZR9+EK^OJQ L'#I^N]/*%U8D-"N);'$_=&GS")H5"[16
M:\\_39)49L;_PMCB.M70,5I[&[;2^LA9'LE:K:1S3]4@W?&&SQTF!$B 37]N
M>-PBE-Z9XZ>5883420OGAJW,E^$#]L>^3NUBN]0S">YR:'A2[B?O;QVL=1:.
M XX%J2+ZEL\S1B<F U%^C/U8K[:%,GB;;W,@QLV/!. '9R4H/PNB9R%X8&%=
MZ9SC2%_N6Z9!JY"*CCW!G[+#M.<L%);L1ZOVH5,#W=.L+6A-O/_B.+8R'&TY
MM_(062G*.M\I$:O-3__6]/,P,AY\Y9@Q.LI)YH?&[15]=:_\4=>^66=D6^:L
M^8!J0<I"_O(MZWL8GVG_NLSA4E03NEZY!F*E' 5G15EN) ZXS1=7O@M'?[S1
MYI)*VUVSLZ/=^^2EG(7X_/#4!CJA,TCD5+Z#O)%]3I7UFMK2\"KWHA+OMKYV
M^F6?V0%_GYLVY/FI\N[[]]#!*P/E!>-*U1Z_!%,6*@N8D;;IMHRK)^K!O9'X
MQ'E$@O*"8!T.&$X(20-&+2,7J\:-#WJ'JUL< 0%EK)L:/^FHBYJ&#;$B\V@(
M)W8BQ^56X?1012E*NV1=NN<:8Y_\HM\8UTT<\L@'IIW;M/X+G#:F!+O1Y#,M
M?"^EK[9R=+49\JY"@87#-[C6!-YF;;6]%62[_T2=V2+%/YS9Z/[9_R\;2Q_$
M$I?<VSD< >?#B56T^EMPV*;_S)=@9.@_D/G56O;@M"0,\FQ$@:7"!?MH:H-#
M/V,<GL-YCW4;?%@NE@EX?MONB*H2O'_[R%V03<>LN&==&@'U&UQ;'>FTYE2C
M-S(NWIQ%<,[L*(7FPAUK3PL4/-"^6);42!_N"W4)3+IE?+?R%/K.J X]#3OK
M%>+(OC8!0VS)5KH<6'#XE2ULR/.RN60*?/Z^SRF9D=]PQ_;.E(+A2ZVK7%1K
M@WX*,1P9Y;"9CT"T9QNLX6X="?!MV;*2I6QVIBVCWKBA(F,SF$T=S#W< XNR
M$QF'&'F3"]Z.0/.:!0R=75_1-X_MI>B-AYGB^V7NE%M7%"A[TY#X%=R&*1XX
MCZ*W7;/C#%;KYN@3YXE\@6J-EEFX.V3]9/VE?<)DP>/J6-/2CFC=-%O9Y(G4
MPSJDON_,TF#F$Q55,^XC^XEA6[?"M(T?!VDB*[!H%"_$?B&+RGE.#EN?O'!J
MTF$5RQIN=8QV;&8RF/&LTYC-3CZSH@BNR%!;I(YI94$/1QY3Q]0.,M(D7.;6
MT5W;FUH&5^0TQ#F8JWYAU++_%'^G6RKIZ2?F\;I?H^M$=&OM#C ;4>LL++-1
M4%?3T+I9M^M4;P24+-IBP3%NM#-!=.NP[DDD -WBLP_W#RN;\U.BE_46/)?C
M*>2UUXXF*L-/S*;7H5PP KU4_AT7[RDUS[SUEY]/'B0\3XS*'Z:(KK'GG>T-
MG+#DD16N8SXR<1^4]YKY**\X/CYY=)?5)=Q=N+ZI E0("YJ""3K!CK+NC]B0
M*ZPH?RA+R!5GHB"\-J)G_600=;:%57V&[VJ[PI[-9("=5*!$YW@R1Q:SM>&X
M<Z!DJ4:=S%C$H"VD(UJH7%_U#S6YPQL'9"'HSB>PX24Z0]BK1]S%(:KN) "T
MTD;AMOI2#V^*H=$[9*7(MTIE$)3YWD<7)[HWV2IH<;PVJM/?Q 8HBU0[?_C&
M^,D0RB9>9A_F3_]^\8[IHOE[\Y26BLKQZ2V?D67S;]@]P9O>[AOZF0<&*&_-
M<1^+;R0 =BR$?]0G*^K[>K-2N'\%V$0_QD@WCG%_^_D-QMN4]YY2B="N\/0T
MA+ 37N#$W]RZWC991P\@ 9Y69MW(\::++.WSA#**!I$ XPSQRC&C&7J)[#J,
M)?SEK1/-PB+6?3EJ$IT&.@SNF $WJ\E?'S$^%B_!RHO2W?1L5L[PFW58GBSO
M^0R[)?Y[!X?EOC(54]$5G264"H_=KW(MLLQ";N.S_!=1;!"5T5NB.74QG5;%
MR(7W-P0*C=,;[@7R%GA/#MRYXBLMKZ2_Q;]5&I>1>?ALK&H,)%.,FIM>*UL+
MVAC]NF<E\BN!ESB>-AE63@A6X#A;L(9%1;E).C^A.]EF-'TFF+ X3Q$ONV:5
M*7Q:$C+,/7X8^7Q+2I&/>/DCQ,Q#8:A]VJSQ46L*U<MS!D&A=VQ%KO?6L>;D
MUX_[&>Z\)P1)4*<M,+WW&@]0V@IQ(0'TCNFBL>;XQ47#*QMR[J_F]:DT6\:1
M:G43OJ XNW6MBHIOJ^Q7[[^LLA\6?"GBW\7+X9MU 7*I$1?1MA YTJKWH3Y&
M->TAT7=&>[FK=*#/G/\V)O;8G+&_ZLZ+&-TT??ZFY/WI]4/MPZWUN+R$' %A
MD6GAEJD9_?WM%IX6=<A1T(D!<(8X[ 7&28*>P*9<:0K6.?1&;^L&O9*)5N=W
MP)Y_LL^R1^O6QM)V7VKP3;M%A\B$^6$!]W'/)&&B3;_X:<E3Y0A,+E0P*$3/
ME]G(AOJ1D3HSP$C=,XM=P=L;BUR(C&HU<G%C61Y*=772NL'/]^E56'S0Q)B+
M09O6:!%..[_-+L+WID:2@+&U@/^.O)S("@E 'S*FL;)H!GM5%R='PPDZO3N*
M1C[4>,Y94C'QA";QR_ 06],,YI&5YI;((H)=$WLPW GG_:Y<#S'R*#;8*+;1
M>ZLJ5B#RTI2I/W9OPV[X@$<*8J1MJ;-59EFB<[@7@P#Q.!U4LFS.^+OVR<]*
M(F3YUJ9%!N&7"*8(_$N(>C[H6"]0,!HB#Q;=I]$-:/UA[86)UYHI,;=[$<"R
M)K7T5,BTT]2GM,)BV-<':5U8IYFG42[2;AHQ3&0__2:4&[UR[Z)0[LN+(J'X
M-1SKQH)R1UM0M[GY6Y3-VDA>/M-[A@:M4N_X0"DP,>_$$-S;?B@WD8%69.IL
MD(M5XFZ<+"_X#LMOC#RTM?]P^>+*6%#@9-7K?L]'TR$3T?JV%:.!5L=*DYH9
M4=^$GA1MKC<$"=9L! 4?."%K+5[KGAA8VOXDB-6.NDNZ&9]T6]Q1*9ZQGCU*
ML&^^NO6RB._2N]U X^$3G5KE6D8\[XD8?43K_FB6S4_P6*R&$;6-3\?QKQ('
M_"34V[D?*-2BW.O8LJK[[7/_W,&6>+H%<%)MMAB63G \T0:7#J MH@A2V2XA
M7+N2FG%,!I-2K'7P<7^AIV[5E/;45#<*<2M;].@*7O0K;$HZ65DRWTCP*.D3
MCY%BJY\>9>2XW)?\S&1M%?1H"=SGM=JVNNM>/X+" ;%K;W?U[L)AFFZ9QR1
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M$)-'9!0A 8[98"0 IA&!;\:D0&.2FK98Q'SKU_J&YCX-'0=P>?;?QB6(S;8
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M/+&V)$ 7\#5<$#N7\KTPI\3JRC67'Z7GOBJ\I9,S7_F'*:P?5H@J/C*/P+G
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MZHG3-C#]/]KYSJ HNRW=%T$017*0# *20;*2&B6#Y"2Q54!R$A"0T"B2DX"
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M5<B2NQEY1/P>!RAMZ9TA84OJ1\3I>&'F#\%LO>C;6>+/KFH^R".GW /R6AP
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M=N^$N0K?!-O*1>EJW,__!5!+ P04    " !G@*]8 !I9O; (  !G-   &
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M[JIYV>86FR'ECDFQ!=/Y"U!+ P04    " !G@*]8.-L,J#X%   (&P  &
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MNW:7Y8L^-[^]*:YX\CNCSE]02P$"% ,4    " !G@*]8&6*TH$$/  !JE@
M$0              @ $     ;7)K<BTR,#(T,#,S,2YX<V102P$"% ,4
M" !G@*]8:L*Q&L\)  !OA   %0              @ %P#P  ;7)K<BTR,#(T
M,#,S,5]C86PN>&UL4$L! A0#%     @ 9X"O6%LX]*X *P  AJ(" !4
M         ( !<AD  &UR:W(M,C R-# S,S%?9&5F+GAM;%!+ 0(4 Q0    (
M &> KUBR%*1-T$P  &*^!  5              "  :5$  !M<FMR+3(P,C0P
M,S,Q7VQA8BYX;6Q02P$"% ,4    " !G@*]8N8MUM/LY  #R#@0 %0
M        @ &HD0  ;7)K<BTR,#(T,#,S,5]P<F4N>&UL4$L! A0#%     @
M9X"O6$0.PM:*2@$ BC,. !4              ( !ULL  &UR:W(M,C R-# S
M,S%X,3!Q+FAT;5!+ 0(4 Q0    ( &> KUCK/,%"H#   %TQ   8
M      "  9,6 @!M<FMR+3(P,C0P,S,Q>#$P<3 P,2YJ<&=02P$"% ,4
M" !G@*]8M:>-\:.L   8MP  &               @ %I1P( ;7)K<BTR,#(T
M,#,S,7@Q,'$P,#(N:G!G4$L! A0#%     @ 9X"O6'_:5'[C<0  NH@  !@
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M &UR:W(M,C R-# S,S%X97@S,F0R+FAT;5!+!08     #  , #(#   ,>@,
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>mrkr-20240331x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrkr="http://www.tapimmune.com/20240331"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mrkr-20240331.xsd" xlink:type="simple"/>
    <context id="As_Of_3_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_7HG6TYGhSkuj85Yk7cyx0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J_5wr1xoCUiUQha0LU7yxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4CuqoUChNU6LCLMJQNy2vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_h4ZLvIQokUOG-qQCkBlAeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_N9zarOSsVEuBpoYtfzkupQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_26_2023_To_1_26_2023_awyJo1ParUe6ER8qP8Er1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2023-01-26</startDate>
            <endDate>2023-01-26</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PKZChDUbxEO2qD8-67k5Hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hteoEo475kS8tfpScfdJoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_O2ehFFy9IkO1iNk3wb4ojA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dPQr3dLFZE-DSSf241ybww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PUYOhITdW02F2X4CUsXlkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TabWhcOewUWWAHC4rI6AMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dAcdkzltg0mbv8cPmlI6WA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bkjZN5Y5rEWwwaBWPP47cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L3GqS7LIaEaMZLbGeyWEVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p2J4oIHCPEuZlK3Ssu23sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ARak6biMC0C2vE3aHgU_OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj8-kTaoPUeqeGIfHnTabg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_JNor-YkRMES_vEoMGuLiUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_uiVzVsnzbEO2OvPv-3o_Jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_X9phuL_RxUqyj7QCXMC4zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_M8QVuqpUVkWUQBZalnnUIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_wZXVoXh7Q0KniAnmTI3IqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_aF3HC3hiPEGwEVjTVodC_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:CpritGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_tSwV_5BIrEK_el6Vtlcjzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_dFfPvaLfIEikU4XiNmZE_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_SJSbS_G9j0aQNGKHeaocXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:CpritGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_j4d_NUsf-U6y0TlpBZ0hiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:CpritGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_31_2021_To_8_31_2021_wLINgxwAtEqXJr9cCHPb-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2021-08-31</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_4_30_2024_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_sE3cONnYgEmmcMHZ2wUk0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_4_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_dqKTucMUbUGZUuzFK_dOyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_n7CziHvjvE--LojpNufD4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_OIylfIWvwk61OIbrkzAtLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_v0PCHlsRw0uzmua5_m8DQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_hcxj8tGJMUufaz5d7_ww7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_30_2022_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_wPOXGWAUdk2rreQDgrYe6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:RelatedPartyServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BindingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_07W_qsYgcEudbi5GDRWobg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CellReadyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8ps6npQK00elvbaMdGpAAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CellReadyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_CellReadyMember_IthHVQzVkEC_BWostaNF4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:CellReadyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_awaPZGwxYkOh-Kh6ZKEEGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_H1facwiFj0qZIcr4nQ49VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wroXSHfJ30-xSPaXlw7fRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HbuT4I4LOEWfD8qUtjixAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_aZw1rDA380KfM4Tw_qsCzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:CpritGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2023_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_nozZmEEAxEWXLrXsS0VZYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_o77qs3ys40OOa0GfLhRa-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_HuG04-O0U0-9tr34MqB3RA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:RelatedPartyServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_caUp8WmODEqDoW7woCj3OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_csS-ol7uukaNejaEqG1D1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_26_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_XIIQwpm8KkCnK2MdeGDs6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:CellReadyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-26</instant>
        </period>
    </context>
    <context id="As_Of_6_26_2023_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember__S3prYqHtE6Us-UKNLgTqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:CellReadyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-26</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_0E4EMJOdr0W3g33PvIH_sQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_31_2021_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_090YrRTZKEOoBAZPdsIihw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2023_srt_RangeAxis_srt_MinimumMember_PkV5_ayFjkm8F2rhSnUmqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-26</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2023_srt_RangeAxis_srt_MaximumMember_e2_Hkwej-0-x0rfYttNybA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-26</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2023_lWBBv-azxUmgoxtZqB0QnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2023-01-26</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2023_UtL_c0KyKEWg0Dz7B0kqYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2023-01-25</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_u5io9Qini0SROgijz_sG3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_N3CIHFtK7keuOQ6DeBbsBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dDnDDGPKLkOOtV5YB9PuYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_W07D8lnky0aimmBd-R3YIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BuQkUd2NSUCXfasuFdBgPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_65JWbw2x0UWpZJA7_fd3rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_qmoIEv97Rk2jUyIAWQnjTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_MCdjUbOPBEuJBGWUJszvmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_vBXDcg9tlkOH2-yBzo50cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_YwRyxwQa5U2Ym0Gma3rUFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_XBUskIaJ10C-ReGlI38TAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_GrantMember_dzr8lBZFQUCRXXMJiuJ70Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_up4ngz1fg02kE_1r6itooQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:CpritGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_xgSQFi7SKUC3P-uEqMdsgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember__N7KeTtie0WOfM9lUAInzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="Duration_6_26_2023_To_6_26_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_I4S7uiZnTE-bi56dzKi0tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:CellReadyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-26</startDate>
            <endDate>2023-06-26</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kLbzwvujTEy1z59aTzl4IQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yie4PE_5UKKtvhQWc8ymQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_wgAA0Ldo_UOtaTkJBKsynw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:CellReadyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_t3VLl29vOk-QUwtoTypBUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_QKfSVv0dhkacuUG8PSdyzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_4_30_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_YTxnqMIXBE2WBHHgARjHqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_4_30_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_0K6azYZMnkS3HVng864fgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_4_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_b7OtDgPp-kyyI1YWR77jEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_K-XuDOatfU2spHjQPAU4OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_9_n_o50vykCM5Ly004kRVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_fMwy5Q-88kG0ISyjxlel4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_RKze1ypjXU6RtzdpbC9cRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_K0gVoKOl8EymtFxIsG-9UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:RelatedPartyServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BindingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_FeJJ4O0CM0OwiGmy1OureA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:RelatedPartyServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BindingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_6_2024_IcLYBeGAjE-ofQtI4ltuRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2024-05-06</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_Qbvl_Q3p3U-i5knuHKFQlQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_employee_YXZ7VHgYFkK0MKSPoxHTNQ">
        <measure>mrkr:employee</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tc_dUdvazYi1EeJDQ7ujmlepg_2_1">0001094038</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tc_AtudQRHr2UmZePQA6BAdOQ_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tc_TollByoMb0KO85NWy8EKZA_4_1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tc_nT7YhQc4O0CbEtz-Lbg0jw_5_1">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="-6"
      id="Hidden_d8A94XILEUSIZkCJWtA08w"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="-6"
      id="Hidden_ypl3Op3GZUeoYe7U6x8r3A"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="-5"
      id="Hidden_xZcP8zevh0SMmFY9mdQCNw"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8900000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="-5"
      id="Hidden_DI79ktFaDU2FiQQuTTR4Cg"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8900000</us-gaap:CommonStockSharesIssued>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Hidden_eP8QxLPiWkuT0RbekEoLwA">DE</dei:EntityIncorporationStateCountryCode>
    <us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      id="Hidden_o_clvdFkYE-lZq-yDAIsKQ">http://fasb.org/us-gaap/2023#RelatedPartyMember</us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      id="Hidden_04FEx9nTU06ez0X5F_GGKg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      id="Hidden_zytu6CC3zEW7oCs1koSO5g"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ"
      xsi:nil="true"/>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_J3sgSDifsEuvuzv0PXFjMA">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_KrSpVflDyk-l4qpz4_kQgQ">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_UaV9EWefqE2lk9tUi8H1pQ">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_110cRvk9ZkyOXaQTe57TmQ">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_sZa5NEdPC0-EpLvGQmqEtQ">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_eK0L9_m9aki7_TvaJc22nQ">001-37939</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_mCe9rrFcIkiXPmIodB_2-A">MARKER THERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tc_iierfnrsWkOrGx-hPXeU0g_1_2">45-4497941</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_MgpVjA9I_k2eiNA11i-EHw">9350 Kirby Drive, Suite 300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_zJ_HE9xE_UWbETRxy9YRTw">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_hb01H1Sa7EWomETqv_2dFg">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tc_56fJIVYxh0iGGeq5wiKTWw_2_2">77054</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_-8ic7h8r50eA9HTOJBCeBw">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_VQonva1sUEO1W8ryv1kfOA">400-6400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tc_3vTbAfAMrUONxSVwrcU25g_2_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tc_57gZF9HuLk-1vWolHO1U1w_2_2">MRKR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_qKtP-7DHEkS5g-RxC2Gnxw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_LwaaLLlVNU29FQQ9HqDNgg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_fU4LbDjUFECtmORUTphTUw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_a7PXN8oB1U2i0Hrgnabfdg">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tc_yrhwra0REECzd9bQ9vbGcA_2_4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tc_4R0p1abLAUquL6ImQADsBg_3_4">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_eEmRwPIS-kev-hgMnW-TDg">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_5_6_2024_IcLYBeGAjE-ofQtI4ltuRg"
      decimals="INF"
      id="Narr_RVUP07ZGck2oQPdHP1B8bg"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8919095</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_P1zv6mzg9EaK6kPA-EOU7A_5_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">11323428</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_4cEicDrV-UGDFJF7s3-DJQ_5_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">15111450</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_St0qa1kJF0-M7P-KVbFIrw_6_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">917009</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_wexfpNN7B0SyURzU5_Tyeg_6_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">988126</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_oYl95mw630m4e2XqqSyvCA_7_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1851462</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_rNMDnu7NnUmNSQ2OEaFJqQ_7_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1027815</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_J5xAC6sVWEKdkFL3fy8Qug_8_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">14091899</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_7fMV_QK0lkmzyBK7rKE2-Q_8_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">17127391</us-gaap:AssetsCurrent>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_k8lAYzqfmkyxJY4CkQ7rQw_9_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">14091899</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_M_ql5Em5V02qVHglPpUa8w_9_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">17127391</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_cxDz8ibUL0mrKUcqhJteoQ_13_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1949700</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_aGM35sKWOkCaEzIp-3uuxg_13_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1745193</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_wXym1NTlx02pHOTkZZFS_w_14_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">353965</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_fF2wKpOOn0y98oMEnOnigA_14_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1329655</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_ef0PYiJxE0uXiMaTmYH5ZQ_15_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">2303665</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_ytRWMYxpGkGGXDLdaYx8ug_15_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">3074848</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_QHg0ufR_ykSYPvYq9EPShA_16_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">2303665</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_NEeb-PDpOUucRrjRRLnOBg_16_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">3074848</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="3"
      id="Narr_x-cDcaXalEeIx8iD95c1iQ"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="3"
      id="Narr_IN5tjbHWck-n4U9xrol5mQ"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="-6"
      id="Narr_WMtyHTcfNU6Vcwelv3Wguw"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="-6"
      id="Narr_GoOscfj_f02uhWs4HMkucQ"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="-6"
      id="Narr_UrZDqDzoXkW5BpEeotfuDw"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="-6"
      id="Narr_CG2wJsRmUUSYvmJwyGMGMA"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="3"
      id="Narr_BN6r02niD0mPDtlwMhDqYQ"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="3"
      id="Narr_ILtN8ZaiZkGsj0blfMs9JQ"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="-6"
      id="Narr_baBnM0bomkyap3-KQIztsw"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="-6"
      id="Narr_ZTeGozHP4kS52hurpBhkEQ"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="-5"
      id="Narr_SteYzzfL-UKZnPV7IDbFLQ"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="-5"
      id="Narr_onZ_dAPsskadu8TIe7nfCw"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_15FBHIvIq0S_S51MKuYg4Q_20_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">8910</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_govGlk1O30-_26Go0UFF4w_20_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">8891</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_B_l-wXGfc0ayI5XubwDNFA_21_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">450458009</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_BlCGDjq_akGaUpnK6DyWDA_21_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">450329515</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_vRnGyLbQo0emdWWBDfrN0Q_22_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-438678685</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_sciHL38CU0ubSgUGpuT3Xw_22_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-436285863</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_hCN5YdMvVUmdh7EUEW6xJA_23_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">11788234</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc__B6ctlztfEKupGVA8EmScw_23_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">14052543</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_QDOFhk1uI0mQhAJEgvYHuQ_24_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">14091899</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_umVTwJuCsU6dnAbAX0v60Q_24_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">17127391</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_GrantMember_dzr8lBZFQUCRXXMJiuJ70Q"
      decimals="0"
      id="Tc_Xisdisujdk-__7tbu4Zx7w_5_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1244061</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_tSwV_5BIrEK_el6Vtlcjzg"
      decimals="0"
      id="Tc_Y8AYJPRmKUyk8ahxzDF05A_5_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1234336</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_6S_jykJjM06fT5aIh-H1oA_6_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1244061</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_3vY0wbljX0qfFcEZqDtQ5w_6_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1234336</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_s6-nV-10xkmyPoEyo868Qg_8_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">2575015</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_nGkY97V0EEGImWp1S-YkKA_8_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">3376497</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_TUF-mBM8NEyy-4GQ76IYTg_9_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1218063</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_EEd1VEez9UmGXcR95iaEXw_9_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">2167318</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_o79xY0s2uUyarltB_yaURg_10_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">3793078</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_6bpyHcGIqk-0SD9HSL7U9w_10_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">5543815</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_onTSb_ktzEegEahN7_V9GQ_11_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-2549017</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_DkzEErHKWUuI1XCTWq3I7w_11_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-4309479</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_HZLn4eN-TUmWk7nRSk2Yqg_13_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">156195</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_U0jB4T_grU6q3LegpxPxGA_13_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">84654</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_vSOOdxm07km6nUmSV2V23Q_14_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-2392822</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_gBt_GdJEkUa_hXBvWroI0Q_14_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-4224825</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_JwuPhQavfkOvW-KUpOnzdg_16_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-742751</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_yl5ucuPpckaJaXHED4kwrg_17_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-742751</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_LKwcPV7SiUyNM_wFD7y4VA_18_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-2392822</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_6dnORrlExUaYXXjkT7BT8A_18_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-4967576</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="2"
      id="Tc_ppRtnx6mokC3Cu0VMpBWVg_21_3"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">-0.27</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="2"
      id="Tc_ppRtnx6mokC3Cu0VMpBWVg_21_3_2"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">-0.27</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="2"
      id="Tc_srN3w7LZBkOfI_Hhnb2eFQ_21_6"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">-0.48</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="2"
      id="Tc_srN3w7LZBkOfI_Hhnb2eFQ_21_6_2"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">-0.48</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="2"
      id="Tc_JpOB3GcQTkyA1V5b1aT6VA_22_6"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="2"
      id="Tc_JpOB3GcQTkyA1V5b1aT6VA_22_6_2"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="2"
      id="Tc_tiwtYm9Grka06hTwZeihFA_23_3"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="2"
      id="Tc_tiwtYm9Grka06hTwZeihFA_23_3_2"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="2"
      id="Tc_xUl_jG-65kWruJOEbt-S_w_23_6"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">-0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="2"
      id="Tc_xUl_jG-65kWruJOEbt-S_w_23_6_2"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">-0.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_BtW_X9ji10moSYyPNXYLBg_26_3"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8901962</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_ikSLvETCjU-meWuYan_b8w_26_6"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8721031</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_ongVgJC-I0mNjk0ZdwgIVg_27_3"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8901962</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_6FOEusaym06wJ7AmBYsm1Q_27_6"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8721031</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p2J4oIHCPEuZlK3Ssu23sA"
      decimals="INF"
      id="Tc_gMbFn58QHkuxiYMfP8p0BA_5_2"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8891420</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p2J4oIHCPEuZlK3Ssu23sA"
      decimals="0"
      id="Tc_OWsp8W0ulk6JcMXR75r1kw_5_5"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">8891</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dPQr3dLFZE-DSSf241ybww"
      decimals="0"
      id="Tc_AgN4EIrkCkyfgDCQtkdyXA_5_8"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">450329515</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_O2ehFFy9IkO1iNk3wb4ojA"
      decimals="0"
      id="Tc_yRZJZljvoEKxzWY5maQg8A_5_11"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-436285863</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_16IYXOUHp0yaYUyPUNGsdA_5_14"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">14052543</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4CuqoUChNU6LCLMJQNy2vg"
      decimals="INF"
      id="Tc_bsLOFFgWx0i5G0zRpUiM7Q_6_2"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">19497</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4CuqoUChNU6LCLMJQNy2vg"
      decimals="0"
      id="Tc_gb5AcMJmXUyqSCVcR3_c2w_6_5"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">19</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J_5wr1xoCUiUQha0LU7yxQ"
      decimals="0"
      id="Tc_qS5fjvnEsEiEsLuvZjtgDg_6_8"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">49077</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_8yLdFWlao0mf6xMxo0oK8w_6_14"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">49096</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_J_5wr1xoCUiUQha0LU7yxQ"
      decimals="0"
      id="Tc_zZF3f_1IGEqNlv-5bWPfpg_7_8"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">79417</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_OnlVWiBESkebU-JsI9OebQ_7_14"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">79417</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wroXSHfJ30-xSPaXlw7fRg"
      decimals="0"
      id="Tc_93H0gkAFkkudnMzPihZWYQ_8_11"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-2392822</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_pzeVdXROT0i195WTxQe8zQ_8_14"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-2392822</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L3GqS7LIaEaMZLbGeyWEVw"
      decimals="INF"
      id="Tc_ijIAy9WkjkSVd1t9i-m_eA_9_2"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8910917</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L3GqS7LIaEaMZLbGeyWEVw"
      decimals="0"
      id="Tc_c8lKYvyPRkKDYEx4ponA9w_9_5"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">8910</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hteoEo475kS8tfpScfdJoA"
      decimals="0"
      id="Tc_YhLpHTKhEka8aZet6l_EPA_9_8"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">450458009</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PKZChDUbxEO2qD8-67k5Hw"
      decimals="0"
      id="Tc_0QiMklXgcUqeWp9vT-sScA_9_11"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-438678685</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_4B55WbgL3ke9MRLJxhcJaQ_9_14"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">11788234</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj8-kTaoPUeqeGIfHnTabg"
      decimals="INF"
      id="Tc_Aq4T4o4pV0iLLo1nLsmAPw_5_2"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8405771</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bj8-kTaoPUeqeGIfHnTabg"
      decimals="0"
      id="Tc_tpZOmReiVUKjEg_350H47g_5_5"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">8406</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bkjZN5Y5rEWwwaBWPP47cQ"
      decimals="0"
      id="Tc_NEO4AWPQOEaPLf0iuKPWUg_5_8"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">447641680</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dAcdkzltg0mbv8cPmlI6WA"
      decimals="0"
      id="Tc_X9SGYKUgm0-XcODhmHvEmg_5_11"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-428049049</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_dDnDDGPKLkOOtV5YB9PuYg"
      decimals="0"
      id="Tc_E7lW4N-HoUGcoUnSRDuGvQ_5_14"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">19601037</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yie4PE_5UKKtvhQWc8ymQ"
      decimals="INF"
      id="Tc_CwYUFWAQck6BzauOs5odqQ_6_2"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">212761</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yie4PE_5UKKtvhQWc8ymQ"
      decimals="0"
      id="Tc_DfYkjLsVdkeAh7XvgFwzmQ_6_5"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">213</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kLbzwvujTEy1z59aTzl4IQ"
      decimals="0"
      id="Tc_Beobs0OBk0mbra-f0GFOLg_6_8"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">619761</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_y6-Y4Bmp70yXYZXJrUsCXg_6_14"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">619974</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mrkr:IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yie4PE_5UKKtvhQWc8ymQ"
      decimals="INF"
      id="Tc_RTNj1EDDqE-AiyPPlM4bSw_7_2"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">180410</mrkr:IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing>
    <mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yie4PE_5UKKtvhQWc8ymQ"
      decimals="0"
      id="Tc_kLx1W3IKO0yWUfqzVBgkEg_7_5"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">180</mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing>
    <mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kLbzwvujTEy1z59aTzl4IQ"
      decimals="0"
      id="Tc_FYTGKF2FDEKpBsobT8qaqQ_7_8"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-180</mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kLbzwvujTEy1z59aTzl4IQ"
      decimals="0"
      id="Tc_0IJjBfHojU6t0RZaUFehAg_8_8"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">659913</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_vWlZJAS13Uqa8BhEOGgbRQ_8_14"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">659913</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HbuT4I4LOEWfD8qUtjixAQ"
      decimals="0"
      id="Tc_Vmz-pSM3tk67G2IeDZT6vg_9_11"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-4967576</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_QIG_PccDLE-fUUGBek9xLw_9_14"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-4967576</us-gaap:NetIncomeLoss>
    <mrkr:StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3yie4PE_5UKKtvhQWc8ymQ"
      decimals="INF"
      id="Tc_hIYUmLpu5EqtLPooG-vItA_10_2"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">-113</mrkr:StockIssuedDuringPeriodSharesFractionalSharesAdjustmentDueToReverseSplit>
    <us-gaap:SharesIssued
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ARak6biMC0C2vE3aHgU_OA"
      decimals="INF"
      id="Tc_oiMsJvD900KksAHkACRXEg_11_2"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8798829</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ARak6biMC0C2vE3aHgU_OA"
      decimals="0"
      id="Tc_m3rUzgog8UuL3E34MMqa0Q_11_5"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">8799</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TabWhcOewUWWAHC4rI6AMA"
      decimals="0"
      id="Tc_7bniK7afSUOTsIiZXjZ6Vg_11_8"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">448921174</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PUYOhITdW02F2X4CUsXlkg"
      decimals="0"
      id="Tc_qCjbZO06IkSveuTgU2fFGQ_11_11"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-433016625</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_N3CIHFtK7keuOQ6DeBbsBg"
      decimals="0"
      id="Tc_1NgzgRcdkUSZiE8NckN0PQ_11_14"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">15913348</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_pIglNnSgSUiQhbb52b1zbQ_5_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-2392822</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_uXID9GdfDka9jltSxsuVog_5_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-4967576</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_IfkVdqM97km8RUyUAiTpLQ_6_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-742751</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_lcbyPeLfb0eT_CcPN0iQWw_7_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-2392822</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_oUPYmP8uoEGVUU0rN1u8Yg_7_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-4224825</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_lq2JRNT8MU-vNgNxW654ZQ_9_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">79417</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_IBQLQl-B3EiHu1zJBRWHpQ_9_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">659913</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_tCr5Hyht80-MzSA7k-19DQ_11_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-71117</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_cpUt-5ELr0mfHdO8s6DIUw_11_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-36452</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_OMrJdOVM0Ea3ceWWd4Fu3Q_12_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">823647</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_-qGDVmD8dEikk5MwMk5Qyg_12_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-1319118</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_QsyPFBkQr0GRW8q8TsiAMQ_13_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1000000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_BgXNCluRRUu7jyMxAybI5Q_14_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-975690</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_y3hF3Hn36E2zgSYLvYOftQ_15_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">204507</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_zjmD2agEpkeuCKaDsyia5w_15_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">111171</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_hzz546DGK0m80ZEYiFDHeA_16_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-3837118</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_RfPvo9M5_0OjHhObc-RbMg_16_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-3098171</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_cknQWdozXEuqWpuL47uv7A_17_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-2790124</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_rOqCM3aFSU-cpE3EA5fotA_18_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-3837118</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_-tFCi7TFtkOJUEYoplS8EQ_18_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-5888295</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_6PNoe54o10KJr6CT3Powlg_20_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-112608</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_wjZ3km3ksU-ctaPTOAAD0g_21_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-112608</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_UR8Htp18GUagpDbLRaMnxw_23_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">619974</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_NhVyLSc0AEqotu6P57Kkzw_24_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">49096</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_bypCZ-RUo0yiQvQPLm2INA_25_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">49096</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_rDeN8Jq9s0a4LFlpBiJeBQ_25_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">619974</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_HX2ES10j60u2j7_SBqTESw_26_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-3788022</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_csU2UliTIkqdmG5d0iQ5PA_26_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-5380929</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_la1NGz_w3EmJGDg_sH_q7g_27_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">15111450</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_dDnDDGPKLkOOtV5YB9PuYg"
      decimals="0"
      id="Tc_A45sf6pCdUWC0m5FGXkZxw_27_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">11782172</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_EgjRfonGs0mWlvm05obl2g_28_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">11323428</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2023_N3CIHFtK7keuOQ6DeBbsBg"
      decimals="0"
      id="Tc_HUdnmsCeEEeyRIf0H_vZwQ_28_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">6401243</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <mrkr:NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_4TLCQrmhd0OMIXhTFeYtUA_31_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">180</mrkr:NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_Dnb6G9TagEutp0uuK1JWhw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;1: NATURE OF OPERATIONS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Marker Therapeutics, Inc., a Delaware corporation (the &#x201c;Company&#x201d; or &#x201c;we&#x201d;), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company&#x2019;s multi tumor associated antigen (multiTAA&#x201d;)-specific T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Purchase Agreement with Cell Ready&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On June 26, 2023, the Company completed the previously announced transaction with Cell Ready, LLC (&#x201c;Cell Ready&#x201d;) pursuant to a Purchase Agreement (the &#x201c;Cell Ready Purchase Agreement), dated May 1, 2023, by and between the Company and Cell Ready. Mr. John Wilson is a member of the Company&#x2019;s board of directors and is serving as the CEO of Cell Ready, therefore Cell Ready is a related party. Pursuant to the Cell Ready Purchase Agreement, effective as of the Closing Date, the Company (i) assigned to Cell Ready the leases for the Company&#x2019;s two manufacturing facilities in Houston, Texas (the &#x201c;Manufacturing Facilities&#x201d;), (ii) sold to Cell Ready all of the equipment and leasehold improvements at the Manufacturing Facilities and (iii) assigned to Cell Ready its rights, title and interest in the Company&#x2019;s Master Services Agreement for Product Supply (the &#x201c;MSA&#x201d;), dated April 7, 2023, by and between the Company, Cell Ready and Indapta Therapeutics, Inc., as well as its rights, title and interest in any contracts related to the equipment and Manufacturing Facilities (collectively, the &#x201c;Purchased Assets&#x201d;). Cell Ready acquired the Purchased Assets for total consideration of $19.0 million. In connection with the purchase of the Manufacturing Facilities, Cell Ready also extended offers of employment to approximately 50 of the Company&#x2019;s former employees in its manufacturing, development, quality, and regulatory affairs functions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Purchased Assets constituted a significant disposition. Based upon the magnitude of the disposition and because the Company is exiting certain manufacturing operations, the disposition represents a significant strategic shift that will have a material effect on the Company&#x2019;s operations and financial results. Accordingly, the assets sold meet the definition of a discontinued operation, as defined by Accounting Standards Codification (&#x201c;ASC&#x201d;) 205-20 &#x2013; Discontinued Operations, and prior comparative periods have been retroactively adjusted to reflect the current presentation. See additional discussion at Note 7.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On February 22, 2024, we entered into a Master Services Agreement for Product Supply (the &#x201c;MSA&#x201d;) with Cell Ready to provide outsourced services previously performed by the Company prior to its asset sale to Cell Ready. Cell Ready, which is owned by one of our directors and shareholders, Mr. John Wilson, is a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. If the services involve the supply of product, Cell Ready is required to supply such product in conformance with the product requirements set forth in the applicable work order(s). Under the MSA, Cell Ready is to use only personnel with sufficient qualifications and experience to supply the services contemplated by the MSA, provide its personnel with adequate training and assume full responsibility for its personnel&#x2019;s compliance with the MSA. Further, Cell Ready is required to provide the Company with assistance and cooperation in order for the Company to obtain and maintain all necessary regulatory approvals, at the Company&#x2019;s expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Organizational Changes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In 2023, the Company implemented changes to its organizational structure due to the transaction with Cell Ready and to reduce operational costs. In connection with these changes, the Company reduced headcount, including the separation of its former Chief Executive Officer, Peter Hoang, in May 2023, and its former Chief Accounting Officer, Michael Loiacono, in June 2023. During the second quarter of 2023, the Company recorded $0.9 million of severance and termination-related costs. The payments of these costs were completed in July of 2023. Effective May 1, 2023, the Company&#x2019;s board of directors appointed Dr. Juan Vera as the Company&#x2019;s President and Chief Executive Officer. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Effective June 30, 2023, the board of directors appointed Eliot M. Lurier as the Company&#x2019;s Interim Chief Financial Officer, whereby Mr. Lurier provided consulting services to the Company pursuant to a consulting agreement between the Company and Danforth Advisors, LLC (&#x201c;Danforth&#x201d;) and received no compensation directly from the Company. On November 17, 2023, the Company terminated the consulting agreement between the Company and Danforth, effective January 16, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 17, 2023, Mr. Lurier ceased serving as the Company&#x2019;s Interim Chief Financial Officer and Dr. Vera was appointed as the Company&#x2019;s Principal Financial and Accounting Officer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On January 26, 2023, the Company effected a one-for-ten (1-for-10) reverse stock split of its common stock (the &#x201c;Reverse Stock Split&#x201d;) and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="As_Of_6_26_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_XIIQwpm8KkCnK2MdeGDs6g"
      decimals="-5"
      id="Narr_kHIA40vHTkSBYESdnjdXiA"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">19000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <mrkr:OffersEmploymentToNumberOfEmployees
      contextRef="Duration_6_26_2023_To_6_26_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_I4S7uiZnTE-bi56dzKi0tw"
      decimals="INF"
      id="Narr_z1j6kAHJNEyA5rfU9eM6hA"
      unitRef="Unit_Standard_employee_YXZ7VHgYFkK0MKSPoxHTNQ">50</mrkr:OffersEmploymentToNumberOfEmployees>
    <us-gaap:SeveranceCosts1
      contextRef="Duration_4_1_2023_To_6_30_2023_wZXVoXh7Q0KniAnmTI3IqA"
      decimals="-5"
      id="Narr_7xd0VSYl_E-Q8DH5eoVDxg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">900000</us-gaap:SeveranceCosts1>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="Duration_1_26_2023_To_1_26_2023_awyJo1ParUe6ER8qP8Er1Q"
      id="Narr_myqp_mw2dEqXRMoMkAvWUA">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_1_26_2023_srt_RangeAxis_srt_MaximumMember_e2_Hkwej-0-x0rfYttNybA"
      decimals="INF"
      id="Narr_CRoFtsxdq02OoXPHz1oEsg"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_1_26_2023_srt_RangeAxis_srt_MinimumMember_PkV5_ayFjkm8F2rhSnUmqw"
      decimals="INF"
      id="Narr_w9XXpVf7xUm1SP5kpIExmw"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:BasisOfAccounting
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_fhnX5OfzDEeUylhYbx0UJQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;2: BASIS OF PRESENTATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results (see Note 7 for information on discontinued operations).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The results for the unaudited condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2024, or for any future interim period. The condensed consolidated balance sheet at December 31, 2023 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2023 and notes thereto included in the Company&#x2019;s annual report on Form 10-K filed on March 26, 2024.&lt;/p&gt;</us-gaap:BasisOfAccounting>
    <mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_SqWBMw6gkEu9DKEC7mEFHA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;3: LIQUIDITY AND FINANCIAL CONDITION &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of March 31, 2024, the Company had cash and cash equivalents of approximately $11.3 million. The Company&#x2019;s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company&#x2019;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing; successfully progress its product candidates through preclinical and clinical development; obtain regulatory approval of one or more of its product candidates; maintain and enforce intellectual property rights; develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity, debt financings and grants. In August 2021, the Company entered into a Controlled Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement (the &#x201c;ATM Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. and RBC Capital Markets, LLC (the &#x201c;Sales Agents&#x201d;), pursuant to which the Company can offer and sell, from time to time at its sole discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $75.0 million. Any shares of its common stock sold will be issued pursuant to the Company&#x2019;s shelf registration statement on Form S-3 (File No. 333-258687), which the SEC declared effective on August 19, 2021. However, our use of the shelf registration statement on Form S-3 will be limited for so long as we are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement and in accordance with the ATM agreement. The Sales Agents are entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and we have provided each of the Sales Agents with indemnification and contribution rights. During the three months ended March 31, 2023, the Company sold 200,261 shares of its common stock under the ATM Agreement for proceeds of $0.6 million. There was no common stock issued under the ATM Agreement during the three months ended March 31, 2024. In April 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement resulting in net proceeds of $0.04 million, after deducting agent commissions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (&#x201c;CPRIT&#x201d;) to support the Company&#x2019;s clinical investigation of MT-401. Through the date of this filing, the Company has received $6.9 million of funds from the CPRIT grant. The Company recorded $0.8 million of grant income related to the CPRIT grant as revenue for the three months ended March 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In September 2022, the Company received notice from the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) that it had awarded the Company a $2.0 million grant from the FDA&#x2019;s Orphan Products Grant program to support the Company&#x2019;s clinical investigation of MT-401 for the treatment of post-transplant AML Through the date of this filing, the Company has received $0.8 million from the FDA grant. The Company recorded $0.3 million and $0.1 million of grant income related to the FDA grant as revenue for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, the Company recorded $0.3 million of grant income receivable, which represented grant income earned in advance of funds to be received from the FDA. In April 2024, the Company received $0.3 million of funds from the FDA grant. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In May 2023, the Company received notice of a $2.0 million grant from the National Institutes of Health Small Business Innovation Research (&#x201c;SBIR&#x201d;) program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents. Through the date of this filing, the Company has received $0.4 million from SBIR. The Company recorded $0.2 million of grant income related to the SBIR grant as revenue for the three months ended March 31, 2024. As of March 31, 2024, the Company recorded $0.2 million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In April 2024, the Company received $0.2 million of funds from the SBIR grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As described in Note 1, on June 26, 2023, the Company completed the transaction with Cell Ready pursuant to the Cell Ready Purchase Agreement for total consideration of $19.0 million. On February 22, 2024, the Company entered into a Master Services Agreement for Product Supply (the &#x201c;MSA&#x201d;) with Cell Ready, a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company expects to continue to incur substantial losses over the next several years during its development phase.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Based on the Company&#x2019;s clinical and research and development plans and its timing expectations related to the progress of its programs, the Company expects that its cash and cash equivalents as of March 31, 2024, including drawdowns of available grant funds, will enable the Company to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2025. Prior to the Cell Ready transaction, there was substantial doubt regarding the Company&#x2019;s ability to continue as a going concern, which was alleviated by the proceeds from the transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has based this estimate on assumptions that may prove to be wrong, and the Company could utilize its available capital resources sooner than it currently expects. Furthermore, the Company&#x2019;s operating plan may change, and it may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of the Company&#x2019;s product candidates and the extent to which the Company may enter into additional collaborations with third parties to participate in their development and commercialization, the Company is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated clinical trials. The Company&#x2019;s future funding requirements will depend on many factors, as it: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;initiates or continues clinical trials of its product candidates;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;continues the research and development of its product candidates and seeks to discover additional product candidates;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;seeks regulatory approvals for any product candidates that successfully complete clinical trials;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;maintains and enforces intellectual property rights;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;enters into contract manufacturing arrangements with Cell Ready or other contract manufacturing organizations for clinical manufacturing supply;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;establishes sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;evaluates strategic transactions the Company may undertake; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;enhances operational, financial and information management systems and hires additional personnel, including personnel to support development of product candidates and, if a product candidate is approved, commercialization efforts.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has sufficient cash available to meet its operating requirements for at least the next twelve months from the issuance of these financial statements. However, the Company does not have sufficient sources of revenue to provide incoming cash flows to sustain its future operations beyond the fourth quarter of 2025. As outlined above, its ability to pursue its long-term planned business activities is dependent upon its successful efforts to raise additional capital and grant income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The current macro-economic environment of decades-high inflation and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company&#x2019;s ability to access capital, which could in the future negatively affect the Company&#x2019;s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company&#x2019;s business and the value of its common stock.&lt;/p&gt;</mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="-5"
      id="Narr_z5NWMk1A_kWpL31Se-1WuA"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">11300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="As_Of_8_31_2021_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_090YrRTZKEOoBAZPdsIihw"
      decimals="-5"
      id="Narr_caFjhUT3wUaLlOzeuorGMQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">75000000.0</us-gaap:CommonStockSharesSubscriptions>
    <mrkr:CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_fMwy5Q-88kG0ISyjxlel4A"
      decimals="3"
      id="Narr_GzeD-3FilEqwwHaiZORhsA"
      unitRef="Unit_Standard_pure_Qbvl_Q3p3U-i5knuHKFQlQ">0.030</mrkr:CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_OIylfIWvwk61OIbrkzAtLg"
      decimals="INF"
      id="Narr_KeFSKWHGkEqYJSgB6m-LlA"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">200261</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_OIylfIWvwk61OIbrkzAtLg"
      decimals="-5"
      id="Narr_i5Ct3d1ysk6pTxG3FaRrig"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_h4ZLvIQokUOG-qQCkBlAeA"
      decimals="INF"
      id="Narr_IL_gWvZON0-BgmQeLA_RdQ"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_1_2024_To_4_30_2024_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_sE3cONnYgEmmcMHZ2wUk0g"
      decimals="INF"
      id="Narr_pm9uA5-6F0OH-s23ZH5eHg"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8178</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_4_1_2024_To_4_30_2024_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_sE3cONnYgEmmcMHZ2wUk0g"
      decimals="-4"
      id="Narr_28ix_zWqmkG_bG65y2TUXA"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">40000.00</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="Duration_8_31_2021_To_8_31_2021_wLINgxwAtEqXJr9cCHPb-A"
      decimals="-5"
      id="Narr_dYp3aCeg80qdUvqCh1EOuw"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">13100000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <mrkr:FundsReceivedFromCpritGrant
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="-5"
      id="Narr_GoVjXRTy2UmckfbpfvosuA"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">6900000</mrkr:FundsReceivedFromCpritGrant>
    <mrkr:RevenueFromGrantRelatedToCprit
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_GrantMember_dzr8lBZFQUCRXXMJiuJ70Q"
      decimals="-5"
      id="Narr_dScZaRDsTUKrpgIWIn1nRQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">800000</mrkr:RevenueFromGrantRelatedToCprit>
    <mrkr:GrantReceived
      contextRef="Duration_9_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_QKfSVv0dhkacuUG8PSdyzg"
      decimals="-5"
      id="Narr_gNeZw5grqE-lLhR1QBu_jw"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">2000000.0</mrkr:GrantReceived>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_9_n_o50vykCM5Ly004kRVQ"
      decimals="-5"
      id="Narr_NVp3u1GQFUifr9ftYTrXHQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">800000</mrkr:FundsReceivedFromGrant>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_9_n_o50vykCM5Ly004kRVQ"
      decimals="-5"
      id="Narr__p3iPRXpBkujLhywjTw2TA"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">300000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_dFfPvaLfIEikU4XiNmZE_A"
      decimals="-5"
      id="Narr_wqxWX2Yis0GYx_dSvp4Bkg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <mrkr:OrphanProductsGrantProgram
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="-5"
      id="Narr_VvkqwOxZ0EOnkk9PF8HBhQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">300000</mrkr:OrphanProductsGrantProgram>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_4_1_2024_To_4_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_b7OtDgPp-kyyI1YWR77jEA"
      decimals="-5"
      id="Narr_3zmf0q4t50SVXsNz79-4sA"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">300000</mrkr:FundsReceivedFromGrant>
    <mrkr:GrantReceived
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_t3VLl29vOk-QUwtoTypBUw"
      decimals="-5"
      id="Narr_lEd5sNbPjE2ztqM_ss-AWg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">2000000.0</mrkr:GrantReceived>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_K-XuDOatfU2spHjQPAU4OA"
      decimals="-5"
      id="Narr_eg4pXPbok0K8PDsToAfwhA"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">400000</mrkr:FundsReceivedFromGrant>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_K-XuDOatfU2spHjQPAU4OA"
      decimals="-5"
      id="Narr_0ZPXIw4PcEiU9Hc-1lDw3g"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherReceivables
      contextRef="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_xgSQFi7SKUC3P-uEqMdsgQ"
      decimals="-5"
      id="Narr_n2UKfHxLN0qmNkeUc51TGQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">200000</us-gaap:OtherReceivables>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_4_1_2024_To_4_30_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_YTxnqMIXBE2WBHHgARjHqg"
      decimals="-5"
      id="Narr_Lom6d0NqRU6MbY7EEUFOHw"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">200000</mrkr:FundsReceivedFromGrant>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="As_Of_6_26_2023_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember__S3prYqHtE6Us-UKNLgTqA"
      decimals="-5"
      id="Narr_QBrXpJ6bQ0-pz-q0v0U6og"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">19000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_VPBE6sfnFkKok_OC3GT0NQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;4: SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals Inc. &#x2013; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada, Inc. All significant intercompany balances and transactions are eliminated upon consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results may differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies, controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense and income taxes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash, Cash Equivalents and Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at March 31, 2024 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limits of $250,000. As of March 31, 2024, the Company had approximately $1.4 million in cash at financial institutions and approximately $9.9 million in U.S. government agency securities, for aggregate cash and cash equivalents of $11.3 million. As of December 31, 2023, the Company had approximately $1.4 million in cash at financial institutions and approximately $13.7 million in U.S. government agency securities, for aggregate cash and cash equivalents of $15.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In the event cash is received from grants in advance of incurring qualifying costs, it is recorded as restricted cash until it is earned and recorded to grant income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Discontinued Operations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Purchased Assets sold to Cell Ready pursuant to the Cell Ready Purchase Agreement constituted a significant disposition and as such, the Company concluded that the disposition of its Purchased Assets represented a strategic shift that had a major effect on its operations and financial results. Therefore, the Purchased Assets, related party revenue, service revenue and related expenses are classified as discontinued operations for all periods presented herein. See Note 7 for further information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Improvements to Reporetable Segment Disclosures&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2023, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued Accounitng Standards Update (&#x201c;ASU&#x201d;) No. 2023-07, Segement Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, among other provisions. The ASU is effective for fiscal year periods beginning after December15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the ASU requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the standard to determine the impact of adoption to its consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Improvements to Income Tax Disclosures&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregtion of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption the guidance can be applied prospectively or retrospectively. We do not expect the adoption of this guiadance to have a material impact on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its consolidated financial position or results of operations upon adoption.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;There have been no material changes in the Company&#x2019;s significant accounting policies to those previously disclosed in the Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 26, 2024.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_GEwIZdV0VUKQykMWgmdJKQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals Inc. &#x2013; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada, Inc. All significant intercompany balances and transactions are eliminated upon consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_EAfUA6JwfkiVuL-CgEfFyg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results may differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies, controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense and income taxes.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_mCGdelzC8kGxJryU5U2H0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash, Cash Equivalents and Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at March 31, 2024 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limits of $250,000. As of March 31, 2024, the Company had approximately $1.4 million in cash at financial institutions and approximately $9.9 million in U.S. government agency securities, for aggregate cash and cash equivalents of $11.3 million. As of December 31, 2023, the Company had approximately $1.4 million in cash at financial institutions and approximately $13.7 million in U.S. government agency securities, for aggregate cash and cash equivalents of $15.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In the event cash is received from grants in advance of incurring qualifying costs, it is recorded as restricted cash until it is earned and recorded to grant income.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <mrkr:CashAtFinancialInstitutions
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="-5"
      id="Narr_3jfdukdB9kubSrcAkORkaw"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1400000</mrkr:CashAtFinancialInstitutions>
    <us-gaap:USGovernmentAgenciesSecuritiesAtCarryingValue
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="-5"
      id="Narr_l4ijpHzo_0qqbPj_ihAzkQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">9900000</us-gaap:USGovernmentAgenciesSecuritiesAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="-5"
      id="Narr_mjdQQuYzPk-bD4XmmGWEOg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">11300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <mrkr:CashAtFinancialInstitutions
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="-5"
      id="Narr_GHAdnjAXVEyssLu_yfYijQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1400000</mrkr:CashAtFinancialInstitutions>
    <us-gaap:USGovernmentAgenciesSecuritiesAtCarryingValue
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="-5"
      id="Narr_A_yFgu05tUigR1KRd61Hvw"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">13700000</us-gaap:USGovernmentAgenciesSecuritiesAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="-5"
      id="Narr_84fAV0AonkS9NQXWAuOohQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">15100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_LY3tGopLiE6_RXH9ruToDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Discontinued Operations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Purchased Assets sold to Cell Ready pursuant to the Cell Ready Purchase Agreement constituted a significant disposition and as such, the Company concluded that the disposition of its Purchased Assets represented a strategic shift that had a major effect on its operations and financial results. Therefore, the Purchased Assets, related party revenue, service revenue and related expenses are classified as discontinued operations for all periods presented herein. See Note 7 for further information.&lt;/p&gt;</us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <mrkr:RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_26zc2tPuFEG7qHdQm20WqQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Improvements to Reporetable Segment Disclosures&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2023, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued Accounitng Standards Update (&#x201c;ASU&#x201d;) No. 2023-07, Segement Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, among other provisions. The ASU is effective for fiscal year periods beginning after December15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the ASU requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the standard to determine the impact of adoption to its consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Improvements to Income Tax Disclosures&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregtion of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption the guidance can be applied prospectively or retrospectively. We do not expect the adoption of this guiadance to have a material impact on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its consolidated financial position or results of operations upon adoption.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;There have been no material changes in the Company&#x2019;s significant accounting policies to those previously disclosed in the Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 26, 2024.&lt;/p&gt;</mrkr:RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_oOZAo9eZV0a1kq68PPfPXg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;5: NET LOSS PER SHARE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table sets forth the computation of net loss per share for the three months ended March 31, 2024 and 2023, respectively:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,392,822)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,224,825)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (742,751)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,392,822)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,967,576)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average common shares outstanding, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,901,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,721,031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average common shares outstanding, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,901,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,721,031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net earnings (loss) per share:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from continuing operations, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.27)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.48)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from discontinued operations, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.09)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.27)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.57)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following securities, rounded to the nearest thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 639,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,297,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock purchase warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,848,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Potentially dilutive securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 639,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,145,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_AOWvAvlIGU2RjwW29ApRng">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,392,822)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,224,825)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (742,751)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,392,822)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,967,576)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average common shares outstanding, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,901,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,721,031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average common shares outstanding, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,901,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,721,031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net earnings (loss) per share:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from continuing operations, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.27)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.48)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from discontinued operations, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.09)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.27)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.57)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_lj0jrUbL1ES_VoYLn1twhg_5_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-2392822</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_BFUh4z-_Pky9r5r146HRtg_5_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-4224825</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_-xL7INOxkk-ARyuhjuLP7w_6_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-742751</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_H6Dzq24v3EaCV93Vs_Tivg_7_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-2392822</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_aTKbLUJU30qhLUa2oERYeg_7_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-4967576</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_2nC5U1mDqk6Mz9FMn_s8FQ_10_3"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8901962</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_2mABBukpukC4Ohot4IGDJQ_10_6"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8721031</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_1-7zsTrFbEG2QWyUKVjTyg_11_3"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8901962</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_G4T6iF7ts0K3s4CJrUOGLg_11_6"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8721031</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="2"
      id="Tc_q-0_2XmY6USw8sVHreOyLA_14_3"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">-0.27</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="2"
      id="Tc_zPOr3yDRX0y8LRIpVvxpPw_14_6"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">-0.48</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="2"
      id="Tc_wqRcIkapzEShMmCn2PX7tA_15_6"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="2"
      id="Tc_M4So9eSkx0itoikB8O10MA_16_3"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="2"
      id="Tc_4GntlMQphUi_hpYWWVfPtQ_16_6"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">-0.57</us-gaap:EarningsPerShareBasic>
    <mrkr:NetLossPerShareTableTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_HBDv7Y9jq0OQI19YlZbKmw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 639,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,297,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock purchase warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,848,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Potentially dilutive securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 639,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,145,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</mrkr:NetLossPerShareTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_W07D8lnky0aimmBd-R3YIg"
      decimals="INF"
      id="Tc_1d42pasvyEarPqtVO-JTLg_4_2"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">639000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_65JWbw2x0UWpZJA7_fd3rA"
      decimals="INF"
      id="Tc_pPO_8iERvk-OBXYG1JBHdw_4_4"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">1297000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BuQkUd2NSUCXfasuFdBgPA"
      decimals="INF"
      id="Tc_zrpthvJsZU67KarEwNlUjQ_5_4"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">1848000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="INF"
      id="Tc_vlPpw9d950Wnr6g-e8RRqA_6_2"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">639000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="INF"
      id="Tc_pj6qC4GHIkuHVFdG7Ibi_A_6_4"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">3145000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_iRLyX7mPSEukaa97wr-WVg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 6: OTHER RECEIVABLE&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. The Company recorded $0.8 million and $1.2 million of grant income related to the CPRIT grant for the three months ended March 31, 2024 and 2023, respectively. At March 31, 2024, the Company recorded $1.2 million of grant income receivable related to the CPRIT grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Additionally, the Company recorded $0.3 million and $0.2 million of grant income related to the FDA and SBIR grants, respectively, for the three months ended March 31, 2024. At March 31, 2024, the Company recorded $0.3 million and $0.2 million of grant income receivable related to the FDA and SBIR grants, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company received $0.3 million and $0.2 million of funds from FDA and SBIR in April 2024, respectively.&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:TenantImprovements
      contextRef="As_Of_3_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_hcxj8tGJMUufaz5d7_ww7g"
      decimals="-5"
      id="Narr_ZMSwoW5vqkK4-owyQT3NnQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">800000</us-gaap:TenantImprovements>
    <us-gaap:TenantImprovements
      contextRef="As_Of_3_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_7HG6TYGhSkuj85Yk7cyx0g"
      decimals="-5"
      id="Narr_2HYOyWU6MkyrGFA6liUljA"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1200000</us-gaap:TenantImprovements>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_3_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_hcxj8tGJMUufaz5d7_ww7g"
      decimals="-5"
      id="Narr_xHCiXMIYjU2DYOHcWC9GCQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1200000</us-gaap:OtherReceivablesNetCurrent>
    <mrkr:RevenueFromOrphanProductsGrantProgram
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_9_n_o50vykCM5Ly004kRVQ"
      decimals="-5"
      id="Narr_huog3dC6NkqPQFCyhLbbpA"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">300000</mrkr:RevenueFromOrphanProductsGrantProgram>
    <mrkr:RevenueFromOrphanProductsGrantProgram
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_K-XuDOatfU2spHjQPAU4OA"
      decimals="-5"
      id="Narr_EdCrK7QxnECUc64n76AsAA"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">200000</mrkr:RevenueFromOrphanProductsGrantProgram>
    <mrkr:OrphanProductsGrantProgram
      contextRef="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember__N7KeTtie0WOfM9lUAInzQ"
      decimals="-5"
      id="Narr_o_5sSG9WvEub6LOZp6RNSQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">300000</mrkr:OrphanProductsGrantProgram>
    <mrkr:OrphanProductsGrantProgram
      contextRef="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_xgSQFi7SKUC3P-uEqMdsgQ"
      decimals="-5"
      id="Narr_Y7F4AGASEUinPpGhmylPNg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">200000</mrkr:OrphanProductsGrantProgram>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_4_1_2024_To_4_30_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_0K6azYZMnkS3HVng864fgA"
      decimals="-5"
      id="Narr_RwtuyXir5k2Ixa_G-AcknQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">300000</mrkr:FundsReceivedFromGrant>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_4_1_2024_To_4_30_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_YTxnqMIXBE2WBHHgARjHqg"
      decimals="-5"
      id="Narr_Z7AY1CJKL0a3eHYqrvpjMQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">200000</mrkr:FundsReceivedFromGrant>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_AT3lwiBXZ0GwOLtCeby0qg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 7: DISCONTINUED OPERATIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;As discussed in Note 1, on June 26, 2023, the Company completed the previously announced transaction with Cell Ready for cash consideration of $19.0 million, resulting in derecognition of the Purchased Assets and a gain on sale of approximately $8.7 million, net of $63,000 in tax. There were no remaining assets and liabilities classified in discontinued operations as of March 31, 2024 or December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company had no activity related to discontinued operations for the three months ended March 31, 2024. Net loss from discontinued operations for the three months ended March 31, 2023, was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Three&#160;Months&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenues:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;"&gt;Related party service revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating expenses:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,894,245&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 348,506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,242,751&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (742,751)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes our cash flows related to discontinued operations for the three months ended March 31, 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Three&#160;Months&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Discontinued operations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;"&gt;Net cash used in operating activities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,790,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;"&gt;Net cash used in investing activities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (113,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Net decrease in cash and cash equivalents from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,903,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Related Party Service Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In April 2022, the Company entered into a binding services agreement (&#x201c;Wilson Wolf Agreement&#x201d;) with Wilson Wolf Manufacturing Corporation (&#x201c;Wilson Wolf&#x201d;). Mr. John Wilson is a member of the Company&#x2019;s board of directors and is serving as the CEO of Wilson Wolf. Wilson Wolf is in the business of creating products and services intended to simplify and expedite the transition of cell therapies and gene-modified cell therapies to mainstream society (the &#x201c;Wilson Wolf Mission&#x201d;). Pursuant to the Wilson Wolf Agreement, Wilson Wolf made a cash payment to the Company in the amount of $8.0 million, as consideration for certain training and research services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In March 2023, the Company recognized the final $2.5 million of revenue pursuant to this $8.0 million agreement and an additional $1.0 million because certain agreed milestones were met. The additional $1.0 million of service fee revenue recognized during the three months ended March 31, 2023 was received in May 2023.&lt;/p&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="As_Of_6_26_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_XIIQwpm8KkCnK2MdeGDs6g"
      decimals="-5"
      id="Narr_yXQeoB4i4kybeijP2iMQwQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">19000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="Duration_6_26_2023_To_6_26_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_I4S7uiZnTE-bi56dzKi0tw"
      decimals="-5"
      id="Narr_TM6Sdo1WkUuPUSoUp-qNDA"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">8700000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="Duration_6_26_2023_To_6_26_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_I4S7uiZnTE-bi56dzKi0tw"
      decimals="0"
      id="Narr_gNDFB5kuHEWXHk7Sn5Zfxg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">63000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Group_wgrvcA1ucky9_DHVPtiLIg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Three&#160;Months&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenues:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;"&gt;Related party service revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating expenses:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,894,245&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 348,506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,242,751&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (742,751)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Three&#160;Months&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Discontinued operations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;"&gt;Net cash used in operating activities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,790,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;"&gt;Net cash used in investing activities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (113,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Net decrease in cash and cash equivalents from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,903,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_HuG04-O0U0-9tr34MqB3RA"
      decimals="0"
      id="Tc_6MLpgD2OPkqvT1LimFd4aw_5_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">3500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="Duration_1_1_2023_To_12_31_2023_0E4EMJOdr0W3g33PvIH_sQ"
      decimals="0"
      id="Tc_HquRAuZrUkePQxJhrODvdQ_6_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">3500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_caUp8WmODEqDoW7woCj3OA"
      decimals="0"
      id="Tc_Z5lUWu2e1kSrL7MpJrFz-g_8_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">3894245</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_csS-ol7uukaNejaEqG1D1Q"
      decimals="0"
      id="Tc_SXrqhDJyUEK0KIdLCbMJSg_9_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">348506</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_0E4EMJOdr0W3g33PvIH_sQ"
      decimals="0"
      id="Tc_eHNCm0ZnOUiL3-Q-4USh5Q_10_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">4242751</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_0E4EMJOdr0W3g33PvIH_sQ"
      decimals="0"
      id="Tc_74PfVAEoJkueUlyF8gVtNA_11_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-742751</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_u5io9Qini0SROgijz_sG3Q"
      decimals="0"
      id="Tc_-6zuHicpWUOBIhH8jag-AQ_5_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-2790000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_u5io9Qini0SROgijz_sG3Q"
      decimals="0"
      id="Tc_OKbLuuLCjk6kDyUPRZK8Vg_6_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-113000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInDiscontinuedOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="-3"
      id="Tc_lxQ7hYCwKkKUL-7CcvmCTw_7_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">-2903000</us-gaap:NetCashProvidedByUsedInDiscontinuedOperations>
    <us-gaap:OtherOperatingIncome
      contextRef="Duration_4_1_2022_To_4_30_2022_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_wPOXGWAUdk2rreQDgrYe6A"
      decimals="-5"
      id="Narr_rLs5nHQDPk-GZqDc2FUMCg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">8000000.0</us-gaap:OtherOperatingIncome>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_3_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_K0gVoKOl8EymtFxIsG-9UQ"
      decimals="-5"
      id="Narr_pdUtCUlIfkSvN3c6DbBuHw"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">2500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherOperatingIncome
      contextRef="Duration_3_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_K0gVoKOl8EymtFxIsG-9UQ"
      decimals="-5"
      id="Narr_aNgglSjFMUeRwrehMyvbDg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">8000000.0</us-gaap:OtherOperatingIncome>
    <mrkr:AdditionalRevenueRecognized
      contextRef="Duration_3_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_K0gVoKOl8EymtFxIsG-9UQ"
      decimals="-5"
      id="Narr_VcsyjXcwBUG9O3ayLWMMSg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1000000.0</mrkr:AdditionalRevenueRecognized>
    <mrkr:AdditionalRevenueRecognized
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_RelatedPartyServiceMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_FeJJ4O0CM0OwiGmy1OureA"
      decimals="-5"
      id="Narr_QD9aucCubUiJpSGz6_cvpQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1000000.0</mrkr:AdditionalRevenueRecognized>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_w7hYwIIYbkqR5-aWkKnemQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;8: ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accounts payable, accrued liabilities, and related party payable consist of the following as of March 31, 2024 and December 31, 2023, respectively:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,202,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 961,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 297,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 303,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Related party payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 354,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,330,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 116,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other taxes payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 126,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 103,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 203,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 205,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total accounts payable, accrued liabilities and related party payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,304,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,075,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The $0.4 million and $1.3 million related-party payable as of March 31, 2024 and December 31, 2023, respectively, reflects amounts payable to Cell Ready for outsourced product development and manufacturing services. See Note 13: Related Party Transactions.&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_WnCc29b4V0ChvdpGo7JEkg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,202,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 961,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 297,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 303,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Related party payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 354,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,330,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 116,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other taxes payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 126,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 103,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 203,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 205,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total accounts payable, accrued liabilities and related party payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,304,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,075,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_33nSZgW9_EylgtpxLMsmKA_3_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1202000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_QaJYEj7s50uT4tRQcz9ozQ_3_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">961000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_XFewb_yd0UefBObKp2PMhQ_4_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">57000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_ALrrLO5P9UWiio1UGexI7w_4_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">57000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_y9-XM6HTNkG1KPAIxmwlzw_5_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">297000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_oXAie1mTNki_VRnvBmTdoQ_5_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">303000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="-3"
      id="Tc_rN0rRwNYAECik7lJYjcBDA_6_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">354000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="-3"
      id="Tc_j3lMUkSf9U-tFzw3B9X5mw_6_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1330000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_4lNdtpmFS0SulDgUES4SKQ_7_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">65000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_SKNFMjaqZEiRBWn_eZazbA_7_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">116000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <mrkr:OtherTaxesPayableCurrent
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_TNcMMBblfEiWiPRLFjThrA_8_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">126000</mrkr:OtherTaxesPayableCurrent>
    <mrkr:OtherTaxesPayableCurrent
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc__W9e3lvInESRP79ICBWxag_8_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">103000</mrkr:OtherTaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_b509-iI3Ckuc27k1a0lN-A_9_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">203000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_5lurzNqBL0WoYBDEHLXbwQ_9_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">205000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <mrkr:AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="0"
      id="Tc_5Ur4MhyQj0e2soNhjiXNvA_10_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">2304000</mrkr:AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent>
    <mrkr:AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent
      contextRef="As_Of_12_31_2023_2GKlGH5st0qNhb1TBFSwwA"
      decimals="0"
      id="Tc_HbKOYpOCNEeTWXpl-AKi3g_10_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">3075000</mrkr:AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_3_31_2024_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_07W_qsYgcEudbi5GDRWobg"
      decimals="-5"
      id="Narr_lvRdiJCYRkuhY0N-K__L3g"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">400000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_8ps6npQK00elvbaMdGpAAw"
      decimals="-5"
      id="Narr_4JZU2sqg10ChKzVPr1b3xw"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_JPDWAj3NFkmRfgJ_XdDEVg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;9: STOCKHOLDERS&#x2019; EQUITY&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Reverse Stock Split&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On January 26, 2023, the Company effected the Reverse Stock Split and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All historical share and per share amounts reflected in this report have been adjusted to reflect the Reverse Stock Split.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Common Stock Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Issuance of Stock Pursuant to ATM Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company did not issue any common stock under the ATM Agreement for the three months ended March 31, 2024. During the three months ended March 31, 2023, the Company sold 200,261 shares of its common stock under the ATM Agreement for proceeds of $0.6 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Stock Purchase Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In December 2022, the Company entered into a purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with Lincoln Park which provides that, upon the terms and subject to the conditions of the agreement, the Company has the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of its common stock (the &#x201c;Purchase Shares&#x201d;) from time to time over a 24-month term, at a variable price with certain market-based terms as defined in the Purchase Agreement. The Purchase Agreement does not exhibit any of the characteristics for liability classification under ASC Topic 480, Distinguishing Liabilities from Equity. Instead, the purchase agreement is indexed to the Company&#x2019;s own stock under ASC Subtopic 815-40, &lt;i style="font-style:italic;"&gt;Contracts in Entity&#x2019;s Own Equity&lt;/i&gt;, and classified as equity. In January 2023, Lincoln Park was issued 180,410 shares of stock as a commitment fee at a value of $0.5 million. During the three months ended March 31, 2023, the Company sold 12,500 shares of its common stock under the Purchase Agreement for proceeds of approximately $33,000. The Company terminated the Purchase Agreement with Lincoln Park on February 29, 2024 effective March 1, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Exercise of Stock Options&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the three months ended March 31, 2024, certain outstanding options were exercised for 19,497 shares of common stock, providing aggregate proceeds to the Company of approximately $49,000.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_1_25_2023_UtL_c0KyKEWg0Dz7B0kqYA"
      decimals="INF"
      id="Narr__QusnTbF5ke897agqGoRYw"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_1_26_2023_lWBBv-azxUmgoxtZqB0QnQ"
      decimals="INF"
      id="Narr_ruHger4Z7EqsyvTqriJSjA"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_N9zarOSsVEuBpoYtfzkupQ"
      decimals="INF"
      id="Narr__7fDki4BKkqg_ozcNRy8fQ"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_v0PCHlsRw0uzmua5_m8DQg"
      decimals="INF"
      id="Narr_hb6LdPcFuEW_OVMLLYuUZQ"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">200261</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_v0PCHlsRw0uzmua5_m8DQg"
      decimals="-5"
      id="Narr_xPQexOuO7kaVYp84bH7R_Q"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_12_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_qmoIEv97Rk2jUyIAWQnjTA"
      decimals="0"
      id="Narr_unxEqLBqdEmgysLojX6IWA"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">25000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mrkr:StockPurchaseAgreementTimeToTimeTermToPurchaseShares
      contextRef="Duration_12_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_qmoIEv97Rk2jUyIAWQnjTA"
      id="Narr_w_GixDNrL0y_BZJ40jq2aQ">P24M</mrkr:StockPurchaseAgreementTimeToTimeTermToPurchaseShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_RKze1ypjXU6RtzdpbC9cRQ"
      decimals="INF"
      id="Narr_lSyDXDJ54kOyPA9GakBnlw"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">180410</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <mrkr:CommitmentFee
      contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_RKze1ypjXU6RtzdpbC9cRQ"
      decimals="-5"
      id="Narr_WDgGZ_HjxEWFOGsoX3eIdw"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">500000</mrkr:CommitmentFee>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_n7CziHvjvE--LojpNufD4g"
      decimals="INF"
      id="Narr_Jhpt2yap-UWiQBVxcTl3Xw"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">12500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_n7CziHvjvE--LojpNufD4g"
      decimals="0"
      id="Narr_QTtV6o6BDk6X8_DH0SJPfA"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">33000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="INF"
      id="Narr_BgWQx1joRUqgQ_5hQ3A-og"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">19497</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="-3"
      id="Narr__8TrozsV6EmRovvSTZmITg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">49000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_H6wexY840Uyz4koETLKTeg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;10: STOCK-BASED COMPENSATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;2024 Equity Incentive Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;There were no equity incentive awards issued during the three months ended March 31, 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;A summary of the Company&#x2019;s stock option activity for the three months ended March 31, 2024 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 737,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,317,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,497)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Canceled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (79,196)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of March&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 639,202&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 720,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options vested and exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 329,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 113,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth stock-based compensation expenses recorded during the respective periods:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock Compensation expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 151,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 221,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock compensation in continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 79,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 372,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock compensation in discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 288,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock compensation expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 79,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 660,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As of March 31, 2024, the total stock-based compensation cost related to unvested awards not yet recognized was $0.3 million. The expected weighted average period compensation costs to be recognized was approximately 1.8 years. Future option grants will impact the compensation expense recognized.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="INF"
      id="Narr_EJkZoSsgwU-FvgKTJSx59w"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_AJJdH-W4K0C8vvJL9EUFGg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 737,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,317,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,497)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Canceled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (79,196)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of March&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 639,202&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 720,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options vested and exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 329,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 113,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_uiVzVsnzbEO2OvPv-3o_Jg"
      decimals="INF"
      id="Tc_2lMdMprpSEuFZrYLlCvQoA_5_2"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">737895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_uiVzVsnzbEO2OvPv-3o_Jg"
      decimals="2"
      id="Tc_NMcYmTKZ706cdM7GZ-gdHg_5_5"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">25.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_uiVzVsnzbEO2OvPv-3o_Jg"
      decimals="0"
      id="Tc__NYfYw3tqkOJd3pzyjqttw_5_8"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1317000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_JNor-YkRMES_vEoMGuLiUQ"
      id="Tc_kpSopFFGf0O7zSwjDmnn9Q_5_10">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_X9phuL_RxUqyj7QCXMC4zg"
      decimals="INF"
      id="Tc_64wW9VoJm0WyzEDzCEFqBA_6_2"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">19497</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_X9phuL_RxUqyj7QCXMC4zg"
      decimals="2"
      id="Tc_B6JR19wirUWCSbb97N8irw_6_5"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">2.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_X9phuL_RxUqyj7QCXMC4zg"
      decimals="INF"
      id="Tc_Y_DFfZfK3kWnfjteg_Fg5g_7_2"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">79196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_X9phuL_RxUqyj7QCXMC4zg"
      decimals="2"
      id="Tc_-7wJT7Ph0EigpE9Q0V5X6A_7_5"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">52.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_M8QVuqpUVkWUQBZalnnUIQ"
      decimals="INF"
      id="Tc_SLgHJDFuRkifKj1OT99KoA_8_2"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">639202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_M8QVuqpUVkWUQBZalnnUIQ"
      decimals="2"
      id="Tc_eRp3ajsiGkmcWmQWfc1t2Q_8_5"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">22.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_M8QVuqpUVkWUQBZalnnUIQ"
      decimals="0"
      id="Tc_d4gHLthxuUyseqSv2uGKtw_8_8"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">720000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_X9phuL_RxUqyj7QCXMC4zg"
      id="Tc_fxAxzTHYCkqJXmpwNKG8Yw_8_10">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_M8QVuqpUVkWUQBZalnnUIQ"
      decimals="INF"
      id="Tc_X7JgPNtJ8E2n4MLSeOHOHA_9_2"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">329916</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_M8QVuqpUVkWUQBZalnnUIQ"
      decimals="2"
      id="Tc_Rcv0HeKF90aK8E-XcCei5w_9_5"
      unitRef="Unit_Divide_USD_shares_Wz_-r_NT10eADl_2_MLQJA">41.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_M8QVuqpUVkWUQBZalnnUIQ"
      decimals="0"
      id="Tc_aIRpchtf20ivy9EQdwQtWA_9_8"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">113000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_X9phuL_RxUqyj7QCXMC4zg"
      id="Tc_bFd99-4msUuqpPiP8win1w_9_10">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <mrkr:StockBasedCompensationExpensesTableTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_7ZnqRKT-HUag_DkrE9MkKw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock Compensation expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 151,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 221,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock compensation in continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 79,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 372,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock compensation in discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 288,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock compensation expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 79,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 660,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrkr:StockBasedCompensationExpensesTableTextBlock>
    <mrkr:StockCompensationInContinuingOperations
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_MCdjUbOPBEuJBGWUJszvmQ"
      decimals="0"
      id="Tc_eoFqVYAMLkWX1RV38XEutQ_5_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">6000</mrkr:StockCompensationInContinuingOperations>
    <mrkr:StockCompensationInContinuingOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_YwRyxwQa5U2Ym0Gma3rUFg"
      decimals="0"
      id="Tc_LAowT3cuC0yGM0qO16Ji5w_5_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">151000</mrkr:StockCompensationInContinuingOperations>
    <mrkr:StockCompensationInContinuingOperations
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_vBXDcg9tlkOH2-yBzo50cg"
      decimals="0"
      id="Tc_CdlWXVyIb0aMBK8pIJpSHw_6_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">73000</mrkr:StockCompensationInContinuingOperations>
    <mrkr:StockCompensationInContinuingOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_XBUskIaJ10C-ReGlI38TAw"
      decimals="0"
      id="Tc_Htm-wSqKdEiJUNVdLK03sA_6_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">221000</mrkr:StockCompensationInContinuingOperations>
    <mrkr:StockCompensationInContinuingOperations
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_8mqDIVlyGEGLrijWjhIjhw_7_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">79000</mrkr:StockCompensationInContinuingOperations>
    <mrkr:StockCompensationInContinuingOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_P_KBlcOiTUGIS8ziGpVtiw_7_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">372000</mrkr:StockCompensationInContinuingOperations>
    <mrkr:StockCompensationInDiscontinuedOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_kBEcqqn4pEuuKVrkEHDJsQ_8_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">288000</mrkr:StockCompensationInDiscontinuedOperations>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_FocWY9Tte0u31dcdfa0Mlw_9_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">79000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_wVH6Ja4tEkSirkWWmb0Phg_9_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">660000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_3_31_2024_sNr6Pf1U5kqjvipkKC7-cQ"
      decimals="-5"
      id="Narr_8fY37ErtVEODZD6EKS7IJw"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Narr_3-hC5KU8HkisMZ3cRqnRUg">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_JbJC7yO950qBb57sGadHVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;11: GRANT INCOME&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;CPRIT&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from CPRIT to support the Company&#x2019;s clinical investigation of MT-401.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;If restricted cash received from grants in advance of incurring qualifying costs, it is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. There was no restricted cash recorded as of March 31, 2024 and December 31, 2023. If qualifying grant income is earned in advance of cash received from grants, it is recognized as revenue and recorded as other receivable. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded $0.8 million and $1.2 million of grant income related to the CPRIT grant as revenue for the three months ended March 31, 2024, and 2023, respectively. As of March 31, 2024, the Company recorded $1.2 million as other receivable, which represented grant income earned in advance of funds to be received from CPRIT.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;FDA&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In September 2022, the Company received notice from the FDA that it had awarded the Company a $2.0 million grant from the FDA&#x2019;s Orphan Products Grant program to support the Company&#x2019;s clinical investigation of MT-401 for the treatment of post-transplant AML. The Company recorded $0.3 million and $0.1 million of grant income related to the FDA grant as revenue for the three months ended March 31, 2024 and March 31, 2023, respectively. As of March 31, 2024, the Company recorded $0.3 million as other receivable, which represented grant income earned in advance of funds to be received from the FDA. In April 2024, the Company received $0.3 million of funds from the FDA grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;SBIR&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In May 2023, the Company announced it had received a $2.0 million grant from the National Institutes of Health Small Business Innovation Research program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents. The Company recorded $0.2 million of grant income related to the SBIR grant as revenue for the three months ended March 31, 2024. As of March 31, 2024, the Company recorded $0.2 million as other receivable, which represented grant income earned in advance of funds to be received from the SBIR. In April 2024, the Company received $0.2 million of funds from the SBIR grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <mrkr:ReceiptOfProductDevelopmentResearchAward
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_up4ngz1fg02kE_1r6itooQ"
      decimals="-5"
      id="Narr_HCVP6F6E8Ea8tWi2GMaHhQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">13100000</mrkr:ReceiptOfProductDevelopmentResearchAward>
    <us-gaap:RestrictedCash
      contextRef="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_aZw1rDA380KfM4Tw_qsCzw"
      decimals="0"
      id="Narr_4vLd-j2J70q9WwEqiZ7rww"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2023_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_j4d_NUsf-U6y0TlpBZ0hiA"
      decimals="0"
      id="Narr_WlBjdtv4a0yiiUfTcHjEtA"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">0</us-gaap:RestrictedCash>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_aF3HC3hiPEGwEVjTVodC_Q"
      decimals="-5"
      id="Narr_OX4NRv87nkaNtFxOa6AatA"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_SJSbS_G9j0aQNGKHeaocXQ"
      decimals="-5"
      id="Narr_H8IznaTIH0q6dtUphGO3wg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_CpritGrantMember_aZw1rDA380KfM4Tw_qsCzw"
      decimals="-5"
      id="Narr_vpRJKVMJnEerehfRr_6lMg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1200000</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_9_30_2022_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_o77qs3ys40OOa0GfLhRa-Q"
      decimals="-5"
      id="Narr_LN_qKDdgRU2zAJIcY9KaRg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">2000000.0</us-gaap:GrantsReceivable>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_9_n_o50vykCM5Ly004kRVQ"
      decimals="-5"
      id="Narr_dVBP-EflcEieIMYR6wXPrQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">300000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_dFfPvaLfIEikU4XiNmZE_A"
      decimals="-5"
      id="Narr_SM6Xnpk5RUq3O3wZ2faaqQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember__N7KeTtie0WOfM9lUAInzQ"
      decimals="-5"
      id="Narr_SPNUVa4mukqkFy93pMjWtA"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">300000</us-gaap:GrantsReceivable>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_4_1_2024_To_4_30_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_0K6azYZMnkS3HVng864fgA"
      decimals="-5"
      id="Narr_AwHLa7B_oUa4VjCDZvJL0g"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">300000</mrkr:FundsReceivedFromGrant>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_5_31_2023_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_nozZmEEAxEWXLrXsS0VZYA"
      decimals="-5"
      id="Narr_Y5GqFGQN9E-zz_qCJ7mgkQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">2000000.0</us-gaap:GrantsReceivable>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_K-XuDOatfU2spHjQPAU4OA"
      decimals="-5"
      id="Narr_q1wxzTKNSEqFQ6d6xhR-pg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_3_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_xgSQFi7SKUC3P-uEqMdsgQ"
      decimals="-5"
      id="Narr_FBsKqzLbCEKbwiSoYYlNMg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">200000</us-gaap:GrantsReceivable>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_4_1_2024_To_4_30_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_YTxnqMIXBE2WBHHgARjHqg"
      decimals="-5"
      id="Narr_TbjoB76cVkezYmxjEl8kMQ"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">200000</mrkr:FundsReceivedFromGrant>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_fnPviX9dnU6YOU0Tt-zh_Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 12: LEGAL PROCEEDINGS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;From time to time, the Company may be party to ordinary, routine litigation incidental to their business. The Company knows of no material, active or pending legal proceedings against the Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of the Company&#x2019;s directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to the Company&#x2019;s interest.&lt;/p&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_B24qhzlVnUyDkgAdVptL1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;13: RELATED PARTY EXPENSES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth related party transaction expenses recorded for the three months ended March 31, 2024 and 2023, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Baylor College of Medicine&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cell Ready&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,186,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Wilson Wolf Manufacturing Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 204,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,186,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 215,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;$0.4 million of related party transactions are included in accounts payable and accrued liabilities as of March 31, 2024. See Note 8 for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Agreements with The Baylor College of Medicine (&#x201c;BCM&#x201d;)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In November 2018, January 2020 and February 2020, the Company entered in Sponsored Research Agreements with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM&#x2019;s Center for Cell and Gene Therapy. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In September 2019, May 2020 and July 2021, the Company entered into Clinical Supply Agreements with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In October 2019, the Company entered in a Workforce Grant Agreement with BCM, which provided for BCM to provide to the Company manpower costs of projects for manufacturing, quality control testing and validation run activities. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2020, the Company entered into a Clinical Trial Agreement with BCM, which provided for BCM to provide to the Company investigator-initiated research studies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has also entered into a Clinical Site Agreement with BCM, which provided for BCM to conduct clinical trials for the Company and is a part of continuing operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;BCM owns shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Purchases from Wilson Wolf&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In 2023, the Company utilized Wilson Wolf for the purchases of cell culture devices called G-Rexes. Mr. John Wilson is a member of the Company&#x2019;s board of directors and is serving as the CEO of Wilson Wolf Manufacturing Corporation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Purchases from Cell Ready, LLC&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company is currently utilizing Cell Ready, LLC for its clinical manufacturing supply and product development. Mr. John Wilson is a member of the Company&#x2019;s board of directors and is serving as the CEO of Cell Ready, LLC. On February 22, 2024, we entered into a Master Services Agreement for Product Supply (the &#x201c;MSA&#x201d;) with Cell Ready. Cell Ready, which is owned by one of our directors and shareholders, Mr. John Wilson, is a contract development and manufacturing organization (CDMO). Under the MSA, it is anticipated Cell Ready will perform a wide variety of services for us, including research and development, and manufacturing in support of our clinical trials. Pursuant to the MSA, the Company may contract with Cell Ready for the provision of various products and services from time to time by entering into work orders with Cell Ready. If the services involve the supply of product, Cell Ready is required to supply such product in conformance with the product requirements set forth in the applicable work order(s). Under the MSA, Cell Ready is to use only personnel with sufficient qualifications and experience to supply the services contemplated by the MSA, provide its personnel with adequate training and assume full responsibility for its personnel&#x2019;s compliance with the MSA. Further, Cell Ready is required to provide the Company with assistance and cooperation in order for the Company to obtain and maintain all necessary regulatory approvals, at the Company&#x2019;s expense. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the three months ended March 31, 2024, the Company entered into Work Order #1 under the MSA, pursuant to which Cell Ready agreed to provide the Company with GMP drug product for Marker MT-401 and/or MT-601. The services include the delivery of final drug product and quality control testing. The Company also requested Cell Ready to provide general support services in connection therewith. During the three months ended March 31, 2024, the Company incurred $1.2 million is expenses related to the &#160;services and manufacturing costs and paid $2.2 million for invoices received. Additional Work Orders are expected to be generated for the remainder of 2024.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Group_5NasPDwdlkaGPfstEmhSBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Baylor College of Medicine&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cell Ready&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,186,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Wilson Wolf Manufacturing Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 204,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,186,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 215,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_H1facwiFj0qZIcr4nQ49VQ"
      decimals="0"
      id="Tc_Lm4PbPyxe0SWu23m7M0p4g_4_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">11000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_CellReadyMember_IthHVQzVkEC_BWostaNF4w"
      decimals="0"
      id="Tc_1-twrCeDBkeWqnPtlRfyVA_5_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1186000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_awaPZGwxYkOh-Kh6ZKEEGg"
      decimals="0"
      id="Tc_17I8e1WyYU-P8m6MOXQxlA_6_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">204000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      decimals="0"
      id="Tc_1Q61ayXmLkanEm-k3XHNbg_7_3"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1186000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="Duration_1_1_2023_To_3_31_2023_3L3k3bdkak6ttWJy2UgQ7w"
      decimals="0"
      id="Tc_GJJpWTAbdEa0KR2ywvLw-w_7_6"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">215000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_3_31_2024_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_07W_qsYgcEudbi5GDRWobg"
      decimals="-5"
      id="Narr_QmCwfbkga0W4cr1LAu1Z7w"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">400000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_wgAA0Ldo_UOtaTkJBKsynw"
      decimals="-5"
      id="Narr_n9DLzIIdBE-wiHE85ic5Wg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">1200000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <mrkr:InvoicesReceivedForServicesAndManufacturingCosts
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_wgAA0Ldo_UOtaTkJBKsynw"
      decimals="-5"
      id="Narr__dhqDA1e_0a2R84Z7i22Zg"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">2200000</mrkr:InvoicesReceivedForServicesAndManufacturingCosts>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_iqv20LEKkUuZI-Mf3y_F1w"
      id="Tb_AqcfKkLDu0eddCPy4F_6FA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 14: SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In April 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement resulting in net proceeds of $0.04 million, after deducting agent commissions.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_1_2024_To_4_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_dqKTucMUbUGZUuzFK_dOyg"
      decimals="INF"
      id="Narr_xBeQGgcTekCvALqPS4P1Zw"
      unitRef="Unit_Standard_shares_vYYfoSGHJ0-am3cA8zzXFQ">8178</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_4_1_2024_To_4_30_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_dqKTucMUbUGZUuzFK_dOyg"
      decimals="-4"
      id="Narr_f_UolWrmK0aNUTTL8znOBw"
      unitRef="Unit_Standard_USD_uyWSxDSNK0idlo36ZyXnsQ">40000.00</us-gaap:ProceedsFromIssuanceOfCommonStock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
